(ROOT (S (NP (NP (JJ Evidence-based) (NNS guidelines)) (PP (IN for) (NP (NP (DT the) (NN diagnosis)) (CC and) (NP (NP (JJ initial) (NN management)) (PP (IN of) (S (VP (VBN suspected) (NP (NP (JJ acute) (JJ bacterial) (NN rhinosinusitis)) (PP (IN in) (NP (NP (NNS adults)) (CC and) (NP (NNS children)))))))))))) (VP (VBD were) (VP (VBN prepared) (PP (IN by) (NP (NP (DT a) (JJ multidisciplinary) (NN expert) (NN panel)) (PP (IN of) (NP (NP (DT the) (JJ Infectious) (NNS Diseases)) (NP (NP (NNP Society)) (PP (IN of) (NP (NNP America))) (VP (VBG comprising) (NP (NP (NNS clinicians) (CC and) (NNS investigators)) (NP (VBG representing) (NP (JJ internal) (NN medicine)) (, ,) (NP (NNS pediatrics)) (, ,) (NP (NP (NN emergency) (NN medicine)) (, ,) (NP (NN otolaryngology)) (, ,) (NP (NP (JJ public) (NN health)) (, ,) (NP (NN epidemiology)) (, ,) (CC and) (NP (ADJP (JJ adult) (CC and) (JJ pediatric)) (JJ infectious) (NN disease) (NNS specialties)))))))))))))) (. .)))
(ROOT (S (NP (NP (NNS Recommendations)) (PP (IN for) (NP (NP (NN diagnosis)) (, ,) (NP (NN laboratory) (NN investigation)) (, ,) (CC and) (NP (JJ empiric) (ADJP (ADJP (JJ antimicrobial)) (CC and) (ADJP (JJ adjunctive))) (NN therapy))))) (VP (VBD were) (VP (VBN developed))) (. .)))
(ROOT (NP (NP (DT This) (NN guideline) (NNS addresses)) (NP (NP (JJ several) (NNS issues)) (PP (IN in) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (NP (NP (JJ acute) (JJ bacterial) (NN rhinosinusitis)) (PRN (-LRB- -LRB-) (NP (NN ABRS)) (-RRB- -RRB-))) (, ,) (NP (NP (VBG including) (-LRB- -LRB-) (CD 1) (-RRB- -RRB-) (NN inability)) (PP (IN of) (NP (VBG existing) (JJ clinical) (NNS criteria))) (S (VP (TO to) (ADVP (RB accurately)) (VP (VB differentiate) (ADJP (JJ bacterial) (PP (IN from) (NP (JJ viral) (JJ acute) (NN rhinosinusitis)))) (, ,) (S (VP (VBG leading) (PP (TO to) (NP (ADJP (ADJP (JJ excessive)) (CC and) (ADJP (JJ inappropriate))) (JJ antimicrobial) (NN therapy))))))))) (: ;) (NP (LST (-LRB- -LRB-) (LS 2) (-RRB- -RRB-)) (NP (NNS gaps)) (PP (IN in) (NP (NP (NN knowledge) (CC and) (NN quality) (NN evidence)) (VP (VBG regarding) (NP (NP (JJ empiric) (JJ antimicrobial) (NN therapy)) (PP (IN for) (NP (NNS ABRS))) (ADJP (JJ due) (PP (TO to) (NP (JJ imprecise) (NN patient) (NN selection) (NNS criteria))))))))) (: ;) (NP (LST (-LRB- -LRB-) (LS 3) (-RRB- -RRB-)) (S (S (VP (VBG changing) (NP (NP (NN prevalence) (CC and) (JJ antimicrobial) (NN susceptibility) (NNS profiles)) (PP (IN of) (NP (NP (JJ bacterial) (NNS isolates)) (VP (VBN associated) (PP (IN with) (NP (NN ABRS))))))))) (: ;) (CC and) (NP (LST (-LRB- -LRB-) (LS 4) (-RRB- -RRB-)) (NP (NN impact)) (PP (IN of) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (VBN conjugated) (NNS vaccines)) (PP (IN for) (NP (NN Streptococcus))))))) (FW pneumoniae) (PP (IN on) (NP (NP (DT the) (NN emergence)) (PP (IN of) (NP (NP (JJ nonvaccine) (NNS serotypes)) (VP (VBN associated) (PP (IN with) (NP (NN ABRS)))))))))))))))) (. .)))
(ROOT (S (NP (NP (DT An) (NN algorithm)) (PP (IN for) (NP (JJ subsequent) (NN management))) (VP (VBN based) (PP (IN on) (NP (NP (NN risk) (NN assessment)) (PP (IN for) (NP (NP (NP (JJ antimicrobial) (NN resistance)) (CC and) (NP (NN evolution))) (PP (IN of) (NP (JJ clinical) (NNS responses))))))))) (VP (VBZ is) (VP (VBN offered) (PRN (-LRB- -LRB-) (NP (NN Figure) (CD 1)) (-RRB- -RRB-)))) (. .)))
(ROOT (S (NP (DT This) (NN guideline)) (VP (VBZ is) (VP (VBN intended) (PP (IN for) (NP (NP (NN use)) (PP (IN by) (NP (NP (DT all) (JJ primary) (NN care) (NNS physicians)) (ADJP (VBN involved) (PP (IN in) (NP (JJ direct) (NN patient) (NN care)))))))) (, ,) (PP (IN with) (NP (NP (JJ particular) (NN applicability)) (PP (TO to) (NP (NP (NNS patients)) (VP (VBN managed) (PP (IN in) (NP (NP (NN community)) (CC or) (NP (NN emergency) (NN department) (NNS settings))))))))))) (. .)))
(ROOT (S (NP (NP (NP (VBN Continued) (NN monitoring)) (PP (IN of) (NP (DT the) (NP (NN epidemiology)) (CC and) (NP (NP (JJ rigorous) (NN investigation)) (PP (IN of) (NP (DT the) (NN efficacy))))))) (CC and) (ADJP (JJ cost-benefit) (PP (IN of) (NP (NP (JJ empiric) (JJ antimicrobial) (NN therapy)) (PP (IN for) (NP (VBN suspected) (NNS ABRS))))))) (VP (VBP are) (ADVP (RB urgently)) (VP (VBN needed) (PP (IN in) (NP (DT both) (NNS children) (CC and) (NNS adults))))) (. .)))
(ROOT (S (VP (VBN Summarized) (SBAR (IN below) (S (VP (VBP are) (NP (NP (DT the) (NNS recommendations)) (VP (VBN made) (PP (IN in) (NP (DT the) (JJ new) (NN guideline))) (PP (IN for) (NP (NP (NNS ABRS)) (PP (IN in) (NP (NP (NNS children)) (CC and) (NP (NNS adults)))))))))))) (. .)))
(ROOT (S (NP (DT The) (NN panel)) (VP (VBD followed) (NP (NP (DT a) (NN process)) (VP (VBN used) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (JJ other) (JJ Infectious) (NNS Diseases)) (SBAR (S (NP (NP (NP (NNP Society)) (PP (IN of) (NP (NNP America)))) (PRN (-LRB- -LRB-) (NP (NNP IDSA)) (-RRB- -RRB-))) (VP (NNS guidelines) (SBAR (S (NP (WDT that)) (VP (VBZ includes) (NP (NP (DT a) (JJ systematic) (NN weighting)) (PP (IN of) (NP (NP (DT the) (NN strength)) (PP (IN of) (NP (NP (NP (NN recommendation)) (PRN (-LRB- -LRB-) (FRAG (ADVP (FW eg)) (, ,) (SQ (`` ``) (ADJP (JJ high) (, ,) (JJ moderate) (PRN (, ,) (JJ low) (PRN (, ,) (ADJP (RB very) (JJ low)) ('' '')))))) (-RRB- -RRB-))) (CC and) (NP (NP (NN quality)) (PP (IN of) (NP (NP (NN evidence)) (S (-LRB- -LRB-) (ADVP (FW eg)) (, ,) (`` ``) (ADJP (JJ strong) (, ,) (JJ weak) ('' ''))))))))))))))))))))))) (-RRB- -RRB-) (S (VP (VBG using) (NP (NP (NP (NP (NP (DT the) (NN GRADE)) (PRN (-LRB- -LRB-) (NP (NP (NP (NN Grading)) (PP (IN of) (NP (NP (NNS Recommendations)) (NP (NNP Assessment))))) (, ,) (NP (NP (NNP Development)) (CC and) (NP (NN Evaluation)))) (-RRB- -RRB-))) (NN system)) (PRN (-LRB- -LSB-) (NP (NP (CD 1)) (: --) (NP (CD 6))) (-RRB- -RSB-))) (PRN (-LRB- -LRB-) (NNP Table) (LST (LS 1)) (-RRB- -RRB-)))))) (. .)))
(ROOT (S (NP (NP (DT A) (JJ detailed) (NN description)) (PP (IN of) (NP (NP (NP (DT the) (NNS methods)) (, ,) (NP (NN background)) (, ,) (CC and) (NP (NN evidence) (NNS summaries))) (SBAR (WHNP (WDT that)) (S (VP (VBP support) (NP (NP (DT each)) (PP (IN of) (NP (DT the) (NNS recommendations)))))))))) (VP (MD can) (VP (VB be) (VP (VBN found) (PP (IN in) (NP (NP (DT the) (JJ full) (NN text)) (PP (IN of) (NP (DT this) (NN guideline)))))))) (. .)))
(ROOT (NP (NP (NN I.)) (FRAG (WHNP (WDT Which) (JJ Clinical) (NNS Presentations)) (NP (NP (JJS Best) (NN Identify) (NNS Patients)) (PP (IN With) (NP (JJ Acute) (JJ Bacterial) (NNP Versus) (JJ Viral) (NN Rhinosinusitis))))) (. ?)))
(ROOT (LST (LS 1) (. .)))
(ROOT (S (NP (DT The) (PP (VBG following) (NP (NP (JJ clinical) (NNS presentations)) (PRN (-LRB- -LRB-) (NP (NP (DT any)) (PP (IN of) (NP (CD 3)))) (-RRB- -RRB-))))) (VP (VBP are) (VP (VBN recommended) (PP (IN for) (S (VP (VBG identifying) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ acute) (JJ bacterial)) (CC vs) (NP (ADJP (JJ viral))) (NP (NN rhinosinusitis)))))))))) (: :)))
(ROOT (NP (NP (NP (NNP i.) (NNP Onset)) (PP (IN with) (NP (NP (JJ persistent) (NNS symptoms)) (CC or) (NP (NP (NNS signs)) (ADJP (JJ compatible) (PP (IN with) (NP (JJ acute) (NN rhinosinusitis)))))))) (, ,) (VP (VBG lasting) (PP (IN for) (NP (CD ≥) (CD 10) (NNS days))) (PP (IN without) (NP (NP (DT any) (NN evidence)) (PP (IN of) (NP (NP (JJ clinical) (NN improvement)) (PRN (-LRB- -LRB-) (ADJP (ADJP (JJ strong)) (, ,) (ADJP (JJ low-moderate))) (-RRB- -RRB-))))))) (: ;)))
(ROOT (LST (LS ii) (. .)))
(ROOT (NP (NP (NN Onset)) (PP (IN with) (NP (NP (NP (JJ severe) (NNS symptoms)) (CC or) (NP (NP (NNS signs)) (PP (IN of) (NP (NP (NP (JJ high) (NN fever)) (PRN (-LRB- -LRB-) (NP (NP (CD ≥) (CD 39) (NN °) (NN C)) (PRN (-LRB- -LSB-) (NP (QP (CD 102) (CD °)) (NN F)) (-RRB- -RSB-))) (-RRB- -RRB-))) (CC and) (NP (JJ purulent) (JJ nasal) (NN discharge)))))) (CC or) (NP (JJ facial) (NN pain)))) (VP (VBG lasting) (PP (IN for) (NP (QP (IN at) (JJS least) (CD 3))))) (: --) (NP (NP (CD 4) (JJ consecutive) (NNS days)) (PP (IN at) (NP (NP (DT the) (NN beginning)) (PP (IN of) (NP (NP (NN illness)) (PRN (-LRB- -LRB-) (ADJP (ADJP (JJ strong)) (, ,) (ADJP (JJ low-moderate))) (-RRB- -RRB-))))))) (: ;) (NP (CC or))))
(ROOT (LST (LS iii) (. .)))
(ROOT (NP (NP (NP (NP (NN Onset)) (PP (IN with) (S (VP (VBG worsening) (NP (NP (NNS symptoms) (CC or) (NNS signs)) (VP (VBN characterized) (PP (IN by) (NP (NP (DT the) (JJ new) (NN onset)) (PP (IN of) (NP (NP (NN fever)) (, ,) (NP (NN headache)) (, ,) (CC or) (NP (NN increase)))))))) (PP (IN in) (NP (JJ nasal) (NN discharge))) (PP (VBG following) (NP (NP (DT a) (NP (JJ typical) (JJ viral) (JJ upper) (JJ respiratory) (NN infection)) (PRN (-LRB- -LRB-) (NP (NN URI)) (-RRB- -RRB-))) (SBAR (WHNP (WDT that)) (S (VP (VBD lasted) (NP (CD 5))))))))))) (: --) (NP (CD 6) (NNS days)) (CC and) (VP (VP (VBD were) (ADVP (RB initially)) (VP (VBG improving))) (ADJP (PRN (-LRB- -LRB-) (`` ``) (JJ double-sickening) ('' '') (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (ADJP (JJ strong) (, ,) (JJ low-moderate)) (-RRB- -RRB-))))) (. .)))
(ROOT (NP (NNP II) (. .)))
(ROOT (SBARQ (WHADVP (WRB When)) (SQ (MD Should) (NP (NNP Empiric) (NNP Antimicrobial) (NN Therapy)) (VP (VB Be) (VP (VBN Initiated) (PP (IN in) (NP (NP (NNS Patients)) (PP (IN With) (NP (NP (NNS Signs) (CC and) (NNS Symptoms)) (NP (NP (JJ Suggestive)) (PP (IN of) (NP (NNP ABRS))))))))))) (. ?)))
(ROOT (LST (LS 2) (. .)))
(ROOT (S (NP (PRP It)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (NP (JJ empiric) (JJ antimicrobial) (NN therapy)) (VP (VB be) (VP (VBN initiated) (ADVP (ADVP (RB as) (RB soon)) (SBAR (IN as) (S (NP (NP (DT the) (JJ clinical) (NN diagnosis)) (PP (IN of) (NP (NN ABRS)))) (VP (VBZ is) (VP (VBN established) (SBAR (IN as) (S (VP (VBN defined) (PP (IN in) (NP (NP (NN recommendation) (CD 1)) (PRN (-LRB- -LRB-) (ADJP (JJ strong) (, ,) (JJ moderate)) (-RRB- -RRB-)))))))))))))))))) (. .)))
(ROOT (NP (NNP III) (. .)))
(ROOT (SQ (MD Should) (NP (NNP Amoxicillin) (NNP Versus) (NNP Amoxicillin-Clavulanate)) (VP (VB Be) (VP (VBN Used) (PP (IN for) (NP (NP (JJ Initial) (NNP Empiric) (NNP Antimicrobial) (NN Therapy)) (PP (IN of) (NP (NN ABRS))))) (PP (IN in) (NP (NNP Children))))) (. ?)))
(ROOT (LST (LS 3) (. .)))
(ROOT (FRAG (ADVP (JJ Amoxicillin-clavulanate) (RB rather) (SBAR (IN than) (S (NP (NP (NNP amoxicillin)) (ADVP (RB alone))) (VP (VBZ is) (VP (VBN recommended) (PP (IN as) (NP (NP (JJ empiric) (JJ antimicrobial) (NN therapy)) (PP (IN for) (NP (NP (NNS ABRS)) (PP (IN in) (NP (NP (NNS children)) (PRN (-LRB- -LRB-) (ADJP (JJ strong) (, ,) (JJ moderate)) (-RRB- -RRB-))))))))))))) (. .)))
(ROOT (NP (CD IV) (. .)))
(ROOT (SQ (MD Should) (NP (NNP Amoxicillin) (NNP Versus) (NNP Amoxicillin-Clavulanate)) (VP (VB Be) (VP (VBN Used) (PP (IN for) (NP (NP (JJ Initial) (NNP Empiric) (NNP Antimicrobial) (NN Therapy)) (PP (IN of) (NP (NN ABRS))))) (PP (IN in) (NP (NNS Adults))))) (. ?)))
(ROOT (LST (LS 4) (. .)))
(ROOT (FRAG (ADVP (JJ Amoxicillin-clavulanate) (RB rather) (SBAR (IN than) (S (NP (NP (NNP amoxicillin)) (ADVP (RB alone))) (VP (VBZ is) (VP (VBN recommended) (PP (IN as) (NP (NP (JJ empiric) (JJ antimicrobial) (NN therapy)) (PP (IN for) (NP (NP (NNS ABRS)) (PP (IN in) (NP (NP (NNS adults)) (PRN (-LRB- -LRB-) (ADJP (ADJP (JJ weak)) (, ,) (ADJP (JJ low))) (-RRB- -RRB-))))))))))))) (. .)))
(ROOT (NP (NN V) (. .)))
(ROOT (SBARQ (WHADVP (WRB When)) (SQ (VBZ Is) (NP (NN High-Dose)) (NP (NNP Amoxicillin-Clavulanate) (NNP Recommended)) (PP (IN During) (NP (JJ Initial) (NNP Empiric) (NNP Antimicrobial) (NN Therapy))) (PP (IN for) (NP (NP (NNS ABRS)) (PP (IN in) (NP (NP (NNP Children)) (CC or) (NP (NNS Adults))))))) (. ?)))
(ROOT (LST (CD 5) (. .)))
(ROOT (S (NP (`` ``) (JJ High-dose) ('' '') (PRN (-LRB- -LRB-) (NP (NP (CD 2) (NN g)) (ADJP (RB orally) (RB twice) (JJ daily) (CC or) (CD 90))) (NN mg/kg/day) (ADJP (RB orally) (RB twice) (JJ daily)) (-RRB- -RRB-)) (NN amoxicillin-clavulanate)) (VP (VBZ is) (VP (VBN recommended) (PP (IN for) (NP (NNS children) (CC and) (NNS adults))) (PP (IN with) (NP (NP (NP (NN ABRS)) (PP (IN from) (NP (NP (JJ geographic) (NNS regions)) (PP (IN with) (NP (NP (NP (JJ high) (JJ endemic) (NNS rates)) (PRN (-LRB- -LRB-) (NP (QP (CD ≥) (CD 10)) (NN %)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (NP (JJ invasive) (JJ penicillin-nonsusceptible)) (PRN (-LRB- -LRB-) (NP (NN PNS)) (-RRB- -RRB-))) (NP (NNP S.) (FW pneumoniae))))))))) (, ,) (NP (NP (DT those)) (PP (IN with) (NP (NP (JJ severe) (NN infection)) (PRN (-LRB- -LRB-) (NP (ADVP (FW eg)) (, ,) (NP (NP (NN evidence)) (PP (IN of) (NP (JJ systemic) (NN toxicity))) (PP (IN with) (NP (NP (NP (NP (NN fever)) (PP (IN of) (NP (QP (CD 39) (CD °)) (NN C)))) (PRN (-LRB- -LSB-) (NP (QP (CD 102) (CD °)) (NN F)) (-RRB- -RSB-))) (CC or) (NP (ADJP (JJR higher))) (, ,) (CC and) (NP (NP (NN threat)) (PP (IN of) (NP (JJ suppurative) (NNS complications)))))))) (-RRB- -RRB-))))) (, ,) (NP (NP (NN attendance)) (PP (IN at) (NP (NN daycare)))) (, ,) (NP (NP (NN age)) (JJR <) (NP (CD 2)) (CC or) (NP (NP (JJR >)) (NP (CD 65) (NNS years)))) (, ,) (NP (JJ recent) (NN hospitalization)) (, ,) (NP (NP (JJ antibiotic) (NN use)) (PP (IN within) (NP (DT the) (JJ past) (NN month)))) (, ,) (CC or) (SBAR (WHNP (WP who)) (S (VP (VBP are) (ADJP (ADJP (JJ immunocompromised)) (PRN (-LRB- -LRB-) (ADJP (ADJP (JJ weak)) (, ,) (ADJP (JJ moderate))) (-RRB- -RRB-)))))))))) (. .)))
(ROOT (NP (NNP VI) (. .)))
(ROOT (SQ (MD Should) (NP (DT a) (JJ Respiratory) (NNP Fluoroquinolone) (NNP Versus)) (NP (DT a) (JJ β-Lactam) (NNP Agent)) (VP (VB Be) (VP (VBN Used) (PP (IN as) (NP (NP (JJ First-line) (NNS Agents)) (PP (IN for) (NP (NP (DT the) (JJ Initial) (NNP Empiric) (NNP Antimicrobial) (NN Therapy)) (PP (IN of) (NP (NNP ABRS))))))))) (. ?)))
(ROOT (NP (CD 6) (. .)))
(ROOT (S (NP (NP (NP (DT A) (JJ β-lactam) (NN agent)) (PRN (-LRB- -LRB-) (NP (NN amoxicillin-clavulanate)) (-RRB- -RRB-))) (CONJP (RB rather) (IN than)) (NP (DT a) (JJ respiratory) (JJ fluoroquinolone))) (VP (VBZ is) (VP (VBN recommended) (PP (IN for) (NP (NP (JJ initial) (JJ empiric) (JJ antimicrobial) (NN therapy)) (PP (IN of) (NP (NP (NN ABRS)) (PRN (-LRB- -LRB-) (ADJP (ADJP (JJ weak)) (, ,) (ADJP (JJ moderate))) (-RRB- -RRB-)))))))) (. .)))
(ROOT (NP (NN VII) (. .)))
(ROOT (SQ (PP (IN Besides) (NP (DT a) (JJ Respiratory) (NN Fluoroquinolone))) (, ,) (MD Should) (SBAR (DT a) (S (NP (NAC (NNP Macrolide) (, ,) (NNP Trimethoprim-Sulfamethoxazole) (, ,) (NNP Doxycycline) (, ,)) (CC or) (NP (DT a) (LS Second) (: -) (CC or) (NNP Third-Generation) (NNP Oral) (NNP Cephalosporin))) (VP (VB Be) (VP (VBN Used) (PP (IN as) (NP (NP (JJ Second-line) (NN Therapy)) (PP (IN for) (NP (NP (NNS ABRS)) (PP (IN in) (NP (NP (NNP Children)) (CC or) (NP (NNS Adults)))))))))))) (. ?)))
(ROOT (NP (CD 7) (. .)))
(ROOT (S (NP (NP (NNS Macrolides)) (PRN (-LRB- -LRB-) (NP (NP (NN clarithromycin)) (CC and) (NP (NN azithromycin))) (-RRB- -RRB-))) (VP (VBP are) (RB not) (VP (VBN recommended) (PP (IN for) (NP (NP (JJ empiric) (NN therapy)) (ADJP (JJ due) (PP (TO to) (NP (NP (JJ high) (NNS rates)) (PP (IN of) (NP (NP (NP (NN resistance)) (PP (IN among) (NP (NP (NNP S.) (FW pneumoniae)) (PRN (-LRB- -LRB-) (NP (CD ∼) (CD 30) (NN %)) (-RRB- -RRB-))))) (PRN (-LRB- -LRB-) (ADJP (JJ strong) (, ,) (JJ moderate)) (-RRB- -RRB-))))))))))) (. .)))
(ROOT (NP (CD 8) (. .)))
(ROOT (S (NP (NP (NN Trimethoprim-sulfamethoxazole)) (PRN (-LRB- -LRB-) (NP (NN TMP/SMX)) (-RRB- -RRB-))) (VP (VBZ is) (RB not) (VP (VBN recommended) (PP (IN for) (NP (JJ empiric) (NN therapy))) (PP (IN because) (IN of) (NP (NP (JJ high) (NNS rates)) (PP (IN of) (NP (NP (NN resistance)) (PP (IN among) (NP (NP (DT both) (NP (FW S.) (FW pneumoniae)) (CC and) (NP (NP (JJ Haemophilus) (NN influenzae)) (PRN (-LRB- -LRB-) (NP (CD ∼) (CD 30) (NN %)) (: --)))) (NP (CD 40) (NN %)))))))) (-RRB- -RRB-) (PRN (-LRB- -LRB-) (ADJP (JJ strong) (, ,) (JJ moderate)) (-RRB- -RRB-)))) (. .)))
(ROOT (NP (CD 9) (. .)))
(ROOT (S (NP (NNP Doxycycline)) (VP (MD may) (VP (VB be) (VP (VBN used) (SBAR (IN as) (S (NP (DT an) (JJ alternative) (NN regimen)) (VP (TO to) (VP (VB amoxicillin-clavulanate) (PP (IN for) (NP (NP (JJ initial) (JJ empiric) (JJ antimicrobial) (NN therapy)) (PP (IN of) (NP (NN ABRS))) (PP (IN in) (NP (NNS adults))))) (SBAR (IN because) (S (NP (PRP it)) (VP (VP (VBZ remains) (ADJP (RB highly) (JJ active) (PP (IN against) (NP (JJ respiratory) (NNS pathogens))))) (CC and) (VP (VBZ has) (NP (NP (JJ excellent) (JJ pharmacokinetic/pharmacodynamic) (-LRB- -LRB-) (NN PK/PD) (-RRB- -RRB-) (NNS properties)) (PRN (-LRB- -LRB-) (NP (JJ weak) (, ,) (JJ low)) (-RRB- -RRB-)))))))))))))) (. .)))
(ROOT (NP (CD 10) (. .)))
(ROOT (S (NP (JJ Second-and) (JJ third-generation) (JJ oral) (NNS cephalosporins)) (VP (VBP are) (ADVP (RB no) (RB longer)) (VP (VBN recommended) (PP (IN for) (NP (NP (JJ empiric) (NN monotherapy)) (PP (IN of) (NP (NP (NNS ABRS)) (ADJP (JJ due) (PP (TO to) (NP (NP (JJ variable) (NNS rates)) (PP (IN of) (NP (NP (NN resistance)) (PP (IN among) (NP (NNP S.) (FW pneumoniae)))))))))))))) (. .)))
(ROOT (S (S (NP (NP (NN Combination) (NN therapy)) (PP (IN with) (NP (NP (NP (DT a) (JJ third-generation) (JJ oral) (NN cephalosporin)) (PRN (-LRB- -LRB-) (NP (NP (NN cefixime)) (CC or) (NP (NN cefpodoxime))) (-RRB- -RRB-))) (CC plus) (NP (NN clindamycin))))) (VP (MD may) (VP (VB be) (VP (VBN used) (PP (IN as) (NP (NP (JJ second-line) (NN therapy)) (PP (IN for) (NP (NP (NNS children)) (PP (IN with) (NP (JJ non))))))))))) (: --) (NP (NP (NN type) (CD I) (NN penicillin) (NN allergy)) (CC or) (PP (IN from) (NP (NP (JJ geographic) (NNS regions)) (PP (IN with) (NP (NP (JJ high) (JJ endemic) (NNS rates)) (PP (IN of) (NP (NP (NNP PNS) (NNP S.) (FW pneumoniae)) (PRN (-LRB- -LRB-) (ADJP (ADJP (JJ weak)) (, ,) (ADJP (JJ moderate))) (-RRB- -RRB-))))))))) (. .)))
(ROOT (NP (CD VIII) (. .)))
(ROOT (SBARQ (WHNP (WDT Which) (JJ Antimicrobial) (NNS Regimens)) (SQ (VP (VBP Are) (VP (VBN Recommended) (PP (IN for) (NP (NP (DT the) (NNP Empiric) (NN Treatment)) (PP (IN of) (NP (NN ABRS))) (PP (IN in) (NP (NP (NNS Adults)) (CC and) (NP (NNS Children)))))) (PP (IN With) (NP (NP (DT a) (NN History)) (PP (IN of) (NP (NNP Penicillin) (NNP Allergy)))))))) (. ?)))
(ROOT (NP (CD 11) (. .)))
(ROOT (S (CC Either) (NP (NP (NP (NN doxycycline)) (PRN (-LRB- -LRB-) (ADJP (RB not) (JJ suitable) (PP (IN for) (NP (NNS children)))) (-RRB- -RRB-))) (CC or) (NP (NP (DT a) (JJ respiratory) (JJ fluoroquinolone)) (PRN (-LRB- -LRB-) (NP (NP (NN levofloxacin)) (CC or) (NP (NN moxifloxacin))) (-RRB- -RRB-)))) (VP (VBZ is) (VP (VBN recommended) (PP (IN as) (NP (NP (DT an) (JJ alternative) (NN agent)) (PP (IN for) (NP (NP (JJ empiric) (JJ antimicrobial) (NN therapy)) (PP (IN in) (NP (NP (NNS adults)) (SBAR (WHNP (WP who)) (S (VP (VBP are) (ADJP (JJ allergic) (PP (TO to) (NP (NP (NN penicillin)) (PRN (-LRB- -LRB-) (ADJP (JJ strong) (, ,) (JJ moderate)) (-RRB- -RRB-)))))))))))))))) (. .)))
(ROOT (NP (CD 12) (. .)))
(ROOT (S (S (NP (NNP Levofloxacin)) (VP (VBZ is) (VP (VBN recommended) (PP (IN for) (NP (NP (NP (NNS children)) (PP (IN with) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NN type) (CD I) (NN hypersensitivity)))))) (PP (TO to) (NP (NN penicillin)))))))) (: ;) (S (NP (NP (NN combination) (NN therapy)) (PP (IN with) (NP (NP (NN clindamycin)) (CC plus) (NP (NP (DT a) (JJ third-generation) (JJ oral) (NN cephalosporin)) (PRN (-LRB- -LRB-) (NP (NP (NN cefixime)) (CC or) (NP (NN cefpodoxime))) (-RRB- -RRB-)))))) (VP (VBZ is) (VP (VBN recommended) (PP (IN in) (NP (NP (NNS children)) (PP (IN with) (NP (NP (NP (NP (DT a) (NN history)) (PP (IN of) (NP (JJ non)))) (: --) (NN type) (CD I) (NN hypersensitivity)) (PP (TO to) (NP (NP (NN penicillin)) (PRN (-LRB- -LRB-) (NP (JJ weak) (, ,) (JJ low)) (-RRB- -RRB-))))))))))) (. .)))
(ROOT (NP (CD IX) (. .)))
(ROOT (SQ (MD Should) (NP (NP (NNP Coverage)) (PP (IN for) (NP (FW Staphylococcus) (FW aureus)))) (S (PRN (-LRB- -LRB-) (NP (RB Especially) (JJ Methicillin-Resistant) (FW S.) (FW aureus)) (-RRB- -RRB-)) (VP (VB Be) (S (VP (VBN Provided) (ADVP (RB Routinely)) (PP (IN During) (NP (NP (JJ Initial) (JJ Empiric) (NN Therapy)) (PP (IN of) (NP (NNP ABRS))))))))) (. ?)))
(ROOT (NP (CD 13) (. .)))
(ROOT (S (SBAR (IN Although) (S (NP (NP (NNP S.) (NN aureus)) (-LRB- -LRB-) (PP (VBG including) (NP (JJ methicillin-resistant) (FW S.) (FW aureus) (PRN (-LRB- -LSB-) (NP (NN MRSA)) (-RRB- -RSB-)))) (-RRB- -RRB-)) (VP (VBZ is) (NP (NP (DT a) (JJ potential) (NN pathogen)) (PP (IN in) (NP (NNP ABRS)))) (, ,) (PP (IN on) (NP (NP (DT the) (NN basis)) (PP (IN of) (NP (NP (NP (JJ current) (NNS data)) (, ,) (NP (NP (JJ routine) (JJ antimicrobial) (NN coverage)) (PP (IN for) (NP (NP (FW S.) (FW aureus)) (CC or) (NP (NNP MRSA)))))) (PP (IN during) (NP (NP (JJ initial) (JJ empiric) (NN therapy)) (PP (IN of) (NP (NN ABRS)))))))))))) (VP (VBZ is) (RB not) (VP (VBN recommended) (PRN (-LRB- -LRB-) (ADJP (JJ strong) (, ,) (JJ moderate)) (-RRB- -RRB-)))) (. .)))
(ROOT (SBARQ (NP (NNP X.)) (SINV (MD Should) (NP (NP (NNP Empiric) (NNP Antimicrobial) (NN Therapy)) (PP (IN for) (NP (NNP ABRS)))) (VP (VB Be) (VP (VBN Administered) (PP (IN for) (NP (CD 5) (: --) (CD 7) (NNS Days) (NP (NNP Versus) (CD 10)) (: --) (NP (QP (CD 14) (NNS Days)))))))) (. ?)))
(ROOT (NP (CD 14) (. .)))
(ROOT (S (NP (NP (DT The) (VBN recommended) (NN duration)) (PP (IN of) (NP (NN therapy))) (PP (IN for) (NP (JJ uncomplicated) (NNS ABRS))) (PP (IN in) (NP (NNS adults)))) (VP (VBZ is) (NP (CD 5) (PRN (: --) (NP (NP (CD 7) (NNS days)) (PRN (-LRB- -LRB-) (ADJP (ADJP (JJ weak)) (, ,) (ADJP (JJ low-moderate))) (-RRB- -RRB-)))))) (. .)))
(ROOT (NP (CD 15) (. .)))
(ROOT (UCP (PP (IN In) (NP (NP (NNS children)) (PP (IN with) (NP (NN ABRS))))) (, ,) (NP (NP (NP (DT the) (JJR longer) (NN treatment) (NN duration)) (PP (IN of) (NP (CD 10)))) (: --) (NP (NP (CD 14) (NNS days)) (VP (VBZ is) (ADVP (RB still)) (VP (VBN recommended) (PRN (-LRB- -LRB-) (ADJP (JJ weak) (, ,) (JJ low-moderate)) (-RRB- -RRB-)))))) (. .)))
(ROOT (NP (NN XI) (. .)))
(ROOT (SQ (VBZ Is) (NP (NP (JJ Saline) (NN Irrigation)) (PP (IN of) (NP (NP (DT the) (JJ Nasal) (NNS Sinuses)) (PP (IN of) (NP (NNP Benefit)))))) (PP (IN as) (NP (NP (JJ Adjunctive) (NN Therapy)) (PP (IN in) (NP (NP (NNS Patients)) (PP (IN With) (NP (NN ABRS))))))) (. ?)))
(ROOT (NP (CD 16) (. .)))
(ROOT (S (NP (NP (JJ Intranasal) (NN saline) (NN irrigation)) (PP (IN with) (NP (CC either) (NP (ADJP (JJ physiologic))) (CC or) (NP (ADJP (JJ hypertonic))) (NP (NN saline))))) (VP (VBZ is) (VP (VBN recommended) (PP (IN as) (NP (NP (DT an) (JJ adjunctive) (NN treatment)) (PP (IN in) (NP (NP (NNS adults)) (PP (IN with) (NP (NP (NN ABRS)) (PRN (-LRB- -LRB-) (ADJP (ADJP (JJ weak)) (, ,) (ADJP (JJ low-moderate))) (-RRB- -RRB-)))))))))) (. .)))
(ROOT (NP (NNP XII) (. .)))
(ROOT (SQ (VBP Are) (NP (JJ Intranasal) (NNS Corticosteroids)) (VP (VBN Recommended) (PP (IN as) (NP (NP (DT an) (NN Adjunct)) (PP (TO to) (NP (JJ Antimicrobial) (NN Therapy))))) (PP (IN in) (NP (NP (NNS Patients)) (PP (IN With) (NP (NN ABRS)))))) (. ?)))
(ROOT (NP (CD 17) (. .)))
(ROOT (S (NP (NP (JJ Intranasal) (NNS corticosteroids)) (PRN (-LRB- -LRB-) (NP (NNS INCSs)) (-RRB- -RRB-))) (VP (VBP are) (VP (VBN recommended) (PP (IN as) (NP (NP (DT an) (NN adjunct)) (PP (TO to) (NP (NP (NNS antibiotics)) (PP (IN in) (NP (NP (DT the) (JJ empiric) (NN treatment)) (PP (IN of) (NP (NP (NNP ABRS)) (, ,) (PP (ADVP (RB primarily)) (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NP (JJ allergic) (NN rhinitis)) (PRN (-LRB- -LRB-) (ADJP (ADJP (JJ weak)) (, ,) (ADJP (JJ moderate))) (-RRB- -RRB-)))))))))))))))))) (. .)))
(ROOT (NP (NN XIII) (. .)))
(ROOT (SQ (MD Should) (NP (NP (NNP Topical) (CC or) (NNP Oral) (NNPS Decongestants)) (CC or) (NP (NNPS Antihistamines))) (VP (VB Be) (VP (VBN Used) (PP (IN as) (NP (JJ Adjunctive) (NN Therapy))) (PP (IN in) (NP (NP (NNS Patients)) (PP (IN With) (NP (NN ABRS))))))) (. ?)))
(ROOT (NP (CD 18) (. .)))
(ROOT (S (NP (NP (DT Neither) (ADJP (ADJP (JJ topical)) (CC nor) (ADJP (JJ oral))) (NNS decongestants)) (CC and/or) (NP (NNS antihistamines))) (VP (VBP are) (VP (VBN recommended) (PP (IN as) (NP (NP (JJ adjunctive) (NN treatment)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NN ABRS)) (PRN (-LRB- -LRB-) (ADJP (ADJP (JJ strong)) (, ,) (ADJP (JJ low-moderate))) (-RRB- -RRB-)))))))))) (. .)))
(ROOT (NP (NNP XIV) (. .)))
(ROOT (SBARQ (WHADJP (WRB How) (JJ Long)) (SQ (MD Should) (NP (NP (JJ Initial) (NNP Empiric) (NNP Antimicrobial) (NN Therapy)) (PP (IN in) (NP (NP (DT the) (NN Absence)) (PP (IN of) (NP (JJ Clinical) (NN Improvement)))))) (VP (VB Be) (VP (VBD Continued) (PP (IN Before) (S (VP (VBG Considering) (NP (NNP Alternative) (NNP Management) (NNS Strategies)))))))) (. ?)))
(ROOT (NP (CD 19) (. .)))
(ROOT (S (NP (DT An) (JJ alternative) (NN management) (NN strategy)) (VP (VBZ is) (VP (VBN recommended) (FRAG (SBAR (IN if) (S (NP (NNS symptoms)) (VP (VBP worsen) (PP (IN after) (NP (CD 48)))))) (PRN (: --) (NP (NP (NP (CD 72) (NNS hours)) (PP (IN of) (NP (JJ initial) (JJ empiric) (JJ antimicrobial) (NN therapy)))) (CC or) (VP (VB fail) (S (VP (TO to) (VP (VB improve) (PP (IN despite) (NP (NP (CD 3)) (: --) (NP (NP (QP (CD 5) (NNS days))) (PP (IN of) (NP (NP (JJ initial) (JJ empiric) (JJ antimicrobial) (NN therapy)) (PRN (-LRB- -LRB-) (ADJP (ADJP (JJ strong)) (CC and) (ADJP (JJ moderate))) (-RRB- -RRB-)))))))))))))))) (. .)))
(ROOT (NP (NN XV) (. .)))
(ROOT (SBARQ (WHNP (WDT What)) (SQ (VBZ Is) (NP (DT the) (NNP Recommended) (NNP Management) (NNP Strategy)) (PP (IN in) (NP (NNPS Patients))) (SBAR (WHNP (WP Who)) (S (ADVP (RB Clinically)) (VP (VBP Worsen) (SBAR (IN Despite) (S (NP (NP (CD 72) (NNS Hours)) (CC or) (NP (NN Fail))) (VP (TO to) (VP (VB Improve) (PP (IN After) (NP (NP (CD 3)) (: --) (NP (NP (NP (QP (CD 5) (NNS Days))) (PP (IN of) (NP (JJ Initial) (NNP Empiric) (NNP Antimicrobial) (NN Therapy)))) (PP (IN With) (NP (DT a) (NN First-line) (NN Regimen)))))))))))))) (. ?)))
(ROOT (NP (CD 20) (. .)))
(ROOT (S (NP (NP (DT An) (NN algorithm)) (PP (IN for) (NP (NP (NN managing) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP fail) (S (VP (TO to) (VP (VB respond) (PP (TO to) (NP (JJ initial) (JJ empiric) (JJ antimicrobial) (NN therapy)))))))))))) (VP (VBZ is) (VP (VBN shown) (PP (IN in) (NP (NNP Figure) (CD 1))))) (. .)))
(ROOT (NP (NP (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (ADVP (RB clinically)) (VP (VBP worsen) (PP (IN despite) (NP (NP (CD 72) (NNS hours)) (CC or) (VP (VBP fail) (S (VP (TO to) (VP (VB improve) (PP (IN after) (NP (NP (CD 3)) (: --) (SBAR (S (NP (NP (QP (CD 5) (NNS days))) (PP (IN of) (NP (NP (JJ empiric) (JJ antimicrobial) (NN therapy)) (PP (IN with) (NP (DT a) (JJ first-line) (NN agent)))))) (VP (MD should) (VP (VB be) (VP (VBN evaluated) (PP (IN for) (NP (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (JJ resistant) (NNS pathogens)))) (, ,) (NP (DT a) (JJ noninfectious) (NN etiology)) (, ,) (NP (NP (NP (NP (JJ structural) (NN abnormality)) (, ,) (CC or) (NP (JJ other) (NNS causes))) (PP (IN for) (NP (NN treatment) (NN failure)))) (PRN (-LRB- -LRB-) (ADJP (ADJP (JJ strong)) (, ,) (ADJP (JJ low))) (-RRB- -RRB-)))))))))))))))))))))) (. .)))
(ROOT (NP (NNP XVI) (. .)))
(ROOT (S (PP (IN In) (S (VP (VBG Managing) (NP (DT the) (NN Patient)) (PP (IN With) (NP (NP (NNP ABRS)) (SBAR (WHNP (WP Who)) (S (VP (VBZ Has) (S (NP (NNP Failed)) (VP (TO to) (VP (VB Respond) (PP (TO to) (NP (NP (NNP Empiric) (NNP Treatment)) (PP (IN With) (NP (DT Both) (NP (NN First-line)) (CC and) (NP (JJ Second-line) (NNS Agents))))))))))))))))) (, ,) (NP (PRP It)) (VP (VBZ Is) (ADJP (JJ Important)) (S (VP (TO to) (VP (VB Obtain) (NP (NNS Cultures)) (PP (TO to) (NP (NNP Document) (NNP Whether)))))) (SBAR (S (NP (EX There)) (VP (VBZ Is) (NP (NP (JJ Persistent) (JJ Bacterial) (NN Infection)) (CC and) (SBAR (IN Whether) (S (NP (JJ Resistant) (NNS Pathogens)) (VP (VBP Are) (ADJP (JJ Present)))))))))) (. .)))
(ROOT (SQ (PP (IN In) (NP (JJ Such) (NNS Patients))) (, ,) (MD Should) (NP (NNS Cultures)) (VP (VB Be) (VP (VBN Obtained) (PP (IN by) (NP (NP (NP (NN Sinus) (NN Puncture)) (CC or) (NP (NNP Endoscopy))) (, ,) (CC or) (VP (VBP Are) (NP (NP (NNS Cultures)) (PP (IN of) (NP (NNP Nasopharyngeal) (NNP Swabs) (NNP Sufficient))))))))) (. ?)))
(ROOT (NP (CD 21) (. .)))
(ROOT (S (NP (PRP It)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (NP (NNS cultures)) (VP (VB be) (VP (VBN obtained) (PP (IN by) (NP (NP (JJ direct) (NN sinus) (NN aspiration)) (CONJP (RB rather) (IN than)) (PP (IN by) (NP (NP (JJ nasopharyngeal) (NN swab)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (VBN suspected) (NN sinus) (NN infection))) (SBAR (WHNP (WP who)) (S (VP (VBP have) (VP (VBN failed) (S (VP (TO to) (VP (VB respond) (PP (TO to) (NP (NP (JJ empiric) (JJ antimicrobial) (NN therapy)) (PRN (-LRB- -LRB-) (ADJP (JJ strong) (, ,) (JJ moderate)) (-RRB- -RRB-))))))))))))))))))))))) (. .)))
(ROOT (NP (CD 22) (. .)))
(ROOT (S (NP (NP (ADJP (RB Endoscopically) (VBN guided)) (NNS cultures)) (PP (IN of) (NP (DT the) (JJ middle) (NN meatus)))) (VP (MD may) (VP (VB be) (VP (VBN considered) (PP (IN as) (NP (NP (DT an) (NN alternative)) (PP (IN in) (NP (NNS adults)))))))) (, ,) (CC but) (S (NP (NP (PRP$ their) (NN reliability)) (PP (IN in) (NP (NNS children)))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN established) (PRN (-LRB- -LRB-) (ADJP (JJ weak) (, ,) (JJ moderate)) (-RRB- -RRB-)))))) (. .)))
(ROOT (NP (CD 23) (. .)))
(ROOT (S (NP (JJ Nasopharyngeal) (NNS cultures)) (VP (VP (VBP are) (ADJP (JJ unreliable))) (CC and) (VP (VBP are) (RB not) (VP (VBN recommended) (PP (IN for) (NP (NP (DT the) (JJ microbiologic) (NN diagnosis)) (PP (IN of) (NP (NP (NN ABRS)) (PRN (-LRB- -LRB-) (ADJP (ADJP (JJ strong)) (, ,) (ADJP (JJ high))) (-RRB- -RRB-))))))))) (. .)))
(ROOT (NP (NN XVII) (. .)))
(ROOT (WHNP (WDT Which) (NNP Imaging) (NNP Technique) (SQ (VBZ Is) (NP (JJS Most)) (ADJP (JJ Useful) (PP (IN for) (NP (NP (NNS Patients)) (PP (IN With) (NP (NP (JJ Severe) (NNS ABRS)) (SBARQ (WHNP (WP Who)) (SQ (VP (VBP Are) (VP (VBN Suspected) (S (VP (TO to) (VP (VB Have) (NP (NP (JJ Suppurative) (NNS Complications)) (ADJP (JJ Such) (PP (IN as) (NP (NP (NP (NNP Orbital)) (CC or) (NP (JJ Intracranial) (NNP Extension))) (PP (IN of) (NP (NN Infection)))))))))))))))))))) (. ?)))
(ROOT (NP (CD 24) (. .)))
(ROOT (FRAG (PP (IN In) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NN ABRS)) (VP (VBN suspected) (S (VP (TO to) (VP (VB have) (NP (NP (JJ suppurative) (NNS complications)) (, ,) (ADVP (NP (NP (ADJP (JJ axial) (CC and) (JJ coronal)) (NNS views)) (PP (IN of) (NP (NP (JJ contrast-enhanced) (JJ computed) (NN tomography)) (PRN (-LRB- -LRB-) (NP (NN CT)) (-RRB- -RRB-))))) (RB rather) (SBAR (IN than) (S (NP (NP (JJ magnetic) (NN resonance) (NN imaging)) (PRN (-LRB- -LRB-) (NP (NNP MRI)) (-RRB- -RRB-))) (VP (VBZ is) (VP (VBN recommended) (S (VP (VP (TO to) (VP (VB localize) (NP (DT the) (NN infection)))) (CC and) (VP (TO to) (VP (VB guide) (NP (NP (JJ further) (NN treatment)) (PRN (-LRB- -LRB-) (ADJP (ADJP (JJ weak)) (, ,) (ADJP (JJ low))) (-RRB- -RRB-))))))))))))))))))))) (. .)))
(ROOT (NP (NNP XVIII) (. .)))
(ROOT (SBARQ (WHADVP (WRB When)) (SQ (SQ (VBZ Is) (NP (NN Referral)) (PP (TO to) (NP (DT a) (NNP Specialist) (NNP Indicated)))) (PP (IN in) (NP (DT a) (NN Patient))) (PP (IN With) (NP (VBN Presumed) (NNS ABRS)))) (. ?)))
(ROOT (NP (CD 25) (. .)))
(ROOT (S (NP (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (VP (VBP are) (ADJP (ADVP (RB seriously)) (JJ ill) (CC and) (JJ immunocompromised))))) (, ,)) (VP (VBP continue) (S (VP (TO to) (VP (VB deteriorate) (ADVP (RB clinically)) (SBAR (IN despite) (S (NP (NP (JJ extended) (NNS courses)) (PP (IN of) (NP (NP (JJ antimicrobial) (NN therapy)) (, ,) (CC or) (VP (VBP have) (NP (NP (JJ recurrent) (NNS bouts)) (PP (IN of) (NP (JJ acute) (NN rhinosinusitis)))) (PP (IN with) (NP (NP (NN clearing)) (PP (IN between) (NP (NNS episodes))))))))) (VP (MD should) (VP (VB be) (VP (VBN referred) (PP (TO to) (NP (NP (DT a) (NN specialist)) (PRN (-LRB- -LRB-) (PP (JJ such) (IN as) (NP (NP (DT an) (NN otolaryngologist)) (, ,) (NP (JJ infectious) (NN disease) (NN specialist)) (, ,) (CC or) (NP (NN allergist)))) (-RRB- -RRB-)))) (PP (IN for) (NP (NN consultation)))))))))))) (. .)))
(ROOT (S (SBAR (IN As) (S (NP (DT this)) (VP (VBZ is) (NP (NP (DT a) (`` ``) (JJ good) (JJ clinical) (NN practice) ('' '') (NN statement)) (CONJP (RB rather) (IN than)) (NP (DT a) (NN recommendation)))))) (, ,) (NP (PRP it)) (VP (VBZ is) (RB not) (ADVP (JJ further)) (VP (VBN graded))) (. .)))
(ROOT (S (PP (IN Throughout) (NP (DT this) (NN guideline))) (, ,) (NP (DT the) (NN term) (NN rhinosinusitis)) (VP (VBZ is) (VP (VBN used) (ADVP (RB interchangeably)) (PP (IN with) (NP (NN sinusitis))))) (. .)))
(ROOT (S (SBAR (IN Because) (S (NP (DT the) (JJ nasal) (NN mucosa)) (VP (VBZ is) (ADJP (JJ contiguous) (PP (IN with) (NP (NP (DT that)) (PP (IN of) (NP (DT the) (JJ paranasal) (NNS sinuses))))))))) (, ,) (NP (NP (DT any) (NN inflammation)) (PP (IN of) (NP (DT the) (NNS sinuses)))) (VP (VBZ is) (ADVP (RB almost) (RB always)) (VP (VBN accompanied) (PP (IN by) (NP (NP (NN inflammation)) (PP (IN of) (NP (DT the) (NP (NP (JJ nasal) (NN cavity)) (PRN (-LRB- -LSB-) (NP (NP (CD 7)) (, ,) (NP (CD 8))) (-RRB- -RSB-))))))))) (. .)))
(ROOT (S (NP (NNP Rhinosinusitis)) (VP (VBZ is) (NP (DT an) (ADJP (RB extremely) (JJ common)) (NN condition))) (. .)))
(ROOT (S (PP (IN In) (NP (NP (DT a) (JJ national) (NN health) (NN survey)) (VP (VBN conducted) (PP (IN during) (NP (CD 2008)))))) (, ,) (NP (NP (QP (RB nearly) (CD 1))) (PP (IN in) (NP (NP (CD 7) (PRN (-LRB- -LRB-) (NP (CD 13.4) (NN %)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (DT all) (JJ noninstitutionalized) (NNS adults)) (NP (JJ aged) (NN ≥) (CD 18) (NNS years))))))) (VP (VBD were) (VP (VBN diagnosed) (PP (IN with) (NP (NP (NN rhinosinusitis)) (PP (IN within) (NP (DT the) (JJ previous) (CD 12) (NNS months))))) (PRN (-LRB- -LSB-) (NP (CD 9)) (-RRB- -RSB-)))) (. .)))
(ROOT (S (NP (NP (NN Incidence) (NNS rates)) (PP (IN among) (NP (NNS adults)))) (VP (VBP are) (ADJP (ADJP (JJR higher)) (PP (IN for) (NP (NP (NNS women)) (PP (IN than) (NP (NP (NNS men)) (PRN (-LRB- -LRB-) (NP (CD ∼) (JJ 1.9-fold)) (-RRB- -RRB-)))))) (, ,) (CC and) (SBAR (S (NP (NP (NNS adults)) (PP (IN between) (NP (NP (CD 45)) (CC and) (NP (CD 74) (NNS years))))) (VP (VBP are) (VP (ADVP (RBS most) (RB commonly)) (PRN (VBN affected) (PRN (-LRB- -LSB-) (NP (CD 9)) (-RRB- -RSB-))))))))) (. .)))
(ROOT (S (NP (JJ Acute) (NN rhinosinusitis)) (VP (VBZ is) (VP (VBN defined) (PP (IN as) (S (NP (NP (DT an) (NN inflammation)) (PP (IN of) (NP (NP (DT the) (JJ mucosal) (NN lining)) (PP (IN of) (NP (NP (DT the) (JJ nasal) (NN passage)) (CC and) (NP (JJ paranasal) (NNS sinuses))))))) (VP (VBG lasting) (PP (RP up) (PP (TO to) (NP (CD 4) (NNS weeks))))))))) (. .)))
(ROOT (S (NP (PRP It)) (VP (MD can) (VP (VB be) (VP (VBN caused) (PP (IN by) (NP (NP (JJ various) (VBG inciting) (NNS factors)) (PP (VBG including) (NP (NP (NP (NNS allergens)) (, ,) (NP (JJ environmental) (NNS irritants)) (, ,) (CC and) (NP (NP (NN infection)) (PP (IN by) (NP (NNS viruses))))) (, ,) (NP (NNS bacteria)) (, ,) (CC or) (NP (NNS fungi))))))))) (. .)))
(ROOT (S (NP (NP (DT A) (JJ viral) (NN etiology)) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (NNP URI)) (CC or) (NP (DT the) (JJ common) (NN cold)))))) (VP (VBZ is) (NP (NP (DT the) (ADJP (RBS most) (JJ frequent)) (NN cause)) (PP (IN of) (NP (JJ acute) (NN rhinosinusitis))))) (. .)))
(ROOT (S (NP (NP (JJ Prospective) (JJ longitudinal) (NNS studies)) (VP (VBN performed) (PP (IN in) (NP (NP (JJ young) (NNS children)) (PRN (-LRB- -LRB-) (NP (CD 6) (PRN (: --) (NP (NP (CD 35) (NNS months)) (PP (IN of) (NP (NN age)))))) (-RRB- -RRB-)))))) (VP (VBD revealed) (SBAR (IN that) (S (NP (JJ viral) (NN URI)) (VP (VBZ occurs) (PP (IN with) (NP (NP (NP (DT an) (NN incidence)) (PP (IN of) (NP (NP (CD 6) (NNS episodes)) (PP (IN per) (NP (JJ patient-year)))))) (PRN (-LRB- -LSB-) (NP (CD 10)) (-RRB- -RSB-)))))))) (. .)))
(ROOT (S (PP (IN In) (NP (NNS adults))) (, ,) (NP (DT the) (NN incidence)) (VP (VBZ is) (VP (VBN estimated) (S (VP (TO to) (VP (VB be) (NP (NP (CD 2)) (: --) (NP (NP (NP (CD 3) (NNS episodes)) (PP (IN per) (NP (NN year)))) (PRN (-LRB- -LSB-) (NP (CD 11)) (-RRB- -RSB-))))))))) (. .)))
(ROOT (S (NP (NP (JJ Secondary) (JJ bacterial) (NN infection)) (PP (IN of) (NP (DT the) (JJ paranasal) (NNS sinuses))) (PP (VBG following) (NP (DT an) (JJ antecedent) (JJ viral) (NNP URI)))) (VP (VP (VBZ is) (ADJP (RB relatively) (JJ uncommon))) (, ,) (VP (VBN estimated) (S (VP (TO to) (VP (VB be) (NP (CD 0.5) (NN %)))))) (: --) (NP (NP (NP (NP (CD 2) (NN %)) (PP (IN of) (NP (NP (JJ adult) (NNS cases)) (PRN (-LRB- -LSB-) (NP (NP (CD 12)) (, ,) (NP (CD 13))) (-RRB- -RSB-))))) (CC and) (NP (NP (QP (RB approximately) (CD 5)) (NN %)) (PP (IN in) (NP (NNS children))))) (PRN (-LRB- -LSB-) (NP (CD 14)) (-RRB- -RSB-)))) (. .)))
(ROOT (S (NP (NP (DT The) (NN prevalence)) (PP (IN of) (NP (DT a) (JJ bacterial) (NN infection))) (PP (IN during) (NP (JJ acute) (NN rhinosinusitis)))) (VP (VBZ is) (VP (VBN estimated) (S (VP (TO to) (VP (VB be) (NP (NP (CD 2) (NN %)) (: --) (NP (CD 10) (NN %)) (, ,))))) (SBAR (IN whereas) (S (NP (JJ viral) (NNS causes)) (VP (VBP account) (PP (IN for) (NP (NP (CD 90) (NN %)) (: --) (NP (NP (CD 98) (NN %)) (PRN (-LRB- -LSB-) (NP (CD 12)) (-RRB- -RSB-)))))))))) (. .)))
(ROOT (S (PP (IN Despite) (NP (DT this))) (, ,) (NP (NNS antibiotics)) (VP (VBP are) (ADVP (RB frequently)) (VP (VBN prescribed) (PP (IN for) (NP (NP (NNS patients)) (VP (VBG presenting) (PP (IN with) (NP (NP (NNS symptoms)) (PP (IN of) (NP (JJ acute) (NN rhinosinusitis)))))))) (, ,) (S (VP (VBG being) (NP (NP (NP (NP (DT the) (JJ fifth) (VBG leading) (NN indication)) (PP (IN for) (NP (JJ antimicrobial) (NNS prescriptions)))) (PP (IN by) (NP (NP (NNS physicians)) (PP (IN in) (NP (NN office) (NN practice)))))) (PRN (-LRB- -LSB-) (NP (CD 15)) (-RRB- -RSB-))))))) (. .)))
(ROOT (NP (NP (NP (DT The) (JJ total) (JJ direct) (NN healthcare)) (SBAR (S (NP (NNS costs) (VP (VBN attributed) (PP (TO to) (NP (NP (DT a) (JJ primary) (JJ medical) (NN diagnosis)) (PP (IN of) (NP (NN sinusitis))))) (PP (IN in) (NP (CD 1996))))) (VP (VBD were) (VP (VBN estimated) (S (VP (TO to) (VP (VB exceed) (NP (NP (QP ($ $) (CD 3) (CD billion))) (PP (IN per) (NP (NN year)))) (PRN (-LRB- -LSB-) (NP (CD 16)) (-RRB- -RSB-)))))))))) (. .)))
(ROOT (S (NP (NP (DT A) (JJ recent) (JJ national) (NN survey)) (PP (IN of) (NP (JJ antibiotic) (NNS prescriptions))) (PP (IN for) (NP (NP (NNP URI)) (PP (IN in) (NP (DT the) (NN outpatient) (NN setting)))))) (VP (VBD showed) (SBAR (IN that) (S (NP (NNS antibiotics)) (VP (VBD were) (VP (VBN prescribed) (PP (IN for) (NP (NP (CD 81) (NN %)) (PP (IN of) (NP (NP (NNS adults)) (PP (IN with) (NP (JJ acute) (NN rhinosinusitis))))))) (PRN (-LRB- -LSB-) (NP (CD 17) (, ,) (CD 18) (-RRB- -RSB-))) (, ,) (PP (IN despite) (NP (DT the) (NN fact) (SBAR (IN that) (S (NP (NP (QP (RB approximately) (CD 70)) (NN %)) (PP (IN of) (NP (NNS patients)))) (VP (VBP improve) (ADVP (RB spontaneously)) (PP (IN in) (ADJP (JJ placebo-controlled) (S (VP (VBN randomized) (NP (NP (JJ clinical) (NNS trials)) (PRN (-LRB- -LSB-) (NP (CD 18)) (-RRB- -RSB-))))))))))))))))) (. .)))
(ROOT (S (ADVP (RB Thus)) (, ,) (NP (NP (NN overprescription)) (PP (IN of) (NP (NNS antibiotics)))) (VP (VBZ is) (NP (NP (DT a) (JJ major) (NN concern)) (PP (IN in) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (JJ acute) (NN rhinosinusitis)))))) (, ,) (PP (ADVP (RB largely)) (JJ due) (PP (TO to) (NP (NP (DT the) (NN difficulty)) (PP (IN in) (NP (VBG differentiating) (NNS ABRS)))))) (PP (IN from) (NP (DT a) (JJ viral) (NNP URI)))) (. .)))
(ROOT (S (S (VP (TO To) (VP (VB address) (NP (DT these) (NNS issues))))) (, ,) (NP (NP (JJ several) (NN practice) (NNS guidelines)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNS ABRS)))))) (S (VP (VBP have) (VP (VBN been) (VP (VBN published) (PP (IN by) (NP (NP (JJ various) (JJ professional) (NNS organizations)) (PP (IN in) (NP (NP (DT the) (NNP United) (NNPS States)) (CC and) (NP (NNP Canada)))))) (PP (IN within) (NP (DT the) (JJ past) (NN decade)))))) (, ,) (S (PP (VBG including) (NP (NP (DT the) (NNP American) (NNP College)) (PP (IN of) (NP (NP (NNP Physicians)) (PRN (-LRB- -LRB-) (NP (CD 2001)) (-RRB- -RRB-)))))) (PRN (-LRB- -LSB-) (NP (NP (CD 19)) (, ,) (NP (CD 20))) (-RRB- -RSB-)))) (PP (PRN (, ,) (NP (NP (NP (NP (DT the) (NNP American) (NNP Academy)) (PP (IN of) (NP (NP (NNP Pediatrics)) (PRN (-LRB- -LRB-) (NP (CD 2001)) (-RRB- -RRB-))))) (PRN (-LRB- -LSB-) (NP (CD 21)) (-RRB- -RSB-))) (, ,) (NP (NP (DT the) (NNP Rhinosinusitis) (NNP Initiative)) (-LRB- -LRB-) (NP (FRAG (VP (VBG representing) (NP (NP (DT the) (JJ American) (NN Academy)) (PP (IN of) (NP (NNP Allergy))))) (, ,) (NP (NNP Asthma) (CC and) (NNP Immunology))) (: ;) (NP (NP (DT the) (NNP American) (NNP Academy)) (PP (IN of) (NP (NNP Otolaryngic) (NNP Allergy)))) (: ;) (NP (NP (NP (DT the) (NNP American) (NNP College)) (PP (IN of) (NP (NNP Allergy)))) (, ,) (NP (NP (NNP Asthma)) (CC and) (NP (NNP Immunology)))) (: ;) (NP (NP (NP (DT the) (NNP American) (NNP Academy)) (PP (IN of) (NP (NNP Otolaryngology)))) (: --) (NP (NP (NP (NNP Head)) (CC and) (NP (NNP Neck) (NNP Surgery))) (PRN (-LRB- -LSB-) (NP (NN AAO-HNS)) (-RRB- -RSB-))))) (: ;)) (CC and) (NP (DT the) (JJ American) (NP (NNP Rhinologic) (NNP Society)))) (-RRB- -RRB-)) (NP (NP (NP (PRN (-LRB- -LRB-) (NP (CD 2004)) (-RRB- -RRB-)) (PRN (-LRB- -LSB-) (NP (CD 7)) (-RRB- -RSB-))) (, ,) (NP (NP (NP (DT the) (NN Sinus) (CC and) (NNP Allergy) (NNP Health) (NNP Partnership)) (PRN (-LRB- -LRB-) (NP (CD 2004)) (-RRB- -RRB-))) (PRN (-LRB- -LSB-) (NP (CD 22)) (-RRB- -RSB-))) (, ,)) (NP (NP (NP (DT the) (NNP Joint) (NNP Council)) (PP (IN of) (NP (NNP Allergy)))) (, ,) (NP (NP (NNP Asthma) (CC and) (NNP Immunology) (PRN (-LRB- -LRB-) (NP (CD 2005)) (-RRB- -RRB-))) (PRN (-LRB- -LSB-) (NP (CD 23)) (-RRB- -RSB-))) (, ,) (NP (NP (NP (DT the) (NNP Agency)) (PP (IN for) (NP (NNP Health) (NNP Care) (NNP Research) (CC and) (NNP Quality) (PRN (-LRB- -LRB-) (NP (CD 2005)) (-RRB- -RRB-))))) (PRN (-LRB- -LSB-) (NP (CD 24)) (-RRB- -RSB-))) (, ,) (CC and) (ADVP (ADVP (RBR more) (RB recently)) (PP (PP (IN by) (NP (DT the) (NN AAO-HNS) (-LRB- -LRB-) (CD 2007) (-RRB- -RRB-))) (NP (PRN (-LRB- -LSB-) (NP (CD 25)) (-RRB- -RSB-)) (, ,) (NP (NP (NP (NP (DT the) (NNP Institute)) (PP (IN for) (NP (NP (JJ Clinical) (NNPS Systems) (NN Improvement)) (PRN (-LRB- -LRB-) (NP (CD 2008)) (-RRB- -RRB-))))) (PRN (-LRB- -LSB-) (NP (CD 26)) (-RRB- -RSB-))) (, ,) (CC and) (NP (NP (DT the) (JJ Canadian) (NN Society)) (PP (IN of) (NP (NNP Otolaryngology))))) (: --) (NP (NP (NP (NNP Head)) (CC and) (NP (NP (NNP Neck) (NNP Surgery)) (PRN (-LRB- -LRB-) (NP (CD 2011)) (-RRB- -RRB-)))) (PRN (-LRB- -LSB-) (NP (CD 27)) (-RRB- -RSB-))))))))) (. .)))
(ROOT (S (NP (DT These) (NNS guidelines)) (VP (VBP offer) (NP (NP (VBG differing) (NNS opinions)) (VP (VBG regarding) (S (VP (CC both) (NP (NP (JJ clinical) (NNS criteria)) (PP (IN for) (S (VP (VBG initiating) (VP (JJ antimicrobial) (NP (NP (NP (NN therapy)) (CC and) (NP (NN choice))) (PP (IN of) (NP (JJ empiric) (JJ antimicrobial) (NNS regimens)))))))))))))) (. .)))
(ROOT (S (NP (DT The) (JJ current) (NN guideline)) (VP (VBD was) (VP (VBN developed) (PP (IN by) (NP (NP (NN IDSA)) (PP (IN with) (NP (DT a) (JJ multidisciplinary) (NN panel))))) (S (VP (TO to) (VP (VB address) (NP (NP (DT some)) (PP (IN of) (NP (NP (DT the) (ADJP (RBR more) (JJ controversial)) (NNS areas)) (PP (VBG concerning) (NP (NP (JJ initial) (JJ empiric) (NN management)) (PP (IN of) (NP (NP (NN ABRS)) (PP (IN in) (NP (DT both) (NNS children) (CC and) (NNS adults))))))))))))))) (. .)))
(ROOT (S (S (NP (NP (DT A) (JJ major) (NN area)) (PP (IN of) (NP (NN emphasis)))) (VP (VBZ includes) (S (VP (VBG identifying) (NP (NP (DT the) (JJ clinical) (NNS presentations)) (SBAR (WHNP (WDT that)) (S (ADVP (RB best)) (VP (VBP distinguish) (ADJP (JJ bacterial) (PP (IN from) (NP (JJ viral) (NN rhinosinusitis)))))))))))) (, ,) (CC and) (NP (NP (DT the) (NN selection)) (PP (IN of) (NP (JJ antimicrobial) (NNS regimens))) (PP (VBN based) (PP (IN on) (S (VP (VBG evolving) (NP (NP (JJ antibiotic) (NN susceptibility) (NNS profiles)) (PP (IN of) (NP (JJ recent) (JJ respiratory) (NNS pathogens)))) (PP (IN in) (NP (DT the) (NNP United) (NNPS States)))))))) (. .)))
(ROOT (S (NP (NP (DT The) (JJ primary) (NN goal)) (PP (IN of) (NP (DT this) (NN guideline)))) (VP (VBZ is) (S (VP (TO to) (VP (VB improve) (NP (NP (DT the) (JJ appropriate) (NN use)) (PP (IN of) (NP (NP (JJ first-line) (NNS antibiotics)) (PP (IN for) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (DT a) (JJ presumptive) (NN diagnosis)) (PP (IN of) (NP (NN ABRS)))))))))))))) (. .)))
(ROOT (S (NP (DT The) (JJ secondary) (NNS goals)) (VP (VBP are) (S (VP (VP (TO to) (VP (VB reduce) (NP (NP (ADJP (JJ excessive) (CC or) (JJ inappropriate)) (NN use)) (PP (IN of) (NP (JJ antimicrobial) (NNS agents))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ acute) (JJ viral) (NN rhinosinusitis)) (CC or) (NP (JJ self-limited) (JJ bacterial) (NN infection))))))))) (, ,) (CC and) (VP (TO to) (VP (VB deter) (NP (NP (DT the) (NN emergence)) (PP (IN of) (NP (JJ antibiotic) (NN resistance))) (PP (IN among) (NP (JJ respiratory) (NNS pathogens))))))))) (. .)))
(ROOT (S (NP (DT The) (NN guideline)) (VP (VBZ is) (ADVP (RB primarily)) (VP (VBN intended) (PP (IN for) (NP (NP (NP (JJ primary) (NN care) (NNS physicians)) (PP (IN in) (NP (NN community)))) (CC and) (NP (DT the) (NN emergency) (NN department) (NNS settings)) (, ,) (PP (VBG including) (NP (NN family) (NNS practitioners))) (, ,) (NP (NNS internists)) (, ,) (NP (NNS pediatricians)) (, ,) (CC and) (NP (NN emergency) (NNS physicians)))))) (. .)))
(ROOT (S (NP (DT The) (VBN expanded) (NN audience)) (VP (VBZ includes) (NP (NP (JJ infectious) (NN disease) (NNS specialists)) (, ,) (NP (NNS otolaryngologists)) (, ,) (NP (NNS allergists)) (, ,) (CC and) (NP (NP (NN head)) (CC and) (NP (NN neck) (NNS surgeons))))) (. .)))
(ROOT (S (NP (PRP It)) (VP (VBZ is) (ADVP (RB also)) (SBAR (IN among) (S (NP (DT the) (JJ first) (NNP IDSA) (JJ clinical) (NN practice) (NNS guidelines)) (VP (TO to) (VP (VB adopt) (NP (DT the) (NN GRADE) (NN system)) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NN quality)) (PP (IN of) (NP (NP (NN evidence)) (CC and) (NP (NP (NN strength)) (PP (IN of) (NP (NP (NNS recommendations)) (PRN (-LRB- -LSB-) (NP (NP (NP (CD 1)) (: --) (NP (CD 6))) (-RRB- -RSB-) (PRN (-LRB- -LRB-) (NNP Table) (LST (LS 1)) (-RRB- -RRB-)))))))))))))))))) (. .)))
(ROOT (PP (DT The) (VBG following) (SBAR (S (NP (CD 18) (JJ clinical) (NNS questions)) (VP (VBP are) (VP (VBN addressed) (PP (IN in) (NP (DT this) (NN guideline))))))) (: :)))
(ROOT (FRAG (NP (NP (NN I.)) (SBAR (WHNP (WDT Which) (JJ clinical) (NNS presentations)) (S (ADVP (RB best)) (VP (VBP identify) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ acute) (JJ bacterial)) (CC vs) (NP (ADJP (JJ viral))) (NP (NN rhinosinusitis))))))))) (. ?)))
(ROOT (NP (NNP II) (. .)))
(ROOT (SBARQ (WHADVP (WRB When)) (SQ (MD should) (NP (JJ empiric) (JJ antimicrobial) (NN therapy)) (VP (VB be) (VP (VBN initiated) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNS signs) (CC and) (NNS symptoms)) (ADJP (JJ suggestive) (PP (IN of) (NP (NNP ABRS))))))))))) (. ?)))
(ROOT (NP (NNP III) (. .)))
(ROOT (SQ (MD Should) (NP (NP (NNP amoxicillin)) (CC vs) (NP (JJ amoxicillin-clavulanate))) (VP (VB be) (VP (VBN used) (PP (IN for) (NP (NP (JJ initial) (JJ empiric) (JJ antimicrobial) (NN therapy)) (PP (IN of) (NP (NP (NN ABRS)) (PP (IN in) (NP (NNS children))))))))) (. ?)))
(ROOT (NP (CD IV) (. .)))
(ROOT (SQ (MD Should) (NP (NP (NNP amoxicillin)) (CC vs) (NP (JJ amoxicillin-clavulanate))) (VP (VB be) (VP (VBN used) (PP (IN for) (NP (NP (NP (JJ initial) (JJ empiric) (JJ antimicrobial) (NN therapy)) (PP (IN of) (NP (NN ABRS)))) (PP (IN in) (NP (NNS adults))))))) (. ?)))
(ROOT (NP (NN V) (. .)))
(ROOT (SBARQ (WHADVP (WRB When)) (SQ (VBZ is) (NP (`` ``) (JJ high-dose) ('' '') (ADJP (JJ amoxicillin-clavulanate) (S (VP (VBN recommended) (PP (IN during) (NP (NP (JJ initial) (JJ empiric) (JJ antimicrobial) (NN therapy)) (PP (IN for) (NP (NP (NNS ABRS)) (PP (IN in) (NP (NP (NNS children)) (CC or) (NP (NNS adults))))))))))))) (. ?)))
(ROOT (NP (NNP VI) (. .)))
(ROOT (SQ (MD Should) (NP (NP (DT a) (ADJP (JJ respiratory) (JJ fluoroquinolone)) (CC vs)) (SBAR (S (NP (DT a) (JJ β-lactam) (NN agent)) (VP (VB be) (VP (VBN used) (PP (IN as) (NP (NP (JJ first-line) (JJ initial) (JJ empiric) (JJ antimicrobial) (NN therapy)) (PP (IN of) (NP (NNP ABRS)))))))))) (. ?)))
(ROOT (NP (NN VII) (. .)))
(ROOT (SQ (PP (IN Besides) (NP (NP (DT a) (NN β-lactam)) (CC or) (NP (DT a) (JJ respiratory) (JJ fluoroquinolone)))) (, ,) (MD should) (NP (NP (DT a) (NN macrolide)) (, ,) (NP (NN TMP/SMX)) (, ,) (NP (NN doxycycline)) (, ,) (CC or) (NP (DT a) (JJ second) (: -) (CC or) (JJ third-generation) (JJ oral) (NN cephalosporin))) (VP (VB be) (VP (VBN used) (PP (IN as) (NP (NP (DT an) (JJ alternative) (NN regimen)) (PP (IN for) (NP (NP (DT the) (JJ initial) (JJ empiric) (NN treatment)) (PP (IN of) (NP (NP (NN ABRS)) (PP (IN in) (NP (NP (NNS children)) (CC or) (NP (NNS adults)))))))))))) (. ?)))
(ROOT (NP (CD VIII) (. .)))
(ROOT (SBARQ (WHNP (WDT Which) (JJ antimicrobial) (NNS regimens)) (SQ (VBP are) (VP (VBN recommended) (PP (IN for) (NP (NP (DT the) (JJ empiric) (NN treatment)) (PP (IN of) (NP (NP (NN ABRS)) (PP (IN in) (NP (NP (NNS children)) (CC and) (NP (NNS adults)))))) (PP (IN with) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NN penicillin) (NN allergy))))))))) (. ?)))
(ROOT (NP (CD IX) (. .)))
(ROOT (SQ (MD Should) (NP (NP (NN coverage)) (PP (IN for) (NP (NP (FW S.) (FW aureus)) (PRN (-LRB- -LRB-) (NP (RB especially) (NNP MRSA)) (-RRB- -RRB-))))) (VP (VB be) (VP (VBN provided) (ADVP (RB routinely)) (PP (IN during) (NP (NP (JJ initial) (JJ empiric) (NN therapy)) (PP (IN of) (NP (NNP ABRS))))))) (. ?)))
(ROOT (S (NP (NNP X.)) (VP (MD Should) (VP (VB empiric) (S (NP (NP (JJ antimicrobial) (NN therapy)) (PP (IN for) (NP (NNP ABRS)))) (VP (VB be) (VP (VBN administered) (PP (IN for) (NP (CD 5) (PRN (: --) (NP (NP (CD 7) (NNS days)) (CC vs) (NP (CD 10))) (: --))))) (NP (CD 14) (NNS days)))))) (. ?)))
(ROOT (NP (NN XI) (. .)))
(ROOT (SQ (VBZ Is) (NP (NP (NN saline) (NN irrigation)) (PP (IN of) (NP (NP (DT the) (JJ nasal) (NNS sinuses)) (PP (IN of) (NP (NN benefit)))))) (PP (IN as) (NP (NP (JJ adjunctive) (NN therapy)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN ABRS))))))) (. ?)))
(ROOT (NP (NNP XII) (. .)))
(ROOT (SQ (VBP Are) (NP (JJ intranasal) (NNS corticosteroids)) (VP (VBD recommended) (PP (IN as) (NP (NP (DT an) (NN adjunct)) (PP (TO to) (NP (NP (JJ antimicrobial) (NN therapy)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN ABRS)))))))))) (. ?)))
(ROOT (NP (NN XIII) (. .)))
(ROOT (SQ (MD Should) (NP (ADJP (ADJP (JJ topical)) (CC or) (ADJP (JJ oral))) (NNS decongestants) (CC or) (NNS antihistamines)) (VP (VB be) (VP (VBN used) (PP (IN as) (NP (NP (JJ adjunctive) (NN therapy)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN ABRS))))))))) (. ?)))
(ROOT (NP (NNP XIV) (. .)))
(ROOT (SBARQ (WHADVP (WRB How) (RB long)) (SQ (MD should) (NP (NP (JJ initial) (JJ empiric) (JJ antimicrobial) (NN therapy)) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (JJ clinical) (NN improvement)))))) (VP (VB be) (VP (VBN continued) (PP (IN before) (S (VP (VBG considering) (NP (JJ alternative) (NN management) (NNS strategies)))))))) (. ?)))
(ROOT (NP (NN XV) (. .)))
(ROOT (SBARQ (WHNP (WP What)) (SQ (VBZ is) (NP (NP (DT the) (VBN recommended) (NN management) (NN strategy)) (PP (IN in) (NP (NNS patients))) (SBAR (WHNP (WP who)) (S (VP (ADVP (RB clinically)) (VBP worsen) (PP (IN despite) (NP (NP (CD 72) (NNS hours)) (CC or) (VP (VBP fail) (S (VP (TO to) (VP (VB improve) (PP (IN after) (NP (NP (CD 3)) (: --) (NP (NP (QP (CD 5) (NNS days))) (PP (IN of) (NP (NP (JJ initial) (JJ empiric) (JJ antimicrobial) (NN therapy)) (PP (IN with) (NP (DT a) (JJ first-line) (NN regimen))))))))))))))))))) (. ?)))
(ROOT (NP (NNP XVI) (. .)))
(ROOT (S (PP (IN In) (S (VP (VBG managing) (NP (NP (NP (DT the) (NN patient)) (PP (IN with) (NP (NNS ABRS)))) (SBAR (WHNP (WP who)) (S (VP (VBZ has) (VP (VBN failed) (S (VP (TO to) (VP (VB respond) (PP (TO to) (NP (NP (JJ empiric) (NN treatment)) (PP (IN with) (NP (ADJP (CC both) (ADJP (JJ first-line)) (CC and) (ADJP (JJ second-line))) (NNS agents)))))))))))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (ADJP (JJ important)) (S (VP (TO to) (VP (VB obtain) (NP (NNS cultures)) (S (VP (TO to) (VP (VB document) (SBAR (SBAR (IN whether) (S (NP (EX there)) (VP (VBZ is) (NP (ADJP (ADJP (JJ persistent)) (ADJP (JJ bacterial))) (NN infection))))) (CC and) (SBAR (IN whether) (S (NP (JJ resistant) (NNS pathogens)) (VP (VBP are) (ADJP (JJ present))))))))))))) (. .)))
(ROOT (SQ (PP (IN In) (NP (JJ such) (NNS patients))) (, ,) (MD should) (NP (NNS cultures)) (VP (VB be) (VP (VBN obtained) (PP (IN by) (NP (NP (NP (NN sinus) (NN puncture)) (CC or) (NP (NN endoscopy))) (, ,) (CC or) (SQ (MD will) (NP (NP (NNS cultures)) (PP (IN from) (NP (JJ nasopharyngeal) (NNS swabs)))) (VP (VBP suffice))))))) (. ?)))
(ROOT (NP (NN XVII) (. .)))
(ROOT (SBARQ (WHNP (WDT Which) (NN imaging) (NN technique)) (SQ (VBZ is) (ADJP (RBS most) (JJ useful) (PP (IN for) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ severe) (NNS ABRS))) (SBAR (WHNP (WP who)) (S (VP (VBP are) (VP (VBN suspected) (S (VP (TO to) (VP (VB have) (NP (NP (JJ suppurative) (NNS complications)) (PP (JJ such) (IN as) (NP (NP (NP (ADJP (JJ orbital))) (CC or) (NP (ADJP (JJ intracranial))) (NP (NN extension))) (PP (IN of) (NP (NN infection))))))))))))))))) (. ?)))
(ROOT (NP (NNP XVIII) (. .)))
(ROOT (FRAG (SBAR (WHADVP (WRB When)) (S (NP (NP (MD should) (NN referral)) (PP (TO to) (NP (DT a) (NN specialist)))) (VP (VB be) (VP (VBN considered) (PP (IN in) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (JJ presumed) (NNS ABRS))))))))))) (. ?)))
(ROOT (S (NP (DT This) (NN guideline)) (VP (VBD was) (VP (VBN prompted) (PP (IN by) (NP (NP (NP (DT a) (NN number)) (PP (IN of) (NP (JJ therapeutic) (NNS dilemmas)))) (VP (ADVP (RB commonly)) (VBN encountered) (PP (IN by) (NP (NP (NNS physicians)) (SBAR (WHNP (WP who)) (S (VP (VBP provide) (NP (JJ primary) (NN care)) (PP (TO to) (NP (NNS children) (CC and) (NNS adults))) (PP (IN with) (NP (NP (DT a) (JJ presumptive) (NN diagnosis)) (PP (IN of) (NP (NN ABRS))))))))))))))) (. .)))
(ROOT (S (NP (NP (DT The) (JJ gold) (NN standard)) (PP (IN for) (NP (NP (DT the) (NN diagnosis)) (PP (IN of) (NP (NN ABRS)))))) (VP (VBZ is) (NP (NP (DT the) (NN recovery)) (PP (IN of) (NP (NP (NNS bacteria)) (PP (IN in) (NP (NP (NP (JJ high) (NN density)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD ≥) (CD 10)) (NN ^) (CD 4) (JJ colony-forming) (NNS units)) (PP (IN per) (NP (NN milliliter)))) (-RRB- -RRB-))) (PP (IN from) (NP (NP (DT the) (NN cavity)) (PP (IN of) (NP (NP (DT a) (JJ paranasal) (NN sinus)) (PRN (-LRB- -LSB-) (NP (NP (CD 7)) (, ,) (NP (CD 12)) (, ,) (NP (CD 13))) (-RRB- -RSB-)))))))))))) (. .)))
(ROOT (S (S (NP (NN Failure) (S (VP (TO to) (VP (VP (ADVP (RB adequately)) (VB decontaminate) (NP (DT the) (JJ paranasal) (NN mucosa)) (PP (IN during) (NP (NN sinus) (NN aspiration)))) (CC or) (VP (TO to) (VP (VB quantify) (NP (DT any) (JJ bacterial) (NNS isolates)) (PP (IN in) (NP (DT the) (NN aspirate))))))))) (VP (VBP are) (NP (NP (DT the) (ADJP (RBS most) (JJ common)) (NNS pitfalls)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (NN misinterpretation)) (PP (IN of) (NP (NNS results))))) (PRN (-LRB- -LRB-) (ADVP (FW ie)) (, ,)) (S (VP (VBG assuming) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN infection)))) (SBAR (WHADVP (WRB when)) (S (ADVP (RB actually)) (NP (DT the) (NNS bacteria)) (VP (VBD recovered) (VP (VBP represent) (NP (NP (NNS contaminants)) (VP (VBN derived) (PP (IN from) (NP (DT the) (NN nose)))))))))))))))))) (-RRB- -RRB-) (. .)))
(ROOT (S (S (VP (VBG Using) (NP (DT this) (NN definition)))) (, ,) (NP (NP (JJ several) (NNS investigators)) (PRN (-LRB- -LSB-) (NP (NP (CD 28)) (: --) (NP (CD 30))) (-RRB- -RSB-))) (VP (VP (VBP have) (VP (VBN confirmed) (NP (NP (DT the) (NN diagnosis)) (PP (IN of) (NP (NN ABRS)))) (PP (IN in) (NP (CC both) (NP (NNS adults)) (CC and) (NP (NNS children)))))) (CC and) (VP (VBD validated) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (JJ appropriate) (JJ antimicrobial) (NN therapy)) (PP (IN in) (S (VP (VBG eradicating) (NP (JJ bacterial) (NNS pathogens)) (PP (IN from) (NP (DT the) (JJ paranasal) (NNS sinuses))))))))) (PRN (-LRB- -LSB-) (NP (CD 12)) (-RRB- -RSB-)))) (. .)))
(ROOT (S (ADVP (RB Furthermore)) (, ,) (NP (NN treatment) (NN failure)) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (NP (DT the) (NN recovery)) (PP (IN of) (NP (JJ antibiotic-resistant) (NNS pathogens)))) (PRN (-LRB- -LSB-) (NP (CD 29)) (-RRB- -RSB-)))))) (. .)))
(ROOT (S (ADVP (RB However)) (, ,) (NP (NN sinus) (NN aspiration)) (VP (VBZ is) (NP (NP (DT an) (JJ invasive) (, ,) (JJ time-consuming) (, ,) (CC and) (ADJP (RB potentially) (JJ painful)) (NN procedure)) (SBAR (WHNP (WDT that)) (S (VP (VBZ does) (RB not) (VP (VB have) (NP (NN utility)) (PP (IN in) (NP (NP (DT the) (JJ daily) (NN practice)) (PP (IN of) (NP (JJ primary) (NN care) (NNS physicians))))))))))) (. .)))
(ROOT (SBAR (IN Although) (S (NP (EX there)) (VP (VBZ has) (VP (VBN been) (NP (NN interest)) (PP (IN in) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (ADJP (RB endoscopically) (VBN guided)) (NNS cultures)) (PP (IN of) (NP (DT the) (JJ middle) (NN meatus))))) (PP (IN as) (NP (NP (DT a) (NN surrogate)) (PP (IN for) (NP (NP (NN sinus) (NNS aspirates)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN ABRS))))))))))) (SBAR (S (PRN (-LRB- -LSB-) (NP (CD 31)) (-RRB- -RSB-)) (, ,) (NP (NP (NN performance)) (PP (IN of) (NP (JJ such) (NNS cultures)))) (VBZ is) (PP (IN beyond) (NP (NP (DT the) (NN scope)) (PP (IN of) (NP (JJS most) (JJ primary) (NN care) (NNS physicians))))) (, ,) (CC and) (S (NP (NP (PRP$ its) (NN validity)) (PP (IN in) (NP (NNS children)))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN established)))))))))) (. .)))
(ROOT (S (S (ADVP (RB Thus)) (, ,) (NP (NP (DT the) (NN diagnosis)) (PP (IN of) (NP (NN ABRS))) (PP (IN in) (NP (NP (JJS most) (VBN randomized) (NP (NP (JJ controlled) (NNS trials)) (PRN (-LRB- -LRB-) (NP (NNS RCTs)) (-RRB- -RRB-)))) (PP (IN of) (NP (JJ antimicrobial) (NN therapy)))))) (VP (VBZ is) (VP (VBN based) (PP (IN on) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (JJ compatible) (NNS symptoms)) (CC and) (NP (NP (NNS signs)) (PP (IN of) (NP (JJ acute) (NN rhinosinusitis)))))))))) (PRN (-LRB- -LRB-) (NNP Table) (LST (LS 2) (-RRB- -RRB-))) (PP (IN with) (NP (NP (JJ radiographic) (NN confirmation)) (PP (IN of) (NP (NN sinus) (NN involvement)))))) (. .)))
(ROOT (S (ADVP (RB Unfortunately)) (, ,) (NP (DT these) (JJ diagnostic) (NNS criteria)) (VP (VBP do) (RB not) (ADVP (RB adequately)) (VP (VB distinguish) (NP (JJ bacterial)) (PP (IN from) (NP (JJ viral) (NN infection))))) (. .)))
(ROOT (S (ADVP (RB Consequently)) (, ,) (NP (NP (DT a) (NN proportion)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBN enrolled) (PP (IN in) (NP (JJ such) (NNS trials))))))) (ADVP (RB likely)) (VP (VBD had) (NP (NP (DT a) (JJ viral) (NNP URI)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VP (VBZ is) (ADJP (JJ self-limited))) (CC and) (VP (MD would) (RB not) (VP (VB be) (VP (VBN expected) (S (VP (TO to) (VP (VB respond) (PP (TO to) (NP (JJ antimicrobial) (NN therapy)))))))))))))) (. .)))
(ROOT (S (NP (DT This) (NN limitation)) (VP (VBZ results) (PP (IN in) (NP (NP (NP (DT an) (NN underestimation)) (PP (IN of) (NP (NP (DT the) (JJ potential) (NN benefit)) (PP (IN of) (NP (JJ antimicrobial) (NN therapy)))))) (PRN (-LRB- -LSB-) (NP (CD 12)) (-RRB- -RSB-))))) (. .)))
(ROOT (S (NP (NP (NNP Imaging) (NNS studies)) (PP (JJ such) (IN as) (NP (NP (JJ plain) (NNS radiographs)) (CC or) (NP (NN CT))))) (VP (VBP are) (ADVP (RB frequently)) (VP (VBN used) (PP (IN by) (NP (NNS clinicians))) (PP (IN for) (NP (NP (DT the) (NN diagnosis)) (PP (IN of) (NP (NN ABRS))))))) (. .)))
(ROOT (S (ADVP (RB Unfortunately)) (, ,) (NP (DT these) (NNS studies)) (VP (VP (VBP are) (ADJP (JJ nonspecific))) (CC and) (VP (VBP do) (RB not) (VP (VB distinguish) (NP (JJ bacterial)) (PP (IN from) (NP (JJ viral) (NN rhinosinusitis)))))) (. .)))
(ROOT (S (NP (NP (NNP Kovatch) (FW et) (FW al)) (PRN (-LRB- -LSB-) (NP (CD 32)) (-RRB- -RSB-))) (VP (VBD found) (SBAR (IN that) (S (NP (NP (QP (JJR more) (IN than) (NN half))) (PP (IN of) (NP (NP (NNS children)) (PP (IN with) (NP (NP (DT both) (NNS symptoms) (CC and) (NNS signs)) (PP (IN of) (NP (DT a) (JJ viral) (NNP URI)))))))) (VP (VBD had) (NP (JJ abnormal) (JJ maxillary) (NN sinus) (NNS radiographs)))))) (. .)))
(ROOT (S (ADVP (RB Conversely)) (, ,) (NP (JJ such) (NNS radiographs)) (VP (VBP are) (ADVP (RB frequently)) (NP (NP (ADJP (JJ abnormal) (PP (IN in) (NP (JJ healthy) (NNS children)))) (-LRB- -LSB-) (NP (CD 32)) (: --) (NP (CD 34)) (NP (-RRB- -RSB-))) (CC and) (PP (IN in) (NP (NP (NNS children)) (VP (VBG undergoing) (NP (NNP CT)) (PP (IN for) (NP (NP (DT a) (JJ nonrespiratory) (NN complaint)) (PRN (-LRB- -LSB-) (NP (CD 35)) (-RRB- -RSB-))))))))) (. .)))
(ROOT (S (NP (NP (NNP Gwaltney) (FW et) (FW al)) (PRN (-LRB- -LSB-) (NP (CD 36)) (-RRB- -RSB-))) (VP (VP (ADVP (RB deliberately)) (VBN obtained) (NP (NNS CTs)) (PP (IN from) (NP (JJ healthy) (JJ young) (NNS adults))) (VP (VBG experiencing) (NP (DT a) (JJ new) (JJ cold)))) (CC and) (VP (VBD found) (SBAR (IN that) (S (NP (NP (CD 87) (NN %)) (PP (IN of) (NP (DT the) (NNS subjects)))) (VP (VBD had) (NP (NP (JJ significant) (NNS abnormalities)) (PP (IN of) (NP (PRP$ their) (JJ maxillary) (NNS sinuses))))))))) (. .)))
(ROOT (S (ADVP (RB Finally)) (, ,) (NP (NNP Kristo) (FW et) (FW al)) (VP (VBN found) (SBAR (IN that) (S (NP (NP (NP (NP (CD 68) (NN %)) (PP (IN of) (NP (JJ symptomatic) (NNS children))) (PP (IN with) (NP (NP (JJ acute) (JJ respiratory) (NN infection)) (PRN (-LRB- -LSB-) (NP (CD 37)) (-RRB- -RSB-))))) (CC and) (NP (NP (CD 42) (NN %)) (PP (IN of) (NP (JJ healthy) (NN schoolchildren))))) (PRN (-LRB- -LSB-) (NP (CD 38)) (-RRB- -RSB-))) (VP (VBD had) (NP (JJ major) (NNS abnormalities)) (PP (IN in) (NP (PRP$ their) (JJ paranasal) (NNS sinuses))) (SBAR (IN as) (S (VP (VBN evaluated) (PP (IN by) (NP (NNP MRI)))))))))) (. .)))
(ROOT (S (ADVP (RB Collectively)) (, ,) (NP (DT these) (NNS studies)) (VP (VBP indicate) (SBAR (IN that) (S (S (PP (IN during) (NP (NP (JJ uncomplicated) (JJ viral) (NNP URI)) (PP (IN in) (NP (NP (NNS children)) (CC and) (NP (NNS adults)))))) (, ,) (NP (DT the) (NN majority)) (VP (MD will) (VP (VB have) (NP (JJ significant) (NNS abnormalities)) (PP (IN in) (NP (NN imaging) (NNS studies)))))) (VP (PRN (-LRB- -LRB-) (NP (CC either) (NP (JJ plain) (NNS radiographs)) (, ,) (NP (NNP CT)) (, ,) (CC or) (NP (NNP MRI))) (-RRB- -RRB-)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADJP (JJ indistinguishable) (PP (IN from) (NP (NP (DT those)) (VP (VBN associated) (PP (IN with) (NP (JJ bacterial) (NN infection)))))))))))))) (. .)))
(ROOT (S (ADVP (RB Accordingly)) (, ,) (S (SBAR (IN while) (S (NP (JJ normal) (NN imaging) (NNS studies)) (VP (MD can) (VP (VB assure) (SBAR (IN that) (S (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (JJ respiratory) (NNS symptoms)))) (ADVP (RB almost) (RB certainly)) (VP (VBZ does) (RB not) (VP (VB have) (NP (NP (NNS ABRS)) (, ,) (NP (DT an) (JJ abnormal) (JJ radiographic) (NN study))))))))))) (VP (MD can) (RB not) (VP (VB confirm) (NP (NP (DT the) (NN diagnosis)) (PP (IN of) (NP (NNP ABRS))))))) (, ,) (CC and) (S (NP (JJ such) (NNS studies)) (VP (VBP are) (ADJP (JJ unnecessary)) (PP (IN during) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (JJ uncomplicated) (NNS ABRS))))))) (. .)))
(ROOT (FRAG (ADVP (RB Furthermore)) (, ,) (NP (NP (NNS studies)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (DT the) (NN entry) (NNS criteria)) (VP (VBD included) (SBAR (S (NP (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (NP (JJ respiratory) (NNS symptoms)) (CC plus) (NP (JJ abnormal) (NNS radiographs))) (CC or) (NP (JJ other) (NN imaging) (NNS studies))))) (PRN (-LRB- -LRB-) (ADVP (FW ie)) (PRN (, ,) (NP (JJS most) (NNS RCTs)) (VP (VBG evaluating) (NP (NP (JJ antimicrobial) (NN treatment)) (PP (IN of) (NP (NN ABRS)))) (PP (IN in) (NP (DT the) (NN literature)))) (-RRB- -RRB-)))) (VP (MD can) (RB not) (VP (VB be) (VP (VBN accepted) (PP (IN as) (ADJP (ADJP (JJ credible)) (CC or) (ADJP (JJ reliable)))) (PP (IN for) (S (VP (VBG evaluating) (NP (NP (DT the) (JJ natural) (NN history)) (PP (IN of) (NP (NP (NN ABRS)) (CC or) (NP (JJ antimicrobial) (NN efficacy))))))))))))))))) (. .)))
(ROOT (S (NP (EX There)) (VP (VBP are) (NP (NP (JJ few) (NNS studies)) (PP (IN in) (NP (NP (NNS adults)) (CC and) (NP (NP (NNS children)) (SBAR (WHNP (WDT that)) (S (VP (VBP have) (VP (VBN correlated) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (JJ respiratory) (NNS signs)) (CC and) (NP (NP (NNS symptoms)) (PP (IN with) (NP (NP (NP (DT the) (NNS findings)) (PP (IN of) (NP (NN sinus) (NN aspiration)))) (PRN (-LRB- -LSB-) (NP (CD 12) (, ,) (CD 28) (, ,) (CD 30) (, ,) (CD 39) (-RRB- -RSB-)))))))))))))))))) (. .)))
(ROOT (NP (NP (NP (DT The) (NN duration)) (PP (IN of) (NP (NP (NNS symptoms)) (PP (IN beyond) (NP (CD 7)))))) (: --) (NP (NP (CD 10) (NNS days)) (VP (VBZ is) (ADVP (RB often)) (VP (VBN used) (PP (IN as) (NP (NP (NP (DT a) (JJ surrogate) (NN criterion)) (SBAR (S (VP (TO to) (VP (VB distinguish) (ADJP (JJ bacterial) (PP (IN from) (NP (JJ viral) (NN infection)))) (PRN (PP (VBN based) (PP (IN on) (NP (NP (DT the) (JJ natural) (NN history)) (PP (IN of) (NP (NN rhinovirus) (NNS infections)))))) (PRN (-LRB- -LSB-) (NP (CD 40)) (-RRB- -RSB-)))))))) (PRN (-LRB- -LRB-) (NP (NN Figure) (CD 2)) (-RRB- -RRB-))))))) (. .)))
(ROOT (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN probability)) (PP (IN of) (S (VP (VBG confirming) (NP (NP (DT a) (JJ bacterial) (NN infection)) (PP (IN by) (NP (NN sinus) (NN aspiration)))))))) (VP (VBZ is) (NP (NP (NP (QP (RB only) (RB about) (CD 60)) (NN %)) (PP (IN among) (NP (NP (JJ adult) (NNS patients)) (PP (IN with) (NP (NP (NNS symptoms)) (VP (VBG lasting) (NP (QP (CD ≥) (CD 7))))))))) (: --) (NP (NP (CD 10) (NNS days)) (PRN (-LRB- -LSB-) (NP (CD 41)) (-RRB- -RSB-))))) (. .)))
(ROOT (S (S (VP (TO To) (VP (VB identify) (NP (NP (ADJP (ADJP (JJ additional)) (ADJP (JJ clinical))) (NNS features)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB distinguish) (PP (IN between) (NP (NP (ADJP (JJ bacterial) (CC and) (JJ viral)) (NN infection)) (, ,) (NP (NP (NP (DT the) (JJ typical) (JJ clinical) (NN course)) (CC and) (NP (NP (JJ natural) (NN history)) (PP (IN of) (NP (NN rhinovirus) (NN infection))))) (PRN (-LRB- -LRB-) (VP (VBN described) (PP (IN by) (NP (NNP Gwaltney) (FW et) (FW al))) (PRN (-LRB- -LSB-) (NP (CD 40)) (-RRB- -RSB-))) (-RRB- -RRB-))))))))))))) (VP (VBZ is) (NP (JJ further) (VBN reviewed))) (. .)))
(ROOT (S (NP (JJ Viral) (NNS URIs)) (VP (VBP are) (VP (VBN characterized) (PP (IN by) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (NP (JJ nasal) (NNS symptoms)) (PRN (-LRB- -LRB-) (NP (NP (NN discharge)) (CC and) (NP (NN congestion/obstruction))) (-RRB- -RRB-))) (CC and/or) (NP (NN cough)))))))) (. .)))
(ROOT (S (NP (NNS Patients)) (VP (MD may) (ADVP (RB also)) (VP (VB complain) (PP (IN of) (NP (DT a) (JJ scratchy) (NN throat))))) (. .)))
(ROOT (S (ADVP (RB Usually)) (NP (DT the) (JJ nasal) (NN discharge)) (VP (VBZ begins) (PP (IN as) (ADJP (JJ clear) (CC and) (JJ watery)))) (. .)))
(ROOT (FRAG (ADVP (RB Often)) (, ,) (ADVP (RB however)) (, ,) (NP (NP (NP (DT the) (NN quality)) (PP (IN of) (NP (JJ nasal) (NN discharge) (NNS changes)))) (PP (IN during) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (DT the) (NN illness)))))) (. .)))
(ROOT (S (JJS Most) (ADVP (RB typically)) (, ,) (NP (DT the) (JJ nasal) (NN discharge)) (VP (VP (VBZ becomes) (ADJP (ADJP (JJR thicker)) (CC and) (ADJP (RBR more) (JJ mucoid)))) (CC and) (VP (MD may) (VP (VB become) (ADJP (ADJP (JJ purulent)) (PRN (-LRB- -LRB-) (ADJP (ADJP (JJ thick)) (, ,) (ADJP (VBN colored)) (, ,) (CC and) (ADJP (JJ opaque))) (-RRB- -RRB-))) (PP (IN for) (NP (JJ several) (NNS days)))))) (. .)))
(ROOT (S (ADVP (RB Then)) (NP (DT the) (NN situation)) (VP (VP (VBZ reverses) (PP (IN with) (S (NP (DT the) (JJ purulent) (NN discharge)) (VP (VBG becoming) (NP (NN mucoid)))))) (CC and) (S (ADVP (RB then)) (ADJP (JJ clear)) (ADVP (RB again)) (, ,) (CC or) (VP (ADVP (RB simply)) (VBG drying)))) (. .)))
(ROOT (S (NP (NP (DT The) (NN transition)) (PP (IN from) (ADJP (JJ clear))) (PP (TO to) (NP (JJ purulent))) (PP (TO to) (NP (JJ clear) (JJ nasal) (NN discharge)))) (VP (VBZ occurs) (PP (IN in) (NP (JJ uncomplicated) (JJ viral) (NNS URIs))) (PP (IN without) (NP (NP (DT the) (NN benefit)) (PP (IN of) (NP (JJ antimicrobial) (NN therapy)))))) (. .)))
(ROOT (S (NP (NP (JJS Most) (NNS patients)) (PP (IN with) (NP (JJ uncomplicated) (JJ viral) (NNS URIs)))) (VP (VBP do) (RB not) (VP (VB have) (NP (NN fever)))) (. .)))
(ROOT (FRAG (ADVP (RB However)) (, ,) (SBAR (IN if) (S (NP (NN fever)) (VP (VBZ is) (ADJP (JJ present))))) (, ,) (NP (PRP it)) (VBZ tends) (TO to) (VB be) (ADJP (JJ present) (JJ early) (PP (IN in) (NP (DT the) (NN illness)))) (, ,) (PP (ADVP (RB often)) (IN in) (NP (NP (NN concert)) (PP (IN with) (NP (NP (JJ other) (JJ constitutional) (NNS symptoms)) (PP (JJ such) (IN as) (NP (NP (NN headache)) (CC and) (NP (NN myalgia)))))))) (. .)))
(ROOT (S (ADVP (RB Typically)) (, ,) (NP (DT the) (NP (NP (NN fever)) (CC and) (NP (JJ constitutional) (NNS symptoms)))) (VP (VBP disappear) (PP (IN in) (NP (NP (DT the) (JJ first) (CD 24)) (: --) (NP (NP (CD 48) (NNS hours)) (CC and) (NP (DT the) (JJ respiratory) (NNS symptoms))))) (VP (VBP become) (ADJP (RBR more) (JJ prominent)))) (. .)))
(ROOT (S (NP (NP (DT The) (NN time) (NN course)) (PP (IN of) (NP (NN illness)))) (VP (VBZ is) (NP (DT an) (JJ important) (NN characteristic))) (. .)))
(ROOT (FRAG (PP (IN In) (NP (NP (JJS most) (NNS cases)) (PP (IN of) (NP (JJ uncomplicated) (JJ viral) (NNP URI))))) (, ,) (NP (NP (JJ respiratory) (NNS symptoms)) (NP (JJ last) (CD 5) (: --) (NP (CD 10) (NNS days)))) (. .)))
(ROOT (S (SBAR (IN Although) (S (NP (DT the) (NN patient)) (VP (MD may) (RB not) (VP (VB be) (ADJP (JJ free) (PP (IN of) (NP (NP (NNS symptoms)) (PP (IN on) (NP (DT the) (JJ 10th) (NN day)))))))))) (, ,) (ADVP (RB almost) (RB always)) (NP (DT the) (JJ respiratory) (NNS symptoms)) (VP (VP (VBP have) (VP (VBN peaked) (PP (IN in) (NP (NP (NN severity)) (PP (IN by) (NP (NNS days) (NP (CD 3)) (: --) (NP (CD 6)))))))) (CC and) (VP (VB have) (VP (VBN begun) (S (VP (TO to) (VP (VB improve))))))) (. .)))
(ROOT (S (PP (IN With) (NP (NP (DT this) (JJ clinical) (NN picture)) (PP (IN of) (NP (NP (DT an) (JJ uncomplicated) (JJ viral) (NNP URI)) (PP (IN for) (NP (NN comparison))))))) (, ,) (NP (JJ several) (JJ clinical) (NNS features)) (VP (VBD were) (VP (VBN proposed) (PP (IN by) (NP (DT the) (NNP Rhinosinusitis) (NNP Initiative))) (S (VP (TO to) (VP (VB correlate) (PP (IN with) (NP (NP (NN ABRS)) (CONJP (RB rather) (IN than)) (NP (JJ viral) (NN URI)))) (PRN (-LRB- -LSB-) (NP (CD 7)) (-RRB- -RSB-))))))) (. .)))
(ROOT (S (PP (IN In) (NP (NP (NN addition)) (PP (TO to) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NNS signs) (CC and) (NNS symptoms))))))) (, ,) (NP (NP (DT the) (NN time) (NN course)) (CC and) (NP (NP (NN pattern)) (PP (IN of) (NP (NN disease) (NN progression))))) (VP (VBD were) (VP (VBN considered) (S (VP (TO to) (VP (VB be) (ADJP (JJ important)) (PP (IN in) (S (VP (VBG differentiating) (ADJP (JJ bacterial)) (PP (IN from) (NP (JJ viral) (NN rhinosinusitis))))))))))) (. .)))
(ROOT (S (S (NP (CD Three) (ADJP (ADJP (JJ typical)) (ADJP (JJ clinical))) (NNS presentations)) (VP (VBD were) (VP (VBN emphasized)))) (: :) (S (LST (-LRB- -LRB-) (LS 1) (-RRB- -RRB-)) (NP (NP (NN onset)) (PP (IN with) (S (NP (JJ persistent) (NNS symptoms)) (VP (WHNP (IN that)) (NP (NP (NP (JJ last) (QP (JJR >) (CD 10)) (NNS days)) (CC and) (QP (VP (VBD were) (RB not) (VP (VBG improving))))) (: ;) (NP (LST (-LRB- -LRB-) (LS 2) (-RRB- -RRB-)) (NP (NP (NN onset)) (PP (IN with) (NP (NP (JJ severe) (NNS symptoms)) (, ,) (VP (VBN characterized) (PP (IN by) (NP (NP (JJ high) (NN fever)) (PP (IN of) (NP (NP (NP (QP (IN at) (JJS least) (CD 39)) (CD °) (NN C)) (PRN (-LRB- -LRB-) (NP (QP (CD 102) (CD °)) (NN F)) (-RRB- -RRB-))) (CC and) (NP (JJ purulent) (JJ nasal) (NN discharge))))))))) (PP (IN for) (NP (NP (QP (IN at) (JJS least) (CD 3))) (: --) (NP (NP (CD 4) (JJ consecutive) (NNS days)) (PP (IN at) (NP (NP (DT the) (NN beginning)) (PP (IN of) (NP (NN illness)))))) (: ;) (CC and) (NP (LST (-LRB- -LRB-) (LS 3) (-RRB- -RRB-)) (NP (NP (NN onset)) (PP (IN with) (NP (NP (VBG worsening) (NNS symptoms)) (, ,) (VP (VBN characterized) (PP (IN by) (NP (NP (JJ typical) (JJ viral) (NNP URI) (NNS symptoms)) (SBAR (WHNP (WDT that)) (S (VP (VBP appear) (S (VP (TO to) (VP (VB improve) (VP (VBN followed) (PP (IN by) (NP (NP (NP (DT the) (JJ sudden) (NN onset)) (PP (IN of) (S (VP (VBG worsening) (NP (NNS symptoms)) (PP (IN after) (NP (CD 5))))))) (: --) (NP (NP (NP (CD 6) (NNS days)) (PRN (-LRB- -LRB-) (`` ``) (JJ double-sickening) ('' '') (-RRB- -RRB-))) (PRN (-LRB- -LSB-) (NP (NP (CD 7)) (, ,) (NP (CD 42))) (-RRB- -RSB-))))))))))))))))))))))))))))) (. .)))
(ROOT (S (S (PP (IN In) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ persistent) (NNS symptoms))))) (, ,) (NP (NP (NP (JJ nasal) (NN discharge)) (PRN (-LRB- -LRB-) (PP (IN of) (NP (DT any) (NN quality))) (-RRB- -RRB-))) (CC and) (NP (NP (JJ daytime) (NN cough)) (PRN (-LRB- -LRB-) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB be) (ADJP (JJR worse)) (PP (IN at) (NP (NN night))))))) (-RRB- -RRB-)))) (VP (VBP are) (S (DT both) (ADJP (JJ common))))) (, ,) (IN whereas) (S (NP (DT the) (NN presence)) (PP (IN of) (NP (NN fever))) (, ,) (NP (NP (NN headache)) (, ,) (CC or) (NP (JJ facial) (NN pain))) (VP (VBZ is) (ADJP (RBR more) (JJ variable)))) (. .)))
(ROOT (S (NP (DT These) (NNS patients)) (VP (VBP come) (PP (TO to) (NP (JJ medical) (NN attention))) (PP (ADVP (RB primarily)) (IN because) (IN of) (NP (NP (JJ respiratory) (NNS symptoms)) (SBAR (WHNP (WDT that)) (S (VP (VP (MD may) (VP (VB be) (NP (JJ low) (NN grade)))) (CC but) (S (ADVP (RB simply)) (VP (VB do) (RB not) (VP (VB resolve)))))))))) (. .)))
(ROOT (S (PP (IN In) (NP (NP (DT the) (NN patient)) (PP (IN with) (NP (JJ severe) (NNS symptoms))))) (, ,) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NP (NN fever)) (, ,) (NP (NN headache)) (, ,) (CC and) (NP (JJ facial) (NN pain))))) (VP (VBZ is) (VP (VBN distinguished) (PP (IN from) (NP (NP (DT an) (JJ uncomplicated) (JJ viral) (NNP URI)) (PP (IN in) (NP (CD 2) (NNS ways))))))) (. .)))
(ROOT (S (PP (IN In) (NP (JJ viral) (NNP URI))) (, ,) (NP (NN fever)) (VP (VP (VBZ is) (ADJP (JJ present)) (ADVP (RB early) (PP (IN in) (NP (DT the) (JJ clinical) (NN illness))))) (CC and) (VP (VBZ disappears) (PP (IN in) (NP (CD 24))) (: --) (NP (NP (CD 48) (NNS hours)) (, ,) (SBAR (IN while) (S (NP (JJ purulent) (JJ nasal) (NN discharge)) (VP (VBZ is) (RB not) (ADVP (RB generally)) (ADJP (JJ present)) (PP (IN until) (NP (NP (DT the) (ADJP (ADJP (JJ fourth)) (CC or) (ADJP (JJ fifth))) (NN day)) (PP (IN of) (NP (NN illness))))))))))) (. .)))
(ROOT (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (NP (DT the) (JJ high) (NN fever)) (CC and) (NP (JJ purulent) (JJ nasal) (NN discharge))) (PP (IN during) (NP (NNP ABRS)))) (VP (VBP occur) (PP (IN for) (NP (QP (IN at) (JJS least) (CD 3)))) (PRN (: --) (NP (NP (CD 4) (JJ consecutive) (NNS days)) (PP (IN at) (NP (NP (DT the) (NN beginning)) (PP (IN of) (NP (DT the) (NN illness)))))))) (. .)))
(ROOT (S (SBAR (IN Although) (S (NP (NP (NP (DT the) (NN triad)) (PP (IN of) (NP (NN headache)))) (, ,) (NP (JJ facial) (NN pain)) (, ,) (CC and) (NP (NN fever))) (VP (VBZ is) (VP (VBN considered) (S (NP (NP (DT a) (JJ classic) (NN presentation)) (PP (IN of) (NP (NN ABRS))) (PP (IN in) (NP (NNS adults))))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (ADJP (JJ uncommon))) (. .)))
(ROOT (S (NP (NP (NN Onset)) (PP (IN with) (NP (JJ persistent) (NNS symptoms)))) (VP (VBZ is) (ADJP (ADVP (RB far) (RBR more)) (JJ frequent))) (. .)))
(ROOT (S (PP (IN In) (NP (NNS children))) (, ,) (NP (NP (DT the) (ADJP (RBS most) (JJ common)) (NNS manifestations)) (PP (IN of) (NP (JJ bacterial) (NN sinusitis)))) (VP (VBP are) (NP (NP (NP (NN cough)) (PRN (-LRB- -LRB-) (NP (CD 80) (NN %)) (-RRB- -RRB-))) (VP (VBN followed) (PP (IN by) (NP (NP (NP (JJ nasal) (NN discharge)) (PRN (-LRB- -LRB-) (NP (CD 76) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (NN fever)) (PRN (-LRB- -LRB-) (NP (CD 63) (NN %)) (-RRB- -RRB-)))))))) (. .)))
(ROOT (S (NP (NP (NNS Parents)) (PP (IN of) (NP (NNS preschoolers)))) (ADVP (RB often)) (VP (VBP report) (NP (JJ malodorous) (NN breath))) (. .)))
(ROOT (S (NP (NP (NN Headache)) (, ,) (NP (JJ facial) (NN pain)) (, ,) (CC and) (NP (VBG swelling))) (VP (VBP are) (ADJP (JJ rare))) (. .)))
(ROOT (S (PP (IN In) (NP (NP (DT the) (NN patient)) (PP (IN with) (NP (VBG worsening) (NNS symptoms))))) (, ,) (NP (EX there)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (JJ new) (NN onset)) (PP (IN of) (NP (NP (NN fever)) (, ,) (NP (DT a) (NN relapse)) (CC or) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (NP (JJ nasal) (NN discharge)) (CC or) (NP (NN cough))) (, ,) (CC or) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (JJ severe) (NN headache)))))))))))) (. .)))
(ROOT (S (NP (DT This) (JJ double-sickening)) (VP (VBZ is) (NP (NP (DT a) (JJ classic) (NN presentation)) (PP (IN for) (NP (NP (DT any) (JJ secondary) (JJ bacterial) (NN complication)) (PP (IN of) (NP (NP (DT a) (JJ viral) (NNP URI)) (ADJP (JJ similar) (PP (TO to) (NP (NP (NNP ABRS)) (, ,) (PP (JJ such) (IN as) (NP (NP (NP (JJ acute) (JJ otitis) (NNS media)) (PRN (-LRB- -LRB-) (NP (NNS AOM)) (-RRB- -RRB-))) (CC and) (NP (NN pneumonia))))))))))))) (. .)))
(ROOT (S (NP (NP (DT The) (NN validity)) (PP (IN of) (NP (DT these) (JJ clinical) (NNS features))) (PP (IN in) (S (VP (VBG predicting) (NP (NN ABRS)))))) (VP (VBZ is) (VP (VBN discussed) (PP (IN in) (NP (NP (NP (DT the) (`` ``) (NN Evidence) (NN Summary) ('' '')) (PP (IN of) (NP (NN recommendation) (CD 1)))) (PP (IN in) (NP (DT the) (NN guideline))))))) (. .)))
(ROOT (S (NP (NP (NP (CD Five) (JJ systematic) (NNS reviews) (CC or) (NNS meta-analyses)) (PP (IN of) (NP (JJ antimicrobial) (NN therapy)))) (CC vs) (NP (NP (NN placebo)) (PP (IN for) (NP (NP (JJ presumed) (NN ABRS)) (PP (IN in) (NP (NNS adults))))))) (VP (VBP have) (VP (VBN been) (VP (VBN published) (PP (IN since) (NP (NP (CD 2005)) (PRN (-LRB- -LSB-) (NP (NP (CD 18)) (, ,) (NP (CD 24)) (, ,) (NP (CD 25)) (, ,) (NP (CD 43)) (, ,) (NP (CD 44))) (-RRB- -RSB-))))))) (. .)))
(ROOT (S (NP (NP (NNS Data)) (PP (IN from) (NP (NP (CD 17) (NNS studies)) (PP (IN in) (NP (NP (NP (JJ adult) (NNS patients)) (CC and) (NP (CD 3) (JJ pediatric) (NNS studies))) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NNS antibiotics)) (VP (VBP have) (VP (VBN been) (PP (VBN compared) (PP (IN with) (NP (NN placebo))))))))))))) (VP (VBP are) (ADJP (JJ available) (PP (IN for) (NP (NP (JJ further) (NN analysis)) (PRN (-LRB- -LRB-) (NP (NNP Table)) (LS 3) (-RRB- -RRB-)))))) (. .)))
(ROOT (S (PP (IN In) (S (VP (VBG evaluating) (NP (NP (DT the) (NN quality)) (PP (IN of) (NP (DT these) (NNS studies))))))) (, ,) (NP (NP (DT the) (JJ single) (ADJP (RBS most) (JJ challenging)) (NN issue)) (PP (IN besides) (NP (NP (JJ methodological) (NNS flaws)) (PP (IN in) (NP (NP (NN randomization)) (, ,) (NP (NN concealment)) (, ,) (CC and) (NP (VBG blinding))))))) (VP (VBZ is) (S (VP (TO to) (VP (VB ensure) (SBAR (IN that) (S (NP (NP (DT the) (NNS patients)) (PP (IN in) (NP (DT the) (NN study) (NNS populations)))) (ADVP (RB actually)) (VP (VBP have) (ADJP (JJ bacterial) (PP (RB rather) (IN than) (NP (NP (JJ viral) (NN rhinosinusitis)) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NN confirmation)))))))) (PP (IN by) (NP (NN sinus) (NNS cultures)))))))))) (. .)))
(ROOT (S (NP (NP (CD Two) (JJ common) (JJ methodological) (NNS flaws)) (VP (VBN identified) (PP (IN in) (NP (DT these) (NNS studies))) (PP (IN among) (NP (JJ adult) (NNS patients))))) (VP (VBP are) (SBAR (IN that) (S (LST (-LRB- -LRB-) (LS 1) (-RRB- -RRB-)) (NP (JJ many) (NNS patients)) (ADVP (RB only)) (VP (VBD had) (NP (NP (NP (CD 7) (NNS days)) (PP (IN of) (NP (NP (NNS symptoms)) (PRN (-LRB- -LRB-) (PP (IN without) (NP (NP (NN qualification)) (PP (IN of) (SBAR (IN whether) (S (NP (DT these) (NNS symptoms)) (VP (VBD had) (VP (VBN begun) (S (VP (TO to) (VP (VB improve) (CC or) (VP (VBD were) (VP (VBG worsening))))))))))))) (-RRB- -RRB-))))) (CC and) (SBAR (IN that) (S (LST (-LRB- -LRB-) (LS 2) (-RRB- -RRB-)) (NP (NN imaging) (NNS studies)) (VP (VBD were) (ADVP (RB often)) (VP (VBN used) (PP (IN as) (NP (DT a) (JJ diagnostic) (NN entry) (NN criterion)))))))))))) (. .)))
(ROOT (S (SBAR (IN Because) (S (NP (DT these) (NN patient) (NN selection) (NNS criteria)) (VP (VBP lack) (NP (NP (NN sensitivity)) (CC and) (NP (NN specificity))) (PP (IN for) (NP (NNS ABRS)))))) (, ,) (NP (EX there)) (VP (VBZ is) (NP (NP (JJ good) (NN reason)) (SBAR (S (VP (TO to) (VP (VB believe) (SBAR (IN that) (S (NP (NP (JJ many) (NNS patients)) (VP (VBN enrolled) (PP (IN in) (NP (DT these) (NNS studies))))) (VP (VBD had) (NP (NP (NP (JJ uncomplicated) (JJ viral) (NN URI)) (CONJP (RB rather) (IN than)) (NP (NN ABRS))) (PRN (-LRB- -LSB-) (NP (CD 12)) (-RRB- -RSB-)))))))))))) (. .)))
(ROOT (S (ADVP (RB Nonetheless)) (, ,) (NP (NP (JJS most)) (PP (IN of) (NP (DT these) (NNS studies)))) (VP (VBP do) (VP (VB show) (NP (NP (DT a) (JJ modest) (NN benefit)) (PP (IN in) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNS antimicrobials)))))))) (. .)))
(ROOT (S (ADVP (RB Overall)) (, ,) (NP (NP (CD 13) (PRN (-LRB- -LRB-) (NP (NP (NP (ADJP (CD 95) (NN %)) (NN confidence) (NN interval)) (PRN (-LRB- -LSB-) (NP (NN CI)) (-RRB- -RSB-))) (, ,) (NP (CD 9)) (: --) (NP (CD 22))) (-RRB- -RRB-))) (NNS adults)) (VP (MD would) (VP (VB need) (S (VP (TO to) (VP (VB be) (VP (VBN treated) (PP (IN with) (NP (NNS antibiotics))) (SBAR (IN before) (S (NP (CD 1) (JJ additional) (NN patient)) (VP (MD would) (VP (VB benefit) (PRN (-LRB- -LRB-) (NP (NNP Table) (LST (LS 3))) (-RRB- -RRB-)))))))))))) (. .)))
(ROOT (S (NP (DT The) (NN finding) (SBAR (IN that) (S (NP (NP (QP (RB approximately) (CD 65)) (NN %)) (PP (IN of) (NP (JJ placebo-treated) (NNS patients)))) (VP (VBD improved) (ADVP (RB spontaneously)) (PP (IN in) (NP (DT these) (NNS studies))))))) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (DT an) (JJ erroneous) (NN conclusion) (SBAR (IN that) (S (NP (NP (DT some) (NNS patients)) (PP (IN with) (NP (NNS ABRS)))) (VP (VBP do) (RB not) (VP (VB require) (NP (NP (JJ antimicrobial) (NN therapy)) (, ,) (SBAR (WHADVP (WRB when)) (S (PP (IN in) (NP (NN fact))) (NP (PRP they)) (VP (MD may) (RB not) (VP (VB have) (NP (NNS ABRS)) (ADVP (IN at) (DT all))))))))))))))) (. .)))
(ROOT (S (NP (PRP One)) (VP (MD can) (ADVP (RB only)) (VP (VB surmise) (SBAR (IN that) (S (NP (NP (DT the) (NN benefit)) (PP (IN of) (NP (JJ antimicrobial) (NN therapy)))) (VP (MD would) (VP (VB have) (VP (VBN been) (ADVP (RB substantially)) (VP (VBN magnified) (SBAR (IN if) (S (NP (NP (JJR more)) (PP (IN of) (NP (DT the) (NN study) (NNS patients)))) (ADVP (RB actually)) (VP (VBD had) (NP (NNS ABRS))))))))))))) (. .)))
(ROOT (S (NP (NP (NNS Studies)) (PP (IN of) (NP (NNS children)))) (VP (VBD showed) (NP (NP (NNS results)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NP (DT the) (NN number)) (VP (VBN needed) (S (VP (TO to) (VP (VB treat) (PRN (-LRB- -LRB-) (NP (NN NNT)) (-RRB- -RRB-))))))) (VP (VBD was) (VP (VBN reduced) (PP (TO to) (NP (CD 5))) (PRN (-LRB- -LRB-) (NP (NP (CD 95) (NN %) (NN CI)) (, ,) (NP (CD 4)) (: --) (NP (CD 15))) (-RRB- -RRB-)))))))) (. .)))
(ROOT (S (S (NP (PRP It)) (VP (VBZ is) (ADJP (JJ probable)) (SBAR (IN that) (S (NP (NP (DT this) (JJ apparent) (NN difference)) (PP (IN in) (NP (NN response) (NNS rates))) (PP (IN between) (NP (NP (NNS children)) (CC and) (NP (NNS adults))))) (VP (VBZ is) (PP (JJ due) (TO to) (NP (NP (ADJP (RBR more) (JJ stringent)) (NN inclusion) (NNS criteria)) (PP (IN for) (NP (NP (NNS ABRS)) (PP (IN in) (NP (DT the) (JJ pediatric) (NNS studies)))))))))))) (: ;) (S (ADVP (RB alternatively)) (, ,) (NP (NP (NNS children)) (PP (IN with) (NP (NN ABRS)))) (VP (MD may) (VP (VB respond) (ADVP (JJR better)) (PP (TO to) (NP (NP (NNS antibiotics)) (PP (IN than) (NP (NNS adults)))))))) (. .)))
(ROOT (S (NP (NP (DT The) (NN practice)) (PP (IN of) (NP (JJ evidence-based) (NN medicine)))) (VP (VBZ requires) (SBAR (IN that) (S (NP (NP (JJ clinical) (NNS decisions)) (VP (VBG regarding) (S (NP (NP (DT the) (NN selection)) (PP (IN of) (NP (JJ empiric) (JJ antimicrobial) (NN therapy))) (PP (IN for) (NP (NNP ABRS)))) (VP (VB be) (VP (VBN supported) (PP (IN by) (NP (NNS RCTs))) (SBAR (IN if) (ADJP (JJ available))))))))))) (. .)))
(ROOT (S (ADVP (RB Unfortunately)) (, ,) (NP (NP (ADJP (RBS most) (VBN published)) (NNS RCTs)) (VP (VBG comparing) (NP (JJ different) (JJ antimicrobial) (NNS regimens)) (PP (IN for) (NP (NNS ABRS))))) (VP (VBP are) (ADVP (RB only)) (VP (VBN powered) (S (VP (TO to) (VP (VB evaluate) (NP (JJ noninferior) (JJ clinical) (NNS outcomes)) (PP (IN without) (NP (JJ microbiological) (NN confirmation)))))))) (. .)))
(ROOT (S (NP (NP (DT This) (NN situation)) (, ,) (VP (VBN coupled) (PP (IN with) (NP (NP (DT the) (JJ high) (NN rate)) (PP (IN of) (NP (NP (JJ spontaneous) (NN recovery)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ uncomplicated) (JJ acute) (NN rhinosinusitis)))))))))) (, ,)) (VP (VP (VP (VBZ allows) (S (NP (NP (NNS agents)) (PP (IN with) (NP (JJ poor) (JJ antimicrobial) (NN efficacy)))) (VP (TO to) (VP (VB appear) (ADJP (JJR more) (JJ efficacious)))))) (, ,) (CC and) (NP (NP (NP (NNS drugs)) (PP (IN with) (S (NP (JJ excellent) (JJ antibacterial) (NN activity)) (VP (TO to) (VP (VB appear) (ADJP (JJR less) (JJ efficacious))))))) (, ,) (SBAR (IN than) (S (NP (PRP they)) (ADVP (RB really)) (VP (VBP are)))) (, ,) (SBAR (S (NP (DT that)) (VP (VBZ is)))))) (, ,) (NP (NP (DT the) (`` ``) (NP (NNP Pollyanna) (NN effect)) ('' '')) (VP (VBN described) (PP (IN by) (NP (NNP Marchant) (FW et) (FW al))) (PRN (-LRB- -LSB-) (NP (CD 65)) (-RRB- -RSB-))))) (. .)))
(ROOT (S (ADVP (RB Thus)) (, ,) (SBAR (IN although) (S (NP (NP (DT a) (NN multitude)) (PP (IN of) (NP (JJ antimicrobial) (NNS regimens)))) (VP (VBP have) (VP (VBN been) (VP (VBN found) (S (VP (TO to) (VP (VB be) (ADJP (JJ noninferior) (PP (TO to) (NP (NNP amoxicillin))) (PP (IN in) (NP (JJ clinical) (NN efficacy)))))))))))) (, ,) (NP (PRP they)) (VP (VBP are) (RB not) (ADJP (RB truly) (JJ equivalent) (PP (TO to) (NP (JJ first-line) (NNS agents)))) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NN ABRS)))))) (. .)))
(ROOT (S (NP (NP (DT The) (NN emergence)) (PP (IN of) (S (VP (VBG increasing) (NP (JJ antimicrobial) (NN resistance)) (PP (IN among) (NP (JJ respiratory) (NNS pathogens))))))) (VP (VBZ initiates) (NP (NP (DT a) (JJ self-perpetuating) (JJ vicious) (NN cycle)) (PP (WHPP (IN in) (WHNP (WDT which))) (NP (NP (JJ broad-spectrum) (NNS antibiotics)) (SBAR (UCP (VBP are) (ADJP (JJ encouraged)) (CC and)) (S (PP (IN in) (NP (NN turn) (NN drive) (NN selection) (NN pressure))) (VP (TO to) (VP (VB promote) (NP (JJR more) (NN resistance)) (PRN (-LRB- -LSB-) (NP (NP (CD 66)) (, ,) (NP (CD 67))) (-RRB- -RSB-)))))))))) (. .)))
(ROOT (S (NP (DT This) (NN dilemma)) (VP (VBZ is) (ADVP (JJ further)) (VP (VBN exacerbated) (PP (IN by) (NP (NP (DT the) (NN lack)) (PP (IN of) (NP (JJ appropriate) (JJ microbiological) (NNS studies))))) (S (VP (TO to) (VP (VB confirm) (NP (NP (DT an) (JJ etiological) (NN diagnosis)) (CC and) (VP (VB assess) (NP (JJ microbiological) (NN outcome))))))))) (. .)))
(ROOT (FRAG (ADVP (RB Finally)) (, ,) (SBAR (IN although) (S (NP (EX there)) (VP (VBP are) (SBAR (S (NP (NP (JJ clear) (NNS exceptions)) (, ,) (NP (NP (DT the) (NN laboratory) (NN designation)) (PP (IN of) (NP (JJ antimicrobial) (NN resistance))))) (VP (MD may) (RB not) (ADVP (RB necessarily)) (VP (VB correlate) (PP (IN with) (NP (JJ poor) (NN patient) (NN outcome)))))))))) (. .)))
(ROOT (S (NP (NP (NN Documentation)) (PP (IN of) (NP (JJ bacterial) (NN persistence))) (PP (IN in) (NP (NP (NN association)) (PP (IN with) (NP (JJ clinical) (NN failure))))) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NP (JJ structural) (NNS abnormalities)) (CC or) (NP (JJ suboptimal) (NN PK/PD) (NNS data))))))) (VP (VBZ is) (ADJP (JJ necessary) (S (VP (TO to) (VP (VB confirm) (NP (NP (DT the) (JJ clinical) (NN relevance)) (PP (IN of) (NP (JJ antimicrobial) (NN resistance))))))))) (. .)))
(ROOT (S (PP (IN As) (NP (NP (DT a) (NN case)) (PP (IN in) (NP (NN point))))) (, ,) (NP (NP (DT the) (NP (NN penicillin) (NN susceptibility) (NNS breakpoints))) (PP (IN of) (NP (NNP S.) (FW pneumoniae))) (PP (IN for) (NP (NP (JJ intravenous) (NN treatment)) (PP (IN of) (NP (JJ nonmeningeal) (NN infection)))))) (VP (VBD were) (VP (VBN revised) (PP (IN in) (NP (CD 2008))) (SBAR (IN by) (FRAG (NP (NP (DT the) (JJ Clinical) (CC and) (NN Laboratory)) (NNPS Standards) (NNP Institute) (PRN (-LRB- -LRB-) (NP (NNP CLSI)) (-RRB- -RRB-))) (-LRB- -LRB-) (NP (NP (`` ``) (JJ intermediate) ('' '') (VP (VBN changed) (PP (IN from) (NP (NP (QP (CD ≤) (CD 1)) (NN μg)) (: /) (NP (NN mL) (PP (TO to) (NP (CD 4) (NN μg) (: /) (NN mL)))))))) (: ;) (NP (`` ``) (JJ resistant) ('' '') (VP (VBN changed) (PP (IN from) (NP (NP (QP (CD ≥) (CD 2)) (NN μg)) (: /) (NP (NN mL)))) (S (VP (TO to) (VP (VB ≥) (NP (CD 8) (NN μg) (: /) (NN mL))))))) (-RRB- -RRB-) (, ,) (SBAR (RB because) (S (NP (NP (JJR earlier) (NNS breakpoints)) (VP (VBN based) (PP (IN on) (NP (NP (JJ achievable) (JJ cerebrospinal) (NN fluid) (NNS concentrations)) (PP (IN of) (NP (NN penicillin))))))) (VP (VBD did) (RB not) (VP (VB correlate) (PP (IN with) (NP (NP (DT a) (JJ suboptimal) (JJ clinical) (NN outcome)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ nonmeningeal) (JJ invasive) (JJ pneumococcal) (NNS infections))))))) (PRN (-LRB- -LSB-) (NP (CD 68)) (-RRB- -RSB-))))))))))) (. .)))
(ROOT (S (SBAR (IN Because) (S (NP (JJ oral) (NNP amoxicillin)) (VP (VBZ has) (NP (NP (JJR better) (NN PK/PD) (NNS properties)) (PP (IN than) (NP (JJ oral) (NN penicillin) (NN VK))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (NP (NP (DT the) (VBN preferred) (JJ oral) (JJ β-lactam) (NN agent)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ nonmeningeal) (JJ pneumococcal) (NNS infections))))))) (. .)))
(ROOT (S (NP (NP (DT The) (VBN revised) (NNS breakpoints)) (PP (IN for) (NP (JJ oral) (NNP amoxicillin)))) (VP (VBP are) (ADJP (DT the) (JJ same) (PP (IN as) (PP (IN for) (NP (NP (JJ intravenous) (NN penicillin)) (PRN (-LRB- -LRB-) (NP (NP (JJ intermediate) (, ,) (NP (CD 4) (NN μg) (: /) (NN mL))) (: ;) (NP (JJ resistant) (, ,) (NP (CD ≥) (CD 8) (NN μg) (: /) (NN mL)))) (-RRB- -RRB-))))))) (. .)))
(ROOT (S (NP (NP (DT The) (JJ clinical) (NN relevance)) (PP (IN of) (NP (NN macrolide) (NN resistance))) (PP (IN among) (NP (NP (NNP H.) (NNS influenzae)) (CC and) (NP (NNP S.) (FW pneumoniae))))) (VP (VBZ has) (ADVP (RB also)) (VP (VBN been) (VP (VBN questioned)))) (. .)))
(ROOT (S (ADVP (RB Nonetheless)) (, ,) (NP (JJ recent) (NNS studies)) (VP (VBP provide) (NP (JJ clear-cut) (NN evidence) (SBAR (IN that) (S (NP (NP (NN infection)) (PP (IN with) (NP (NP (ADJP (JJ macrolide-resistant))) (CC and) (NP (ADJP (JJ penicillin-resistant))) (NP (NN pneumococci))))) (VP (VBZ is) (NP (NP (NP (DT a) (JJ notable) (NN risk) (NN factor)) (PP (IN for) (NP (NN treatment) (NN failure)))) (PP (IN with) (NP (DT these) (NNS agents)))) (PP (IN in) (NP (JJ community-acquired) (JJ respiratory) (NN tract) (NNS infections))) (NP (-LRB- -LSB-) (NP (CD 69)) (: --) (NP (CD 72)) (-RRB- -RSB-))))))) (. .)))
(ROOT (S (NP (JJ Similar) (NNS data)) (VP (VBP exist) (SBAR (WHADVP (WRB when)) (S (NP (JJ inappropriate) (JJ antimicrobial) (NN therapy)) (VP (VBD was) (VP (VBN administered) (PP (TO to) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NN ABRS)) (VP (VBN caused) (PP (IN by) (NP (NP (NNP H.) (NNS influenzae)) (PP (IN on) (NP (NP (DT the) (NN basis)) (PP (IN of) (NP (NP (NN posttreatment) (NN sinus) (NN puncture) (NNS studies)) (PRN (-LRB- -LSB-) (NP (CD 12)) (-RRB- -RSB-)))))))))))))))))) (. .)))
(ROOT (S (NP (DT A) (JJ related) (NN concern)) (VP (VBZ is) (UCP (SBAR (IN that) (S (NP (NP (DT the) (NN emergence)) (PP (IN of) (NP (JJ antimicrobial) (NN resistance)))) (VP (VBZ is) (NP (DT a) (JJ dynamic) (NN process))))) (CC and) (ADVP (RB constantly)) (VBG evolving))) (. .)))
(ROOT (S (NP (NP (JJ Antimicrobial) (NNS regimens)) (VP (VBN found) (S (VP (TO to) (VP (VB be) (ADJP (JJ effective) (PP (IN in) (NP (NP (NNS RCTs)) (VP (VBN performed) (NP (RB prior) (TO to) (NP (DT the) (NN emergence)) (PP (IN of) (NP (NP (NP (JJ antimicrobial) (NN resistance)) (PRN (-LRB- -LRB-) (FW eg) (, ,))) (NN β-lactamase))) (: --) (VP (VBG producing) (NP (NP (NNP H.) (NNS influenzae)) (PP (IN in) (NP (DT the) (NNS 1970s))))))))))))))) (-RRB- -RRB-) (ADVP (RB clearly)) (VP (MD can) (RB not) (VP (VB be) (VP (VBN relied) (PP (IN upon) (PP (IN for) (NP (JJ contemporary) (NN treatment)))) (PP (IN without) (NP (NP (NN confirmation)) (PP (IN by) (NP (NN susceptibility) (NN testing)))))))) (. .)))
(ROOT (S (NP (DT This) (JJ further)) (VP (VBZ diminishes) (NP (NP (DT the) (NN value)) (PP (IN of) (NP (NNS RCTs)))) (PP (IN in) (NP (NP (DT the) (NN selection)) (PP (IN of) (NP (JJ contemporary) (JJ empiric) (JJ antimicrobial) (NNS regimens))) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NN ABRS)))))))) (. .)))
(ROOT (S (PP (IN For) (NP (NP (PDT all) (DT the) (NNS reasons)) (VP (VBN stated) (ADVP (IN above))))) (, ,) (NP (NP (JJ antimicrobial) (NNS recommendations)) (PP (IN for) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (NNP ABRS)))))) (VP (VBP need) (S (VP (TO to) (VP (VB be) (VP (VBN reevaluated)))))) (. .)))
(ROOT (S (NP (DT The) (JJ current) (NN IDSA) (NN practice) (NN guideline)) (VP (VBZ aims) (S (VP (TO to) (ADVP (RB critically)) (VP (VB review) (NP (NP (DT the) (NN evidence)) (CC and) (VP (VB formulate) (NP (NP (NNS recommendations)) (SBAR (WHNP (WDT that)) (S (VP (VBP address) (NP (NP (DT some)) (PP (IN of) (NP (DT these) (JJ therapeutic) (NNS dilemmas)))) (PP (IN in) (NP (NN ABRS))))))) (S (VP (VBG using) (NP (DT the) (NN GRADE) (NN system)))))))))) (. .)))
(ROOT (S (`` ``) (VP (VB Practice) (SBAR (S (NP (NNS guidelines)) (VP (VBP are) (ADVP (RB systematically)) (NP (VBN developed) (NNS statements) (S (VP (TO to) (VP (VP (VB assist) (NP (NNS practitioners))) (CC and) (NP (NP (NNS patients)) (PP (IN in) (S (VP (VBG making) (NP (NP (NNS decisions)) (PP (IN about) (NP (NP (JJ appropriate) (NN healthcare)) (PP (IN for) (NP (JJ specific) (JJ clinical) (NNS circumstances))))))))))))))))) ('' '') (PRN (-LRB- -LSB-) (NP (CD 73)) (-RRB- -RSB-))) (. .)))
(ROOT (S (NP (NP (NNS Attributes)) (PP (IN of) (NP (JJ good) (NNS guidelines)))) (VP (VBP include) (NP (NP (NP (NN validity)) (, ,) (NP (NN reliability)) (, ,) (NP (NN reproducibility)) (, ,) (NP (JJ clinical) (NN applicability)) (, ,) (NP (JJ clinical) (NN flexibility)) (, ,) (NP (NN clarity)) (, ,) (NP (JJ multidisciplinary) (NN process)) (, ,) (NP (NP (NN review)) (PP (IN of) (NP (NN evidence)))) (, ,) (CC and) (NP (NN documentation))) (PRN (-LRB- -LSB-) (NP (CD 73)) (-RRB- -RSB-)))) (. .)))
(ROOT (S (NP (NP (DT A) (NN panel)) (PP (IN of) (NP (NP (JJ multidisciplinary) (NNS experts)) (PP (IN in) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (NP (NN ABRS)) (PP (IN in) (NP (NP (NNS children)) (CC and) (NP (NNS adults))))))))))) (VP (VBD was) (VP (VBN convened) (PP (IN in) (NP (NNP April) (CD 2008))))) (. .)))
(ROOT (S (NP (DT The) (NN panel)) (VP (VBD consisted) (PP (IN of) (NP (NP (NP (NNS internists) (CC and) (NNS pediatricians)) (CONJP (RB as) (RB well) (IN as)) (NP (NP (JJ infectious) (NN disease)) (CC and) (NP (NN emergency) (NNS physicians)))) (CC and) (NP (DT an) (JJ otolaryngologic) (NN specialist))))) (. .)))
(ROOT (S (NP (NN Panel) (NNS participants)) (VP (VBD included) (NP (NP (NP (NNS representatives)) (PP (IN from) (NP (NP (DT the) (NNP American) (NNP College)) (PP (IN of) (NP (NNP Physicians)))))) (, ,) (NP (NP (NNP Society)) (PP (IN of) (NP (NNP Academic) (NNP Emergency) (NNP Medicine)))) (, ,) (NP (NP (NNP Centers)) (PP (IN for) (NP (NP (NNP Disease) (NNP Control)) (CC and) (NP (NNP Prevention))))) (, ,) (NP (DT the) (NNP GRADE) (NNP Working) (NNP Group)) (, ,) (CC and) (NP (NP (DT the) (NNP IDSA) (NNPS Standards)) (CC and) (NP (NNP Practice) (NNS Guidelines) (NNP Committee))))) (. .)))
(ROOT (S (NP (DT The) (NN group)) (VP (VBD convened) (NP (DT a) (JJ face-to-face) (NN meeting)) (PP (IN in) (NP (NP (NNP December) (CD 2008)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (S (NP (NP (DT an) (NN outline)) (PP (IN of) (NP (DT the) (NN guideline)))) (VP (VBD was) (VP (VBN discussed)))) (CC and) (S (NP (NP (NP (DT the) (NN process)) (PP (IN of) (NP (NN guideline) (NN development)))) (VP (VBG using) (NP (DT the) (NNP GRADE) (NN approach)))) (VP (VBD was) (ADVP (RB briefly)) (VP (VBN reviewed))))))))) (. .)))
(ROOT (S (NP (NN GRADE)) (VP (VBZ is) (NP (NP (DT a) (ADJP (RB newly) (VBN created)) (NN system)) (PP (IN for) (S (VP (VBG evaluating) (NP (NP (DT the) (NN quality)) (PP (IN of) (NP (NP (NN evidence)) (CC and) (NP (NP (NN strength)) (PP (IN of) (NP (NP (NNS recommendations)) (PP (IN for) (NP (NN healthcare)))))))))))))) (. .)))
(ROOT (S (NP (NP (DT The) (NP (JJ essential) (NNS steps))) (PP (IN for) (S (VP (VBG developing) (NP (NP (NNS recommendations)) (PP (IN by) (NP (DT the) (NNP GRADE) (NN approach)))))))) (VP (VBP are) (VP (VBN summarized) (PP (IN in) (NP (NNP Figure) (CD 3))))) (. .)))
(ROOT (S (NP (DT The) (JJ first) (NN task)) (VP (VBZ is) (S (VP (TO to) (VP (VP (VB identify)) (CC and) (VP (VB formulate) (S (NP (JJ precise) (NNS questions)) (VP (TO to) (VP (VB be) (VP (VBN addressed) (S (IN by) (NP (DT the) (NN guideline)) (-LRB- -LRB-) (NP (NP (NNS steps) (NP (CD 1)) (: --) (PRN (LST (LS 3)) (-RRB- -RRB-)))))))))))))) (. .)))
(ROOT (S (NP (DT These)) (VP (MD should) (VP (VP (VB address) (NP (ADJP (RB clinically) (JJ important)) (NNS outcomes))) (CC and) (VP (VB focus) (PP (IN on) (NP (NP (JJ specific) (NN patient) (NNS populations) (CC and) (NNS interventions)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADJP (JJ relevant)) (PP (IN at) (NP (NP (DT the) (NN point)) (PP (IN of) (NP (NN care) (PRN (-LRB- -LRB-) (NP (NNS steps) (NP (NP (CD 4)) (: --) (NP (CD 6)))) (-RRB- -RRB-)))))))))))))) (. .)))
(ROOT (S (S (NP (DT The) (JJ next) (NN task)) (VP (VBZ is) (S (VP (TO to) (VP (VB search) (PP (IN for) (NP (JJ available) (NN evidence)))))))) (, ,) (VP (VBP prepare) (NP (NP (NP (DT an) (NN evidence) (NN profile)) (, ,) (CC and) (NP (NN grade))) (NP (NP (DT the) (NN quality)) (PP (IN of) (NP (NP (NN evidence)) (PP (IN for) (NP (NP (DT each) (JJ important) (NN outcome)) (PRN (-LRB- -LRB-) (NP (NNS steps) (NP (NP (CD 7)) (: --) (NP (CD 8)))) (-RRB- -RRB-))))))))) (. .)))
(ROOT (S (S (NP (DT The) (JJ final) (NN task)) (VP (VBZ is) (S (VP (TO to) (VP (VB formulate) (NP (NP (NNS recommendations)) (VP (VBN based) (PP (IN on) (NP (NP (DT the) (NN balance)) (PP (IN of) (NP (NP (ADJP (ADJP (JJ desirable)) (CC vs) (ADJP (JJ undesirable))) (NNS consequences)) (PP (IN for) (NP (DT the) (NN intervention)))))))))))))) (, ,) (CC and) (S (VP (VB make) (NP (NP (DT a) (NN value) (NN judgment)) (VP (VBG regarding) (NP (NP (DT the) (NN strength)) (PP (IN of) (NP (DT the) (NN recommendation)))))))) (. .)))
(ROOT (S (ADVP (RB Thus)) (, ,) (NP (DT the) (NNP GRADE) (NN approach)) (VP (VBZ separates) (NP (NNS decisions)) (PP (VBG regarding) (NP (NP (DT the) (NN quality)) (PP (IN of) (NP (NN evidence))) (PP (IN from) (NP (NP (NN strength)) (PP (IN of) (NP (NNS recommendations)))))))) (. .)))
(ROOT (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT a) (JJ fundamental) (NN difference)) (PP (IN from) (NP (NP (DT the) (JJ previous) (NNP IDSA)) (PRN (: --) (NP (NP (NP (NNP US) (NNP Public) (NNP Health) (NNP Service)) (VP (VBG grading) (NP (NN system)))) (PRN (-LRB- -LSB-) (NP (CD 74)) (-RRB- -RSB-)))))))) (. .)))
(ROOT (S (NP (JJ High-quality) (NN evidence)) (VP (VBZ does) (RB not) (ADVP (RB necessarily)) (VP (VB constitute) (NP (NP (JJ strong) (NNS recommendations)) (, ,) (CC and) (S (ADVP (RB conversely)) (, ,) (NP (JJ strong) (NNS recommendations)) (VP (MD can) (ADVP (RB still)) (VP (VB arise) (PP (IN from) (NP (JJ low-quality) (NN evidence))) (SBAR (IN if) (S (NP (PRP one)) (VP (MD can) (VP (VB be) (ADJP (JJ confident) (SBAR (IN that) (S (NP (DT the) (VBN desired) (NNS benefits)) (ADVP (RB clearly)) (VP (VBP outweigh) (NP (DT the) (JJ undesirable) (NNS consequences)))))))))))))))) (. .)))
(ROOT (S (NP (NP (DT The) (JJ main) (NNS advantages)) (PP (IN of) (NP (DT the) (NNP GRADE) (NN approach)))) (VP (VBP are) (NP (NP (DT the) (ADJP (JJ detailed) (CC and) (JJ explicit)) (NNS criteria)) (PP (IN for) (S (S (VP (VBG grading) (NP (NP (DT the) (NN quality)) (PP (IN of) (NP (NN evidence)))))) (CC and) (NP (NP (DT the) (JJ transparent) (NN process)) (PP (IN for) (S (VP (VBG making) (NP (NNS recommendations)))))))))) (. .)))
(ROOT (S (NP (NP (DT The) (NN quality)) (PP (IN of) (NP (NN evidence)))) (VP (VBZ reflects) (NP (NP (DT the) (NN extent)) (SBAR (WHPP (TO to) (WHNP (WDT which))) (S (NP (NP (DT the) (NN confidence)) (PP (IN in) (NP (NP (NNS estimates)) (PP (IN of) (NP (DT the) (NNS effects)))))) (VP (VBZ is) (ADJP (JJ adequate) (S (VP (TO to) (VP (VB support) (NP (DT a) (JJ particular) (NN recommendation))))))))))) (. .)))
(ROOT (S (ADVP (RB Hence)) (, ,) (NP (NP (NNS judgments)) (PP (IN about) (NP (NP (DT the) (NN quality)) (PP (IN of) (NP (NN evidence)))))) (VP (VBP are) (ADVP (RB always)) (VP (VBN made) (ADVP (JJ relative) (PP (TO to) (NP (NP (DT the) (JJ specific) (NN context)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (DT this) (NN evidence)) (VP (VBZ is) (VP (VBN used)))))))))) (. .)))
(ROOT (S (NP (DT The) (NN GRADE) (NN system)) (VP (VBZ categorizes) (NP (NP (DT the) (NN quality)) (PP (IN of) (NP (NP (NN evidence)) (PP (IN as) (ADJP (ADJP (ADJP (ADJP (JJ high)) (, ,) (ADJP (JJ moderate))) (, ,) (ADJP (JJ low))) (, ,) (CC or) (ADJP (ADJP (RB very) (JJ low)) (PRN (-LRB- -LRB-) (NNP Table) (LST (LS 1) (-RRB- -RRB-))))))))) (PRN (-LRB- -LSB-) (NP (CD 6)) (-RRB- -RSB-))) (. .)))
(ROOT (S (NP (JJ High-quality) (NN evidence)) (VP (VBZ indicates) (SBAR (IN that) (S (NP (JJ further) (NN research)) (VP (VBZ is) (ADJP (RB very) (JJ unlikely) (S (VP (TO to) (VP (VB change) (NP (NP (PRP$ our) (NN confidence)) (PP (IN in) (NP (NP (DT the) (NN estimate)) (PP (IN of) (NP (NNS effects)))))))))))))) (. .)))
(ROOT (S (NP (JJ Moderate-quality) (NN evidence)) (VP (VBZ indicates) (SBAR (IN that) (S (NP (JJ further) (NN research)) (VP (VP (VBZ is) (ADJP (JJ likely) (S (VP (TO to) (VP (VB have) (NP (DT an) (JJ important) (NN impact)) (PP (IN on) (NP (NP (PRP$ our) (NN confidence)) (PP (IN in) (NP (NP (DT the) (NN estimate)) (PP (IN of) (NP (NN effect)))))))))))) (CC and) (VP (MD may) (VP (VB change) (NP (DT the) (NN estimate)))))))) (. .)))
(ROOT (S (NP (JJ Low-quality) (NN evidence)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (JJ further) (NN research)) (VP (VBZ is) (ADJP (RB very) (JJ likely) (S (VP (TO to) (VP (VB have) (NP (DT an) (JJ important) (NN impact)) (S (PP (IN on) (NP (NP (PRP$ our) (NN confidence)) (PP (IN in) (NP (NP (DT the) (NN estimate)) (PP (IN of) (NP (NN effect))))))) (CC or) (VP (VB change) (NP (DT the) (NN estimate)))))))))))) (. .)))
(ROOT (S (NP (RB Very) (JJ low-quality) (NN evidence)) (VP (VBZ indicates) (SBAR (IN that) (S (NP (NP (DT any) (NN estimate)) (PP (IN of) (NP (NN effect)))) (VP (VBZ is) (ADJP (RB very) (JJ uncertain)))))) (. .)))
(ROOT (S (NP (NN Expert) (NN opinion)) (VP (VBZ is) (RB not) (NP (NP (DT a) (NN category)) (PP (IN of) (NP (NN evidence))))) (. .)))
(ROOT (S (NP (NN Expert) (NN opinion)) (VP (VBZ represents) (NP (NP (DT an) (NN interpretation)) (PP (IN of) (NP (NP (NN evidence)) (VP (VBG ranging) (PP (PP (IN from) (NP (NP (NNS observations)) (PP (IN in) (NP (NP (NP (DT an) (NN expert) (POS 's)) (JJ own) (NN practice)) (PRN (-LRB- -LRB-) (NP (NP (JJ uncontrolled) (NNS observations)) (, ,) (NP (NN case) (NNS reports))) (-RRB- -RRB-)))))) (PP (TO to) (NP (NP (DT the) (NN interpretation)) (PP (IN of) (NP (NP (NNS RCTs) (CC and) (NNS meta-analyses)) (VP (VBN known) (PP (TO to) (NP (DT the) (NN expert))) (PP (IN in) (NP (DT the) (NN context) (PP (IN of) (S (VP (JJ other) (NP (NP (NNS experiences)) (CC and) (NP (NN knowledge))))))))))))))))))) (. .)))
(ROOT (S (NP (NP (DT The) (NN quality)) (PP (IN of) (NP (NN evidence)))) (VP (MD may) (VP (VB be) (VP (VBN upgraded) (CC or) (VBN downgraded) (PP (IN by) (NP (JJ additional) (NNS considerations)))))) (. .)))
(ROOT (S (PP (IN For) (NP (NN example))) (, ,) (NP (NP (JJ high-quality) (NN evidence)) (VP (VBN based) (PP (IN on) (NP (NNS RCTs))))) (VP (MD may) (VP (VB be) (VP (VBN downgraded) (ADJP (JJ due) (PP (TO to) (NP (NP (NNS limitations)) (PP (IN in) (NP (NP (NN study) (NN design) (CC or) (NN implementation)) (, ,) (NP (NP (JJ imprecise) (NNS estimates)) (PRN (-LRB- -LRB-) (NP (FW eg) (, ,) (JJ wide) (NN confidence) (NNS intervals)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ unexplained) (NN variability)) (PP (IN in) (NP (NNS results)))) (, ,) (NP (NP (NN indirectness)) (PP (IN of) (NP (DT the) (NN evidence)))) (, ,) (CC and) (NP (NN publication) (NN bias)))))))))) (. .)))
(ROOT (S (ADVP (RB Conversely)) (, ,) (NP (NP (JJ low-quality) (NN evidence)) (VP (VBN based) (PP (IN on) (NP (JJ observational) (NNS studies))))) (VP (MD may) (VP (VB warrant) (S (VP (VBG upgrading) (SBAR (IN if) (S (NP (NP (DT the) (NN magnitude)) (PP (IN of) (NP (DT the) (NN treatment) (NN effect)))) (VP (VBZ is) (ADJP (RB very) (JJ large)) (, ,) (SBAR (IN if) (S (NP (EX there)) (VP (VBZ is) (NP (NP (NN evidence)) (PP (IN of) (NP (NP (DT a) (NN dose)) (PRN (: --) (NP (NP (NN response) (NN relation)) (, ,) (CC or) (SBAR (IN if) (S (NP (DT all) (JJ plausible) (NNS biases)) (VP (MD would) (VP (VB decrease) (NP (NP (DT the) (NN magnitude)) (PP (IN of) (NP (DT an) (JJ apparent) (NN treatment) (NN effect))))))))))))))))))))))) (. .)))
(ROOT (S (S (VP (TO To) (VP (VB facilitate) (NP (DT this) (NN process))))) (, ,) (NP (NP (DT a) (NN software) (NN program)) (PRN (-LRB- -LRB-) (NP (NN GRADEprofiler)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN used) (S (VP (TO to) (VP (VB produce) (NP (NP (NN evidence) (NNS tables)) (PP (VBG including) (NP (NP (NP (DT the) (NN assessment)) (PP (IN of) (NP (NP (NN quality)) (PP (IN of) (NP (NN evidence)))))) (CC and) (NP (NP (DT a) (NN summary)) (PP (IN of) (NP (NP (NNS findings)) (PRN (-LRB- -LRB-) (NP (NP (NP (DT the) (NN effect) (NN size)) (PP (IN in) (NP (DT the) (NN intervention) (CC and) (NN comparison) (NNS groups)))) (, ,) (CC and) (NP (NP (DT the) (NN magnitude)) (PP (IN of) (NP (ADJP (ADJP (JJ relative)) (CC and) (ADJP (JJ absolute))) (NNS effects))))) (-RRB- -RRB-))))))))))))) (. .)))
(ROOT (S (ADVP (RB Thus)) (NP (DT the) (NN evidence) (NN profile)) (VP (VBZ is) (NP (NP (DT a) (JJ transparent) (NN summary)) (PP (IN of) (NP (NP (NN evidence)) (SBAR (WHPP (IN on) (WHNP (WDT which))) (S (NP (NP (DT those)) (VP (VBG making) (NP (NNS recommendations)))) (VP (MD can) (VP (VB base) (NP (PRP$ their) (NNS judgments)))))))))) (. .)))
(ROOT (S (NP (NP (DT The) (NN strength)) (PP (IN of) (NP (NN recommendation)))) (VP (VBZ is) (RB not) (VP (ADVP (RB solely)) (VBN linked) (PP (TO to) (NP (NP (DT the) (NN quality)) (PP (IN of) (NP (NN evidence))))))) (. .)))
(ROOT (S (ADVP (RB Rather)) (, ,) (NP (NP (DT the) (JJ key) (NN determinant)) (PP (IN of) (NP (NP (DT the) (NN strength)) (PP (IN of) (NP (DT a) (NN recommendation)))))) (VP (VBZ is) (NP (NP (NP (DT the) (NN balance)) (PP (IN between) (NP (DT the) (ADJP (ADJP (JJ desirable)) (CC and) (ADJP (JJ undesirable))) (NNS outcomes)))) (PRN (-LRB- -LRB-) (NP (ADVP (FW ie)) (, ,) (NP (NP (NNS risks)) (CC vs) (NP (NNS benefits)))) (-RRB- -RRB-))) (PP (IN for) (NP (NP (DT a) (ADJP (RB clinically) (JJ important)) (NN question)) (PRN (-LRB- -LSB-) (NP (CD 1)) (-RRB- -RSB-))))) (. .)))
(ROOT (S (NP (DT This)) (VP (VBZ implies) (NP (NP (NP (DT a) (JJ careful) (NN selection)) (PP (IN of) (NP (DT the) (ADJP (ADJP (JJ important)) (ADJP (JJ clinical))) (NNS questions))) (SBAR (S (VP (TO to) (VP (VB be) (VP (VBN addressed))))))) (CC and) (NP (NP (DT the) (JJ key) (NNS outcomes)) (SBAR (S (VP (TO to) (VP (VB be) (VP (VBN evaluated))))))))) (. .)))
(ROOT (S (NP (NP (JJ Other) (NNS factors)) (SBAR (WHNP (WDT that)) (S (VP (VBP determine) (NP (NP (DT the) (NN strength)) (PP (IN of) (NP (NN recommendation)))))))) (VP (VBP are) (NP (NP (DT the) (NN resource) (NNS implications)) (CC and) (NP (NP (NN variability)) (PP (IN in) (NP (NNS values) (CC and) (NNS preferences))) (PP (IN for) (CC or) (PP (IN against) (NP (NP (DT an) (JJ alternative) (NN management) (NN strategy)) (VP (VBN considered) (PP (IN by) (NP (DT the) (NN guideline) (NN panel)))))))))) (. .)))
(ROOT (S (S (NP (QP (RB Only) (CD 2)) (NNS grades)) (VP (VBP are) (VP (VBN assigned) (PP (IN for) (NP (NP (DT the) (NN strength)) (PP (IN of) (NP (NP (NN recommendation)) (PP (IN in) (NP (NNP GRADE)))))))))) (: :) (S (ADJP (JJ strong) (CC or) (JJ weak))) (. .)))
(ROOT (S (NP (DT A) (JJ strong) (NN recommendation)) (VP (VBZ reflects) (NP (NP (DT a) (JJ high) (NN degree)) (PP (IN of) (NP (NP (NN confidence)) (SBAR (WHNP (IN that)) (S (NP (NP (DT the) (JJ desirable) (NNS effects)) (PP (IN of) (NP (DT an) (NN intervention)))) (VP (VBP outweigh) (NP (DT the) (JJ undesirable) (NNS effects))))))))) (. .)))
(ROOT (S (NP (DT A) (JJ weak) (NN recommendation)) (VP (VBZ denotes) (SBAR (IN that) (NP (NP (NP (DT the) (JJ desirable) (NNS effects)) (PP (IN of) (ADJP (JJ adhering) (PP (TO to) (NP (DT a) (NN recommendation))) (ADVP (RB probably)) (ADJP (VP (VBP outweigh) (NP (DT the) (JJ undesirable) (NNS effects))))))) (, ,) (CC but) (S (NP (DT the) (NN panel)) (VP (VBZ is) (ADJP (RBR less) (JJ confident))))))) (. .)))
(ROOT (S (NP (DT The) (NNP GRADE) (NN approach)) (VP (VBZ offers) (S (NP (DT a) (JJ structured) (, ,) (JJ systematic) (, ,) (CC and) (JJ transparent) (NN process)) (VP (TO to) (VP (VB formulate) (NP (NP (NNS recommendations)) (PP (VBN based) (PP (IN on) (NP (NP (JJ explicit) (NNS criteria)) (SBAR (WHNP (WDT that)) (S (VP (VBP go) (PP (IN beyond) (NP (NP (RB just) (DT the) (NN quality)) (PP (IN of) (NP (NP (JJ available) (NN evidence)) (PRN (-LRB- -LRB-) (VP (VB please) (VP (VB visit) (NP (DT the) (NNP GRADE) (NN website)) (PP (IN at) (NP (NN http://www.gradeworkinggroup.org/))) (PP (IN for) (NP (JJR more) (NN information))))) (-RRB- -RRB-))))))))))))))))) (. .)))
(ROOT (S (NP (NP (DT A) (NN series)) (PP (IN of) (NP (JJ monthly) (NNS teleconferences)))) (VP (VBD was) (VP (VBN conducted) (S (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NP (DT a) (NN list)) (PP (IN of) (NP (JJ clinical) (NNS questions))) (S (VP (TO to) (VP (VB be) (VP (VBN addressed) (PP (IN by) (NP (DT the) (NN guideline)))))))) (VP (VBD was) (VP (VBN generated))))) (, ,) (VP (VBN discussed) (, ,) (CC and) (VP (VBN prioritized)))))) (. .)))
(ROOT (S (NP (PRP It)) (VP (VBD was) (VP (VBN determined) (PP (IN by) (NP (NP (DT the) (NN panel)) (SBAR (WHNP (WDT that)) (SBAR (IN because) (S (NP (NP (DT the) (NN entity)) (PP (IN of) (NP (JJ chronic) (NN rhinosinusitis)))) (VP (VBZ is) (ADJP (ADJP (RB so) (RB fundamentally) (JJ different) (PP (IN from) (NP (NP (JJ acute) (NN rhinosinusitis)) (PP (IN in) (NP (NP (NN patient) (NNS populations)) (, ,) (NP (NN epidemiology)) (, ,) (NP (NN pathophysiology)) (, ,) (CC and) (NP (NN management) (NNS strategies))))))) (, ,) (SBAR (S (NP (DT the) (JJ current) (NN guideline)) (VP (MD would) (ADVP (RB only)) (VP (VB address) (NP (NP (NNS issues)) (ADJP (VBN related) (PP (TO to) (NP (NP (DT the) (JJ initial) (NN management)) (PP (IN of) (NP (NP (NN ABRS)) (PP (IN in) (NP (CC both) (NP (NNS adults)) (CC and) (NP (NNS children))))))))))))))))))))))) (. .)))
(ROOT (S (NP (NP (NN Consensus)) (PP (IN among) (NP (DT the) (NN panel) (NNS members))) (PP (IN in) (S (VP (VBG grading) (NP (NP (DT the) (NN quality)) (PP (IN of) (NP (NP (NP (NN evidence)) (CC and) (NP (NN strength))) (PP (IN of) (NP (NNS recommendations)))))))))) (VP (VBD was) (VP (VBN developed) (S (VP (VBG using) (NP (NP (DT the) (NNP GRADE) (`` ``) (NN grid) ('' '') (NN technique)) (CC and) (NP (DT the) (NNP Delphi) (NN method))))) (PRN (-LRB- -LSB-) (NP (CD 3)) (-RRB- -RSB-)))) (. .)))
(ROOT (S (NP (NP (DT The) (NN draft) (NNS recommendations)) (VP (VBD were) (VP (VBN circulated) (PP (TO to) (NP (NP (DT all) (NN panel) (NNS members)) (CC and) (NP (DT each) (NN member))))))) (VP (VBD was) (VP (VBN asked) (S (VP (TO to) (VP (VB provide) (NP (NP (DT an) (NN opinion)) (PP (VBG regarding) (NP (NP (PRP$ their) (NN assessment)) (PP (IN of) (NP (NP (DT the) (NNS recommendations)) (SBAR (S (-LRB- -LRB-) (CC either) (S (ADVP (RB strongly)) (VP (VBP agree))) (, ,) (VBP agree) (PP (IN with) (NP (NP (NN reservation)) (, ,) (CC or) (VBP reject))) (-RRB- -RRB-)))))))) (PP (IN along) (PP (IN with) (NP (NP (DT the) (NNS reasons)) (PP (IN for) (NP (PRP$ their) (NN judgment))))))))))) (. .)))
(ROOT (S (PP (IN After) (NP (DT each) (NN round))) (, ,) (NP (DT an) (JJ impartial) (NN facilitator)) (VP (VBD provided) (NP (NP (DT an) (JJ anonymous) (NN summary)) (PP (IN of) (NP (NP (DT the) (JJ independent) (NN panel) (NNS responses)) (CONJP (RB as) (RB well) (IN as)) (NP (PRP$ their) (NN justification)))))) (. .)))
(ROOT (S (NP (NNS Panelists)) (VP (VBD were) (VP (VBN encouraged) (S (VP (TO to) (VP (VB revise) (NP (PRP$ their) (JJR earlier) (NNS answers)) (PP (IN in) (NP (NP (NN light)) (PP (IN of) (NP (NP (DT the) (NNS replies)) (PP (IN from) (NP (NP (DT the) (JJ other) (NNS members)) (PP (IN of) (NP (DT the) (NN panel)))))))))))))) (. .)))
(ROOT (S (NP (DT The) (NN process)) (VP (VBD was) (VP (VBN repeated) (SBAR (IN until) (S (NP (NN consensus)) (VP (VBD was) (VP (VBN developed) (PP (IN for) (NP (NP (CD 80) (NN %)) (PP (IN of) (NP (DT the) (NNS responses))) (PP (IN for) (NP (DT each) (JJ clinical) (NN question))))))))))) (. .)))
(ROOT (S (SBAR (IN Because) (S (NP (DT this)) (VP (VBD was) (NP (NP (DT the) (JJ first) (NN guideline)) (SBAR (S (VP (TO to) (VP (VB use) (NP (NP (DT the) (NN GRADE) (NN system)) (, ,) (NP (NP (NN preparation)) (PP (IN of) (NP (DT the) (NN evidence) (NN profile))))))))))))) (VP (VBD was) (VP (VBN assisted) (PP (IN by) (NP (NP (DT a) (NNP GRADE) (NN representative)) (PP (IN on) (NP (NP (DT the) (NN panel)) (SBAR (WHNP (WP who)) (S (VP (VBD provided) (NP (NP (JJ expert) (NN advice)) (PP (IN on) (NP (JJ methodological) (NNS issues)))) (PP (IN throughout) (NP (DT the) (NN guideline) (NN development)))))))))))) (. .)))
(ROOT (S (NP (DT The) (NN panel)) (VP (VP (VBD met) (PP (IN on) (NP (CD 2) (JJ additional) (NNS occasions)))) (CC and) (VP (VBD held) (NP (JJ multiple) (NNS teleconferences)) (S (VP (TO to) (VP (VB complete) (NP (NP (DT the) (NN work)) (PP (IN of) (NP (DT the) (NN guideline))))))))) (. .)))
(ROOT (S (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT the) (NNS teleconferences)))) (VP (VBD was) (S (VP (TO to) (VP (VB discuss) (S (NP (DT the) (NNS questions)) (, ,) (VP (VB distribute) (S (VP (VBG writing) (NP (NNS assignments))))))))))) (, ,) (CC and) (S (VP (VB finalize) (NP (NNS recommendations)))) (. .)))
(ROOT (S (NP (NP (DT All) (NNS members)) (PP (IN of) (NP (DT the) (NN panel)))) (VP (VBD participated) (PP (IN in) (NP (NP (DT the) (NP (NN preparation)) (CC and) (NP (NN review))) (PP (IN of) (NP (DT the) (NN draft) (NN guideline)))))) (. .)))
(ROOT (S (NP (NP (NN Feedback)) (PP (IN from) (NP (JJ external) (VBP peer) (NNS reviews)))) (VP (VBD was) (VP (VBN obtained))) (. .)))
(ROOT (S (NP (DT The) (NN guideline)) (VP (VP (VBD was) (VP (VBN reviewed))) (CC and) (VP (VP (VBN approved) (PP (IN by) (NP (NP (DT the) (NNP IDSA) (NNPS Standards)) (CC and) (NP (NNP Practice) (NNS Guidelines) (NNP Committee))))) (CC and) (NP (NP (DT the) (NNP Board)) (PP (IN of) (NP (NNS Directors))) (ADJP (RB prior) (PP (TO to) (NP (NN dissemination))))))) (. .)))
(ROOT (S (NP (NP (JJ Statistical) (NN analysis)) (PP (VBG including) (NP (NP (NP (JJ relative) (NN risk)) (PRN (-LRB- -LRB-) (NP (NN RR)) (-RRB- -RRB-))) (, ,) (NP (NP (NNS odds) (NNS ratios)) (PRN (-LRB- -LRB-) (NP (NNS ORs)) (-RRB- -RRB-))) (, ,) (NP (ADJP (CD 95) (NN %)) (NNS CIs)) (, ,) (NP (ADJP (JJ positive) (CC and) (JJ negative)) (JJ predictive) (NNS values)) (, ,) (CC and) (NP (NN χ) (NN ^) (CD 2) (NNS statistics))))) (VP (VBD was) (VP (VBN performed) (S (VP (VBG using) (NP (NP (DT the) (NNP Prism) (CD 4.0) (NN software) (NN package)) (PRN (-LRB- -LRB-) (NP (NP (NNP GraphPad)) (, ,) (NP (NNP San) (NNP Diego)) (, ,) (NP (NNP California))) (-RRB- -RRB-))))))) (. .)))
(ROOT (S (NP (NN Evidence) (NN summary) (NNS profiles)) (VP (VBD were) (VP (VBN generated)) (S (VP (VBG using) (NP (NP (NN GRADEprofiler) (CD 3.2.2) (NN software)) (PRN (-LRB- -LRB-) (NP (NN GRADE) (NNP Working) (NNP Group)) (-RRB- -RRB-)))))) (. .)))
(ROOT (S (NP (PRP We)) (VP (VP (VBD identified) (NP (JJ up-to-date) (JJ valid) (JJ systematic) (NNS reviews)) (PP (PP (IN from) (NP (NP (DT the) (NN MEDLINE) (NN database)) (CC and) (NP (DT the) (NNP Cochrane) (NNP Library)))) (, ,) (CC and) (RB also) (, ,) (PP (IN in) (NP (VBN selected) (NNS cases))))) (, ,) (NP (NP (NN reference) (NNS lists)) (PP (IN of) (NP (NP (DT the) (ADJP (RBS most) (JJ recent)) (JJ narrative) (NNS reviews)) (CC or) (NP (NP (NNS studies)) (PP (IN on) (NP (DT the) (NN topic)))))))) (. .)))
(ROOT (SINV (SBAR (IN Unless) (S (VP (VBN specified) (ADVP (RB otherwise))))) (, ,) (NP (DT the) (NN search) (NN period)) (VBD was) (NP (NP (CD 1980)) (: --) (NP (CD 2011)) (CC and) (NP (DT the) (NN search))) (VP (VBD was) (ADJP (JJ restricted) (PP (TO to) (NP (DT the) (JJ English) (NN literature))))) (. .)))
(ROOT (S (NP (NNPS Articles)) (VP (VBD were) (ADVP (RB also)) (VP (VBN retrieved) (PP (IN by) (NP (NP (NNS searches)) (PP (IN for) (NP (NP (JJ clinical) (NN diagnosis)) (, ,) (NP (NNS symptoms)) (CC and) (NP (NNS signs)) (, ,) (NP (NN microbiology)) (, ,) (NP (JJ antimicrobial) (NN resistance)) (, ,) (NP (NN CT)))))) (VP (VB scan) (, ,) (NP (NP (NNP MRI)) (, ,) (NP (JJ intranasal) (NNS steroids)) (, ,) (NP (NN saline) (NNS irrigations)) (, ,) (CC and) (NP (NNS complications)))))) (. .)))
(ROOT (S (NP (DT The) (NN panel) (NNS members)) (VP (VBD contributed) (NP (NN reference) (NNS lists)) (PP (IN in) (NP (DT these) (NNS areas)))) (. .)))
(ROOT (S (NP (NP (DT The) (NN quality)) (PP (IN of) (NP (NN evidence)))) (VP (VBD was) (VP (VBN evaluated) (PP (IN after) (NP (DT the) (NN literature) (NN review))))) (. .)))
(ROOT (S (NP (PRP We)) (VP (VP (VBD based) (NP (NP (PRP$ our) (NNS judgments)) (PP (IN on) (NP (DT these) (JJ systematic) (NNS reviews))))) (CC and) (PRN (, ,) (SBAR (IN if) (FRAG (ADJP (JJ applicable)))) (, ,)) (PP (IN on) (NP (NP (JJ additional) (NNS studies)) (VP (VBN published) (SBAR (IN after) (S (NP (DT the) (NNS reviews)) (VP (VBD were) (VP (VBN done))))))))) (. .)))
(ROOT (S (SBAR (WHADVP (WRB When)) (S (NP (DT no) (JJ systematic) (NN review)) (VP (VBD was) (ADJP (JJ available))))) (, ,) (NP (PRP we)) (VP (VBD evaluated) (S (NP (DT the) (JJ original) (NNS studies)) (VP (TO to) (VP (VB inform) (NP (NP (NNS judgments)) (PP (IN about) (NP (NP (DT the) (NN quality)) (PP (IN of) (NP (NP (DT the) (JJ underlying) (NN evidence)) (PP (IN from) (NP (NP (DT a) (JJ crude) (NN examination)) (PP (IN of) (NP (DT these) (NNS studies)))))))))))))) (. .)))
(ROOT (FRAG (UCP (NP (JJ Primary) (JJ key) (NN search) (NNS terms)) (VBD were) (SBAR (IN as) (S (VP (VBZ follows)) (: :))) (NP (NP (NP (JJ Amoxicillin-clavulanic) (NN acid)) (, ,) (NP (JJ Antimicrobial) (NN resistance)) (, ,) (NP (JJ Appropriate) (JJ antimicrobial) (, ,) (NNS β-lactams)) (, ,) (NP (NNPS Decongestants)) (, ,) (NP (NNPS Fluoroquinolones)) (, ,) (NP (NNP H.) (NNS influenzae)) (, ,) (NP (NNP Hypertonic)) (CC and) (NP (JJ isotonic) (NN saline))) (, ,) (NP (NNP M.) (NNP catarrhalis)) (, ,) (NP (NP (NNP Pathogens)) (, ,) (NP (NP (NNP Rhinosinusitis)) (PRN (-LRB- -LRB-) (NP (NP (NNS children)) (CC and) (NP (NNS adults))) (-RRB- -RRB-))) (, ,) (NP (NNP Sinusitis)) (, ,) (NP (NN Sinus) (NN aspiration))) (, ,) (NP (NNP S.) (FW pneumoniae)) (, ,) (NP (NN Stewardship)) (, ,) (NP (NNP Steroids)) (, ,) (CC and) (NP (NNP Upper) (JJ respiratory)))) (. .)))
(ROOT (S (NP (NP (DT All) (NNS members)) (PP (IN of) (NP (DT the) (NN expert) (NN panel)))) (VP (VBD complied) (PP (IN with) (NP (NP (DT the) (NN IDSA) (NN policy)) (PP (VBG regarding) (NP (NP (NP (NNS conflicts)) (PP (IN of) (NP (NN interest)))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ requires) (NP (NP (NN disclosure)) (PP (IN of) (NP (NP (DT any) (JJ financial) (CC or) (JJ other) (NN interest)) (SBAR (WHNP (WDT that)) (S (VP (MD might) (VP (VB be) (VP (VBN construed) (PP (IN as) (S (VP (VBG constituting) (NP (DT an) (JJ actual) (, ,) (JJ potential) (, ,) (CC or) (JJ apparent) (NN conflict))))))))))))))))))))) (. .)))
(ROOT (S (NP (NP (NNS Members)) (PP (IN of) (NP (DT the) (NN expert) (NN panel)))) (VP (VBD completed) (NP (NP (DT a) (NNS conflicts)) (PP (IN of) (NP (NP (NN interest) (NN disclosure) (NN statement)) (PP (IN from) (NP (DT the) (NNP IDSA))))))) (. .)))
(ROOT (FRAG (S (NP (NN Information)) (VP (VBD was) (VP (VBN requested) (S (VP (VBG regarding) (NP (NN employment))))))) (, ,) (NP (NP (NNS consultancies)) (, ,) (NP (NN stock) (NN ownership)) (, ,) (NP (NN honoraria)) (, ,) (NP (NN research) (NN funding)) (, ,) (NP (NN expert) (NN testimony)) (, ,) (CC and) (NP (NP (NN membership)) (PP (IN on) (NP (NN company) (JJ advisory) (NNS committees))))) (. .)))
(ROOT (S (NP (DT The) (NN panel)) (VP (VBD made) (NP (NNS decisions)) (PP (IN on) (NP (NP (DT a) (JJ case-by-case) (NN basis)) (PP (IN as) (PP (TO to) (SBAR (IN whether) (S (NP (NP (DT an) (NN individual) (POS 's)) (NN role)) (VP (MD should) (VP (VB be) (VP (VBN limited) (PP (IN as) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (DT a) (VBN perceived) (NN conflict))))))))))))))) (. .)))
(ROOT (S (NP (DT No) (VBG limiting) (NNS conflicts)) (VP (VBD were) (VP (VBN identified))) (. .)))
(ROOT (S (PP (IN At) (NP (NP (JJ annual) (NNS intervals)) (, ,) (NP (DT the) (NN panel) (NN chair)))) (, ,) (NP (NP (DT the) (NN liaison) (NN advisor)) (, ,) (CC and) (NP (NP (DT the) (NN chair)) (PP (IN of) (NP (NP (DT the) (NNPS Standards)) (CC and) (NP (NNP Practice) (NNS Guidelines) (NNP Committee)))))) (VP (MD will) (VP (VB determine) (NP (DT the) (NN need) (S (VP (TO to) (VP (VB update) (NP (NP (DT the) (NN guideline)) (VP (VBN based) (PP (IN on) (NP (NP (DT an) (NN examination)) (PP (IN of) (NP (DT the) (JJ current) (NN literature))))))))))))) (. .)))
(ROOT (S (SBAR (IN If) (FRAG (ADJP (JJ necessary)))) (, ,) (NP (DT the) (JJ entire) (NN panel)) (VP (MD will) (VP (VB reconvene) (S (VP (TO to) (VP (VB discuss) (NP (JJ potential) (NNS changes))))))) (. .)))
(ROOT (SBAR (WHADVP (WRB When)) (S (ADJP (JJ appropriate)) (, ,) (NP (DT the) (NN panel)) (VP (MD will) (VP (VP (VB recommend) (NP (NP (JJ full) (NN revision)) (PP (IN of) (NP (DT the) (NN guideline)))) (PP (TO to) (NP (NP (DT the) (NNP IDSA) (NNPS Standards)) (CC and) (NP (NNP Practice) (NNS Guidelines) (NNP Committee))))) (CC and) (NP (NP (DT the) (NNP IDSA) (NNP Board)) (PP (IN for) (NP (NP (NN review)) (CC and) (NP (NN approval)))))))) (. .)))
(ROOT (NP (NP (NN I.)) (FRAG (WHNP (WDT Which) (JJ Clinical) (NNS Presentations)) (NP (NP (JJS Best) (NN Identify) (NNS Patients)) (PP (IN With) (NP (JJ Acute) (JJ Bacterial) (NNP Versus) (JJ Viral) (NN Rhinosinusitis))))) (. ?)))
(ROOT (LST (LS 1) (. .)))
(ROOT (S (NP (DT The) (PP (VBG following) (NP (NP (JJ clinical) (NNS presentations)) (PRN (-LRB- -LRB-) (NP (NP (DT any)) (PP (IN of) (NP (CD 3)))) (-RRB- -RRB-))))) (VP (VBP are) (VP (VBN recommended) (PP (IN for) (S (VP (VBG identifying) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ acute) (JJ bacterial)) (CC vs) (NP (ADJP (JJ viral))) (NP (NN rhinosinusitis)))))))))) (: :)))
(ROOT (NP (NP (NP (NNP i.) (NNP Onset)) (PP (IN with) (NP (NP (JJ persistent) (NNS symptoms)) (CC or) (NP (NP (NNS signs)) (ADJP (JJ compatible) (PP (IN with) (NP (JJ acute) (NN rhinosinusitis)))))))) (, ,) (VP (VBG lasting) (PP (IN for) (NP (CD ≥) (CD 10) (NNS days))) (PP (IN without) (NP (NP (DT any) (NN evidence)) (PP (IN of) (NP (NP (JJ clinical) (NN improvement)) (PRN (-LRB- -LRB-) (ADJP (ADJP (JJ strong)) (, ,) (ADJP (JJ low-moderate))) (-RRB- -RRB-))))))) (: ;)))
(ROOT (LST (LS ii) (. .)))
(ROOT (NP (NP (NN Onset)) (PP (IN with) (NP (NP (NP (JJ severe) (NNS symptoms)) (CC or) (NP (NP (NNS signs)) (PP (IN of) (NP (NP (NP (JJ high) (NN fever)) (PRN (-LRB- -LRB-) (NP (NP (CD ≥) (CD 39) (NN °) (NN C)) (PRN (-LRB- -LSB-) (NP (QP (CD 102) (CD °)) (NN F)) (-RRB- -RSB-))) (-RRB- -RRB-))) (CC and) (NP (JJ purulent) (JJ nasal) (NN discharge)))))) (CC or) (NP (JJ facial) (NN pain)))) (VP (VBG lasting) (PP (IN for) (NP (QP (IN at) (JJS least) (CD 3))))) (: --) (NP (NP (CD 4) (JJ consecutive) (NNS days)) (PP (IN at) (NP (NP (DT the) (NN beginning)) (PP (IN of) (NP (NP (NN illness)) (PRN (-LRB- -LRB-) (ADJP (ADJP (JJ strong)) (, ,) (ADJP (JJ low-moderate))) (-RRB- -RRB-))))))) (: ;) (NP (CC or))))
(ROOT (LST (LS iii) (. .)))
(ROOT (NP (NP (NP (NP (NN Onset)) (PP (IN with) (S (VP (VBG worsening) (NP (NP (NNS symptoms) (CC or) (NNS signs)) (VP (VBN characterized) (PP (IN by) (NP (NP (DT the) (JJ new) (NN onset)) (PP (IN of) (NP (NP (NN fever)) (, ,) (NP (NN headache)) (, ,) (CC or) (NP (NN increase)))))))) (PP (IN in) (NP (JJ nasal) (NN discharge))) (PP (VBG following) (NP (NP (DT a) (JJ typical) (JJ viral) (NNP URI)) (SBAR (WHNP (WDT that)) (S (VP (VBD lasted) (NP (CD 5))))))))))) (: --) (NP (CD 6) (NNS days)) (CC and) (VP (VP (VBD were) (ADVP (RB initially)) (VP (VBG improving))) (ADJP (PRN (-LRB- -LRB-) (`` ``) (JJ double-sickening) ('' '') (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (ADJP (JJ strong) (, ,) (JJ low-moderate)) (-RRB- -RRB-))))) (. .)))
(ROOT (S (S (NP (NP (DT The) (JJ clinical) (NN diagnosis)) (PP (IN of) (NP (NN ABRS)))) (VP (VBZ requires) (NP (DT a) (JJ 2-step) (NN process))) (: :)) (S (VP (LST (-LRB- -LRB-) (LS 1) (-RRB- -RRB-)) (NP (NP (NN evidence)) (PP (IN of) (NP (NN sinusitis))) (PP (VBN based) (PP (IN on) (NP (NP (JJ compatible) (NNS symptoms) (CC and) (NNS signs)) (CC and) (NP (LST (-LRB- -LRB-) (LS 2) (-RRB- -RRB-)) (NN evidence) (S (ADJP (JJ suggestive) (PP (IN of) (ADJP (JJ bacterial) (PP (RB rather) (IN than) (NP (NP (JJ viral) (NN infection)) (PP (VBN based) (PP (IN on) (NP (NP (JJ typical) (NN onset)) (CC and) (NP (NP (JJ temporal) (NN progression)) (PP (IN of) (NP (DT the) (JJ clinical) (NN course)))))))))))))))))))) (. .)))
(ROOT (S (NP (NP (JJR Earlier) (NNS studies)) (SBAR (WHNP (WDT that)) (S (VP (VBD evaluated) (NP (NP (DT the) (NN utility)) (PP (IN of) (NP (NP (JJ clinical) (NNS symptoms)) (CC and) (NP (NNS signs)))) (PP (IN for) (NP (NP (DT the) (NN diagnosis)) (PP (IN of) (NP (JJ acute) (NN rhinosinusitis)))))))))) (VP (VBD were) (VP (VBN based) (PP (IN on) (NP (NP (NN sinus) (NNS radiographs)) (CC or) (NP (NN CT) (NN imaging)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP do) (RB not) (VP (VB differentiate) (ADJP (JJ bacterial) (PP (IN from) (NP (NP (JJ viral) (NN rhinosinusitis)) (-LRB- -LSB-) (NP (CD 75)) (, ,) (NP (CD 76)) (-RRB- -RSB-)))))))))))) (. .)))
(ROOT (S (NP (DT These) (NNS studies)) (VP (VBD identified) (NP (NP (JJ several) (ADJP (JJ major) (CC and) (JJ minor)) (NNS symptoms)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADJP (JJ useful) (S (VP (TO to) (VP (VB identify) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ acute) (NN rhinosinusitis)))) (PRN (-LRB- -LRB-) (NP (ADVP (FW ie)) (, ,) (NP (NP (NN presence)) (PP (IN of) (NP (NP (QP (IN at) (JJS least) (CD 2)) (JJ major) (NNS symptoms)) (, ,) (CC or) (NP (NP (CD 1) (JJ major)) (CC plus) (NP (NN ≥) (CD 2) (JJ minor) (NNS symptoms))))) (SBAR (IN as) (S (VP (VBN summarized) (PP (IN in) (NP (NNP Table) (LS 2)))))))) (-RRB- -RRB-)) (PRN (-LRB- -LSB-) (NP (CD 7)) (-RRB- -RSB-))))))))))) (. .)))
(ROOT (S (ADVP (RB However)) (, ,) (S (VP (TO to) (VP (VB increase) (NP (NP (DT the) (NN likelihood)) (PP (IN of) (NP (NP (NP (DT a) (JJ bacterial)) (CONJP (RB rather) (IN than)) (NP (ADJP (JJ viral))) (NP (NN infection))) (, ,) (NP (ADJP (ADJP (JJ additional)) (ADJP (JJ clinical))) (NNS criteria)))))))) (VP (VBP are) (VP (VBN required))) (. .)))
(ROOT (S (NP (CD Two) (NNS studies)) (VP (VBN performed) (PP (IN in) (NP (NP (JJ adult) (NNS patients)) (VP (VBN attempted) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (JJ predictive) (NN value)) (PP (IN of) (NP (NP (NNS symptoms) (CC and) (NNS signs)) (PP (IN for) (NP (JJ maxillary) (NN sinusitis)))))))))))) (PP (VBN compared) (PP (IN with) (NP (NP (NN sinus) (NN puncture)) (PRN (-LRB- -LSB-) (NP (NP (CD 77)) (: --) (NP (CD 79))) (-RRB- -RSB-)))))) (. .)))
(ROOT (S (ADVP (RB Unfortunately)) (, ,) (S (S (NP (DT these) (NNS comparisons)) (VP (VBD were) (VP (VBN based) (S (PP (IN on) (NP (NP (DT the) (NN quality) (CC and) (NN appearance)) (PP (IN of) (NP (DT the) (NN sinus))))) (VP (VB aspirate) (PRN (-LRB- -LRB-) (FRAG (ADVP (FW ie)) (, ,) (ADJP (JJ purulent) (CC vs) (JJ mucopurulent) (CC or) (ADJP (JJ nonpurulent)))) (-RRB- -RRB-)) (PP (RB rather) (IN than) (NP (NN culture) (NNS results)))))))) (, ,) (CC and) (S (ADVP (RB therefore)) (VP (VBP are) (PP (IN of) (NP (ADJP (RB very) (JJ limited)) (NN value))) (PRN (-LRB- -LRB-) (NNP Table) (LS 4) (-RRB- -RRB-))))) (. .)))
(ROOT (S (NP (DT A) (JJ subsequent) (NN analysis)) (VP (VBD evaluated) (NP (NP (DT the) (JJ predictive) (NN value)) (PP (IN of) (NP (DT these) (ADJP (ADJP (JJ same)) (ADJP (JJ clinical))) (NNS parameters))) (PP (IN for) (NP (JJ culture-proven) (JJ maxillary) (NN sinusitis)))) (VP (PP (IN in) (NP (DT a) (JJ Danish) (JJ general) (NN practice) (JJ adult) (NN population))) (NP (PRN (-LRB- -LSB-) (NP (CD 78)) (-RRB- -RSB-))))) (. .)))
(ROOT (NP (NP (NP (NP (RB Only) (JJ maxillary) (NN toothache)) (PRN (-LRB- -LRB-) (NP (NP (NP (NN OR)) (, ,) (NP (CD 2.9))) (PRN (-LRB- -LSB-) (NP (NP (CD 95) (NN %) (NN CI)) (, ,) (NP (CD 1.3)) (: --) (NP (CD 6.3))) (-RRB- -RSB-))) (-RRB- -RRB-))) (CC and) (NP (NP (NP (NN temperature)) (ADJP (JJR >) (SBAR (S (NP (NP (NP (CD 38) (NN °) (NN C)) (PRN (-LRB- -LRB-) (NP (QP (JJR >) (CD 100.4)) (NN °) (NN F)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NP (NP (NN OR)) (, ,) (NP (CD 4.6))) (PRN (-LRB- -LSB-) (NP (NP (ADJP (CD 95) (NN %)) (NN CI)) (, ,) (NP (CD 1.9)) (: --) (NP (CD 11.2))) (-RRB- -RSB-))) (-RRB- -RRB-))) (VP (VBD were) (ADVP (RB significantly)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ positive) (NN sinus) (NN culture)) (PP (IN for) (NP (NNP S.) (FW pneumoniae) (CC or) (NNP H.) (NNS influenzae))))))))))) (PRN (-LRB- -LRB-) (NP (NNP Table) (CD 5)) (-RRB- -RRB-)))) (. .)))
(ROOT (S (ADVP (RB However)) (, ,) (S (NP (JJ maxillary) (NN toothache)) (VP (VBZ is) (NP (NP (DT an) (JJ uncommon) (NN manifestation)) (PP (IN of) (NP (NN ABRS))) (PP (IN except) (PP (IN in) (NP (JJ odontogenic) (NN sinusitis))))))) (, ,) (CC and) (S (NP (NP (QP (JJR >) (CD 50)) (NN %)) (PP (IN of) (NP (NN sinus) (NNS aspirates)))) (PP (IN in) (NP (DT this) (NN study))) (VP (VBD yielded) (NP (DT no) (NN growth)))) (. .)))
(ROOT (S (ADVP (RB Thus)) (, ,) (NP (EX there)) (VP (VBP are) (NP (NP (DT no) (JJ validated) (NNS studies)) (SBAR (WHNP (WDT that)) (S (VP (VBD examined) (NP (NP (NP (DT the) (JJ predictive) (NN value)) (PP (IN of) (NP (NP (JJ specific) (JJ clinical) (NNS symptoms)) (CC or) (NP (NP (NNS signs)) (PP (IN for) (NP (NP (DT the) (NN diagnosis)) (PP (IN of) (NP (NN ABRS))))))))) (VP (VBN based) (PP (IN on) (NP (NP (JJ bacterial) (NNS cultures)) (PP (IN of) (NP (NN sinus) (NNS aspirates)))))))))))) (. .)))
(ROOT (S (NP (DT The) (JJ current) (NN guideline)) (VP (VBZ recommends) (NP (NP (DT the) (NN adoption)) (PP (IN of) (NP (NP (JJ characteristic) (NNS patterns)) (PP (IN of) (NP (NP (JJ clinical) (NNS presentations)) (PP (IN for) (NP (NP (DT the) (JJ clinical) (NN diagnosis)) (PP (IN of) (NP (NNP ABRS)))))))))) (, ,) (S (VP (VBG taking) (PP (IN into) (NP (NN account))) (FRAG (CONJP (RB not) (RB only)) (NP (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (JJ respiratory) (NNS symptoms)))) (CONJP (CC but) (RB also)) (NP (NP (NP (DT the) (NN severity)) (PP (IN of) (NP (NP (NN illness)) (, ,) (NP (JJ temporal) (NN progression)) (, ,) (CC and) (NP (JJ classic) (JJ double-sickening)))) (PP (IN in) (NP (DT the) (JJ clinical) (NN course)))) (SBAR (S (VP (TO to) (VP (VB differentiate) (ADJP (JJ bacterial) (PP (IN from) (NP (JJ acute) (JJ viral) (NN rhinosinusitis)))))))))))))) (. .)))
(ROOT (S (NP (DT These) (NNS recommendations)) (VP (VBP are) (VP (VBN intended) (S (VP (TO to) (VP (VB improve) (NP (NP (DT the) (NN likelihood)) (PP (IN of) (S (VP (VBG separating) (NP (JJ acute) (JJ bacterial)) (S (IN from) (NP (JJ viral) (NN rhinosinusitis)) (ADVP (RB solely)) (VBN based) (PP (IN on) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NNS symptoms))))) (VP (VBP ≥) (NP (NP (CD 7)) (: --) (NP (CD 10) (NNS days)))))))))))))) (. .)))
(ROOT (S (NP (DT These) (NN inclusion) (NNS criteria)) (VP (VBD were) (VP (ADVP (JJ first)) (VBN proposed) (PP (IN in) (NP (CD 2003))) (PP (IN by) (NP (NP (DT a) (JJ multidisciplinary) (NN consensus) (NN panel)) (VP (ADVP (RB jointly)) (VBN established) (PP (IN by) (NP (NP (NP (CD 5) (JJ national) (NNS societies)) (PP (IN of) (NP (NN otolaryngology)))) (: --) (NP (NP (NP (NP (NP (NN head)) (CC and) (NP (NN neck) (NN surgery))) (, ,) (NP (NN allergy)) (, ,) (NP (NN asthma)) (, ,) (NP (NN immunology)) (, ,) (CC and) (NP (NP (JJ otolaryngic) (NN allergy)) (CC and) (NP (NN rhinology)))) (PRN (-LRB- -LSB-) (NP (CD 42)) (-RRB- -RSB-))) (PRN (-LRB- -LRB-) (VP (VB See) (`` ``) (NP (NNP Overview)) ('' '') (NP (NN section))) (-RRB- -RRB-)))))))))) (. .)))
(ROOT (S (NP (NP (DT A) (JJ similar) (NN definition)) (PP (IN for) (NP (NN ABRS)))) (-LRB- -LRB-) (NP (ADVP (FW ie)) (PRN (, ,) (NP (NP (JJ persistent) (NNS symptoms)) (PP (IN after) (NP (NP (CD 10) (NNS days)) (PP (IN with) (NP (NP (NP (JJR <) (CD 12) (NNS weeks) (POS ')) (NN duration)) (CC or) (NP (NP (NN worsening)) (PP (IN of) (NP (NNS symptoms)))))))) (PP (IN after) (NP (CD 5) (NNS days)))) (-RRB- -RRB-))) (VP (VBZ has) (VP (VBN been) (VP (VBN adopted) (PP (IN by) (NP (NP (DT the) (JJ European) (NN Position) (NN Paper)) (PP (IN on) (NP (NP (NNP Rhinosinusitis)) (CC and) (NP (JJ Nasal) (NNS Polyps)))))) (NP (CD 2007) (PRN (-LRB- -LSB-) (NP (CD 80)) (-RRB- -RSB-)))))) (. .)))
(ROOT (S (NP (NP (DT The) (NN validity)) (PP (IN of) (NP (DT these) (NN inclusion) (NNS criteria)))) (VP (VBZ has) (VP (VBN been) (ADVP (RB primarily)) (VP (VBN verified) (PP (IN in) (NP (JJ pediatric) (NNS patients)))))) (. .)))
(ROOT (NP (NP (NP (NP (NP (NNP Wald) (FW et) (FW al)) (PRN (-LRB- -LSB-) (NP (CD 30)) (-RRB- -RSB-))) (VBN performed) (NN sinus) (NN puncture)) (PP (IN in) (NP (JJ pediatric) (NNS patients))) (SBAR (WHNP (WP who)) (S (VP (VP (VBD presented) (PP (IN with) (NP (CC either) (NP (JJ persistent) (NNS symptoms)) (CC or) (NP (JJ severe) (NN disease))))) (CC and) (VP (VBD recovered) (NP (JJ significant) (NNS pathogens)) (PP (IN in) (NP (JJ high) (NN density))) (PP (IN in) (NP (NP (CD 77) (NN %)) (PP (IN of) (NP (DT the) (NNS children)))))))))) (. .)))
(ROOT (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (DT the) (NN probability)) (PP (IN of) (NP (NP (VBG confirming) (NP (JJ bacterial) (NN infection)) (PP (IN by) (NP (NN sinus) (NN aspiration)))) (PP (IN among) (NP (NP (JJ adult) (NNS patients)) (PP (IN with) (NP (JJ respiratory) (NNS symptoms)))))))) (VP (VBP ≥) (NP (NP (CD 7)) (: --) (S (NP (NP (CD 10) (NNS days)) (PP (IN without) (S (VP (VBG qualifying) (NP (JJ additional) (NNS characteristics)) (PP (IN in) (NP (JJ clinical) (NN presentation))))))) (VP (VBZ is) (NP (RB only) (NP (NP (QP (RB approximately) (CD 60)) (NN %)) (PRN (-LRB- -LSB-) (NP (CD 41)) (-RRB- -RSB-)))))))) (. .)))
(ROOT (S (ADVP (RB Similarly)) (, ,) (PP (IN in) (NP (NP (DT a) (ADJP (RBR more) (JJ recent)) (JJ placebo-controlled) (NN RCT)) (PP (IN of) (NP (NP (JJ antimicrobial) (NN therapy)) (PP (IN for) (NP (NP (NNS ABRS)) (PP (IN in) (NP (NP (NNS adults)) (PP (IN with) (NP (JJ respiratory) (NNS symptoms))))))))))) (VP (VBP ≥) (NP (CD 7) (NNS days)) (, ,) (SBAR (S (NP (NP (QP (RB only) (CD 64)) (NN %)) (PP (IN of) (NP (VBN enrolled) (NNS patients)))) (VP (VBD had) (NP (JJ positive) (JJ bacterial) (NNS cultures)) (PP (IN by) (NP (NN sinus) (NN puncture))) (PRN (-LRB- -LSB-) (NP (CD 45)) (-RRB- -RSB-)))))) (. .)))
(ROOT (S (NP (DT This)) (VP (VBZ suggests) (SBAR (IN that) (NP (NP (NP (DT the) (JJ current) (NN practice)) (PP (IN of) (S (VP (VBG basing) (NP (NP (DT the) (NN diagnosis)) (PP (IN of) (NP (NN ABRS)))) (PP (ADVP (RB solely)) (IN on) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (CD 7))))))))) (: --) (S (NP (NP (NP (CD 10) (NNS days)) (PP (IN of) (NP (JJ compatible) (JJ respiratory) (NNS symptoms)))) (PP (IN without) (S (VP (VBG qualifying) (NP (JJ additional) (NNS characteristics)) (PP (IN in) (NP (JJ clinical) (NN presentation))))))) (VP (VBZ is) (ADJP (JJ inadequate)) (PP (IN in) (S (VP (VBG differentiating) (ADJP (JJ bacterial)) (PP (IN from) (NP (JJ viral) (JJ acute) (NN rhinosinusitis))))))))))) (. .)))
(ROOT (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN utility)) (PP (IN of) (NP (NP (JJ such) (JJ clinical) (NNS criteria)) (PP (IN for) (S (VP (VBG initiating) (NP (NP (JJ empiric) (JJ antimicrobial) (NN therapy)) (PP (IN in) (NP (NNS adults)))))))))) (VP (VBZ remains) (S (VP (TO to) (VP (VB be) (VP (VBN validated)))))) (. .)))
(ROOT (S (NP (NP (JJ Further) (NN evidence)) (PP (IN in) (NP (NP (NN support)) (PP (IN of) (S (VP (VBG adopting) (NP (NP (ADJP (RBR more) (JJ stringent)) (JJ clinical) (NNS criteria)) (PP (IN for) (NP (NN ABRS)))))))))) (VP (VBZ is) (VP (VBN suggested) (PP (IN by) (NP (NP (DT the) (JJ different) (NN response) (NNS rates)) (PP (IN among) (NP (NP (NNS children) (CC and) (NNS adults)) (VP (VBN enrolled) (PP (IN in) (NP (NP (JJ placebo-controlled) (NNS RCTs)) (PP (IN of) (NP (JJ antimicrobial) (NN therapy)))))))))))) (. .)))
(ROOT (S (PP (IN In) (NP (NP (CD 3) (NNS RCTs)) (VP (VBN performed) (PP (IN in) (NP (NP (NNS children)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NP (ADJP (RBR more) (JJ stringent)) (NNS criteria)) (PP (IN of) (ADJP (ADJP (JJ persistent)) (, ,) (ADJP (JJ severe)) (, ,) (CC or) (S (VP (VBG worsening) (NP (NNS presentations))))))) (VP (VBD were) (VP (VBN used) (PP (IN as) (NP (NN patient) (NN selection) (NNS criteria))) (PRN (-LRB- -LSB-) (NP (NP (CD 61)) (, ,) (NP (CD 62)) (, ,) (NP (CD 81))) (-RRB- -RSB-))))))))))) (, ,) (NP (ADJP (RB significantly) (JJR higher)) (NP (NN cure) (NNS rates))) (VP (VBD were) (VP (VBN demonstrated) (PP (IN with) (S (NP (NNS antibiotics)) (VP (VBN compared) (PP (IN with) (FRAG (NP (NN placebo)) (-LRB- -LRB-) (NP (NP (NP (NN mean)) (, ,) (NP (NP (CD 78) (NN %)) (CC vs) (NP (CD 60) (NN %))) (, ,) (ADVP (RB respectively))) (: ;) (NP (NP (NP (NN OR)) (, ,) (NP (CD 2.52))) (PRN (-LRB- -LSB-) (NP (NP (ADJP (CD 95) (NN %)) (NN CI)) (, ,) (NP (CD 1.52)) (: --) (NP (CD 4.18))) (-RRB- -RSB-))) (, ,) (CC and) (PRN (NP (NN NNT)) (IN of) (LST (CD 5) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NNP Table) (LS 3) (-RRB- -RRB-)))))))))) (. .)))
(ROOT (S (NP (NP (DT A) (JJ fourth) (NN RCT)) (PRN (-LRB- -LSB-) (NP (CD 63)) (-RRB- -RSB-))) (VP (VBD was) (RB not) (VP (VBN included) (PP (IN in) (NP (NP (DT this) (NN analysis)) (SBAR (IN as) (S (NP (NNS patients)) (VP (VBD were) (VP (VBN treated) (PP (IN with) (NP (NP (JJ inadequate) (NN dosing)) (PP (IN of) (NP (NNS antimicrobials))))))))))))) (. .)))
(ROOT (S (S (PP (IN In) (NP (NN contrast))) (PRN (, ,) (PP (IN among) (NP (NP (JJ placebo-controlled) (NNS RCTs)) (PP (IN in) (NP (NP (NNS adults)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NP (NN duration)) (PP (IN of) (NP (NNS symptoms)))) (VP (VBP ≥) (NP (CD 7))))))))) (: --)) (NP (CD 10) (NNS days)) (VP (VBD was) (NP (DT the) (JJ primary) (NN inclusion) (NNS criteria)))) (, ,) (NP (NP (DT the) (JJ beneficial) (NN effect)) (PP (IN of) (NP (JJ antimicrobial) (NN therapy)))) (VP (VBD was) (FRAG (ADJP (RBR less) (JJ prominent)) (-LRB- -LRB-) (NP (NP (NP (CD 73) (NN %)) (CC vs) (NP (CD 65) (NN %))) (: ;) (NP (NN OR)) (, ,) (NP (NP (CD 1.44)) (PRN (-LRB- -LSB-) (NP (NP (ADJP (CD 95) (NN %)) (NN CI)) (, ,) (NP (CD 1.24)) (: --) (NP (CD 1.68)) (-RRB- -RSB-) (, ,) (CC and) (NP (NP (NN NNT)) (PP (IN of) (NP (CD 13))))) (-RRB- -RRB-)))))) (. .)))
(ROOT (S (NP (NP (DT The) (NNS criteria)) (PP (IN of) (NP (JJ persistent) (NNS symptoms)))) (VP (VBP ≥) (NP (NP (CD 10) (NNS days)) (NP (NP (NN duration)) (CC and) (VP (VBG worsening) (NP (NP (NNS symptoms)) (CC or) (NP (NNS signs))) (PP (IN within) (NP (CD 5)))))) (: --) (SBAR (NP (CD 10) (NNS days)) (IN after) (S (NP (NP (JJ initial) (NN improvement)) (PRN (-LRB- -LRB-) (NP (JJ double-sickening)) (-RRB- -RRB-))) (VP (VBD were) (VP (VBN based) (PP (IN on) (NP (NP (JJR earlier) (NNS studies)) (PP (IN of) (NP (NP (NP (NP (DT the) (JJ natural) (NN history)) (PP (IN of) (NP (NN rhinovirus) (NNS infections)))) (PRN (-LRB- -LSB-) (NP (CD 40)) (-RRB- -RSB-))) (PRN (-LRB- -LRB-) (NP (NN Figure) (CD 2)) (-RRB- -RRB-))))))))))) (. .)))
(ROOT (S (SBAR (IN Although) (S (NP (NP (NP (CD 25) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NN rhinovirus) (NN infection)) (VP (ADVP (RB prospectively)) (VBN studied) (PP (IN by) (NP (NNP Gwaltney) (FW et) (FW al))))))))) (PRN (-LRB- -LSB-) (NP (CD 40)) (-RRB- -RSB-))) (VP (VBD had) (NP (NP (NNS symptoms)) (ADJP (JJR longer) (PP (IN than) (NP (CD 14) (NNS days)))))))) (, ,) (NP (PRP$ their) (JJ clinical) (NN course)) (VP (VBD was) (VP (VBG improving) (PP (IN before) (NP (DT the) (JJ 10-day) (NN mark))))) (. .)))
(ROOT (NP (NP (NP (DT The) (NN criterion)) (PP (IN of) (NP (NP (NP (NP (JJ severe) (NNS symptoms)) (CC or) (NP (NP (NNS signs)) (PP (IN of) (NP (NP (NP (JJ high) (NN fever)) (PRN (-LRB- -LRB-) (NP (NP (CD ≥) (CD 39) (NN °) (NN C)) (PRN (-LRB- -LSB-) (NP (QP (CD 102) (CD °)) (NN F)) (-RRB- -RSB-))) (-RRB- -RRB-))) (CC and) (NP (JJ purulent) (JJ nasal) (NN discharge)))))) (CC or) (NP (JJ facial) (NN pain))) (VP (VBG lasting) (PP (IN for) (NP (CD 3))))))) (: --) (S (NP (NP (CD 4) (NNS days)) (PP (IN at) (NP (NP (DT the) (NN beginning)) (PP (IN of) (NP (NN illness)))))) (VP (VBZ identifies) (NP (NP (DT a) (NN subpopulation)) (PP (IN with) (NP (NP (JJ severe) (NN disease)) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (JJ antimicrobial) (NN therapy)) (VP (VBZ is) (ADVP (RB clearly)) (VP (VBN warranted) (PP (IN before) (NP (DT the) (JJ 10-day) (`` ``) (VBG waiting) ('' '') (NN period)))))))))))) (. .)))
(ROOT (S (S (NP (DT This) (NN criterion)) (VP (VBD was) (RB not) (VP (VBN included) (PP (IN in) (NP (NP (DT the) (NN AAO-HNS) (NN guideline)) (PP (IN for) (NP (JJ adult) (NN rhinosinusitis))))) (PRN (-LRB- -LSB-) (NP (CD 13)) (-RRB- -RSB-))))) (, ,) (CC but) (S (VP (VBD was) (VP (VBN included) (PP (IN in) (NP (NP (DT the) (NN consensus) (NNS recommendations)) (PP (IN by) (NP (NNP Meltzer) (FW et) (FW al))))) (PRN (-LRB- -LSB-) (NP (CD 42)) (-RRB- -RSB-))))) (. .)))
(ROOT (S (NP (NP (ADJP (RBR More) (JJ stringent)) (NNS criteria)) (PP (IN of) (NP (NN patient) (NN selection))) (VP (VBN based) (PP (IN on) (NP (NP (NN duration)) (CONJP (RB as) (RB well) (IN as)) (NP (NP (JJ characteristic) (NN progression)) (PP (IN of) (NP (DT the) (JJ clinical) (NN course)))))))) (VP (MD should) (VP (VP (VB improve) (NP (NP (DT the) (NN differentiation)) (PP (IN of) (NP (NP (NN ABRS)) (PP (IN from) (NP (JJ viral) (NN rhinosinusitis))))))) (CC and) (VP (VB identify) (NP (NP (DT the) (NN patient) (NN population)) (ADJP (RBS most) (JJ likely) (S (VP (TO to) (VP (VB benefit) (PP (IN from) (NP (JJ empiric) (JJ antimicrobial) (NN therapy))))))))))) (. .)))
(ROOT (S (NP (NP (NN Adoption)) (PP (IN of) (NP (NP (ADJP (RBR more) (JJ stringent)) (JJ clinical) (NNS criteria)) (PP (IN for) (NP (NP (DT the) (NN diagnosis)) (PP (IN of) (NP (NN ABRS)))))))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (NN delay)) (PP (IN of) (NP (NP (JJ appropriate) (JJ antimicrobial) (NN therapy)) (PP (IN in) (NP (DT some) (NNS patients))))))))) (. .)))
(ROOT (S (S (ADVP (RB However)) (, ,) (NP (ADJP (JJR more) (JJ accurate)) (NN distinction)) (VP (MD will) (VP (VB be) (VP (VBN made) (PP (IN between) (NP (ADJP (ADJP (JJ bacterial)) (CC vs) (ADJP (JJ viral))) (NN rhinosinusitis))))))) (, ,) (CC and) (S (NP (NP (DT the) (NN overuse)) (PP (IN of) (NP (NNS antibiotics)))) (VP (MD will) (VP (VB be) (VP (VBN minimized))))) (. .)))
(ROOT (S (S (VP (VBG Reserving) (NP (NP (JJ antimicrobial) (NN therapy)) (PP (IN for) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NP (JJ severe)) (CC or) (NP (ADJP (JJ prolonged))) (NP (NN manifestation))) (PP (IN of) (NP (NN ABRS)))))))))) (VP (VBZ fails) (S (VP (TO to) (VP (VP (VB address) (NP (NP (NN quality)) (PP (IN of) (NP (NN life))))) (CC or) (NP (NN productivity) (NNS issues)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (ADJP (ADJP (JJ mild)) (CC or) (ADJP (JJ moderate))) (NNS symptoms)) (PP (IN of) (NP (NN ABRS))))))))))) (. .)))
(ROOT (S (NP (NP (JJ Radiographic) (NN confirmation)) (PP (IN of) (NP (NN sinus) (NN disease))) (PP (IN for) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ uncomplicated) (NN ABRS)))))) (VP (VP (VBZ is) (RB not) (ADJP (JJ necessary))) (CC and) (VP (VBZ is) (RB not) (VP (VBN advised)))) (. .)))
(ROOT (S (NP (NP (DT The) (JJ clinical) (NN differentiation)) (PP (IN of) (NP (JJ bacterial))) (PP (IN from) (NP (JJ viral) (JJ acute) (NN rhinosinusitis)))) (VP (VBZ remains) (ADJP (JJ problematic)) (PP (IN without) (NP (NP (JJ direct) (NN sinus) (NN aspiration)) (CC and) (NP (NN culture))))) (. .)))
(ROOT (S (NP (NP (JJ Additional) (NNS RCTs)) (PP (IN of) (NP (NP (JJ antibiotic) (CC vs) (NP (NN placebo)) (PP (IN in) (NP (JJ adult) (NNS patients)))) (VP (VBG meeting) (NP (JJ stringent) (JJ clinical) (NNS criteria))))) (SBAR (IN as) (S (VP (VBN outlined) (ADVP (RB above)))))) (VP (VBP are) (ADVP (RB urgently)) (VP (VBN needed))) (. .)))
(ROOT (S (NP (JJ Such) (NNS studies)) (VP (MD should) (VP (VB incorporate) (NP (DT both) (UCP (JJ pre) (: -) (CC and) (NP (NP (JJ posttherapy) (NN sinus) (NNS cultures)) (SBAR (S (VP (TO to) (VP (VB provide) (NP (NP (JJ critical) (NN information)) (PP (VBG regarding) (NP (NP (NP (DT the) (JJ natural) (NN history)) (PP (IN of) (NP (NN sinus) (NN infection)))) (CC and) (NP (NP (NN efficacy)) (PP (IN of) (NP (JJ antimicrobial) (NN therapy)))))))))))))))) (. .)))
(ROOT (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (JJ endoscopic) (JJ middle) (NN meatus) (NNS cultures))) (PP (IN in) (NP (NP (NN lieu)) (PP (IN of) (NP (NN sinus) (NN aspiration)))))) (VP (MD should) (VP (VB be) (VP (ADVP (JJ further)) (VBN evaluated) (PP (IN for) (NP (DT this) (NN purpose)))))) (. .)))
(ROOT (NP (NNP II) (. .)))
(ROOT (SBARQ (WHADVP (WRB When)) (SQ (MD Should) (NP (NNP Empiric) (NNP Antimicrobial) (NN Therapy)) (VP (VB Be) (VP (VBN Initiated) (PP (IN in) (NP (NP (NNS Patients)) (PP (IN With) (NP (NP (NNS Signs) (CC and) (NNS Symptoms)) (NP (NP (JJ Suggestive)) (PP (IN of) (NP (NNP ABRS))))))))))) (. ?)))
(ROOT (LST (LS 2) (. .)))
(ROOT (S (NP (PRP It)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (NP (JJ empiric) (JJ antimicrobial) (NN therapy)) (VP (VB be) (VP (VBN initiated) (ADVP (ADVP (RB as) (RB soon)) (SBAR (IN as) (S (NP (NP (DT the) (JJ clinical) (NN diagnosis)) (PP (IN of) (NP (NN ABRS)))) (VP (VBZ is) (VP (VBN established) (SBAR (IN as) (S (VP (VBN defined) (PP (IN in) (NP (NP (NN recommendation) (CD 1)) (PRN (-LRB- -LRB-) (ADJP (JJ strong) (, ,) (JJ moderate)) (-RRB- -RRB-)))))))))))))))))) (. .)))
(ROOT (SBAR (IN Because) (S (NP (NP (NN adoption)) (PP (IN of) (NP (NP (ADJP (RBR more) (JJ stringent)) (JJ clinical) (NNS criteria)) (VP (VBN based) (PP (IN on) (NP (NP (JJ characteristic) (NN onset)) (CC and) (NP (JJ clinical) (NNS presentations)))))))) (VP (VBZ is) (S (ADJP (RBR more) (JJ likely)) (S (VP (TO to) (VP (VB identify) (NP (NP (NP (NNS patients)) (PP (IN with) (NP (JJ bacterial)))) (PP (RB rather) (IN than) (NP (JJ acute) (JJ viral) (NN rhinosinusitis))))))) (, ,) (NP (NP (NN withholding)) (CC or) (VP (VBG delaying) (NP (JJ empiric) (JJ antimicrobial) (NN therapy)))) (VP (VBZ is) (RB not) (VP (VBN recommended)))))) (. .)))
(ROOT (S (S (VP (VB Prompt) (NP (NP (NN initiation)) (PP (IN of) (NP (JJ antimicrobial) (NN therapy)))) (SBAR (S (ADVP (ADVP (RB as) (RB soon)) (SBAR (IN as) (S (NP (NP (DT the) (JJ clinical) (NN diagnosis)) (PP (IN of) (NP (NN ABRS)))) (VP (VBZ is) (VP (VBN established) (SBAR (IN as) (S (VP (VBN defined) (PP (IN in) (NP (NN recommendation) (CD 1))))))))))) (VP (MD should) (VP (VB shorten) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NN illness)))))))))) (, ,) (VP (VBP provide) (NP (NP (JJR earlier) (JJ symptomatic) (NN relief)) (, ,) (VP (VP (VB restore) (NP (NP (NN quality)) (PP (IN of) (NP (NN life))))) (, ,) (CC and) (VP (VBP prevent) (NP (NP (NN recurrence)) (CC or) (NP (JJ suppurative) (NNS complications))))))) (. .)))
(ROOT (S (NP (DT This) (NN recommendation)) (VP (VBZ contravenes) (NP (NP (NP (DT a) (JJ popular) (NN management) (NN strategy)) (PP (IN of) (`` ``) (NP (JJ watchful) (NN waiting)) ('' ''))) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (JJ antibiotic) (NN therapy)) (VP (VBZ is) (VP (VBN withheld) (SBAR (IN unless) (S (NP (NNS patients)) (VP (VBP fail) (S (VP (TO to) (VP (VB respond) (PP (TO to) (NP (JJ symptomatic) (NN management))) (PRN (-LRB- -LSB-) (NP (CD 13) (, ,) (CD 82) (-RRB- -RSB-))))))))))))))) (. .)))
(ROOT (S (NP (NP (DT The) (NNS proponents)) (PP (IN of) (NP (DT this) (NN approach)))) (VP (VP (VBP cite) (NP (NP (NP (DT the) (NNS findings)) (PP (IN of) (NP (NP (NNS RCTs)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NP (NP (QP (RB approximately) (CD 70)) (NN %)) (PP (IN of) (NP (NNS patients)))) (PP (IN in) (NP (DT the) (NN placebo) (NN arm)))) (VP (VBD improved) (ADVP (RB spontaneously)) (PP (IN by) (NP (CD 7))))))))) (PRN (: --) (NP (NP (CD 12) (NNS days)) (PRN (-LRB- -LSB-) (NP (CD 25)) (-RRB- -RSB-))) (, ,)))) (CC and) (SBAR (IN that) (S (NP (NP (DT a) (NN strategy)) (PP (IN of) (S (VP (VBG delaying) (NP (JJ antimicrobial) (NNS prescriptions)) (PP (IN for) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ mild) (JJ upper) (JJ respiratory) (NN tract) (NNS infections))))))))) (VP (VBZ is) (NP (NP (DT an) (JJ effective) (NNS means)) (PP (IN of) (S (VP (VBG reducing) (NP (NP (JJ antibiotic) (NN usage)) (PRN (-LRB- -LSB-) (NP (CD 83)) (-RRB- -RSB-))))))))))) (. .)))
(ROOT (S (ADVP (RB However)) (, ,) (SBAR (IN as) (S (VP (VBN discussed) (ADVP (ADVP (RBR earlier)) (PP (IN in) (NP (DT this) (NN review))))))) (, ,) (NP (NP (DT the) (JJ high) (JJ spontaneous) (NN resolution) (NN rate)) (PP (IN in) (NP (DT these) (JJ placebo-controlled) (NNS RCTs)))) (VP (VBZ is) (ADVP (RBS most) (RB certainly)) (ADJP (JJ due) (PP (TO to) (NP (NP (ADJP (RBR less) (JJ stringent)) (NN patient) (NN selection)) (CC and) (NP (NP (DT the) (NN inclusion)) (PP (IN of) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD had) (NP (NP (JJ viral)) (CONJP (RB rather) (IN than)) (NP (ADJP (JJ true))) (NP (NNS ABRS))))))))))))) (. .)))
(ROOT (S (PP (IN In) (NP (NN contrast))) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NP (ADJP (RBR more) (JJ stringent)) (NN inclusion) (NNS criteria)) (PP (JJ such) (IN as) (NP (NP (DT those)) (VP (VBN outlined) (PP (IN in) (NP (NN recommendation) (CD 1))))))) (VP (VBD were) (VP (VBN employed))))) (, ,) (NP (NP (NNP Wald) (FW et) (FW al)) (PRN (-LRB- -LSB-) (NP (CD 61)) (-RRB- -RSB-))) (VP (VBD reported) (NP (NP (DT a) (ADJP (RB considerably) (JJR lower)) (JJ spontaneous) (NN improvement) (NN rate)) (PP (IN of) (NP (QP (RB only) (CD 32)) (NN %))) (PP (IN at) (NP (NP (CD 14) (NNS days)) (PP (IN in) (NP (NP (NNS children)) (VP (VBG receiving) (NP (NN placebo)))))))) (, ,) (PP (VBN compared) (PP (IN with) (NP (NP (CD 64) (NN %)) (PP (IN in) (NP (NP (DT those)) (VP (VBN treated) (PP (IN with) (NP (JJ amoxicillin-clavulanate))))))))) (, ,) (S (VP (VBG giving) (NP (NP (DT an) (NN NNT)) (PP (IN of) (NP (CD 3) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 95) (NN %) (NN CI)) (, ,) (NP (CD 1.7)) (: --) (NP (CD 16.7))) (: ;) (NP (NP (NN P)) (ADJP (JJR <) (NP (CD .05))))) (-RRB- -RRB-)))))))) (. .)))
(ROOT (S (NP (DT This) (NN RCT)) (VP (VBZ is) (ADJP (JJ notable)) (PP (CONJP (RB not) (RB only)) (PP (IN for) (NP (NP (PRP$ its) (JJ stringent) (NN inclusion/exclusion) (NNS criteria)) (PP (IN for) (S (VP (VBG initiating) (NP (JJ antimicrobial) (NN therapy))))))) (, ,) (CONJP (CC but) (RB also)) (PP (IN for) (NP (NP (PRP$ its) (NN adoption)) (PP (IN of) (NP (NP (DT a) (JJ clinical) (NN severity) (NN score)) (PP (IN for) (S (VP (VBG monitoring) (NP (NN patient) (NN progress))))))))))) (. .)))
(ROOT (S (ADVP (RB Thus)) (, ,) (NP (DT a) (JJ watchful) (VBG waiting) (NN strategy)) (VP (VBZ is) (ADJP (RB only) (JJ reasonable)) (SBAR (IN if) (S (S (NP (CD one)) (VP (VBZ is) (ADJP (JJ uncertain) (PP (IN about) (NP (NP (DT the) (NN diagnosis)) (PP (IN of) (NP (NN ABRS) (NN owing))) (PP (TO to) (NP (JJ mild) (NNS symptoms)))))))) (CC but) (S (VP (MD can) (RB not) (VP (VB be) (VP (VBN recommended) (SBAR (WHADVP (WRB when)) (S (NP (NP (ADJP (RBR more) (JJ stringent)) (JJ clinical) (NNS criteria)) (PP (IN for) (NP (NP (DT the) (NN diagnosis)) (PP (IN of) (NP (NNS ABRS)))))) (VP (VBP are) (VP (VBN applied)))))))))))) (. .)))
(ROOT (S (S (S (VP (VB Prompt) (NP (NP (JJ antimicrobial) (NN therapy)) (PP (IN for) (NP (NNS patients)))) (ADJP (RBR more) (JJ likely) (S (VP (TO to) (VP (VB have) (NP (ADJP (ADJP (ADJP (JJ acute)) (ADJP (JJ bacterial))) (CONJP (RB rather) (IN than)) (ADJP (JJ viral))) (NN rhinosinusitis)))))))) (VP (MD should) (VP (VB shorten) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NN illness))))))) (, ,) (VP (VBP provide) (NP (NP (JJR earlier) (NN symptom) (NN relief)) (, ,) (VP (VP (VB restore) (NP (NP (NN quality)) (PP (IN of) (NP (NN life))))) (, ,) (CC and) (VP (VBP prevent) (NP (NP (JJ recurrent) (NN infection)) (CC or) (NP (JJ suppurative) (NNS complications))))))) (. .)))
(ROOT (FRAG (S (VP (VB Prompt) (SBAR (S (NP (JJ antimicrobial) (NN therapy)) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (NN overuse)) (PP (IN of) (NP (NNS antibiotics))))))))))) (, ,) (NP (NP (VBD enhanced) (NN cost)) (, ,) (CC and) (NP (NP (NN risk)) (PP (IN of) (NP (NP (JJ adverse) (NNS effects)) (PP (IN in) (NP (DT those) (NNS patients))) (SBAR (WHNP (WP who)) (S (VP (VBP do) (VP (VB have) (NP (NP (JJ true) (JJ bacterial) (NN infection)) (CC but) (NP (JJ mild) (NN disease))))))))))) (. .)))
(ROOT (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN patient) (NN selection) (NNS criteria)) (VP (VBN specified) (PP (IN in) (NP (NN recommendation) (CD 1))))) (VP (VBP make) (S (NP (DT this) (NN possibility)) (ADJP (RBR less) (JJ likely)))) (. .)))
(ROOT (S (S (NP (NP (NP (DT Some) (NNS patients)) (PP (IN with) (NP (JJ mild)))) (CC but) (NP (JJ persistent) (NNS symptoms))) (VP (MD may) (VP (VB be) (VP (VBN observed) (PP (IN without) (NP (JJ antibiotic) (NN treatment))) (PP (IN for) (NP (CD 3) (NNS days)))))) (PRN (-LRB- -LRB-) (SBAR (IN because) (S (NP (NP (CD 84) (NN %)) (PP (IN of) (NP (JJ clinical) (NNS failures)))) (VP (VBD occurred) (PP (IN within) (NP (NP (CD 72) (NNS hours)) (PP (IN in) (NP (NP (NNS children)) (VP (VBG receiving) (NP (NN placebo)))))))))) (-RRB- -RRB-)) (PRN (-LRB- -LSB-) (NP (CD 61)) (-RRB- -RSB-))) (. .)))
(ROOT (S (S (NP (JJ Such) (NNS patients)) (VP (VBP require) (NP (JJ close) (NN observation)))) (: ;) (S (NP (JJ antimicrobial) (NN therapy)) (VP (MD should) (VP (VB be) (VP (VBN initiated) (ADVP (RB promptly)) (PP (IN after) (NP (CD 3) (NNS days))) (SBAR (IN if) (S (NP (EX there)) (VP (VBZ is) (ADVP (RB still)) (NP (DT no) (NN improvement))))))))) (. .)))
(ROOT (S (NP (NP (RBR More) (JJ placebo-controlled) (NNS RCTs)) (SBAR (WHNP (WDT that)) (S (VP (VBP incorporate) (NP (DT both) (NP (JJ pre) (: -) (CC and) (JJ posttherapy) (NN sinus) (NNS cultures)) (CC and) (NP (NP (DT a) (JJ clinical) (NN severity)) (VP (VBG scoring) (NP (NN system))))))))) (VP (VBP are) (ADVP (RB urgently)) (VP (VBN needed) (S (VP (TO to) (VP (VB provide) (NP (NP (JJ critical) (NN information)) (PP (VBG regarding) (NP (NP (NP (DT the) (JJ natural) (NN history)) (PP (IN of) (NP (NN ABRS)))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT the) (NP (NP (NN timeliness)) (CC and) (NP (NN efficacy)))) (PP (IN of) (NP (JJ antimicrobial) (NN therapy)))))))))))) (. .)))
(ROOT (NP (NNP III) (. .)))
(ROOT (SQ (MD Should) (NP (NNP Amoxicillin) (NNP Versus) (NNP Amoxicillin-Clavulanate)) (VP (VB Be) (VP (VBN Used) (PP (IN for) (NP (NP (JJ Initial) (NNP Empiric) (NNP Antimicrobial) (NN Therapy)) (PP (IN of) (NP (NN ABRS))))) (PP (IN in) (NP (NNP Children))))) (. ?)))
(ROOT (LST (LS 3) (. .)))
(ROOT (FRAG (ADVP (JJ Amoxicillin-clavulanate) (RB rather) (SBAR (IN than) (S (NP (NP (NNP amoxicillin)) (ADVP (RB alone))) (VP (VBZ is) (VP (VBN recommended) (PP (IN as) (NP (NP (JJ empiric) (JJ antimicrobial) (NN therapy)) (PP (IN for) (NP (NP (NNS ABRS)) (PP (IN in) (NP (NP (NNS children)) (PRN (-LRB- -LRB-) (ADJP (JJ strong) (, ,) (JJ moderate)) (-RRB- -RRB-))))))))))))) (. .)))
(ROOT (S (NP (DT The) (NN recommendation) (SBAR (WDT that) (S (ADJP (JJ amoxicillin-clavulanate) (PP (RB rather) (IN than) (NP (NP (NNP amoxicillin)) (ADVP (RB alone)))))))) (VP (VB be) (VP (VBN considered) (SBAR (IN as) (S (NP (NP (JJ first-line) (NN therapy)) (PP (IN for) (NP (NN ABRS)))) (VP (VBZ is) (VP (VBN based) (PP (IN on) (NP (NP (CD 2) (NNS observations)) (: :) (NP (NP (NP (NP (LST (-LRB- -LRB-) (LS 1) (-RRB- -RRB-)) (NP (DT the) (VBG increasing) (NN prevalence)) (PP (IN of) (NP (NNP H.) (NNS influenzae))) (PP (IN among) (NP (NP (JJ other) (JJ upper) (JJ respiratory) (NN tract) (NNS infections)) (PP (IN of) (NP (NP (NNS children)) (, ,) (RB particularly) (NP (NNP AOM)))))) (, ,) (PP (IN since) (NP (NP (DT the) (NN introduction)) (PP (IN of) (S (VP (VBN conjugated) (NP (NP (JJ pneumococcal) (NNS vaccines)) (PRN (-LRB- -LSB-) (NP (CD 84)) (-RRB- -RSB-))))))))) (: ;) (CC and) (NP (NP (LST (-LRB- -LRB-) (LS 2) (-RRB- -RRB-)) (NP (DT the) (JJ high) (NN prevalence)) (PP (IN of) (NP (NN β-lactamase))) (: --) (VP (VBG producing) (NP (JJ respiratory) (NNS pathogens)) (PP (IN in) (NP (NN ABRS))))) (PRN (-LRB- -LRB-) (NP (RB particularly) (NNP H.) (NNS influenzae) (CC and) (NN Moraxella) (NN catarrhalis)) (-RRB- -RRB-)))) (PP (IN among) (NP (JJ recent) (JJ respiratory) (NN tract) (NNS isolates)))) (PRN (-LRB- -LSB-) (NP (CD 85)) (-RRB- -RSB-))))))))))) (. .)))
(ROOT (FRAG (SBAR (IN Although) (S (NP (NP (NP (JJR earlier) (NNS studies)) (SBAR (WHNP (IN that)) (S (VP (VBN compared) (NP (NNP amoxicillin)) (S (VP (TO to) (VP (VB amoxicillin-clavulanate) (VP (VBD did) (RB not) (VP (VB find) (NP (NP (DT a) (JJ superior) (NN outcome)) (PP (IN with) (NP (JJ amoxicillin-clavulanate) (PRN (-LRB- -LSB-) (NP (CD 62) (, ,) (NP (CD 64))) (-RRB- -RSB-)))))))))))))) (, ,) (NP (DT these) (NNS studies))) (VP (VBD were) (VP (VBN performed) (PP (IN in) (NP (NP (DT an) (NN era)) (SBAR (WHADVP (WRB when)) (S (NP (CC both) (NP (NP (NP (DT the) (NN prevalence)) (PP (IN of) (NP (NNP H.) (NNS influenzae)))) (PRN (-LRB- -LRB-) (NP (CD 33) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (DT the) (NN proportion)) (PP (IN of) (NP (NN β-lactamase))))) (: --) (S (S (VP (VBG producing) (NP (NP (NNP H.) (NNS influenzae)) (PRN (-LRB- -LRB-) (NP (CD 18) (NN %)) (-RRB- -RRB-))))) (VP (VBD were) (ADJP (ADJP (RB relatively) (JJ low)) (PRN (-LRB- -LSB-) (NP (CD 30)) (-RRB- -RSB-))))))))))))) (. .)))
(ROOT (S (PP (IN In) (NP (NN contrast))) (NP (NP (PRN (, ,) (CC both) (NP (NP (NP (DT the) (NN prevalence)) (PP (IN of) (NP (NNP H.) (NNS influenzae)))) (PRN (-LRB- -LRB-) (NP (CD 40) (NN %)) (: --))) (NP (CD 45) (NN %)) (-RRB- -RRB-)) (CC and) (NAC (NN proportion) (PP (IN of) (NP (NN β-lactamase)))) (PRN (: --) (S (VP (VBG producing) (NP (NP (NNP H.) (NNS influenzae)) (PRN (-LRB- -LRB-) (NP (CD 37) (NN %)) (: --))) (NP (CD 50) (NN %)))))) (-RRB- -RRB-) (PRN (-LRB- -LRB-) (VP (VBN extrapolated) (PP (IN from) (NP (NP (JJ middle) (NN ear) (NN fluid) (NNS cultures)) (PP (IN of) (NP (NP (NNS children)) (PP (IN with) (NP (NN AOM)))))))) (-RRB- -RRB-))) (VP (VBP have) (ADVP (RB markedly)) (VP (VBN increased) (PP (IN among) (NP (NP (JJ other) (JJ upper) (JJ respiratory) (NN tract) (NNS infections)) (PP (IN since) (NP (NP (DT the) (JJ widespread) (NN use)) (PP (IN of) (S (VP (VBN conjugated) (NP (NP (JJ pneumococcal) (NNS vaccines)) (PRN (-LRB- -LSB-) (NP (CD 86)) (-RRB- -RSB-)))))))))))) (. .)))
(ROOT (S (NP (NP (DT The) (NN microbiology)) (PP (IN of) (NP (NP (JJ acute) (NN sinusitis)) (PP (IN in) (NP (NP (NNS children)) (VP (VBN obtained) (PP (IN by) (NP (NN sinus) (NN puncture))))))))) (VP (VBZ is) (VP (VBN summarized) (PP (IN in) (NP (NNP Table) (CD 6))))) (. .)))
(ROOT (S (NP (DT The) (NNS data)) (VP (VBD were) (VP (VBN analyzed) (PP (VBG according) (PP (PP (TO to) (NP (NP (NNS reports)) (VP (VBN published) (ADVP (RB prior) (PP (TO to) (NP (CD 2000))))))) (CC and) (PP (ADVP (JJR more) (RB recently)) (IN in) (NP (CD 2010))))))) (. .)))
(ROOT (S (S (NP (NP (DT The) (NN microbiology)) (PP (IN of) (NP (NP (NN ABRS)) (PP (IN in) (NP (NNS children)))))) (VP (VBD was) (VP (ADVP (JJ last)) (VP (VBN studied) (PP (IN in) (NP (NN detail))) (PP (IN in) (NP (CD 1984))) (PRN (-LRB- -LSB-) (NP (CD 81)) (-RRB- -RSB-)))))) (, ,) (CC and) (S (NP (DT no) (JJ current) (NNS data)) (VP (VBP are) (ADJP (JJ available)))) (. .)))
(ROOT (S (ADVP (RB Thus)) (, ,) (NP (ADJP (RBR more) (JJ recent)) (NNS data)) (VP (VBD were) (VP (VP (VBN extrapolated) (PP (IN from) (NP (NP (JJ middle) (NN ear) (NN fluid) (NNS cultures)) (PP (IN of) (NP (NP (NNS children)) (PP (IN with) (NP (NP (JJ acute) (NNP AOM)) (PP (IN in) (NP (DT the) (NN post)))))))))) (PRN (: --) (NP (NP (JJ pneumococcal) (NN vaccine) (NN era)) (PRN (-LRB- -LSB-) (NP (NP (CD 84)) (, ,) (NP (CD 86)) (, ,) (NP (CD 91))) (-RRB- -RSB-)))))) (. .)))
(ROOT (S (SBAR (IN Whereas) (S (NP (NNP S.) (FW pneumoniae)) (VP (VBD was) (ADJP (ADJP (RBR more) (JJ common)) (PP (IN than) (NP (NP (NNP H.) (NNS influenzae)) (ADVP (RB prior) (PP (TO to) (NP (CD 2000)))))))))) (, ,) (NP (NP (DT the) (NN prevalence)) (PP (IN of) (NP (NNP H.) (NNP influenzae)))) (VP (VBZ has) (ADVP (RB clearly)) (VP (VBN increased) (SBAR (IN while) (S (NP (NP (DT that)) (PP (IN of) (NP (NNP S.) (FW pneumoniae)))) (VP (VBZ has) (VP (VBN decreased) (PP (IN in) (NP (DT the) (NN post))))))))) (PRN (: --) (NP (NP (JJ pneumococcal) (NN vaccine) (NN era)) (, ,) (ADJP (JJ such) (SBAR (IN that) (S (ADVP (RB currently)) (NP (PRP they)) (VP (VBP are) (ADJP (ADJP (RB approximately) (JJ equal)) (PRN (-LRB- -LSB-) (NP (CD 86)) (-RRB- -RSB-))))))))) (. .)))
(ROOT (S (NP (NP (NNP Ampicillin) (NN resistance)) (PP (IN among) (NP (NNP H.) (NNS influenzae))) (ADJP (JJ due) (PP (TO to) (NP (NN β-lactamase) (NN production))))) (VP (VBZ is) (ADJP (ADJP (RB highly) (JJ prevalent) (JJ worldwide)) (PRN (-LRB- -LSB-) (NP (CD 85)) (-RRB- -RSB-)))) (. .)))
(ROOT (S (PP (IN In) (NP (NP (DT the) (NNP United) (NNPS States)) (PP (IN during) (NP (CD 2005))))) (NP (: --) (NP (CD 2007)) (, ,) (NP (CD 27) (NN %)) (: --) (NP (NP (CD 43) (NN %)) (PP (IN of) (NP (NP (NNP H.) (NNS influenzae)) (NP (JJ clinical) (NNS isolates)))))) (VP (VBD were) (ADJP (JJ resistant) (PP (TO to) (NP (NP (NNP amoxicillin)) (CC but) (ADJP (ADJP (JJ susceptible) (PP (TO to) (NP (JJ amoxicillin-clavulanate) (-LRB- -LSB-) (NP (NP (CD 93)) (: --) (NP (CD 95))) (-RRB- -RSB-)))) (PRN (-LRB- -LRB-) (NP (NNP Table) (CD 7)) (-RRB- -RRB-))))))) (. .)))
(ROOT (S (ADVP (RB Furthermore)) (, ,) (NP (NP (NN treatment) (NN failure)) (PP (IN from) (NP (NP (NNP amoxicillin)) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN isolation)) (PP (IN of) (NP (NN β-lactamase))))))))) (: --) (S (VP (VBG producing) (NP (NNP H.) (NNS influenzae)))) (VP (VBZ has) (VP (VBN been) (ADVP (RB well)) (VP (VBN documented) (PP (IN in) (NP (NP (NNS children)) (PP (IN with) (NP (NP (NN ABRS)) (PRN (-LRB- -LSB-) (NP (NP (CD 81)) (, ,) (NP (CD 96))) (-RRB- -RSB-))))))))) (. .)))
(ROOT (S (ADVP (RB Accordingly)) (, ,) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NN clavulanate)))) (VP (MD would) (VP (VP (VB improve) (NP (NP (DT the) (NN coverage)) (PP (IN of) (NP (JJ many) (NN β-lactamase))))) (: --) (S (VP (VP (VBG producing) (NP (NP (JJ respiratory) (NNS pathogens)) (PP (IN in) (NP (NP (NNS children)) (PP (IN with) (NP (NP (NN ABRS)) (, ,) (VP (VBN estimated) (S (VP (TO to) (VP (VB be) (NP (NP (NP (QP (RB approximately) (CD 25)) (NN %)) (PP (IN of) (NP (NP (DT all) (NNS patients)) (PP (IN with) (NP (NN ABRS)))))) (, ,) (PP (VBG including) (NP (QP (RB approximately) (CD 25)) (NN %)))))))) (: --)))))) (NP (NP (CD 35) (NN %)) (PP (IN of) (NP (NNP H.) (NNS influenzae))))) (CC and) (NP (NP (NP (CD 90) (NN %)) (PP (IN of) (NP (NNP M.) (NN catarrhalis) (NNS infections)))) (PRN (-LRB- -LSB-) (NP (CD 94)) (-RRB- -RSB-))))))) (. .)))
(ROOT (S (NP (NP (DT The) (NN addition)) (PP (IN of) (NP (NN clavulanate))) (PP (TO to) (NP (NNP amoxicillin)))) (ADVP (RB substantially)) (VP (VBZ improves) (NP (NP (DT the) (NN coverage)) (PP (IN for) (NP (NP (DT both) (NP (JJ ampicillin-resistant) (NN H.) (NNS influenzae)) (CC and) (NP (NN M.) (NN catarrhalis))) (PP (IN in) (NP (NNP ABRS))))))) (. .)))
(ROOT (UCP (S (NP (NP (DT The) (NN combination)) (PP (IN of) (NP (NP (NN clavulanate)) (PP (IN with) (NP (NNP amoxicillin))) (PP (IN for) (NP (NP (JJ empiric) (NN therapy)) (PP (IN of) (NP (NN ABRS)))))))) (VP (VBZ adds) (PP (TO to) (NP (DT the) (NN cost))))) (, ,) (NP (NP (NP (VBD increased) (NN likelihood)) (PP (IN of) (NP (NP (JJ adverse) (NNS effects)) (ADJP (JJ due) (PP (TO to) (NP (NN diarrhea))))))) (, ,) (CC and) (NP (NP (JJ rare) (NNS instances)) (PP (IN of) (NP (NP (NN hypersensitivity) (NN reaction)) (ADJP (JJ due) (PP (TO to) (NP (NN clavulanate)))))))) (. .)))
(ROOT (FRAG (PP (IN In) (NP (NP (NNS children)) (PP (IN with) (S (VP (VBG vomiting) (SBAR (IN that) (S (VP (VP (VBZ precludes) (NP (NP (NN administration)) (PP (IN of) (NP (JJ oral) (NNS antibiotics))))) (, ,) (SBAR (S (NP (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NN ceftriaxone)))) (PRN (-LRB- -LRB-) (NP (CD 50) (NN mg/kg/day)) (-RRB- -RRB-))) (VP (MD may) (VP (VB be) (VP (VP (VBN given) (ADVP (RB intravenously))) (CC or) (ADVP (RB intramuscularly))))))))))))))) (. .)))
(ROOT (S (NP (NP (NN Therapy)) (PP (IN with) (NP (DT an) (JJ oral) (JJ antibiotic)))) (VP (MD may) (VP (VB be) (VP (VBN initiated) (ADVP (NP (CD 24) (NNS hours)) (RB later)) (, ,) (PP (VBD provided) (SBAR (S (NP (DT the) (NN vomiting)) (VP (VBZ has) (VP (VBN resolved))))))))) (. .)))
(ROOT (S (NP (NP (NP (VBN Continued) (NN surveillance)) (PP (IN of) (NP (NP (JJ antimicrobial) (NN susceptibility) (NNS profiles)) (PP (IN of) (NP (DT all) (JJ respiratory) (NNS pathogens)))))) (PRN (-LRB- -LRB-) (ADJP (CC both) (ADJP (JJ regional)) (CC and) (ADJP (JJ national))) (-RRB- -RRB-))) (VP (MD should) (VP (VB be) (VP (VBN performed) (PP (IN at) (NP (NP (JJ regular) (NNS intervals)) (SBAR (S (VP (TO to) (VP (VB guide) (NP (JJ initial) (JJ empiric) (JJ antimicrobial) (NN therapy))))))))))) (. .)))
(ROOT (NP (CD IV) (. .)))
(ROOT (SQ (MD Should) (NP (NNP Amoxicillin) (NNP Versus) (NNP Amoxicillin-Clavulanate)) (VP (VB Be) (VP (VBN Used) (PP (IN for) (NP (NP (JJ Initial) (NNP Empiric) (NNP Antimicrobial) (NN Therapy)) (PP (IN of) (NP (NN ABRS))))) (PP (IN in) (NP (NNS Adults))))) (. ?)))
(ROOT (LST (LS 4) (. .)))
(ROOT (FRAG (ADVP (JJ Amoxicillin-clavulanate) (RB rather) (SBAR (IN than) (S (NP (NP (NNP amoxicillin)) (ADVP (RB alone))) (VP (VBZ is) (VP (VBN recommended) (PP (IN as) (NP (NP (JJ empiric) (JJ antimicrobial) (NN therapy)) (PP (IN for) (NP (NP (NNS ABRS)) (PP (IN in) (NP (NP (NNS adults)) (PRN (-LRB- -LRB-) (ADJP (ADJP (JJ weak)) (, ,) (ADJP (JJ low))) (-RRB- -RRB-))))))))))))) (. .)))
(ROOT (S (NP (NP (NNP National) (NN surveillance) (NNS data)) (PP (IN in) (NP (DT the) (NNP United) (NNPS States)))) (VP (VBP indicate) (SBAR (IN that) (FRAG (PP (IN during) (NP (CD 2005))) (PRN (: --) (S (NP (NP (CD 2007)) (, ,) (NP (NP (DT the) (NN prevalence) (NN rate)) (PP (IN of) (NP (NN β-lactamase)))) (: --) (VP (VBG producing) (NP (NNP H.) (NNS influenzae)))) (VP (VBD was) (NP (CD 27) (NN %)))) (: --)) (NP (NP (NP (CD 43) (NN %)) (PRN (-LRB- -LSB-) (NP (NP (CD 93)) (: --) (NP (CD 95))) (-RRB- -RSB-))) (PRN (-LRB- -LRB-) (NP (NNP Table) (CD 7)) (-RRB- -RRB-)))))) (. .)))
(ROOT (S (NP (NP (DT The) (NN rate)) (PP (IN of) (NP (NNP amoxicillin) (NN resistance)))) (VP (VP (VBD varied) (PP (PP (IN from) (NP (NN region))) (PP (TO to) (NP (NN region)))) (, ,) (S (VP (VBG ranging) (PP (PP (IN from) (NP (NP (CD 35) (NN %)) (PP (IN in) (NP (DT the) (NNP Southeast))))) (PP (TO to) (NP (NP (CD 25) (NN %)) (PP (IN in) (NP (DT the) (NNP Southwest))))))))) (, ,) (CC but) (SBAR (S (NP (EX there)) (VP (VBD was) (ADJP (ADJP (JJ little)) (CC or) (NP (NP (DT no) (JJ regional) (NN difference)) (PP (IN in) (NP (NP (DT the) (NN susceptibility)) (PP (TO to) (NP (NN amoxicillin-clavulanate))))))))))) (. .)))
(ROOT (S (PP (IN As) (PP (IN with) (NP (NNS children)))) (, ,) (NP (NN posttreatment) (NN sinus) (NNS cultures)) (VP (VP (VBP are) (VP (ADVP (RB rarely)) (VBN performed) (PP (IN in) (NP (NP (NNS adults)) (PP (IN in) (NP (NNP North) (NNP America))))))) (, ,) (CC and) (SBAR (S (NP (EX there)) (VP (VBP are) (NP (NP (NP (DT no) (NNS reports)) (PP (IN of) (NP (NP (JJ positive) (NN sinus) (NNS cultures)) (PP (IN for) (NP (NN β-lactamase)))))) (: --) (VP (VBG producing) (NP (NP (NNP H.) (NNS influenzae)) (PP (VBG following) (NP (NP (NNP amoxicillin) (NN therapy)) (PP (IN in) (NP (NP (NNS adults)) (PP (IN with) (NP (NN ABRS)))))))))))))) (. .)))
(ROOT (S (ADVP (RB However)) (, ,) (PP (IN in) (NP (CD one) (JJ Scandinavian) (NN study))) (, ,) (NP (NP (NP (DT a) (JJ high) (NN percentage)) (PRN (-LRB- -LRB-) (NP (CD 49) (NN %)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ antimicrobial) (NN treatment) (NN failure)))))) (VP (VBD had) (NP (NP (JJ positive) (NNS cultures)) (PP (IN for) (NP (NN β-lactamase)))) (PRN (: --) (S (VP (VBG producing) (NP (NNP H.) (NNS influenzae)) (PP (IN by) (NP (NN sinus) (NN puncture))) (PRN (-LRB- -LSB-) (NP (CD 77)) (-RRB- -RSB-)))))) (. .)))
(ROOT (S (NP (NP (NP (JJS Most)) (PP (IN of) (NP (DT these) (NNS patients)))) (PRN (-LRB- -LRB-) (NP (CD 66) (NN %)) (-RRB- -RRB-))) (VP (VP (VBD had) (VP (VBN received) (NP (NN phenoxymethyl) (NN penicillin)))) (CC and) (SBAR (S (NP (NN none)) (VP (VBD had) (VP (VBN received) (NP (CC either) (NP (NNP amoxicillin)) (CC or) (NP (NN ampicillin)))))))) (. .)))
(ROOT (S (ADVP (RB Thus)) (, ,) (NP (NP (DT the) (NN recommendation)) (PP (IN of) (S (VP (VBG choosing) (NP (NP (NN amoxicillin-clavulanate)) (PP (IN over) (NP (NNP amoxicillin)))) (PP (IN as) (NP (NP (JJ first-line) (NN therapy)) (PP (IN for) (NP (NP (NNS ABRS)) (PP (IN in) (NP (NNS adults))))))))))) (VP (VBZ is) (ADJP (RB relatively) (JJ weak))) (. .)))
(ROOT (FRAG (ADVP (RB Furthermore)) (, ,) (SBAR (IN although) (S (NP (NNP M.) (NN catarrhalis)) (VP (VBZ is) (ADVP (RB almost) (RB uniformly)) (ADJP (JJ resistant) (PP (TO to) (NP (NP (NNP amoxicillin)) (CC but) (S (JJ susceptible) (TO to) (FRAG (ADJP (JJ amoxicillin-clavulanate))) (, ,) (NP (PRP it)) (VP (VBZ is) (NP (NP (DT a) (ADJP (RBR less) (JJ frequent)) (NN cause)) (PP (IN of) (NP (NN ABRS))) (PP (IN in) (NP (NP (NNS adults)) (VP (VBN compared) (PP (IN with) (NP (NNS children))))))))))))))) (. .)))
(ROOT (S (ADVP (RB Nevertheless)) (, ,) (PP (IN in) (NP (NP (DT a) (JJ recent) (NN study)) (PP (IN in) (NP (NP (NNS adults)) (SBAR (WHNP (WDT that)) (S (VP (VBD examined) (NP (NP (DT the) (NN microbiology)) (PP (IN of) (NP (NN ABRS)))) (PP (IN by) (NP (NP (NN sinus) (NN puncture)) (PRN (-LRB- -LSB-) (NP (CD 45)) (-RRB- -RSB-))))))))))) (, ,) (NP (NNP H.) (NNS influenzae)) (VP (VBD was) (VP (VBN isolated) (PP (IN in) (NP (NP (CD 36) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ positive) (JJ bacterial) (NNS cultures)) (ADJP (JJ consistent) (PP (IN with) (NP (NN ABRS)))))))))) (, ,) (PP (VBN compared) (PP (IN with) (NP (NP (CD 38) (NN %)) (PP (IN for) (NP (NP (NNP S.) (FW pneumoniae)) (CC and) (NP (NP (NP (CD 16) (NN %)) (PP (IN for) (NP (NNP M.) (NN catarrhalis)))) (PRN (-LRB- -LRB-) (NP (NNP Table) (CD 6)) (-RRB- -RRB-)))))))))) (. .)))
(ROOT (S (ADVP (RB Unfortunately)) (, ,) (NP (NP (DT the) (NN rate)) (PP (IN of) (NP (NN β-lactamase)))) (: --) (S (VP (VBG producing) (NP (NNP H.) (NNS influenzae)))) (VP (VBD was) (RB not) (VP (VBN reported) (PP (IN in) (NP (DT this) (NN study))))) (. .)))
(ROOT (S (UCP (ADVP (RB Interestingly)) (, ,) (ADJP (JJ similar) (PP (TO to) (NP (DT the) (NN case)))) (PP (IN with) (NP (NP (NNP AOM)) (PP (IN in) (NP (NNS children)))))) (, ,) (NP (NP (DT the) (NN introduction)) (PP (IN of) (NP (VBN conjugated) (JJ pneumococcal) (NNS vaccines)))) (ADVP (RB also)) (VP (VBD had) (NP (NP (DT a) (JJ significant) (NN impact)) (PP (IN on) (NP (NP (DT the) (NN frequency)) (PP (IN of) (NP (NP (NN recovery)) (PP (IN of) (NP (NP (DT both) (NNP H.) (NN influenzae)) (CC and) (NP (NNP S.) (FW pneumoniae)))) (PP (IN in) (NP (NP (NNS adults)) (PP (IN with) (NP (JJ maxillary) (NN sinusitis))))))))))) (. .)))
(ROOT (S (NP (NP (NNP Brook) (FW et) (FW al)) (PRN (-LRB- -LSB-) (NP (CD 97)) (-RRB- -RSB-))) (VP (VBN obtained) (NP (JJ middle) (NN meatus) (NNS cultures)) (PP (IN from) (NP (CD 156) (NNS adults))) (PP (IN with) (NP (NP (NN ABRS)) (SBAR (IN between) (S (NP (NP (NP (NP (CD 1997)) (CC and) (NP (NP (CD 2000)) (PRN (-LRB- -LRB-) (NP (NN prevaccination)) (-RRB- -RRB-)))) (CC and) (NP (CD 229))) (NNS patients)) (NP (NP (PP (IN between) (NP (CD 2001) (CC and) (CD 2005)))) (PRN (-LRB- -LRB-) (NP (NN postvaccination)) (-RRB- -RRB-)))))))) (. .)))
(ROOT (S (S (NP (NP (DT The) (NN recovery)) (PP (IN of) (NP (NNP S.) (FW pneumoniae)))) (VP (VBD was) (ADVP (RB significantly)) (VP (VBN reduced) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 46) (NN %)) (NP (NN prevaccination))) (CC vs) (NP (ADJP (CD 35) (NN %))) (NP (NN postvaccination))) (: ;) (NP (NP (NN P)) (ADJP (JJR <) (NP (CD .05)))) (-RRB- -RRB-))) (, ,) (SBAR (IN whereas) (S (NP (NP (DT that)) (PP (IN of) (NP (NNP H.) (NNS influenzae)))) (VP (VBD was) (ADVP (RB significantly)) (VP (VBN increased) (-LRB- -LRB-) (NP (NP (CD 36) (NN %) (NN prevaccination)) (CC vs) (NP (CD 43) (NN %)) (NP (NN postvaccination))))))))) (: ;) (PRN (S (NP (NN P)) (ADJP (JJR <) (NP (CD .05)))) (-RRB- -RRB-)) (. .)))
(ROOT (S (PP (IN In) (NP (DT the) (JJ same) (NN study))) (, ,) (NP (NP (DT the) (NN proportion)) (PP (IN of) (NP (NN β-lactamase)))) (: --) (S (VP (VBG producing) (NP (NNP H.) (NNS influenzae)))) (ADVP (RB also)) (VP (VBD increased) (ADVP (RB slightly)) (PRN (-LRB- -LRB-) (PP (PP (IN from) (NP (CD 33) (NN %))) (PP (TO to) (NP (CD 39) (NN %)))) (-RRB- -RRB-)) (, ,) (SBAR (IN although) (S (NP (DT this) (NN difference)) (VP (VBD was) (RB not) (ADJP (RB statistically) (JJ significant)))))) (. .)))
(ROOT (S (ADVP (RB Thus)) (, ,) (NP (NP (DT the) (NN recommendation)) (PP (IN of) (NP (NP (NN amoxicillin-clavulanate)) (PP (IN in) (NP (NP (JJ adult) (NNS patients)) (PP (IN with) (NP (NN ABRS)))))))) (VP (VBZ is) (ADVP (RB primarily)) (PP (VBN based) (PP (IN on) (NP (NP (ADJP (FW in) (FW vitro)) (NN susceptibility) (NNS data)) (CC and) (NP (NP (DT the) (JJ current) (NN prevalence) (NNS rates)) (PP (IN of) (NP (NP (NN β-lactamase) (NN production)) (PP (IN among) (NP (NNP H.) (NNS influenzae)))))))))) (. .)))
(ROOT (S (NP (NP (DT The) (NN addition)) (PP (IN of) (NP (NN clavulanate))) (PP (TO to) (NP (NNP amoxicillin)))) (VP (MD will) (VP (VB improve) (NP (NP (DT the) (NN coverage)) (PP (IN of) (NP (CC both) (NP (JJ ampicillin-resistant) (NN H.) (NNS influenzae)) (CC and) (NP (NN M.) (NN catarrhalis))))) (PP (IN in) (NP (NP (NNS adults)) (PP (IN with) (NP (NN ABRS))))))) (. .)))
(ROOT (S (S (NP (NP (DT The) (NN addition)) (PP (IN of) (NP (NN clavulanate))) (PP (TO to) (NP (NNP amoxicillin)))) (VP (VBZ adds) (PP (TO to) (NP (NP (DT the) (NN cost)) (PP (IN of) (NP (NNS antibiotics))))))) (, ,) (NP (NP (NP (DT a) (JJ potential) (VBN increased) (NN risk)) (PP (IN of) (NP (NN diarrhea)))) (, ,) (CC and) (NP (NP (JJ rare) (NNS instances)) (PP (IN of) (NP (NP (NN hypersensitivity) (NN reaction)) (ADJP (JJ due) (PP (TO to) (NP (NN clavulanate)))))))) (. .)))
(ROOT (S (NP (JJ Standard-dose) (NN amoxicillin-clavulanate)) (VP (VBZ is) (VP (VBN recommended) (PP (IN as) (NP (NP (JJ first-line) (NN therapy)) (PP (IN for) (NP (NP (NNS ABRS)) (PP (IN in) (NP (DT both) (NNS children) (CC and) (NNS adults))))))))) (. .)))
(ROOT (S (ADVP (RB However)) (, ,) (NP (DT this) (NN regimen)) (VP (VBZ is) (ADJP (JJ inadequate) (PP (IN for) (NP (NP (NNP PNS) (NNP S.) (FW pneumoniae)) (, ,) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NP (DT the) (NN mechanism)) (PP (IN for) (NP (NN ampicillin) (NN resistance)))) (VP (VBZ is) (PP (JJ due) (TO to) (NP (NP (DT a) (NN mutation)) (PP (IN in) (NP (NP (NP (NN penicillin) (NN binding) (NN protein) (CD 3)) (PRN (-LRB- -LRB-) (NP (NN PBP3)) (-RRB- -RRB-))) (SBAR (WHNP (WDT that)) (S (VP (MD can) (RB not) (VP (VB be) (VP (VBN overcome) (PP (IN by) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (DT a) (NN β-lactamase) (NN inhibitor))))))))))))))))))))) (. .)))
(ROOT (S (PP (IN In) (NP (NN addition))) (, ,) (NP (EX there)) (VP (VBP are) (VP (VBG increasing) (NP (NP (NNS reports)) (PP (IN of) (NP (NN β-lactamase)))) (: --) (NP (JJ positive) (, ,) (NP (NP (JJ amoxicillin-clavulanate) (: --) (JJ resistant) (NNS strains)) (PP (IN of) (NP (NP (NNP H.) (NNS influenzae)) (VP (VBN isolated) (PP (IN from) (NP (NP (JJ various) (NNS parts)) (PP (IN of) (NP (NP (DT the) (NN world)) (PRN (-LRB- -LSB-) (NP (CD 85) (, ,) (NP (CD 98))) (-RRB- -RSB-))))))))))))) (. .)))
(ROOT (S (NP (NP (DT The) (NN prevalence)) (PP (IN of) (NP (DT these) (NNS isolates))) (PP (IN in) (NP (DT the) (NNP United) (NNPS States)))) (VP (VBZ is) (ADVP (RB currently)) (ADJP (JJ unknown))) (. .)))
(ROOT (S (NP (NP (VBN Continued) (NN surveillance)) (PP (IN of) (NP (NP (JJ antimicrobial) (NN susceptibility) (NNS profiles)) (PP (IN of) (NP (DT all) (JJ respiratory) (NNS pathogens)))))) (VP (MD should) (VP (VB be) (VP (VBN performed) (ADVP (DT both) (ADVP (RB nationally)) (CC and) (RB regionally))))) (. .)))
(ROOT (NP (NN V) (. .)))
(ROOT (SBARQ (WHADVP (WRB When)) (SQ (VBZ Is) (NP (NN High-Dose)) (NP (NNP Amoxicillin-Clavulanate) (NNP Recommended)) (PP (IN During) (NP (JJ Initial) (NNP Empiric) (NNP Antimicrobial) (NN Therapy))) (PP (IN for) (NP (NP (NNS ABRS)) (PP (IN in) (NP (NP (NNP Children)) (CC or) (NP (NNS Adults))))))) (. ?)))
(ROOT (LST (CD 5) (. .)))
(ROOT (S (NP (JJ High-dose) (PRN (-LRB- -LRB-) (NP (NP (CD 2) (NN g)) (ADJP (RB orally) (RB twice) (JJ daily) (CC or) (CD 90))) (NN mg/kg/day) (ADJP (RB orally) (RB twice) (JJ daily)) (-RRB- -RRB-)) (NN amoxicillin-clavulanate)) (VP (VBZ is) (VP (VBN recommended) (PP (IN for) (NP (NNS children) (CC and) (NNS adults))) (PP (IN with) (NP (NP (NN ABRS)) (PP (IN from) (NP (NP (JJ geographic) (NNS regions)) (PP (IN with) (NP (NP (NP (JJ high) (JJ endemic) (NNS rates)) (PRN (-LRB- -LRB-) (NP (QP (CD ≥) (CD 10)) (NN %)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (NP (JJ invasive) (NNP PNS) (NNP S.) (FW pneumoniae)) (, ,) (NP (NP (DT those)) (PP (IN with) (NP (NP (JJ severe) (NN infection)) (PRN (-LRB- -LRB-) (NP (ADVP (FW eg)) (, ,) (NP (NP (NN evidence)) (PP (IN of) (NP (JJ systemic) (NN toxicity))) (PP (IN with) (NP (NP (NP (NP (NN fever)) (PP (IN of) (NP (QP (CD 39) (CD °)) (NN C)))) (PRN (-LRB- -LSB-) (NP (QP (CD 102) (CD °)) (NN F)) (-RRB- -RSB-))) (CC or) (NP (ADJP (JJR higher))) (, ,) (CC and) (NP (NP (NN threat)) (PP (IN of) (NP (JJ suppurative) (NNS complications)))))))) (-RRB- -RRB-))))) (, ,) (NP (NP (NN attendance)) (PP (IN at) (NP (NN daycare)))) (, ,) (NP (NP (NN age)) (ADJP (JJR <) (NP (CD 2)))) (CC or) (NP (QP (JJR >) (CD 65)) (NNS years))) (, ,) (NP (JJ recent) (NN hospitalization)) (, ,) (NP (NP (JJ antibiotic) (NN use)) (PP (IN within) (NP (DT the) (JJ past) (NN month)))) (, ,) (CC or) (SBAR (WHNP (WP who)) (S (VP (VBP are) (ADJP (ADJP (JJ immunocompromised)) (PRN (-LRB- -LRB-) (ADJP (ADJP (JJ weak)) (, ,) (ADJP (JJ moderate))) (-RRB- -RRB-)))))))))))))))) (. .)))
(ROOT (S (S (NP (JJ High-dose) (NNP amoxicillin)) (VP (VBZ is) (VP (VBN preferred) (SBAR (IN over) (S (NP (JJ standard-dose) (NNP amoxicillin)) (ADVP (RB primarily)) (VP (TO to) (VP (VB cover) (NP (NP (NNP PNS) (NNP S.) (FW pneumoniae)) (CC and) (NP (NP (DT the) (ADJP (JJR less) (JJ common)) (NN occurrence)) (PP (IN of) (NP (JJ ampicillin-resistant) (JJ non-β-lactamase)))))))))))) (: --) (S (VP (VBG producing) (NP (NP (NNP H.) (NN influenzae)) (PRN (-LRB- -LSB-) (NP (CD 94)) (-RRB- -RSB-))))) (. .)))
(ROOT (S (NP (NP (VBN Increased) (NN resistance)) (PP (IN among) (NP (NNP PNS) (NNP S.) (FW pneumoniae)))) (VP (VBZ is) (PP (PP (JJ due) (TO to) (NP (NP (NNS alterations)) (PP (IN in) (NP (NN PBP3))))) (CC and) (NP (RB not) (NN β-lactamase) (NN production)))) (. .)))
(ROOT (S (NP (NP (DT The) (NN frequency)) (PP (IN of) (NP (NNP PNS) (NNP S.) (FW pneumoniae)))) (VP (VBZ is) (ADJP (RB highly) (JJ variable)) (PP (VBG depending) (PP (IN on) (NP (DT the) (JJ geographic) (NN region)))) (, ,) (S (VP (VBG being) (NP (ADJP (JJS highest)) (PP (IN in) (NP (DT the) (NNP Southeast))) (PRN (-LRB- -LRB-) (NP (CD ∼) (CD 25) (NN %)) (-RRB- -RRB-)) (CC and) (ADJP (JJS lowest) (PP (IN in) (NP (DT the) (NNP Northwest))) (PRN (-LRB- -LRB-) (NP (CD ∼) (CD 9) (NN %)) (-RRB- -RRB-))) (PRN (-LRB- -LSB-) (NP (CD 93)) (-RRB- -RSB-)))))) (. .)))
(ROOT (S (NP (S (VP (VBG Using) (NP (NP (JJ pre-2008) (NN CLSI) (NNS breakpoints)) (PP (IN for) (NP (NP (JJ oral) (NN treatment)) (PP (IN of) (NP (ADJP (JJ penicillin-intermediate)) (-LRB- -LRB-) (NP (NP (NP (JJ minimum) (JJ inhibitory) (NN concentration)) (PRN (-LRB- -LSB-) (NP (NN MIC)) (-RRB- -RSB-))) (NP (CD ≤) (CD 1) (NN μg) (: /) (NN mL))) (: ;)))))) (ADJP (JJ treatable) (PP (IN with) (NP (JJ high-dose) (NNP amoxicillin)))))) (-RRB- -RRB-) (CC and) (JJ penicillin-resistant) (NNP S.) (FW pneumoniae) (-LRB- -LRB-) (NP (NP (NN MIC) (NN ≥) (CD 2) (NN μg)) (: /) (NP (NN mL))) (: ;)) (ADJP (JJ untreatable) (PP (IN with) (NP (JJ high-dose) (NNP amoxicillin)))) (S (VP (-RRB- -RRB-))) (, ,) (NP (NP (DT the) (NNPS Centers)) (PP (IN for) (NP (NP (NNP Disease) (NNP Control)) (CC and) (NP (NNP Prevention))))) (VP (VBD showed) (PP (IN in) (NP (NP (DT a) (JJ 10-state) (NN surveillance) (NN study)) (PP (IN in) (NP (NP (CD 2006)) (: --) (NP (NP (CD 2007)) (SBAR (WHNP (WDT that)) (S (NP (NP (CD 15) (NN %)) (CC and) (NP (NP (CD 10) (NN %)) (PP (IN of) (NP (DT all) (JJ invasive) (NNP S.) (FW pneumoniae) (NNS isolates))))) (VP (VBD were) (ADJP (ADJP (JJ penicillin-intermediate)) (CC and) (ADJP (JJ penicillin-resistant)) (, ,) (ADVP (RB respectively))))))) (, ,))))) (SBAR (IN whereas) (S (NP (CD 75) (NN %)) (VP (VBD were) (ADJP (JJ susceptible) (PRN (-LRB- -LSB-) (NP (CD 68)) (-RRB- -RSB-))))))) (. .)))
(ROOT (FRAG (S (NP (NP (JJR Higher) (NN susceptibility) (NNS profiles)) (PP (IN for) (NP (NNP S.) (FW pneumoniae)))) (VP (VBD were) (VP (VBN reported) (PP (IN by) (NP (NP (NNP Harrison) (FW et) (FW al)) (PRN (-LRB- -LRB-) (ADJP (NP (CD 89) (NN %)) (JJ susceptible)) (-RRB- -RRB-)) (PRN (-LRB- -LSB-) (NP (CD 94)) (-RRB- -RSB-))))))) (, ,) (NP (NP (NP (NP (NNP Critchley) (FW et) (FW al)) (PRN (-LRB- -LRB-) (ADJP (NP (CD 92) (NN %)) (JJ susceptible)) (-RRB- -RRB-)) (PRN (-LRB- -LSB-) (NP (CD 93)) (-RRB- -RSB-))) (, ,) (CC and) (NP (NP (NNP Sahm) (FW et) (FW al)) (PRN (-LRB- -LRB-) (ADJP (NP (CD 92) (NN %)) (JJ susceptible)) (-RRB- -RRB-)))) (PRN (-LRB- -LSB-) (NP (CD 95)) (-RRB- -RSB-)) (PRN (-LRB- -LRB-) (NP (NNP Table) (CD 7)) (-RRB- -RRB-))) (. .)))
(ROOT (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NN introduction)) (PP (IN of) (NP (NP (DT the) (JJ 13-valent) (JJ pneumococcal) (VBN conjugated) (NN vaccine)) (PRN (-LRB- -LRB-) (NP (NN PCV13)) (-RRB- -RRB-)))) (PP (IN in) (NP (CD 2010)))) (VP (MD may) (ADVP (RB further)) (VP (VB decrease) (NP (NP (NP (DT the) (NN prevalence)) (PP (IN of) (NP (JJ invasive) (JJ pneumococcal) (NNS infections)))) (PP (VBG including) (NP (NP (DT those)) (VP (VBN caused) (PP (IN by) (NP (DT some) (NNP PNS) (NNP S.) (FW pneumoniae) (NNS isolates))))))) (PRN (-LRB- -LSB-) (NP (CD 99)) (-RRB- -RSB-)))) (. .)))
(ROOT (S (NP (DT This)) (VP (MD would) (VP (VB suggest) (ADVP (IN that) (PP (IN unless) (NP (NP (NP (DT the) (JJ endemic) (NN rate)) (PP (IN of) (NP (NNP PNS) (NNP S.)))) (SBAR (FW pneumoniae) (S (VP (VBZ is) (SBAR (S (NP (ADJP (ADJP (ADJP (RB unusually) (JJ high)) (PRN (-LRB- -LRB-) (NP (CD ≥) (CD 10) (NN %)) (-RRB- -RRB-))) (, ,) (ADJP (JJ standard-dose))) (NN amoxicillin-clavulanate)) (VP (MD should) (VP (VB suffice) (PP (IN as) (NP (NP (JJ first-line) (NN therapy)) (PP (IN for) (NP (NP (JJ nonmeningeal) (JJ pneumococcal) (NNS infections)) (PP (VBG including) (NP (NN ABRS))))))))))))))))))) (. .)))
(ROOT (S (NP (EX There)) (VP (VBP are) (NP (NP (DT no) (JJ clinical) (NNS data)) (PP (IN in) (NP (DT the) (NN literature))) (NP (WHNP (IN that)) (PP (VBN compared) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (ADJP (JJ high-dose) (CC vs) (JJ standard-dose)) (NNP amoxicillin))))) (PRN (, ,) (RB either) (UCP (PP (PP (IN with)) (CC or) (PP (IN without)) (NP (NN clavulanate))) (, ,) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNS children)) (CC or) (NP (NNS adults)))) (PP (IN with) (NP (NN ABRS)))))))))) (. .)))
(ROOT (S (S (ADVP (RB However)) (, ,) (NP (EX there)) (VP (VBZ is) (S (NP (JJ indirect) (NN evidence)) (VP (TO to) (VP (VB support) (NP (NP (JJ high-dose) (NN amoxicillin-clavulanate)) (PP (IN as) (NP (NP (JJ initial) (JJ empiric) (NN therapy)) (PP (IN of) (NP (NN ABRS)))))) (PP (IN among) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (VBN increased) (NN risk) (NNS factors)) (PP (IN for) (NP (NP (NNP PNS) (NNP S.) (FW pneumoniae)) (PRN (-LRB- -LRB-) (PP (JJ such) (IN as) (NP (NP (DT those)) (PP (IN with) (NP (NP (NP (JJ prior) (NN hospitalization)) (CC or) (NP (JJ recent) (JJ antimicrobial) (NN use))) (, ,) (NP (NP (NN attendance)) (PP (IN at) (NP (NN daycare)))) (, ,) (NP (NP (NN age)) (NP (JJR <) (NP (NP (CD 2)) (CC or) (NP (NP (JJR >)) (NP (CD 65) (NNS years)))))))))) (-RRB- -RRB-))))))))))))) (, ,) (CC and) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VP (VBP are) (ADJP (RB severely) (JJ ill))) (CC and) (VP (MD may) (VP (VB have) (NP (NP (DT a) (JJ poor) (NN outcome)) (PP (IN from) (NP (NN treatment) (NN failure)))) (PRN (-LRB- -LSB-) (NP (NP (CD 100)) (, ,) (NP (CD 101))) (-RRB- -RSB-)))))))) (. .)))
(ROOT (S (NP (EX There)) (VP (VBP are) (ADVP (RB also)) (NP (NP (JJ theoretical) (NNS advantages)) (PP (IN of) (NP (NP (JJ high-dose) (NNP amoxicillin)) (PP (IN in) (NP (NP (DT the) (JJ empiric) (NN treatment)) (PP (IN of) (NP (NN ABRS))))))))) (. .)))
(ROOT (S (NP (NP (NNP Fallon) (FW et) (FW al)) (PRN (-LRB- -LSB-) (NP (CD 102)) (-RRB- -RSB-))) (VP (VBD utilized) (NP (NNP Monte) (NNP Carlo) (NNS simulations)) (S (VP (TO to) (VP (VB predict) (NP (NP (JJ steady-state) (JJ bactericidal) (NN time)) (: --) (NP (NP (NP (NN concentration) (NNS profiles)) (PP (IN of) (NP (JJ various) (JJ oral) (NN β-lactam) (NNS regimens)))) (SBAR (S (VP (TO to) (VP (VB achieve) (NP (NP (JJ pharmacodynamic) (NN exposure)) (PP (IN against) (NP (JJ various) (NNS pathogens))) (VP (VBG causing) (NP (NNP AOM) (CC and) (NNP ABRS)))))))))))))) (. .)))
(ROOT (S (PP (IN Against) (NP (NNP S.) (FW pneumoniae))) (, ,) (NP (JJ high-dose) (NP (NNP amoxicillin) (PRN (-LRB- -LRB-) (NP (CD 90) (NN mg/kg/day)) (-RRB- -RRB-)))) (VP (VBD achieved) (NP (NP (DT the) (JJS greatest) (JJ cumulative) (NN fraction)) (PP (IN of) (NP (NP (NN response)) (, ,) (VP (VBN followed) (PP (IN by) (NP (NP (JJ standard-dose) (NN amoxicillin-clavulanate)) (CC and) (NP (NNP amoxicillin) (NNS regimens))))))))) (. .)))
(ROOT (S (NP (NN Amoxicillin-clavulanate)) (ADVP (RB also)) (VP (VBD achieved) (NP (NP (DT the) (JJS highest) (JJ cumulative) (NN fraction)) (PP (IN of) (NP (NP (NN response)) (PP (IN against) (NP (NNP H.) (NN influenzae) (NNS isolates))))))) (. .)))
(ROOT (FRAG (ADVP (RB Apart) (PP (IN from) (NP (NNP PNS) (NNP S.) (FW pneumoniae)))) (, ,) (NP (NP (DT the) (NN emergence)) (PP (IN of) (NP (NN β-lactamase))) (PRN (: --) (S (NP (NP (JJ negative) (JJ ampicillin-resistant) (NN H.) (NN influenzae)) (PRN (-LRB- -LRB-) (PP (JJ due) (TO to) (NP (NN PBP3) (NN mutation))) (-RRB- -RRB-))) (VP (MD may) (ADVP (RB also)) (VP (VB favor) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (JJ high-dose) (NNP amoxicillin))) (PP (IN during) (NP (NP (JJ initial) (JJ empiric) (NN treatment)) (PP (IN of) (NP (NN ABRS)))))) (PRN (-LRB- -LSB-) (NP (CD 85)) (-RRB- -RSB-))))))) (. .)))
(ROOT (S (NP (NNS Clinicians)) (VP (MD should) (VP (VB be) (ADJP (JJ alert)) (PP (TO to) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (JJ such) (NNS isolates))))) (, ,) (SBAR (IN although) (S (NP (NP (NNS reports)) (PP (IN in) (NP (DT the) (NNP United) (NNPS States)))) (VP (VBP are) (ADJP (VBN limited))))))) (. .)))
(ROOT (S (NP (NP (DT The) (JJ main) (NNS disadvantages)) (PP (IN of) (NP (JJ high-dose) (NN amoxicillin-clavulanate)))) (VP (VBP are) (NP (NP (DT the) (VBN added) (NP (NN cost) (CC and) (NN potential))) (PP (IN for) (NP (ADJP (JJR more) (JJ adverse)) (NNS effects))))) (. .)))
(ROOT (S (ADVP (RB Thus)) (, ,) (PP (IN despite) (NP (NP (DT the) (JJ theoretical) (NNS advantages)) (PP (IN of) (NP (ADJP (JJ high-dose) (CC vs) (JJ standard-dose)) (NN amoxicillin-clavulanate))))) (, ,) (SBAR (IN until) (S (NP (NP (NP (JJ clear) (NN evidence)) (PP (IN of) (NP (NP (JJ high) (NN failure) (NNS rates)) (PRN (-LRB- -LRB-) (NP (QP (CD ≥) (CD 10)) (NN %)) (-RRB- -RRB-))))) (PP (IN from) (NP (JJ standard-dose) (JJ amoxicillin-clavulanate)))) (VP (VBZ emerges)))) (, ,) (NP (DT the) (NN panel) (NN consensus)) (VP (VBZ is) (PP (TO to) (NP (NP (NN reserve) (JJ high-dose) (NN amoxicillin-clavulanate)) (PP (IN for) (NP (NP (NP (NNS patients)) (PP (IN from) (NP (JJ geographic) (NNS regions)))) (PP (IN with) (NP (NP (JJ high) (JJ endemic) (NNS rates)) (PP (IN of) (NP (NP (NP (NNP PNS) (NNP S.) (FW pneumoniae)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD ≥) (CD 10)) (NN %)) (, ,) (S (VP (VBG using) (S (NP (CD 2008) (NNS CLSI)) (VP (VBN revised) (NP (NNS breakpoints))))))) (-RRB- -RRB-))) (, ,) (NP (DT those) (ADJP (RB seriously) (JJ ill) (PP (IN with) (NP (NP (NN evidence)) (PP (IN of) (NP (NP (NP (JJ systemic) (NN toxicity)) (PRN (-LRB- -LRB-) (NP (FW eg) (, ,) (NP (NP (NP (NP (NN fever)) (PP (IN of) (NP (QP (CD 39) (CD °)) (NN C)))) (PRN (-LRB- -LSB-) (NP (QP (CD 102) (CD °)) (NN F)) (-RRB- -RSB-))) (CC or) (ADJP (JJR higher)))) (-RRB- -RRB-))) (CC and) (NP (NP (NN threat)) (PP (IN of) (NP (JJ suppurative) (NNS complications))))))))) (, ,) (NP (NP (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBP are) (ADJP (JJ immunocompromised)))))) (, ,) (CC and) (NP (NP (DT those)) (PP (IN with) (NP (NN risk) (NNS factors))))) (PP (IN for) (S (VP (VBG acquiring) (NP (NNP PNS) (NNP S.) (FW pneumoniae)) (SBAR (IN as) (S (VP (VBN outlined) (ADVP (IN above))))))))))))))))))) (. .)))
(ROOT (S (SBAR (IN Until) (S (NP (NP (DT a) (JJ clear) (NN need)) (PP (IN for) (NP (JJ high-dose) (NN amoxicillin-clavulanate)))) (VP (VBZ is) (VP (VBN demonstrated) (PP (IN by) (NP (NP (RB unacceptably) (JJ high) (NN failure) (NNS rates)) (PP (IN from) (NP (JJ standard-dose) (NN amoxicillin-clavulanate))))) (, ,) (S (VP (VBG delaying) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (JJ high-dose) (NN amoxicillin-clavulanate))) (PP (IN as) (NP (NP (JJ empiric) (NN therapy)) (PP (IN for) (NP (NP (DT all) (NNS patients)) (PP (IN with) (NP (JJ presumed) (NN ABRS)))))))))))))) (VP (VP (MD may) (VP (VB be) (ADJP (RBR more) (JJ cost-effective)))) (CC and) (VP (VBP result) (PP (IN in) (NP (NP (JJR fewer) (JJ adverse) (NNS effects)) (CC and) (NP (NP (JJR less) (JJ antibiotic) (NN selection) (NN pressure)) (PP (IN for) (NP (NN resistance)))))))) (. .)))
(ROOT (S (NP (JJ Standard-dose) (NN amoxicillin-clavulanate)) (VP (VBZ is) (ADJP (JJ inadequate) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NN ABRS)) (VP (VBN caused) (PP (IN by) (NP (NP (NNP PNS) (NNP S.) (FW pneumoniae)) (CC and) (NP (NP (DT the) (JJ rare) (NN occurrence)) (PP (IN of) (NP (JJ ampicillin-resistant) (NN β-lactamase)))))))))))) (: --) (NP (JJ negative) (NN H.) (NNS influenzae))) (. .)))
(ROOT (S (NP (PRP It)) (VP (MD should) (VP (VB be) (VP (VBN noted) (SBAR (IN that) (S (NP (NP (DT the) (NN prevalence)) (PP (IN of) (NP (NP (ADJP (JJ resistant))) (CC or) (NP (JJ intermediate) (NNP S.) (FW pneumoniae)))) (PP (IN in) (NP (DT a) (VBN given) (NN community)))) (VP (MD may) (VP (VB vary) (FRAG (CONJP (RB not) (RB only)) (ADVP (ADVP (RB geographically) (CC but) (RB also)) (RB temporally)))))))))) (. .)))
(ROOT (S (NP (DT This)) (VP (VBZ is) (VP (VBN evidenced) (PP (IN by) (NP (NP (DT the) (NN shift)) (PP (IN in) (NP (NNP S.) (FW pneumoniae) (NN susceptibility) (NNS profiles))) (PP (IN in) (NP (DT some) (NNS communities))) (PP (VBG following) (NP (NP (DT the) (NN introduction)) (PP (IN of) (NP (NP (NP (DT the) (JJ 7-valent) (JJ pneumococcal) (NN conjugate) (NN vaccine)) (PRN (-LRB- -LRB-) (NP (NN PCV7)) (-RRB- -RRB-))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD resulted) (PP (IN in) (NP (NP (NP (DT the) (JJ subsequent) (NN emergence)) (PP (IN of) (NP (NP (ADJP (RB highly) (JJ virulent) (CC and) (JJ resistant)) (JJ nonvaccine) (NNS serotypes)) (PP (IN of) (NP (NP (NNP S.) (FW pneumoniae)) (PP (JJ such) (IN as) (NP (NNS serotypes) (CD 14) (CC and) (NP (NN 19A))))))))) (PRN (-LRB- -LSB-) (NP (NP (CD 86)) (, ,) (NP (CD 103))) (-RRB- -RSB-))))))))))))))) (. .)))
(ROOT (S (PP (IN In) (NP (CD 2010))) (, ,) (NP (NN PCV13)) (VP (VBD replaced) (NP (NP (DT the) (NN PCV7)) (PP (IN for) (NP (DT all) (NNS children)))) (PRN (-LRB- -LSB-) (NP (CD 104)) (-RRB- -RSB-))) (. .)))
(ROOT (S (NP (NN PCV13)) (VP (VP (VBZ contains) (NP (NP (CD 6) (JJ additional) (JJ pneumococcal) (NN serotype) (NNS antigens)) (PP (VBG including) (NP (NN serotype) (NN 19A))))) (CC and) (VP (VBZ is) (VP (VBN expected) (S (VP (TO to) (ADVP (RB dramatically)) (VP (VB reduce) (NP (NNP PNS) (NNP S.) (FW pneumoniae) (NN disease)))))))) (. .)))
(ROOT (S (NP (NP (NN Protection)) (PP (IN against) (NP (NN serotype) (NN 19A) (NN disease)))) (VP (VBZ has) (VP (VBN been) (VP (VBN documented) (PP (IN in) (NP (DT a) (NN PCV13) (NN vaccine) (NN effectiveness) (NN study))) (PRN (-LRB- -LSB-) (NP (CD 99)) (-RRB- -RSB-))))) (. .)))
(ROOT (S (ADVP (RB Thus)) (, ,) (NP (NNS decisions)) (VP (VBG regarding) (SBAR (S (NP (JJ appropriate) (NN dosing) (NNS regimens)) (VP (MD should) (VP (VB be) (VP (VBN guided) (PP (IN by) (NP (NP (JJ antimicrobial) (NN susceptibility) (NNS profiles)) (PP (IN of) (NP (JJ prevalent) (NNS pathogens))))) (PP (IN through) (NP (NP (JJ diligent) (NN surveillance)) (PP (IN by) (NP (ADJP (JJ local) (CC or) (JJ national)) (NN reporting) (NNS agencies))))))))))) (. .)))
(ROOT (S (NP (JJR More) (NNS studies)) (VP (VBP are) (VP (VBN needed) (S (VP (TO to) (ADVP (RB directly)) (VP (VB compare) (NP (NP (DT the) (NN cost-effectiveness)) (PP (IN of) (NP (JJ high-dose) (CC vs) (JJ standard-dose) (NN amoxicillin-clavulanate)))) (PP (IN as) (NP (NP (JJ initial) (JJ empiric) (JJ antimicrobial) (NN therapy)) (PP (IN of) (NP (NP (JJ presumed) (NN ABRS)) (PP (IN in) (NP (CC both) (NP (NNS adults)) (CC and) (NP (NNS children))))))))))))) (. .)))
(ROOT (NP (NNP VI) (. .)))
(ROOT (SBARQ (SINV (MD Should) (NP (NP (DT a) (JJ Respiratory) (NN Fluoroquinolone)) (CC vs) (NP (DT a) (JJ β-Lactam) (NNP Agent))) (VP (VB Be) (VP (VBN Used) (PP (IN as) (NP (NP (JJ First-line) (NNS Agents)) (PP (IN for) (NP (NP (DT the) (JJ Initial) (NNP Empiric) (NNP Antimicrobial) (NN Therapy)) (PP (IN of) (NP (NNP ABRS)))))))))) (. ?)))
(ROOT (NP (CD 6) (. .)))
(ROOT (S (NP (NP (NP (DT A) (JJ β-lactam) (NN agent)) (PRN (-LRB- -LRB-) (NP (NN amoxicillin-clavulanate)) (-RRB- -RRB-))) (CONJP (RB rather) (IN than)) (NP (DT a) (JJ respiratory) (JJ fluoroquinolone))) (VP (VBZ is) (VP (VBN recommended) (PP (IN for) (NP (NP (JJ initial) (JJ empiric) (JJ antimicrobial) (NN therapy)) (PP (IN of) (NP (NP (NN ABRS)) (PRN (-LRB- -LRB-) (ADJP (ADJP (JJ weak)) (, ,) (ADJP (JJ moderate))) (-RRB- -RRB-)))))))) (. .)))
(ROOT (S (NP (NP (DT The) (JJ respiratory) (NNS fluoroquinolones)) (PRN (-LRB- -LRB-) (NP (CC both) (NP (NN levofloxacin)) (CC and) (NP (NN moxifloxacin))) (-RRB- -RRB-))) (VP (VBP have) (VP (VBN remained) (ADJP (ADJP (RB highly) (JJ active) (PP (IN against) (NP (DT all) (JJ common) (JJ respiratory) (NNS pathogens)))) (, ,) (PP (VBG including) (NP (NNP PNS) (NNP S.) (FW pneumoniae) (CC and) (NN β-lactamase))) (PRN (: --) (S (VP (VBG producing) (NP (NP (NP (NNP H.) (NNS influenzae)) (CC or) (NP (NN M.) (NN catarrhalis))) (PRN (-LRB- -LSB-) (NP (NP (CD 105)) (, ,) (NP (CD 106))) (-RRB- -RSB-))))))))) (. .)))
(ROOT (S (ADVP (RB Nevertheless)) (, ,) (NP (JJ respiratory) (NNS fluoroquinolones)) (VP (VBD were) (RB not) (PP (JJ superior) (PP (TO to) (NP (JJ β-lactam) (NNS antibiotics)))) (PP (IN in) (NP (NP (CD 8) (NNS RCTs)) (PP (IN of) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NN ABRS))))))) (PRN (-LRB- -LSB-) (NP (CD 107)) (: --)) (NP (CD 114))) (-RRB- -RSB-) (. .)))
(ROOT (S (NP (NP (DT A) (NN meta-analysis)) (PP (IN of) (NP (DT these) (NNS trials)))) (VP (VBD confirmed) (SBAR (IN that) (S (NP (NP (JJ initial) (NN treatment)) (PP (IN with) (NP (DT the) (JJR newer) (NNS fluoroquinolones)))) (VP (VBD conferred) (NP (DT no) (NN benefit)) (PP (IN over) (NP (JJ β-lactam) (NNS antibiotics))) (PRN (-LRB- -LSB-) (NP (CD 115)) (-RRB- -RSB-)))))) (. .)))
(ROOT (S (NP (NP (DT The) (NN comparator) (NNS agents)) (PP (IN in) (NP (DT these) (NNS trials)))) (VP (VP (VBD were) (ADJP (JJ amoxicillin-clavulanate)) (PP (IN in) (NP (NP (CD 5) (, ,) (NN cefuroxime)) (PP (IN in) (NP (CD 2)))))) (, ,) (CC and) (NP (NP (NN cefdinir)) (PP (IN in) (NP (CD 1))))) (. .)))
(ROOT (S (ADVP (RB Specifically)) (, ,) (PP (IN in) (NP (NP (DT a) (NN subset) (NN analysis)) (PP (IN of) (NP (NP (CD 5) (NNS studies)) (SBAR (WHNP (WDT that)) (S (VP (VBD evaluated) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (NP (DT the) (JJ respiratory) (NNS fluoroquinolones)) (PRN (-LRB- -LRB-) (NP (NP (NN moxifloxacin)) (, ,) (NP (NN levofloxacin)) (, ,) (CC or) (NP (NN gatifloxacin))) (-RRB- -RRB-)))))))))))) (NP (EX there)) (VP (VBD was) (NP (DT no) (NN difference)) (PP (IN in) (NP (JJ clinical) (NNS outcomes))) (PP (VBN compared) (PP (IN with) (NP (JJ amoxicillin-clavulanate) (CC or) (NP (NN cefuroxime)))))) (. .)))
(ROOT (S (NP (JJ Clinical) (NN success)) (VP (VBD was) (VP (VBN observed) (PP (IN in) (NP (NP (NP (ADJP (CD 87) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (CD 924)) (PP (IN of) (NP (CD 1062)))) (-RRB- -RRB-))) (PP (IN of) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (DT the) (NNS fluoroquinolones))))))) (PP (VBN compared) (SBAR (IN with) (S (NP (NP (CD 86) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (CD 922)) (PP (IN of) (NP (CD 1071)))) (-RRB- -RRB-))) (VP (VBN treated) (PP (IN with) (NP (NP (DT a) (NN β-lactam)) (PRN (-LRB- -LRB-) (NP (NNP Table) (CD 8)) (-RRB- -RRB-)))))))))))) (. .)))
(ROOT (S (NP (JJ Adverse) (NNS events)) (VP (VBD occurred) (ADVP (RBR more) (RB frequently)) (PP (IN with) (NP (NP (DT the) (NNS fluoroquinolones)) (PP (IN than) (PP (IN with) (NP (NN β-lactam) (NNS antibiotics)))))) (PP (IN in) (NP (CD 2) (JJ double-blind) (NNS RCTs)))) (. .)))
(ROOT (S (S (NP (NP (DT A) (NN limitation)) (PP (IN of) (NP (DT these) (NNS RCTs)))) (VP (VBZ is) (SBAR (IN that) (S (NP (NN none)) (VP (VBD evaluated) (NP (JJ high-dose) (NN amoxicillin-clavulanate)) (PP (IN as) (NP (DT a) (NN comparator)))))))) (: ;) (S (ADVP (RB accordingly)) (, ,) (NP (PRP it)) (VP (VBZ is) (RB not) (ADJP (JJ possible)) (S (VP (TO to) (VP (ADVP (RB directly)) (VB assess) (NP (DT any) (NN difference)) (PP (IN between) (NP (NP (DT a) (ADJP (JJ respiratory) (JJ fluoroquinolone))) (CC and) (NP (NP (DT the) (ADJP (RB currently) (VBN recommended)) (JJ first-line) (NNS agents)) (PP (IN for) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ severe) (NN infection)) (CC or) (NP (NP (DT those)) (PP (IN at) (NP (NP (NN risk)) (PP (IN for) (NP (NNP PNS) (NNP S.) (FW pneumoniae) (NN infection)))))))))))))))))) (. .)))
(ROOT (S (NP (PRP It)) (VP (VBZ is) (ADVP (RB also)) (ADJP (JJ possible)) (SBAR (IN that) (S (NP (JJ high-dose) (NN amoxicillin-clavulanate)) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (ADJP (JJR more) (JJ adverse)) (NNS effects)) (VP (VBN compared) (PP (IN with) (NP (DT a) (JJ fluoroquinolone))))))))))) (. .)))
(ROOT (S (NP (NP (DT The) (CD one) (NN RCT)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (DT the) (JJ microbiological) (NNS data)) (VP (VBD were) (ADJP (ADJP (ADVP (RBS most)) (JJ complete)) (PRN (-LRB- -LRB-) (S (NP (DT all) (NNS patients)) (VP (VBD had) (NP (NNS cultures)) (PP (IN by) (NP (NP (JJ maxillary) (NN sinus) (NN puncture)) (CC or) (NP (NP (NN endoscopy)) (PP (IN of) (NP (DT the) (JJ middle) (NN meatus)))))) (PP (IN within) (NP (CD 24) (NNS hours))) (PP (IN before) (NP (NP (DT the) (NN initiation)) (PP (IN of) (NP (NN treatment))))))) (-RRB- -RRB-))))))) (VP (VBD found) (SBAR (IN that) (S (NP (NP (QP (RB only) (CD 51)) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (CD 292)) (PP (IN of) (NP (CD 576)))) (-RRB- -RRB-))) (VP (VBD had) (S (NP (DT a) (NN pathogen)) (VP (VBD identified) (PRN (-LRB- -LSB-) (NP (CD 107)) (-RRB- -RSB-)))))))) (. .)))
(ROOT (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (NP (DT the) (JJ combined) (ADJP (ADJP (JJ clinical)) (CC and) (ADJP (JJ microbiological))) (NNS outcomes)) (PP (IN at) (NP (CD 14)))) (: --) (NP (NP (CD 21) (NNS days)) (PP (IN of) (NP (NN therapy)))) (VP (VBD were) (NP (NP (NP (CD 86) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (CD 83)) (PP (IN of) (NP (CD 96)))) (-RRB- -RRB-))) (CC and) (NP (NP (NP (CD 88) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (CD 85)) (PP (IN of) (NP (CD 97)))) (-RRB- -RRB-))) (PP (IN for) (NP (NP (NN moxifloxacin)) (CC and) (NP (NN amoxicillin-clavulanate)))))) (, ,) (ADVP (RB respectively))) (. .)))
(ROOT (S (NP (PRP It)) (VP (VBZ is) (ADJP (JJ likely) (SBAR (IN that) (S (NP (NP (DT each)) (PP (IN of) (NP (DT the) (NN study) (NNS arms)))) (VP (VBD included) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (DT a) (JJ viral)) (CONJP (RB rather) (IN than)) (NP (JJ bacterial) (NN infection)))))))))) (. .)))
(ROOT (FRAG (PP (ADVP (RB However)) (PRN (, ,) (PP (ADVP (RB even)) (IN among) (NP (NP (NP (NNS patients)) (PP (IN with) (NP (JJ positive) (NNS cultures)))) (PP (IN by) (NP (NN sinus) (NN puncture))))) (, ,)) (SBAR (S (NP (DT a) (JJ recent) (JJ placebo-controlled) (NNP RCT)) (VP (VBD reported) (SBAR (IN that) (S (NP (NP (DT the) (JJ clinical) (NN response) (NN rate)) (PP (TO to) (NP (NN moxifloxacin)))) (VP (VBD was) (RB not) (ADJP (RB significantly) (JJ different) (PP (IN from) (NP (NN placebo))) (-LRB- -LRB-) (ADJP (NP (NP (CD 78) (NN %)) (CC vs) (NP (CD 67) (NN %)))))))))))) (PRN (-RRB- -RRB-) (PRN (-LRB- -LSB-) (NP (CD 45)) (-RRB- -RSB-))) (. .)))
(ROOT (S (ADVP (RB Thus)) (, ,) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (JJ respiratory) (NNS fluoroquinolones))) (PP (IN for) (NP (NP (NP (DT the) (JJ empiric) (NN treatment)) (PP (IN of) (NP (JJ moderate)))) (PP (TO to) (NP (JJ severe) (NN infection))) (PP (IN in) (NP (NN ABRS)))))) (VP (VBZ remains) (S (VP (TO to) (VP (VB be) (VP (VBN determined)))))) (. .)))
(ROOT (S (PP (IN At) (NP (JJ present))) (, ,) (NP (JJ respiratory) (NNS fluoroquinolones)) (VP (MD should) (VP (VB be) (VP (VBN reserved) (PP (IN for) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBP have) (VP (VBN failed) (S (VP (TO to) (VP (VB respond) (PP (TO to) (NP (JJ first-line) (NNS agents))))))))))))))) (, ,) (NP (NP (NP (DT those)) (PP (IN with) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NN penicillin) (NN allergy)))))) (, ,) (CC and) (PP (IN as) (NP (NP (JJ second-line) (NN therapy)) (PP (IN for) (NP (NP (NNS patients)) (PP (IN at) (NP (NN risk))) (PP (IN for) (NP (NNP PNS) (NNP S.) (FW pneumoniae) (NN infection)))))))) (. .)))
(ROOT (S (NP (DT This) (NN recommendation)) (VP (VBZ places) (NP (DT a) (ADJP (RB relatively) (JJ high)) (NN value)) (PP (IN on) (S (VP (VBG limiting) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (JJ antibiotic) (NN resistance)) (CC and) (NP (NN resource) (NN use))))))))) (. .)))
(ROOT (NP (NP (NP (NN Therapy)) (PP (IN with) (NP (NP (DT a) (NN β-lactam)) (VP (VBN provided) (NP (JJ comparable) (NN efficacy)) (PP (IN in) (NP (NP (DT the) (JJ clinical) (NN resolution)) (PP (IN of) (NP (NNS symptoms))))) (PP (VBN compared) (PP (IN with) (NP (NP (NNS fluoroquinolones)) (PP (IN without) (NP (NP (VBN added) (NN cost)) (CC or) (NP (JJ adverse) (NNS effects))))))))))) (. .)))
(ROOT (S (NP (NNS Fluoroquinolones)) (VP (VBP are) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NP (JJ adverse) (NNS effects)) (PP (VBG including) (NP (NP (NP (JJ central) (JJ nervous) (NN system) (NNS events)) (PRN (-LRB- -LRB-) (NP (NP (NNS seizures)) (, ,) (NP (NNS headaches)) (, ,) (NP (NN dizziness)) (, ,) (NP (NN sleep) (NNS disorders))) (-RRB- -RRB-))) (, ,) (NP (JJ peripheral) (NN neuropathy)) (, ,) (NP (NP (NN photosensitivity)) (PP (IN with) (NP (NN skin) (NN rash)))) (, ,) (NP (NP (NNS disorders)) (PP (IN of) (NP (NP (NN glucose) (NN homeostasis)) (PRN (-LRB- -LRB-) (NP (NP (NN hypoglycemia)) (CC and) (NP (NN hyperglycemia))) (-RRB- -RRB-))))) (, ,) (NP (NP (NN prolongation)) (PP (IN of) (NP (NNP QT) (NNP interval)))) (, ,) (NP (JJ hepatic) (NN dysfunction)) (, ,) (CC and) (NP (JJ skeletomuscular) (NNS complaints)))))))))) (. .)))
(ROOT (S (NP (NP (NN Risk)) (PP (IN of) (NP (NNPS Achilles) (NN tendon) (NN rupture)))) (VP (VP (VBZ is) (ADJP (RB particularly) (JJ high)) (PP (IN in) (NP (DT the) (JJ adult) (NN population))) (PRN (-LRB- -LRB-) (NP (NP (VBN estimated) (NN prevalence) (NN rate)) (, ,) (NP (CD 15)) (: --) (NP (NP (CD 20)) (PP (IN per) (NP (CD 100) (CD 000))))) (-RRB- -RRB-))) (, ,) (PP (ADVP (RB particularly)) (IN among) (NP (NP (DT those)) (PP (IN with) (S (VP (VBG advancing) (NP (NP (NN age)) (CC and) (NP (JJ antecedent) (NN steroid) (NN therapy))))))))) (. .)))
(ROOT (S (S (VP (VBG Limiting) (NP (NP (DT the) (NN overuse)) (PP (IN of) (NP (NNS fluoroquinolones)))))) (VP (MD may) (VP (VB slow) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NN resistance))) (PP (IN against) (NP (NP (DT this) (NN class)) (PP (IN of) (NP (JJ antimicrobial) (NNS agents)))))))) (. .)))
(ROOT (S (NP (NP (DT The) (NN role)) (PP (IN of) (NP (DT the) (JJ respiratory) (NNS fluoroquinolones))) (PP (IN in) (NP (NP (NP (DT the) (JJ initial) (JJ empiric) (NN treatment)) (PP (IN of) (NP (NN ABRS)))) (PP (IN in) (NP (NP (DT an) (NN era)) (PP (IN of) (S (VP (VBG increasing) (NP (JJ antimicrobial) (NN resistance)))))))))) (VP (VBZ remains) (ADJP (JJ uncertain))) (. .)))
(ROOT (FRAG (NP (NP (ADJP (RB Appropriately) (VBN powered)) (NNS RCTs)) (SBAR (WHNP (WDT that)) (S (ADVP (RB directly)) (VP (VBP compare) (NP (DT the) (NN efficacy)) (, ,) (SBAR (S (NP (NP (JJ adverse) (NNS effects)) (, ,) (CC and) (NP (ADJP (ADJP (JJ cost-benefit) (PP (IN of) (NP (DT the) (JJ respiratory) (NNS fluoroquinolones)))) (CC vs) (ADJP (JJ high-dose))) (NN amoxicillin-clavulanate))) (VP (VBP are) (VP (VBN warranted))))))))) (. .)))
(ROOT (NP (NN VII) (. .)))
(ROOT (SQ (PP (IN Besides) (NP (DT a) (JJ Respiratory) (NN Fluoroquinolone))) (, ,) (MD Should) (NP (NP (DT a) (NNP Macrolide) (, ,) (NN TMP/SMX)) (, ,) (NP (NNP Doxycycline)) (, ,) (CC or) (NP (DT a) (LS Second) (: -) (CC or) (NNP Third-Generation) (NNP Oral) (NNP Cephalosporin))) (VP (VB Be) (VP (VBN Used) (PP (IN as) (NP (NP (JJ Second-line) (NN Therapy)) (PP (IN for) (NP (NP (NNS ABRS)) (PP (IN in) (NP (NP (NNP Children)) (CC or) (NP (NNS Adults)))))))))) (. ?)))
(ROOT (NP (CD 7) (. .)))
(ROOT (S (NP (NP (NNS Macrolides)) (PRN (-LRB- -LRB-) (NP (NP (NN clarithromycin)) (CC and) (NP (NN azithromycin))) (-RRB- -RRB-))) (VP (VBP are) (RB not) (VP (VBN recommended) (PP (IN for) (NP (NP (JJ empiric) (NN therapy)) (ADJP (JJ due) (PP (TO to) (NP (NP (JJ high) (NNS rates)) (PP (IN of) (NP (NP (NP (NN resistance)) (PP (IN among) (NP (NP (NNP S.) (FW pneumoniae)) (PRN (-LRB- -LRB-) (NP (CD ∼) (CD 30) (NN %)) (-RRB- -RRB-))))) (PRN (-LRB- -LRB-) (ADJP (JJ strong) (, ,) (JJ moderate)) (-RRB- -RRB-))))))))))) (. .)))
(ROOT (NP (CD 8) (. .)))
(ROOT (S (NP (NN TMP/SMX)) (VP (VBZ is) (RB not) (VP (VBN recommended) (PP (IN for) (NP (NP (JJ empiric) (NN therapy)) (ADJP (JJ due) (PP (TO to) (NP (NP (JJ high) (NNS rates)) (PP (IN of) (NP (NP (NN resistance)) (PP (IN among) (NP (DT both) (NP (FW S.) (FW pneumoniae)) (CC and) (NP (NP (NP (NNP H.) (NNS influenzae)) (PRN (-LRB- -LRB-) (NP (NP (CD ∼) (CD 30) (NN %)) (: --) (NP (CD 40) (NN %))) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (ADJP (ADJP (JJ strong)) (, ,) (ADJP (JJ moderate))) (-RRB- -RRB-)))))))))))))) (. .)))
(ROOT (NP (CD 9) (. .)))
(ROOT (S (NP (NNP Doxycycline)) (VP (MD may) (VP (VB be) (VP (VBN used) (SBAR (IN as) (S (NP (DT an) (JJ alternative) (NN regimen)) (VP (TO to) (VP (VB amoxicillin-clavulanate) (PP (IN for) (NP (NP (JJ initial) (JJ empiric) (JJ antimicrobial) (NN therapy)) (PP (IN of) (NP (NN ABRS))) (PP (IN in) (NP (NNS adults))))) (SBAR (IN because) (S (NP (PRP it)) (VP (VP (VBZ remains) (ADJP (RB highly) (JJ active) (PP (IN against) (NP (JJ respiratory) (NNS pathogens))))) (CC and) (VP (VBZ has) (NP (NP (JJ excellent) (NN PK/PD) (NNS properties)) (PRN (-LRB- -LRB-) (NP (JJ weak) (, ,) (JJ low)) (-RRB- -RRB-)))))))))))))) (. .)))
(ROOT (NP (CD 10) (. .)))
(ROOT (S (NP (LS Second) (NP (: -) (CC and) (JJ third-generation) (JJ oral) (NNS cephalosporins))) (VP (VBP are) (ADVP (RB no) (RB longer)) (VP (VBN recommended) (PP (IN for) (NP (NP (NP (JJ empiric) (NN monotherapy)) (PP (IN of) (NP (NN ABRS) (NN owing)))) (PP (TO to) (NP (NP (JJ variable) (NNS rates)) (PP (IN of) (NP (NP (NN resistance)) (PP (IN among) (NP (NNP S.) (FW pneumoniae))))))))))) (. .)))
(ROOT (S (S (NP (NP (NN Combination) (NN therapy)) (PP (IN with) (NP (NP (NP (DT a) (JJ third-generation) (JJ oral) (NN cephalosporin)) (PRN (-LRB- -LRB-) (NP (NP (NN cefixime)) (CC or) (NP (NN cefpodoxime))) (-RRB- -RRB-))) (CC plus) (NP (NN clindamycin))))) (VP (MD may) (VP (VB be) (VP (VBN used) (PP (IN as) (NP (NP (JJ second-line) (NN therapy)) (PP (IN for) (NP (NP (NNS children)) (PP (IN with) (NP (JJ non))))))))))) (: --) (NP (NP (NN type) (CD I) (NN penicillin) (NN allergy)) (CC or) (NP (NP (DT those)) (PP (IN from) (NP (NP (JJ geographic) (NNS regions)) (PP (IN with) (NP (NP (JJ high) (JJ endemic) (NNS rates)) (PP (IN of) (NP (NP (NNP PNS) (NNP S.) (FW pneumoniae)) (PRN (-LRB- -LRB-) (ADJP (ADJP (JJ weak)) (, ,) (ADJP (JJ moderate))) (-RRB- -RRB-)))))))))) (. .)))
(ROOT (SBAR (IN Because) (S (NP (NNS RCTs)) (VP (VBP have) (RB not) (VP (VBN found) (NP (JJ significant) (NNS differences)) (PP (IN in) (NP (NN response) (NNS rates))) (S (S (PRN (PP (TO to) (NP (NP (JJ various) (JJ antimicrobial) (NNS regimens)) (PP (IN for) (NP (NN ABRS))))) (NP (QP (-LRB- -LSB-) (CD 24) (, ,) (CD 44))) (-RRB- -RSB-)) (, ,) (NP (NP (NN selection)) (PP (IN of) (NP (JJ alternative) (JJ antimicrobial) (NNS agents)))) (VP (VBZ is) (ADVP (RB primarily)) (PP (VBN based) (PP (IN on) (NP (NP (NP (JJ known) (NN prevalence)) (PP (IN of) (NP (JJ respiratory) (NNS pathogens)))) (PP (IN in) (NP (NP (DT the) (NN community)) (, ,) (NP (NP (JJ antimicrobial) (NN spectrum)) (-LRB- -LRB-) (PP (VBG including) (NP (NNP PNS) (NNP S.) (FW pneumoniae) (CC and) (NN β-lactamase))) (: --) (VP (VBG producing) (NP (NP (NNP H.) (NNS influenzae)) (CC and) (NP (NN M.) (NN catarrhalis))))))))))) (-RRB- -RRB-)) (, ,) (NP (NP (NN cost)) (, ,) (NP (NN dosing) (NN convenience)) (CC and) (NP (NP (NN tolerance)) (CC or) (NP (JJ adverse) (NNS effects)))))))) (. .)))
(ROOT (S (NP (NP (NN TMP/SMX)) (, ,) (NP (NN doxycycline)) (, ,) (NP (NNS macrolides)) (, ,) (LS second) (: -) (CC or) (NP (JJ third-generation) (NNS cephalosporins)) (, ,) (CC and) (NP (NNS fluoroquinolones))) (VP (VBP have) (DT all) (VP (VBN been) (VP (VBN recommended) (PP (IN as) (NP (NP (NNS alternatives)) (PP (TO to) (NP (NP (NNP amoxicillin)) (CC or) (NP (JJ amoxicillin-clavulanate)))))) (PP (IN in) (NP (DT the) (JJ past))) (PRN (-LRB- -LSB-) (NP (CD 116)) (-RRB- -RSB-))))) (. .)))
(ROOT (S (ADVP (RB However)) (, ,) (NP (NP (NN surveillance)) (PP (IN of) (NP (NP (JJ recent) (JJ respiratory) (NNS isolates)) (PP (IN in) (NP (DT the) (NNP United) (NNPS States)))))) (VP (VBZ indicates) (NP (NP (DT a) (ADJP (ADJP (JJ variable)) (CC but) (ADJP (JJ significant))) (NN increase)) (PP (IN in) (NP (ADJP (JJ penicillin-intermediate) (CC and) (ADJP (NP (NN macrolide))) (CC or) (ADJP (JJ TMP/SMX-resistant))) (NNP S.) (FW pneumoniae) (CC and) (NN β-lactamase)))) (: --) (S (VP (VBG producing) (NP (NP (NNP H.) (NN influenzae)) (PRN (-LRB- -LSB-) (NP (NP (CD 93)) (: --) (NP (CD 95))) (-RRB- -RSB-)))))) (PRN (-LRB- -LRB-) (NP (NNP Table) (CD 7)) (-RRB- -RRB-)) (. .)))
(ROOT (S (NP (ADJP (ADJP (JJ Cross-resistant)) (CC and) (ADJP (JJ multidrug-resistant))) (NNP S.) (FW pneumoniae)) (VP (VBZ is) (ADVP (RB also)) (NP (S (VP (VBG increasing) (PRN (-LRB- -LRB-) (NP (NP (JJ regional) (NN prevalence) (NNS rates)) (, ,) (NP (CD 9) (NN %)) (: --) (NP (NP (CD 25) (NN %)) (PP (IN in) (NP (DT the) (NNP United) (NNPS States)))) (PP (IN during) (NP (NP (CD 2005)) (: --) (NP (CD 2006))))) (-RRB- -RRB-)))) (PRN (-LRB- -LSB-) (NP (CD 93)) (-RRB- -RSB-)))) (. .)))
(ROOT (S (NP (S (ADVP (RB Accordingly)) (, ,) (NP (JJ antimicrobial) (NNS agents)) (VP (ADVP (RB previously)) (VBN recommended) (PP (IN as) (NP (NP (DT an) (NN alternative)) (PP (TO to) (NP (NP (NNP amoxicillin)) (CC or) (NP (ADJP (JJ amoxicillin-clavulanate))) (, ,) (PP (JJ such) (IN as) (NP (NP (NNS macrolides)) (, ,) (NP (NN TMP-SMX)) (, ,) (CC or) (LS second)))))))) (: -)) (CC or) (JJ third-generation) (JJ oral) (NNS cephalosporins)) (, ,) (VP (MD can) (ADVP (RB no) (RB longer)) (VP (VB be) (VP (VBN recommended) (PP (IN because) (IN of) (NP (NP (VBG increasing) (NN resistance)) (PP (IN among) (NP (NP (NNP S.) (FW pneumoniae)) (CC and/or) (NP (NNP H.) (NNS influenzae))))))))) (. .)))
(ROOT (S (NP (NP (DT The) (NN prevalence)) (PP (IN of) (NP (NP (JJ macrolide-resistant) (NNP S.) (FW pneumoniae)) (PP (IN in) (NP (DT the) (NNP United) (NNPS States)))))) (VP (VBZ has) (VP (VBN escalated) (ADVP (RB dramatically)) (PP (IN since) (NP (NP (DT the) (CD 1990s)) (PRN (-LRB- -LSB-) (NP (CD 117)) (-RRB- -RSB-)))))) (. .)))
(ROOT (NP (NP (NP (NN Surveillance) (NNS data)) (PP (IN from) (NP (NP (NP (DT the) (NN TRUST)) (PRN (-LRB- -LRB-) (VP (VBG Tracking) (NP (NN Resistance)) (PP (IN in) (NP (DT the) (NNP United) (NNPS States) (NN Today)))) (-RRB- -RRB-))) (CC and) (NP (NP (NN PROTEKT)) (PRN (-LRB- -LRB-) (NP (NP (JJ Prospective) (JJ Resistant) (NNP Organism) (NNP Tracking)) (CC and) (NP (NP (NNP Epidemiology)) (PP (IN of) (NP (DT the) (NNP Ketolide) (NNP Telithromycin))))) (-RRB- -RRB-)))))) (SBAR (S (NP (NNS studies)) (VP (VBP reveal) (SBAR (IN that) (S (SBAR (IN whereas) (S (NP (NP (QP (RB only) (CD 5)) (NN %)) (PP (IN of) (NP (NP (NNP S.) (FW pneumoniae) (JJ clinical) (NNS isolates)) (PP (IN in) (NP (DT the) (NNP United) (NNPS States)))))) (VP (VBD were) (ADJP (JJ resistant) (PP (TO to) (NP (NP (NNS macrolides)) (PP (IN in) (NP (CD 1993))))))))) (, ,) (NP (QP (JJR >) (CD 30)) (NN %)) (VP (VBD had) (VP (VBN become) (ADJP (JJ resistant) (PP (IN by) (NP (CD 2006) (PRN (-LRB- -LSB-) (NP (CD 117)) (-RRB- -RSB-)))))))))))) (. .)))
(ROOT (S (PP (IN During) (NP (NP (CD 2005)) (: --) (NP (NP (CD 2007)) (, ,) (NP (NP (CD 43) (NN %)) (PP (IN of) (NP (JJ invasive) (NNP S.) (FW pneumoniae) (NNS isolates))))))) (VP (VBD were) (ADJP (JJ macrolide-resistant)) (PRN (-LRB- -LRB-) (NP (NNP Table) (CD 7)) (-RRB- -RRB-))) (. .)))
(ROOT (S (ADVP (RB Importantly)) (, ,) (NP (NP (DT the) (ADJP (RBR more) (JJ prevalent)) (JJ low-level) (JJ resistant) (NNS genotypes)) (VP (VBN caused) (PP (IN by) (NP (NP (NN efflux) (NNS mutations)) (PRN (-LRB- -LRB-) (NP (NP (NN mefA)) (CC or) (NP (NN mefE))) (-RRB- -RRB-)))))) (VP (VBD were) (VP (VBG being) (VP (ADVP (RB gradually)) (VBN replaced) (PP (IN by) (NP (NP (NP (ADJP (RB highly) (JJ resistant)) (NN methylation) (NNS mutations)) (PRN (-LRB- -LRB-) (NP (NN ermB)) (-RRB- -RRB-))) (, ,) (ADJP (JJ such) (SBAR (IN that) (S (PP (IN by) (NP (NP (CD 2006) (, ,) (JJ ermB-mediated) (NN resistance)) (-LRB- -LRB-) (PP (VBG including) (NP (NP (NN resistance)) (ADJP (JJ due) (PP (TO to) (NP (NP (NN ermB)) (CC and) (NP (NN mefA) (NNS combinations))))))) (-RRB- -RRB-))) (VP (VBD accounted) (PP (IN for) (NP (NP (CD 42) (NN %)) (PP (IN of) (NP (DT all) (JJ macrolide-resistant) (NNP S.) (FW pneumoniae))))) (PRN (-LRB- -LSB-) (NP (CD 118)) (-RRB- -RSB-))))))))))) (. .)))
(ROOT (S (NP (NP (NN Macrolide) (NN resistance)) (PP (IN among) (NP (NNP S.) (FW pneumoniae)))) (VP (VBZ is) (VP (ADVP (RB strongly)) (VBN correlated) (PP (TO to) (NP (NP (JJ prior) (JJ antibiotic) (NN use)) (, ,) (ADVP (RB particularly)) (NP (NP (NNS macrolides)) (, ,) (NP (NNS β-lactams)) (, ,) (CC and) (NP (NN TMP-SMX))))))) (, ,) (CC and) (S (NP (NP (NP (JJ multidrug) (NN resistance)) (CC or) (NP (NN cross-resistance))) (PP (TO to) (NP (DT these) (NNS antibiotics)))) (VP (VBZ is) (ADJP (JJ common)) (PRN (-LRB- -LSB-) (NP (CD 117)) (-RRB- -RSB-)))) (. .)))
(ROOT (S (NP (NP (DT The) (NN prevalence)) (PP (IN of) (NP (NN macrolide) (NN resistance)))) (VP (VBZ is) (ADJP (JJS highest) (PP (IN among) (NP (NP (NNS isolates)) (PP (IN from) (NP (NP (NNS children)) (NP (NP (JJR <) (CD 2) (NNS years)) (PP (IN of) (NP (NN age)))))))) (PRN (-LRB- -LRB-) (NP (NP (NP (QP (JJR >) (CD 50)) (NN %)) (PP (IN during) (NP (CD 2000)))) (: --) (NP (CD 2006))) (-RRB- -RRB-))) (PRN (-LRB- -LSB-) (NP (CD 118)) (-RRB- -RSB-))) (. .)))
(ROOT (S (PP (IN In) (NP (NP (NN contrast)) (PP (TO to) (NP (NP (JJ low-level) (NN resistance)) (VP (VBN mediated) (PP (IN by) (NP (NP (NNP mefA)) (, ,) (NP (NP (JJ high-level) (NN resistance)) (VP (VBN mediated) (PP (IN by) (NP (NN ermB)))))))))))) (VP (MD can) (RB not) (VP (VB be) (VP (VBN overcome) (PP (IN during) (NP (NP (NN therapy)) (PP (IN with) (NP (NNS macrolides))))) (PP (IN despite) (NP (PRP$ their) (JJ excellent) (NN PK/PD) (NNS properties)))))) (. .)))
(ROOT (S (NP (NP (SBAR (IN Although) (S (NP (NP (DT the) (NN association)) (PP (IN between) (NP (NP (ADJP (FW in) (FW vitro)) (NN resistance)) (CC and) (NP (JJ adverse) (JJ clinical) (NN outcome)))) (PP (IN in) (NP (JJ acute) (NN rhinosinusitis)))) (VP (VBZ remains) (ADJP (RB generally) (JJ unproven))))) (PRN (-LRB- -LRB-) (ADJP (JJ owing) (PP (TO to) (NP (NP (NN lack)) (PP (IN of) (NP (JJ microbiological) (NN documentation)))))) (-RRB- -RRB-)) (, ,) (NN treatment) (NN failure)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ ermB-mediated) (NN resistance)) (PP (IN in) (NP (JJ bacteremic) (JJ pneumococcal) (NN disease))))))) (VP (VBZ has) (VP (VBN been) (ADVP (RB well)) (VP (VBN documented) (PRN (-LRB- -LSB-) (NP (CD 119)) (-RRB- -RSB-))))) (. .)))
(ROOT (S (PP (IN In) (NP (NP (NN light)) (PP (IN of) (NP (DT these) (NNS findings))))) (, ,) (NP (NNS macrolides)) (VP (VBP are) (ADVP (RB no) (RB longer)) (VP (VBN recommended) (PP (IN for) (NP (NP (JJ empiric) (JJ antimicrobial) (NN therapy)) (PP (IN of) (NP (NP (NNP S.) (FW pneumoniae) (NNS infections)) (PRN (-LRB- -LSB-) (NP (CD 82) (PRN (, ,) (NP (CD 93)) (-RRB- -RSB-)))))))))) (. .)))
(ROOT (S (SBAR (IN Although) (S (NP (NN telithromycin)) (VP (VBZ remains) (ADJP (RB highly) (JJ active) (PP (IN against) (NP (NP (DT all) (JJ respiratory) (NNS isolates)) (PP (VBG including) (NP (JJ penicillin-resistant) (NNP S.) (FW pneumoniae))))))))) (PRN (-LRB- -LSB-) (NP (CD 93)) (-RRB- -RSB-)) (, ,) (NP (PRP it)) (VP (VBZ is) (ADVP (RB no) (RB longer)) (VP (VBN approved) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNS ABRS))))) (ADVP (JJ due) (PP (TO to) (NP (NP (JJ rare)) (CC but) (NP (NP (JJ severe) (NNS instances)) (PP (IN of) (NP (NN hepatotoxcity))))) (PRN (-LRB- -LSB-) (NP (CD 120)) (-RRB- -RSB-)))))) (. .)))
(ROOT (S (NP (NN TMP/SMX)) (VP (VBZ is) (ADVP (RB also)) (VP (ADVP (RB no) (RBR longer)) (VBN recommended) (PP (IN for) (NP (NP (JJ empiric) (NN treatment)) (PP (IN of) (NP (NP (NNS ABRS)) (ADJP (JJ due) (PP (TO to) (NP (NP (JJ high) (NNS rates)) (PP (IN of) (NP (NP (NN resistance)) (PP (IN among) (NP (DT both) (NP (FW S.) (FW pneumoniae)) (CC and) (NP (NNP H.) (NNS influenzae))))))))))))))) (. .)))
(ROOT (S (NP (NP (NNP Harrison) (FW et) (FW al)) (PRN (-LRB- -LSB-) (NP (CD 94)) (-RRB- -RSB-))) (VP (VBD evaluated) (NP (NP (NP (DT the) (NN susceptibility)) (PP (TO to) (NP (JJ common) (JJ pediatric) (NNS antibiotics))) (PP (IN among) (NP (NNP S.) (FW pneumoniae)))) (, ,) (NP (JJ nontypeable) (NN H.) (NNS influenzae)) (, ,) (CC and) (NP (NP (NNP M.) (NN catarrhalis)) (VP (VBN isolated) (PP (IN from) (NP (CD 2005))) (PP (IN through) (NP (CD 2007))))))) (. .)))
(ROOT (S (NP (NP (NN TMP/SMX) (NN resistance) (NNS rates)) (PP (VBG according) (PP (TO to) (NP (NNP CLSI) (NNS breakpoints))))) (VP (VBD were) (NP (NP (NP (NP (CD 50) (NN %)) (PP (IN for) (NP (NNP S.) (FW pneumoniae)))) (PRN (-LRB- -LRB-) (NP (NP (CD 75) (NN %)) (PP (IN for) (NP (NN serotype) (NN 19A)))) (-RRB- -RRB-))) (, ,) (NP (NP (CD 27) (NN %)) (PP (IN for) (NP (NNP H.) (NNS influenzae)))) (, ,) (CC and) (NP (NP (NP (CD 2) (NN %)) (PP (IN for) (NP (NNP M.) (NN catarrhalis)))) (PRN (-LRB- -LRB-) (NP (NP (CD 73) (NN %)) (PP (VBG according) (PP (TO to) (NP (NNP PK/PD) (NNS breakpoints))))) (-RRB- -RRB-))))) (. .)))
(ROOT (S (NP (NP (NN Resistance)) (PP (TO to) (NP (NN TMP/SMX))) (PP (IN among) (NP (NNP S.) (FW pneumoniae) (NNS isolates)))) (VP (VBZ is) (PP (JJ due) (PP (TO to) (NP (NP (NNS mutations)) (PP (IN in) (NP (DT the) (JJ dihydrofolate) (NN reductase) (NN gene)))) (PRN (-LRB- -LSB-) (NP (CD 121)) (-RRB- -RSB-))) (, ,) (CC and) (VP (VBZ is) (S (ADVP (RB strongly)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ prior) (NN exposure)) (PP (TO to) (NP (NP (NN TMP/SMX)) (, ,) (NP (NNS macrolides)) (, ,) (CC or) (NP (NN penicillin)))))) (PRN (-LRB- -LSB-) (NP (CD 117)) (-RRB- -RSB-))))))) (. .)))
(ROOT (S (S (ADVP (RB Not) (RB surprisingly)) (, ,) (NP (NN TMP/SMX) (NN resistance) (NNS rates)) (VP (VBP are) (ADVP (RB significantly)) (ADJP (ADJP (JJR higher)) (PRN (-LRB- -LRB-) (NP (QP (JJR >) (CD 80)) (NN %)) (-RRB- -RRB-))) (PP (IN among) (NP (NN macrolide))))) (: -) (CC or) (NP (JJ penicillin-resistant) (NNP S.) (ADJP (ADVP (FW pneumoniae))) (PRN (-LRB- -LSB-) (NP (CD 122)) (-RRB- -RSB-))) (. .)))
(ROOT (S (ADVP (RB Similarly)) (, ,) (PP (IN among) (NP (NP (NNP H.) (NN influenzae) (NNS isolates)) (VP (VBN collected) (PP (IN during) (NP (CD 2001)))))) (: --) (NP (NP (NP (CD 2005)) (PP (IN in) (NP (DT the) (NNP TRUST) (NN program)))) (, ,) (NP (NP (NN resistance) (NNS rates)) (PP (TO to) (NP (NN TMP/SMX))))) (VP (VBD was) (NP (NP (CD 25) (NN %)) (PRN (-LRB- -LSB-) (NP (CD 95)) (-RRB- -RSB-)))) (. .)))
(ROOT (S (NP (NN Resistance)) (VP (VBZ is) (ADJP (ADJP (RB twice) (IN as) (JJ common)) (PP (IN among) (NP (NN β-lactamase)))) (: --) (S (VP (VBG producing) (NP (NNP H.) (NNS influenzae)) (PP (IN as) (PP (IN among) (NP (PRP$ its) (JJ non-β-lactamase)))) (PRN (: --) (S (VP (VBG producing) (NP (NP (NNS counterparts)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 32) (NN %)) (CC vs) (NP (CD 16) (NN %))) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-))) (PRN (-LRB- -LSB-) (NP (CD 123)) (-RRB- -RSB-)))))))) (. .)))
(ROOT (S (ADVP (RB Additionally)) (, ,) (NP (NN TMP/SMX)) (VP (VBZ has) (VP (VBN been) (VP (VBN associated) (PP (IN with) (NP (NP (ADJP (JJ rare) (CC but) (JJ severe)) (JJ adverse) (NNS reactions)) (PP (IN from) (NP (NP (JJ toxic) (JJ epidermal) (NN necrolysis)) (PRN (-LRB- -LSB-) (NP (CD 124)) (-RRB- -RSB-))))))))) (. .)))
(ROOT (S (NP (NNP Doxycycline)) (VP (VBZ has) (VP (VBN remained) (ADJP (JJ active) (PP (IN against) (NP (DT all) (JJ common) (JJ respiratory) (NNS pathogens)))) (, ,) (SBAR (IN although) (S (NP (EX there)) (VP (VBP are) (NP (NP (JJ few) (VBN published) (NNS reports)) (PP (IN for) (NP (NP (JJ recent) (NNS isolates)) (PP (IN in) (NP (DT the) (NNP United) (NNPS States)))))) (PRN (-LRB- -LSB-) (NP (NP (CD 125)) (, ,) (NP (CD 126))) (-RRB- -RSB-))))))) (. .)))
(ROOT (S (NP (NP (NNS Data)) (PP (IN from) (NP (NP (JJ national) (NNS surveys)) (PP (IN in) (NP (NNP Canada)))))) (VP (VBP reveal) (SBAR (IN that) (S (NP (NN doxycycline)) (VP (VBZ is) (FRAG (ADJP (ADJP (RB highly) (JJ active) (PP (IN against) (NP (DT all) (JJ recent) (JJ respiratory) (NNS pathogens)))) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 93.2) (NN %)) (PP (IN of) (NP (NNP S.) (FW pneumoniae)))) (, ,) (NP (NP (CD 98.1) (NN %)) (PP (IN of) (NP (NNP H.) (NNS influenzae)))) (, ,) (CC and) (NP (NP (CD 99.7) (NN %)) (PP (IN of) (NP (NNP M.) (NN catarrhalis))))) (-RRB- -RRB-))) (-LRB- -LRB-) (NP (NP (NP (NP (NNP G.) (NNP G.) (NNP Zhanel)) (, ,) (NAC (NNP University) (PP (IN of) (NP (NNP Manitoba)))) (, ,) (NP (NNP Winnipeg))) (PRN (: ;) (NP (NP (VBN written) (NN communication)) (, ,) (NP (NNP August) (CD 2010))) (-RRB- -RRB-))) (PRN (-LRB- -LSB-) (NP (NP (CD 127)) (, ,) (NP (CD 128))) (-RRB- -RSB-)))))))) (. .)))
(ROOT (S (ADVP (RB Similarly)) (, ,) (PP (IN in) (NP (NP (NP (NNP England)) (, ,) (NP (NNP Wales)) (, ,)) (CC and) (NP (NNP Northern) (NNP Ireland)))) (, ,) (NP (NP (JJ recent) (JJ invasive) (NNS isolates)) (PP (IN of) (NP (DT both) (NP (FW S.) (FW pneumoniae)) (CC and) (NP (NNP H.) (NNS influenzae))))) (VP (VBP have) (VP (VBN remained) (ADJP (RB highly) (JJ susceptible) (PP (TO to) (NP (NP (NN doxycycline)) (PRN (-LRB- -LRB-) (NP (NP (CD 91) (NN %)) (CC and) (NP (CD 99) (NN %)) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-))))) (PRN (-LRB- -LSB-) (NP (CD 129)) (-RRB- -RSB-)))) (. .)))
(ROOT (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN rate)) (PP (IN of) (NP (NN cross-resistance))) (PP (TO to) (NP (NN doxycycline))) (PP (IN among) (NP (NP (NN PNS) (NN S.pneumoniae)) (PP (IN in) (NP (NNP North) (NNP America)))))) (VP (VP (VBZ is) (ADJP (JJ unknown))) (CC but) (VP (VBZ is) (VP (VBN expected) (S (VP (TO to) (VP (VB be) (ADJP (JJR higher)) (PP (IN in) (NP (DT these) (NNS isolates))) (PP (VBN compared) (PP (IN with) (NP (JJ penicillin-susceptible) (NNS strains)))))))))) (. .)))
(ROOT (S (PP (IN In) (NP (CD one) (JJ Swedish) (NN study))) (, ,) (NP (NP (DT the) (NN rate)) (PP (IN of) (NP (NN doxycycline) (NN resistance)))) (VP (VBD was) (NP (CD 24) (NN %)) (PP (IN among) (NP (NNP PNS) (NNP S.) (FW pneumoniae))) (PP (VBN compared) (PP (IN with) (NP (NP (NP (CD 2) (NN %)) (PP (IN among) (NP (NP (JJ penicillin-susceptible) (NNS isolates)) (VP (VBN collected) (PP (IN during) (NP (CD 2001))))))) (: --) (NP (CD 2004) (PRN (-LRB- -LSB-) (NP (CD 130)) (-RRB- -RSB-))))))) (. .)))
(ROOT (S (NP (NP (DT The) (NN PK/PD) (NNS properties)) (PP (IN of) (NP (NN doxycycline)))) (VP (VBP are) (ADJP (ADJP (JJ favorable)) (CC and) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (PP (IN of) (NP (NP (DT the) (JJ respiratory) (NNS fluoroquinolones)) (PRN (-LRB- -LSB-) (NP (CD 125)) (-RRB- -RSB-))))))))) (. .)))
(ROOT (S (NP (NP (DT A) (JJ recent) (JJ prospective) (JJ double-blind) (NN trial)) (PP (IN of) (NP (NP (NN doxycycline)) (CC vs) (NP (NN levofloxacin)))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (VBN hospitalized) (NNS patients)) (PP (IN with) (NP (JJ community-acquired) (NN pneumonia)))))))) (VP (VBD demonstrated) (NP (NP (NP (NP (JJ similar) (JJ clinical) (NN response) (NNS rates)) (CC and) (NP (NP (NN length)) (PP (IN of) (NP (NN stay))))) (CC but) (PP (IN at) (NP (NP (DT a) (ADJP (RB significantly) (JJR lower)) (NN cost)) (PP (IN for) (NP (NN doxycycline)))))) (PRN (-LRB- -LSB-) (NP (CD 126)) (-RRB- -RSB-)))) (. .)))
(ROOT (S (NP (DT These) (NNS data)) (VP (VBP support) (NP (NP (DT the) (NN recommendation)) (PP (IN of) (NP (NP (NN doxycycline)) (PP (IN for) (NP (NP (NP (DT the) (NN outpatient) (NN treatment)) (PP (IN of) (NP (JJ community-acquired) (NN pneumonia)))) (PP (IN in) (NP (DT the) (CD 2007) (NNP IDSA) (NN guideline)))))))) (PRN (-LRB- -LSB-) (NP (CD 131)) (-RRB- -RSB-))) (. .)))
(ROOT (S (NP (EX There)) (VP (VBP are) (NP (NP (NP (QP (RB only) (CD 5)) (NNS RCTs)) (PP (IN of) (NP (NN doxycycline))) (PP (IN for) (NP (NP (NNS ABRS)) (PP (IN in) (NP (NP (DT the) (JJ English) (NN literature)) (PP (IN since) (NP (CD 1980)))))))) (, ,) (PP (VBG including) (NP (NP (NP (CD 2) (JJ placebo-controlled) (NNS trials)) (PRN (-LRB- -LSB-) (NP (NP (CD 46)) (, ,) (NP (CD 132))) (-RRB- -RSB-))) (CC and) (NP (NP (CD 3) (JJ comparative) (NNS trials)) (PP (IN with) (NP (NP (NN brodimoprim)) (, ,) (NP (NN spiramycin)) (, ,) (CC and) (NP (NN loracarbef))))) (, ,) (NP (ADVP (RB respectively)) (-LRB- -LSB-) (NP (NP (CD 133)) (: --) (NP (CD 135))) (-RRB- -RSB-)))))) (. .)))
(ROOT (S (NP (DT The) (JJ clinical) (NN success) (NNS rates)) (VP (VBD were) (NP (CD 80) (NN %)) (PP (IN for) (NP (NP (NN doxycycline)) (CC and) (NP (NP (CD 67) (NN %)) (PP (IN for) (NP (NN placebo)))))) (S (PP (IN in) (NP (CD one) (NN study))) (UCP (PRN (-LRB- -LSB-) (NP (CD 47)) (-RRB- -RSB-)) (, ,) (CC and) (NP (NP (NP (CD 85) (NN %)) (PP (IN for) (NP (NP (DT both) (NNS groups)) (PP (IN in) (NP (DT the) (JJ second) (NN study)))))) (PRN (-LRB- -LSB-) (NP (CD 46)) (-RRB- -RSB-)))))) (. .)))
(ROOT (S (PP (IN Of) (NP (DT the) (CD 3) (JJ comparative) (NNS trials))) (, ,) (NP (RB only) (DT the) (JJ Scandinavian) (NN study)) (VP (VBD enrolled) (NP (NP (JJ sufficient) (NNS patients)) (PRN (-LRB- -LSB-) (NP (CD 135)) (-RRB- -RSB-)))) (. .)))
(ROOT (S (PP (IN In) (NP (DT this) (JJ double-blind) (, ,) (JJ randomized) (NN study))) (, ,) (NP (CD 662) (NNS patients)) (VP (VP (VBD were) (VP (VBN enrolled))) (CC and) (S (NP (CC both) (NP (JJ pre) (: -) (CC and) (NN posttreatment) (NN sinus) (NNS punctures))) (VP (VBD were) (VP (VBN performed))))) (. .)))
(ROOT (S (ADVP (RB However)) (, ,) (NP (QP (RB only) (CD 50)) (NN %)) (VP (VP (VBD yielded) (NP (JJ positive) (NN pretreatment) (NNS cultures))) (CC and) (VP (VBD were) (ADJP (JJ evaluable) (PP (IN for) (NP (JJ bacteriological) (NN eradication)))))) (. .)))
(ROOT (S (PP (IN In) (NP (DT the) (JJ intent-to-treat) (NN analysis))) (, ,) (NP (DT the) (JJ clinical) (NN success) (NN rate)) (VP (VBD was) (NP (CD 91) (NN %)) (PP (IN in) (NP (DT both) (NNS groups))) (PRN (-LRB- -LRB-) (NP (NP (CD 300)) (PP (IN of) (NP (CD 330))) (PP (IN for) (NP (NP (NN doxycycline)) (CC vs) (NP (NP (CD 303)) (PP (IN of) (NP (CD 332))) (PP (IN for) (NP (NN loracarbef))))))) (-RRB- -RRB-))) (. .)))
(ROOT (S (PP (IN In) (NP (DT the) (JJ evaluable) (NNS patients))) (, ,) (NP (DT the) (JJ clinical) (NN success) (NN rate)) (VP (VBD was) (NP (NP (CD 93) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (CD 153)) (PP (IN of) (NP (CD 164)))) (-RRB- -RRB-))) (VP (PP (IN in) (NP (DT the) (NN doxycycline) (NN group))) (NP (NP (NP (NP (CC vs) (NP (NP (CD 98) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (CD 165)) (PP (IN of) (NP (CD 168)))) (-RRB- -RRB-))) (PP (IN in) (NP (DT the) (NN loracarbef) (NN group)))) (PRN (-LRB- -LRB-) (NP (NP (NP (NN P)) (ADJP (JJ =) (NP (CD .05)))) (PP (IN with) (NP (NP (NNP Yates) (POS 's)) (NN correction)))) (-RRB- -RRB-))) (SBAR (IN within) (S (NP (CD 3) (NNS days)) (VP (NN posttreatment))))) (, ,) (CC and) (NP (NP (CD 92) (NN %)) (PP (IN for) (NP (NP (DT both) (NNS groups)) (PP (IN at) (NP (NN follow-up) (CD 1)))))) (: --) (NP (NP (CD 2) (NNS weeks) (NN posttreatment)) (PRN (-LRB- -LRB-) (NP (NP (CD 121)) (PP (IN of) (NP (CD 131))) (PP (IN for) (NP (NP (NN doxcycline)) (CC vs) (NP (NP (CD 129)) (PP (IN of) (NP (CD 140))) (PP (IN for) (NP (NN loracarbef))))))) (-RRB- -RRB-)))))) (. .)))
(ROOT (S (NP (DT The) (JJ microbiological) (NN eradication) (NN rate) (NN posttreatment)) (VP (VBD was) (NP (NP (CD 81) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (CD 133)) (PP (IN of) (NP (CD 164)))) (-RRB- -RRB-))) (PP (IN for) (NP (NP (NN doxycycline)) (CC and) (NP (NP (NP (CD 80) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (CD 135)) (PP (IN of) (NP (CD 168)))) (-RRB- -RRB-))) (PP (IN for) (NP (NN loracarbef))))))) (. .)))
(ROOT (S (NP (NP (JJ Microbiological) (NN failure)) (PP (JJ due) (TO to) (NP (NP (NN presence)) (PP (IN of) (NP (NP (DT the) (JJ same) (NN pathogen)) (PP (IN in) (NP (DT the) (NN posttreatment) (NNS cultures)))))))) (VP (VBD occurred) (PP (IN in) (NP (CD 27))) (ADVP (PRN (-LRB- -LRB-) (NP (CD 16) (NN %)) (-RRB- -RRB-)) (PP (IN of) (NP (NP (JJ doxycycline-treated) (NNS patients)) (CC and) (NP (NP (CD 21) (PRN (-LRB- -LRB-) (NP (CD 13) (NN %)) (-RRB- -RRB-))) (PP (IN of) (NP (JJ loracarbef-treated) (NNS patients)))))))) (. .)))
(ROOT (S (NP (DT A) (JJ different) (NN organism)) (VP (VBD was) (VP (VBN isolated) (PP (IN from) (NP (NP (NN posttreatment) (NNS cultures)) (PP (IN in) (NP (NP (CD 4) (PRN (-LRB- -LRB-) (NP (CD 2.4) (NN %)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (NP (NN doxcycline)) (CC vs) (NP (NP (CD 12)) (PRN (-LRB- -LRB-) (NP (CD 7.1) (NN %)) (-RRB- -RRB-)))) (PP (IN of) (NP (NN loracarbef) (NNS patients))))))))))) (. .)))
(ROOT (S (NP (NP (DT The) (NN significance)) (PP (IN of) (NP (DT these) (NN posttreatment) (NNS cultures)))) (VP (VBZ is) (ADJP (JJ difficult) (SBAR (S (VP (TO to) (VP (VB interpret)))))) (SBAR (IN since) (S (NP (PRP they)) (VP (VBP do) (RB not) (ADVP (RB always)) (VP (VBP correlate) (PP (IN with) (NP (DT the) (JJ clinical) (NN response)))))))) (. .)))
(ROOT (S (ADVP (RB Nevertheless)) (, ,) (NP (NP (DT the) (JJ available) (JJ clinical)) (CONJP (RB as) (RB well) (IN as)) (NP (ADJP (JJ microbiological))) (CC and) (NP (NN PK/PD) (NNS data))) (VP (VBP do) (VP (VB support) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NN doxycycline))) (SBAR (IN as) (S (NP (DT an) (NN alternative)) (VP (TO to) (VP (VB amoxicillin-clavulanate) (PP (IN for) (NP (NP (JJ empiric) (JJ antimicrobial) (NN therapy)) (PP (IN of) (NP (NN ABRS))) (PP (IN in) (NP (NNS adults))))) (PP (IN at) (NP (NP (JJ low) (NN risk)) (PP (IN for) (NP (NP (NN acquisition)) (PP (IN of) (NP (NNP PNS) (NNP S.) (FW pneumoniae)))))))))))))) (. .)))
(ROOT (S (NP (DT The) (ADJP (FW in) (FW vitro)) (NN activity)) (IN of) (JJ second) (: -) (CC and) (NP (NP (JJ third-generation) (JJ oral) (NNS cephalosporins)) (PRN (-LRB- -LRB-) (PP (JJ such) (IN as) (NP (NP (NN cefaclor)) (, ,) (NP (NN cefprozil)) (, ,) (NP (NN cefuroxime) (NN axetil)) (, ,) (NP (NN cefpodoxime)) (, ,) (NP (NN cefdinir)) (, ,) (CC and) (NP (NN cefixime)))) (-RRB- -RRB-))) (VP (VBP are) (ADJP (RB highly) (JJ variable)) (PP (RB particularly) (IN against) (NP (ADJP (ADJP (JJ penicillin-intermediate)) (CC and) (ADJP (JJ resistant))) (NNP S.) (FW pneumoniae)))) (. .)))
(ROOT (S (S (S (PP (IN Among) (NP (DT these) (JJ oral) (NNS cephalosporins))) (, ,) (NP (NP (NN cefpodoxime)) (, ,) (NP (NN cefuroxime) (NN axetil)) (, ,) (CC and) (NP (NN cefdinir))) (VP (VBP are) (ADJP (ADJP (RB moderately) (JJ active) (PP (IN against) (NP (JJ penicillin-intermediate) (NNP S.) (FW pneumoniae)))) (PRN (-LRB- -LRB-) (ADJP (NP (QP (JJR <) (CD 50)) (NN %)) (JJ susceptible)) (-RRB- -RRB-))) (VP (VBN followed) (PP (IN by) (NP (NN cefixime)))))) (, ,) (IN whereas) (UCP (NN cefaclor) (CC and) (NN cefprozil) (VP (VBP are) (S (ADJP (JJ inactive)) (PRN (-LRB- -LSB-) (NP (NP (CD 95)) (, ,) (NP (CD 136)) (, ,) (NP (CD 137))) (-RRB- -RSB-)))))) (. .)))
(ROOT (S (NP (NP (JJ Oral) (NNS cephalosporins)) (PP (VBG including) (NP (NP (NN cefpodoxime)) (CC and) (NP (NN cefdinir))))) (VP (VBP are) (ADJP (JJ inactive) (PP (IN against) (NP (NAC (JJ penicillin-resistant) (NNP S.) (FW pneumoniae)) (PRN (-LRB- -LSB-) (NP (NP (CD 136)) (, ,) (NP (CD 138))) (-RRB- -RSB-)))))) (. .)))
(ROOT (S (NP (JJ Intravenous) (NN ceftriaxone) (CC and) (NN cefotaxime)) (VP (VBP remain) (ADJP (JJ active)) (PP (PP (IN against) (NP (NP (RB nearly) (DT all) (NNP S.) (FW pneumoniae)) (, ,) (PP (VBG including) (NP (JJ penicillin-resistant) (NNS strains))))) (, ,) (CC and) (VP (VBP are) (VP (VBN preferred) (PP (IN as) (NP (NP (NP (JJ second-line) (JJ empiric) (NN therapy)) (PRN (-LRB- -LRB-) (PP (IN in) (NP (NP (NN place)) (PP (IN of) (NP (JJ high-dose) (NN amoxicillin-clavulanate))))) (-RRB- -RRB-))) (PP (IN for) (NP (NP (VBN hospitalized) (NNS patients)) (PP (IN with) (NP (JJ severe) (NNS infections))))))))))) (. .)))
(ROOT (S (NP (NNP Cefpodoxime)) (VP (VBZ is) (NP (NP (DT the) (ADJP (RBS most) (JJ active)) (JJ oral) (NN cephalosporin)) (PP (IN against) (NP (NP (NP (DT both) (NNP H.) (NN influenzae) (CC and) (NN M.) (NN catarrhalis)) (PRN (-LRB- -LRB-) (NP (DT both) (NN β-lactamase) (ADJP (ADJP (JJ positive)) (CC and) (ADJP (JJ negative)))) (-RRB- -RRB-))) (, ,) (VP (VBN followed) (PP (IN by) (NP (NP (NN cefixime)) (, ,) (NP (NN cefuroxime)) (, ,) (CC and) (NP (NP (NN cefdinir)) (PRN (-LRB- -LSB-) (NP (NP (CD 138)) (, ,) (NP (CD 139))) (-RRB- -RSB-)))))))))) (. .)))
(ROOT (S (NP (NNP Cefaclor) (CC and) (NN cefprozil)) (VP (VBP are) (NP (RBS least) (ADJP (ADJP (JJ active)) (PRN (-LRB- -LRB-) (NP (NNP Table) (CD 7)) (-RRB- -RRB-))))) (. .)))
(ROOT (S (S (VP (VBN Based) (PP (IN on) (NP (DT these))) (ADVP (FW in) (FW vitro)) (NP (NNS data)))) (, ,) (NP (PRP it)) (VP (VBZ is) (ADJP (JJ clear)) (SBAR (IN that) (S (S (NP (JJ considerable) (NN variability)) (VP (VBZ exists) (PP (IN in) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (JJ second))))))) (: -) (CC and) (NP (NP (JJ third-generation) (JJ oral) (NNS cephalosporins)) (, ,) (PP (ADVP (RB particularly)) (IN against) (NP (NP (NNP S.) (FW pneumoniae)) (CC and) (NP (NNP H.) (NNS influenzae)))))))) (. .)))
(ROOT (S (PP (IN For) (NP (DT this) (NN reason))) (, ,) (NP (DT these) (NNS agents)) (VP (VBP are) (ADVP (RB no) (RB longer)) (VP (VBN recommended) (PP (IN as) (NP (NP (NN monotherapy)) (PP (IN for) (NP (NP (DT the) (JJ initial) (JJ empiric) (NN treatment)) (PP (IN of) (NP (NP (NN ABRS)) (PP (IN in) (NP (NP (NNS children)) (CC or) (NP (NNS adults)))))))))))) (. .)))
(ROOT (S (SBAR (IN If) (S (NP (DT an) (JJ oral) (NN cephalosporin)) (VP (VBZ is) (S (VP (TO to) (VP (VB be) (VP (VBN used)))))))) (, ,) (NP (NP (NP (DT a) (JJ third-generation) (NN cephalosporin)) (PRN (-LRB- -LRB-) (NP (FW eg) (, ,) (NN cefixime) (CC or) (NN cefpodoxime)) (-RRB- -RRB-))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN clindamycin)))))) (VP (VBZ is) (VP (VBN recommended) (PP (IN for) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NN ABRS)) (PP (IN from) (NP (NP (JJ geographic) (NNS regions)) (PP (IN with) (NP (NP (JJ high) (JJ endemic) (NNS rates)) (PP (IN of) (NP (NP (NNP PNS) (NNP S.) (FW pneumoniae)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD ≥) (CD 10)) (NN %)) (VP (VBG using) (NP (NP (CD 2008) (NNS CLSI)) (VP (VBN revised) (NP (NNS breakpoints)))))) (-RRB- -RRB-)))))))))))))) (. .)))
(ROOT (S (ADVP (RB However)) (, ,) (NP (NN clindamycin) (NN resistance)) (VP (VBZ is) (VP (VBN reported) (ADVP (RB frequently)) (PP (IN among) (NP (NP (NNP S.) (FW pneumoniae) (NN serotype) (NN 19A) (NNS isolates)) (PRN (-LRB- -LRB-) (NP (CD ∼) (CD 31) (NN %)) (-RRB- -RRB-)))) (PRN (-LRB- -LSB-) (NP (CD 94)) (-RRB- -RSB-)))) (. .)))
(ROOT (S (PP (IN In) (NP (JJ such) (NNS instances))) (PRN (, ,) (NP (DT a) (JJ fluoroquinolone) (-LRB- -LRB-) (NN levofloxacin) (CC or) (NN moxifloxacin)) (-RRB- -RRB-)) (VP (VBZ is) (VP (VBN recommended) (PP (IN as) (NP (DT an) (NN alternative))))) (. .)))
(ROOT (S (NP (NP (DT The) (VBN recommended) (NN first-line)) (CC and) (NP (NP (JJ second-line) (NNS regimens)) (PP (IN for) (NP (NP (JJ empiric) (JJ antimicrobial) (NN therapy)) (PP (IN of) (NP (NP (NN ABRS)) (PP (IN in) (NP (NP (NNS children)) (CC and) (NP (NNS adults)))))))))) (VP (VBP are) (VP (VBN summarized) (PP (IN in) (NP (NP (NNP Tables) (CD 9)) (CC and) (NP (CD 10)))) (, ,) (ADVP (RB respectively)))) (. .)))
(ROOT (S (NP (DT The) (JJ respiratory) (NNS fluoroquinolones)) (VP (VP (VP (VBP are) (ADJP (JJ active) (PP (IN against) (NP (NP (DT both) (NP (NN β-lactamase)) (: --) (NP (ADJP (JJ positive) (CC and) (: --)) (JJ negative) (JJ respiratory) (NNS pathogens))) (ADJP (JJ common) (PP (IN in) (NP (NN ABRS)))))))) (CC and) (VP (MD can) (VP (VB be) (VP (VBN administered) (PP (IN with) (NP (RB once) (: -) (CC or) (JJ twice-daily) (NN dosing) (NNS regimens))))))) (CC and) (VP (VBD improved) (NP (NN compliance)))) (. .)))
(ROOT (S (NP (NN Doxycycline)) (VP (VBZ appears) (ADJP (ADJP (RBR more) (JJ cost-effective)) (PP (IN than) (NP (DT the) (JJ respiratory) (NNS fluoroquinolones))))) (. .)))
(ROOT (S (NP (NP (NN Third-generation) (JJ oral) (NNS cephalosporins)) (PRN (-LRB- -LRB-) (NP (FW eg) (, ,) (NP (NP (NN cefixime)) (CC or) (NP (NN cefpodoxime)))) (-RRB- -RRB-))) (VP (VBP are) (VP (ADVP (RB well)) (VBN tolerated) (PP (IN with) (NP (JJ minimal) (JJ adverse) (NNS effects))))) (. .)))
(ROOT (S (ADVP (RB However)) (, ,) (NP (NP (PRP$ their) (NN coverage)) (PP (IN for) (NP (NNP S.) (FW pneumoniae)))) (VP (VBZ is) (ADJP (JJ variable))) (. .)))
(ROOT (S (S (NP (DT The) (JJ respiratory) (NNS fluoroquinolones)) (VP (VBP are) (ADJP (ADJP (RBR more) (JJ costly)) (PP (IN than) (NP (NN doxycycline)))))) (, ,) (CC and) (S (S (VP (VBG escalating) (NP (NP (NN resistance)) (PP (IN with) (NP (VBN increased) (NN usage)))))) (VP (VBZ is) (NP (DT a) (NN concern)))) (. .)))
(ROOT (S (S (ADJP (JJ Similar) (PP (TO to) (NP (NP (JJ other) (NNS fluoroquinolones)) (, ,) (NP (NN moxifloxacin))))) (S (VP (VBZ has) (VP (VBN been) (VP (VBN associated) (PP (IN with) (NP (NP (JJ severe) (NN hepatotoxicity)) (PRN (-LRB- -LSB-) (NP (NP (CD 140)) (, ,) (NP (CD 141))) (-RRB- -RSB-))))))))) (. .)))
(ROOT (S (S (NP (NNP Doxycycline)) (VP (VBZ is) (RB not) (VP (VBN recommended) (PP (IN for) (NP (NNS children)))))) (VBP ≤) (NP (NP (CD 8) (NNS years)) (PP (IN of) (NP (NN age))) (ADJP (JJ due) (PP (TO to) (NP (NP (NN staining)) (PP (IN of) (NP (NNS teeth))))))) (. .)))
(ROOT (S (NP (JJ Oral) (JJ third-generation) (NNS cephalosporins)) (VP (VP (VBP are) (ADJP (RB relatively) (JJ costly))) (CC and) (VP (MD may) (VP (VB cause) (NP (NP (NN diarrhea)) (CC or) (NP (NN hypersensitivity) (NNS reactions)))))) (. .)))
(ROOT (S (NP (NNP Clindamycin)) (VP (VBZ is) (NP (NP (NP (DT an) (JJ important) (NN cause)) (PP (IN of) (NP (NN Clostridium) (NN difficile)))) (PRN (: --) (S (NP (NP (VBN associated) (NN enterocolitis)) (, ,) (CC and) (NP (NN clindamycin) (NN resistance))) (VP (VBZ is) (ADJP (ADJP (JJ common) (PP (IN among) (NP (NNP S.) (FW pneumoniae) (NN serotype) (NN 19A) (NNS isolates)))) (PRN (-LRB- -LRB-) (NP (CD ∼) (CD 31) (NN %)) (-RRB- -RRB-)))))))) (. .)))
(ROOT (S (NP (NP (DT The) (NP (NN introduction)) (CC and) (NP (JJ large-scale) (NN implementation))) (PP (IN of) (NP (NN PCV7)))) (VP (VBZ has) (VP (VBN led) (PP (TO to) (NP (NP (DT the) (NN emergence)) (PP (IN of) (NP (NP (NP (JJR more) (ADJP (JJ virulent) (CC and) (JJ resistant))) (JJ nonvaccine) (NNS serotypes)) (PP (JJ such) (IN as) (NP (NP (NN serotype) (NN 19A)) (PRN (-LRB- -LSB-) (NP (NP (CD 86)) (, ,) (NP (CD 103))) (-RRB- -RSB-)))))))))) (. .)))
(ROOT (S (NP (NP (DT The) (NN introduction)) (PP (IN of) (NP (NN PCV13))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ contains) (NP (NP (CD 6) (JJ additional) (NN serotype) (NNS antigens)) (PP (VBG including) (NP (NN serotype) (NN 19A))))))) (, ,)) (VP (VBZ is) (VP (VBN anticipated) (S (VP (TO to) (VP (VB decrease) (NP (NP (CC both) (NP (ADJP (JJ overall))) (CC and) (NP (ADJP (JJ resistant))) (NP (JJ invasive) (JJ pneumococcal) (NN disease))) (PRN (-LRB- -LSB-) (NP (CD 99)) (-RRB- -RSB-)))))))) (. .)))
(ROOT (S (ADVP (RB However)) (, ,) (NP (JJ ongoing) (NN surveillance)) (VP (VBZ is) (VP (VBN required) (S (VP (TO to) (VP (VB detect) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (NP (JJ other) (VBG emerging) (JJ nonvaccine) (NNS serotypes)) (PP (IN of) (NP (NNP PNS) (NNP S.) (FW pneumoniae))))))))))) (. .)))
(ROOT (S (S (NP (NNP Doxycycline)) (VP (MD should) (VP (VB be) (VP (VBN included) (PP (IN in) (NP (NP (ADJP (ADJP (JJ national)) (CC and) (ADJP (JJ regional))) (NN surveillance) (NNS studies)) (PP (IN of) (NP (JJ respiratory) (NNS pathogens))))))))) (, ,) (CC and) (S (NP (NP (RBR more) (NNS RCTs)) (PP (IN with) (NP (NP (DT this) (JJ antimicrobial) (NN agent)) (PP (IN in) (NP (NP (DT the) (JJ empiric) (NN treatment)) (PP (IN of) (NP (NP (NNS adults)) (PP (IN with) (NP (NNS ABRS)))))))))) (VP (VBP are) (VP (VBN warranted)))) (. .)))
(ROOT (S (PP (IN Among) (NP (DT the) (JJ third-generation) (JJ oral) (NNS cephalosporins))) (, ,) (NP (NN cefditoren)) (VP (VBZ appears) (S (VP (TO to) (VP (VB have) (NP (NP (DT the) (JJS best) (JJ intrinsic) (NN activity)) (PP (IN against) (NP (DT all) (JJ common) (JJ respiratory) (NNS pathogens))) (PP (VBG including) (NP (NP (NNP PNS) (NNP S.)) (NP (FW pneumoniae) (PRN (-LRB- -LSB-) (NP (NP (CD 137)) (, ,) (NP (CD 142))) (-RRB- -RSB-)))))))))) (. .)))
(ROOT (S (NP (NP (RBR More) (NNS RCTs)) (PP (IN with) (NP (NP (DT this) (NN agent)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNS ABRS)))))))) (VP (VBP are) (VP (VBN warranted) (PP (IN in) (NP (CC both) (NP (NNS adults)) (CC and) (NP (NNS children)))))) (. .)))
(ROOT (NP (CD VIII) (. .)))
(ROOT (SBARQ (WHNP (WDT Which) (JJ Antimicrobial) (NNS Regimens)) (SQ (VP (VBP Are) (VP (VBN Recommended) (PP (IN for) (NP (NP (DT the) (NNP Empiric) (NN Treatment)) (PP (IN of) (NP (NN ABRS))) (PP (IN in) (NP (NP (NNS Adults)) (CC and) (NP (NNS Children)))))) (PP (IN With) (NP (NP (DT a) (NN History)) (PP (IN of) (NP (NNP Penicillin) (NNP Allergy)))))))) (. ?)))
(ROOT (NP (CD 11) (. .)))
(ROOT (S (CC Either) (NP (NP (NP (NN doxycycline)) (PRN (-LRB- -LRB-) (ADJP (RB not) (JJ suitable) (PP (IN for) (NP (NNS children)))) (-RRB- -RRB-))) (CC or) (NP (NP (DT a) (JJ respiratory) (JJ fluoroquinolone)) (PRN (-LRB- -LRB-) (NP (NP (NN levofloxacin)) (CC or) (NP (NN moxifloxacin))) (-RRB- -RRB-)))) (VP (VBZ is) (VP (VBN recommended) (PP (IN as) (NP (NP (DT an) (JJ alternative) (NN agent)) (PP (IN for) (NP (NP (JJ empiric) (JJ antimicrobial) (NN therapy)) (PP (IN in) (NP (NP (NNS adults)) (SBAR (WHNP (WP who)) (S (VP (VBP are) (ADJP (JJ allergic) (PP (TO to) (NP (NP (NN penicillin)) (PRN (-LRB- -LRB-) (ADJP (JJ strong) (, ,) (JJ moderate)) (-RRB- -RRB-)))))))))))))))) (. .)))
(ROOT (NP (CD 12) (. .)))
(ROOT (S (S (NP (NNP Levofloxacin)) (VP (VBZ is) (VP (VBN recommended) (PP (IN for) (NP (NP (NP (NNS children)) (PP (IN with) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NN type) (CD I) (NN hypersensitivity)))))) (PP (TO to) (NP (NN penicillin)))))))) (: ;) (S (NP (NP (NN combination) (NN therapy)) (PP (IN with) (NP (NP (NN clindamycin)) (CC plus) (NP (NP (DT a) (JJ third-generation) (JJ oral) (NN cephalosporin)) (PRN (-LRB- -LRB-) (NP (NP (NN cefixime)) (CC or) (NP (NN cefpodoxime))) (-RRB- -RRB-)))))) (VP (VBZ is) (VP (VBN recommended) (PP (IN in) (NP (NP (NNS children)) (PP (IN with) (NP (NP (NP (NP (DT a) (NN history)) (PP (IN of) (NP (JJ non)))) (: --) (NN type) (CD I) (NN hypersensitivity)) (PP (TO to) (NP (NP (NN penicillin)) (PRN (-LRB- -LRB-) (NP (JJ weak) (, ,) (JJ low)) (-RRB- -RRB-))))))))))) (. .)))
(ROOT (S (PP (IN In) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (DT a) (JJ questionable) (NN history)) (PP (IN of) (NP (NN penicillin) (NN allergy))))))) (, ,) (NP (NN skin) (NN testing)) (VP (VBZ is) (VP (ADVP (RB strongly)) (VBN recommended) (S (VP (TO to) (VP (VB confirm) (CC or) (VB exclude) (NP (DT an) (JJ immediate) (NN hypersensitivity) (NN response))))))) (. .)))
(ROOT (FRAG (SBAR (IN If) (S (NP (NP (DT an) (NN immunoglobulin) (NN E)) (: --) (S (NP (JJ mediated) (JJ immediate-type) (NN hypersensitivity) (NN response)) (VP (VBZ is) (VP (VBN documented)))) (, ,) (NP (NP (NP (DT a) (JJ respiratory) (JJ fluoroquinolone)) (PRN (-LRB- -LRB-) (NP (NP (NN levofloxacin)) (, ,) (NP (NN moxifloxacin))) (-RRB- -RRB-))) (CC or) (NP (NN doxycycline)))) (VP (VBZ is) (VP (VBN recommended) (PP (IN for) (NP (NNS adults))))))) (. .)))
(ROOT (S (NP (NP (NNPS Macrolides)) (CC and) (NP (NN TMP/SMX)) (, ,) (VP (ADVP (RB previously)) (VBN preferred) (PP (IN for) (NP (NP (JJ empiric) (NN treatment)) (PP (IN of) (NP (NN ABRS))))) (PP (IN in) (NP (NP (NNS patients)) (ADJP (JJ allergic) (PP (TO to) (NP (NN penicillin))))))) (, ,)) (VP (MD can) (ADVP (RB no) (RB longer)) (VP (VB be) (VP (VBN recommended) (PP (IN because) (IN of) (NP (NP (VBG increasing) (NN resistance)) (PP (IN among) (NP (DT both) (NP (FW S.) (FW pneumoniae)) (CC and) (NP (NNP H.) (NNS influenzae))))))))) (. .)))
(ROOT (S (NP (DT The) (JJ respiratory) (NNS fluoroquinolones)) (VP (VBP remain) (ADJP (ADJP (RB highly) (JJ active) (PP (IN against) (NP (DT all) (JJ common) (NNS pathogens))) (PP (IN in) (NP (NN ABRS)))) (CC and) (SBAR (S (NP (PRP$ their) (NN ability) (S (VP (TO to) (ADVP (RB rapidly)) (VP (VB eradicate) (NP (NNS bacteria)) (PP (IN from) (NP (DT the) (JJ maxillary) (NNS sinuses))))))) (VP (VBZ is) (ADVP (RB well)) (VP (VBN established) (PRN (-LRB- -LSB-) (NP (NP (CD 143)) (, ,) (NP (CD 144))) (-RRB- -RSB-)))))))) (. .)))
(ROOT (S (NP (NNP Doxycycline)) (VP (VBZ is) (ADVP (RB also)) (ADJP (RB highly) (JJ active) (PP (IN against) (NP (DT all) (JJ common) (NNS pathogens))) (PP (IN in) (NP (NP (NN ABRS)) (CC and) (NP (PRP$ its) (NN PK/PD) (NNS properties))))) (VP (VBP are) (ADJP (JJ similar) (PP (TO to) (NP (DT the) (JJ respiratory) (NNS fluoroquinolones)))))) (. .)))
(ROOT (S (PP (IN For) (NP (NP (NNS children)) (PP (IN with) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (JJ immediate-type) (NN hypersensitivity) (NN response))))))) (, ,) (NP (NN levofloxacin)) (VP (VBZ is) (VP (VBN recommended) (PP (IN as) (NP (NP (DT an) (JJ alternative)) (PP (TO to) (ADJP (JJ amoxicillin-clavulanate))))) (, ,) (SBAR (IN because) (S (S (NP (NP (NN experience)) (PP (IN with) (NP (NP (NN moxifloxacin)) (PP (IN in) (NP (NNS children)))))) (VP (VBZ is) (ADJP (RB relatively) (JJ scant)))) (CC and) (S (NP (NN doxycycline)) (VP (VBZ is) (RB not) (VP (VBN recommended) (ADJP (JJ due) (PP (TO to) (NP (NP (NN staining)) (PP (IN of) (NP (NNS teeth))))))))))))) (. .)))
(ROOT (S (SBAR (IN Although) (S (NP (NP (NN use)) (PP (IN of) (NP (NN levofloxacin))) (PP (IN in) (NP (NNS children)))) (VP (VBZ is) (ADVP (RB currently)) (VP (VBN approved) (PP (IN by) (NP (NP (DT the) (NNP US) (NNP Food) (CC and) (NNP Drug) (NNP Administration)) (PRN (-LRB- -LRB-) (NP (NNP FDA)) (-RRB- -RRB-)))) (PP (RB only) (IN for) (NP (NP (NNS patients)) (PP (VBG following) (NP (NP (JJ inhalational) (NN exposure)) (PP (TO to) (NP (NN anthrax)))))) (PRN (-LRB- -LSB-) (NP (CD 145)) (-RRB- -RSB-))))))) (, ,) (NP (NP (PRP$ its) (NN safety) (NN profile)) (PP (IN in) (NP (NNS children)))) (VP (VBZ has) (VP (VBN been) (VP (VBN studied) (NP (ADVP (RB extensively)) (-LRB- -LSB-) (NP (NP (CD 146)) (: --) (NP (CD 149))) (-RRB- -RSB-))))) (. .)))
(ROOT (S (NP (DT The) (NP (NP (NN safety)) (CC and) (NP (NP (NN tolerability)) (PP (IN of) (NP (NN levofloxacin))) (PP (IN in) (NP (NNS children)))))) (VP (VBD was) (VP (VBN assessed) (ADVP (RB prospectively)) (PP (IN among) (NP (NP (CD 2523) (NNS children)) (SBAR (WHNP (WP who)) (S (VP (VP (VBD participated) (PP (IN in) (NP (JJ several)))) (NP (NP (ADJP (VP (VBN randomized)) (CC but) (ADJP (JJ nonblinded))) (NN efficacy) (NNS trials)) (PP (IN in) (NP (DT the) (NNP Pediatric) (NNP Levaquin) (NNP Program)))) (PRN (-LRB- -LSB-) (NP (CD 149)) (-RRB- -RSB-))))))))) (. .)))
(ROOT (S (NP (NNP Levofloxacin)) (VP (VBD was) (ADVP (RB well)) (VP (VBN tolerated) (PP (PP (IN during)) (CC and) (PP (IN for) (NP (CD 12) (NNS months)))) (PP (VBG following) (NP (NN therapy))) (SBAR (IN as) (S (VP (VBN evidenced) (PP (IN by) (NP (NP (DT a) (JJ similar) (NN incidence) (CC and) (NN character)) (PP (IN of) (NP (NP (JJ adverse) (NNS events)) (PP (IN in) (NP (NP (NNS children)) (VP (VBG receiving) (NP (NP (NN levofloxacin)) (VP (VBN compared) (PP (IN with) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (JJ nonfluoroquinolone) (NNS antibiotics))))))))))))))))))))) (. .)))
(ROOT (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NP (JJ musculoskeletal) (NNS events)) (PRN (-LRB- -LRB-) (NP (NP (NN tendonopathy)) (, ,) (NP (NN arthritis)) (, ,) (CC or) (NP (NN arthralgia))) (-RRB- -RRB-)))) (VP (VBG involving) (NP (JJ weight-bearing) (NNS joints)))) (VP (VBD was) (ADJP (JJR greater)) (PP (IN in) (NP (JJ levofloxacin-treated) (NNS children))) (PP (PP (IN at) (NP (CD 2) (NP (NP (NNS months)) (PRN (-LRB- -LRB-) (NP (NP (CD 1.9) (NN %)) (CC vs) (NP (CD 0.79) (NN %))) (: ;) (S (NP (NN P)) (VP (JJ =) (NP (CD .025)))) (-RRB- -RRB-))))) (CC and) (PP (IN at) (NP (NP (CD 12) (NNS months)) (PRN (-LRB- -LRB-) (NP (NP (CD 2.9) (NN %)) (CC vs) (NP (CD 1.6) (NN %))) (: ;) (S (NP (NN P)) (VP (JJ =) (NP (CD .047)))) (-RRB- -RRB-))))) (PRN (-LRB- -LSB-) (NP (CD 150)) (-RRB- -RSB-))) (. .)))
(ROOT (S (ADVP (RB Similarly)) (, ,) (NP (NP (DT the) (NN safety) (NN profile)) (PP (IN of) (NP (NP (NN ciprofloxacin)) (PP (IN in) (NP (NNS children)))))) (VP (VBD was) (VP (VBN assessed) (ADVP (RB prospectively)) (PP (IN among) (NP (NP (CD 684) (NNS children)) (VP (VBN enrolled) (PP (IN in) (NP (JJ several) (VBN randomized) (JJ double-blind) (NN efficacy) (NNS trials)))))))) (. .)))
(ROOT (FRAG (SBAR (IN Although) (S (NP (DT the) (NN difference)) (VP (VBD was) (RB not) (ADJP (RB statistically) (JJ significant))))) (, ,) (NP (NP (DT the) (NN rate)) (PP (IN of) (NP (NN arthropathy))) (PP (IN at) (NP (CD 6) (NNS weeks))) (PP (IN among) (NP (NP (CD 335) (NNS children)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NN ciprofloxacin)))))))) (VBD was) (ADJP (JJR higher)) (IN than) (IN among) (NP (CD 349) (NNS children)) (WHNP (WP who)) (VBD received) (NP (DT a) (JJ nonfluoroquinolone) (NN comparator)) (CC both) (PP (IN at) (NP (CD 6) (NNS weeks))) (-LRB- -LRB-) (NP (NP (CD 9.3) (NN %)) (CC vs) (NP (CD 6.0) (NN %))) (. .)))
(ROOT (FRAG (S (ADVP (RB respectively)) (VP (PRN (PRN (-LRB- -LSB-) (NP (NP (ADJP (CD 95) (NN %)) (NN CI)) (, ,) (NP (QP (CD −) (CD .8))) (PP (TO to) (NP (CD 7.2)))) (-RRB- -RSB-)) (-RRB- -RRB-)) (CC and) (NP (NP (NP (CD 1) (NN year)) (PP (IN of) (NP (NN follow-up)))) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 13.7) (NN %)) (CC vs) (NP (CD 9.5) (NN %)) (, ,) (ADVP (RB respectively))) (PRN (-LRB- -LSB-) (NP (NP (ADJP (CD 95) (NN %)) (NN CI)) (, ,) (NP (NP (QP (CD −) (CD .6))) (PP (TO to) (NP (CD 9.1))))) (-RRB- -RSB-))) (-RRB- -RRB-))) (PRN (-LRB- -LSB-) (NP (CD 150)) (-RRB- -RSB-)))) (. .)))
(ROOT (S (NP (NP (JJ Achilles) (NN tendon) (NN rupture)) (, ,) (NP (NP (DT a) (JJ known) (NN complication)) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (JJ fluoroquinolone) (NNS antibiotics)) (PP (IN in) (NP (NNS adults))))))))) (, ,)) (VP (VBZ is) (ADJP (RB extremely) (JJ rare)) (PP (IN in) (NP (DT the) (JJ pediatric) (NN population)))) (. .)))
(ROOT (S (NP (NP (DT The) (NNP American) (NNP Association)) (PP (IN of) (NP (NNP Pediatrics)))) (ADVP (RB recently)) (VP (VBD issued) (NP (NP (DT a) (NN policy) (NN statement)) (PP (VBG concerning) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (NNS fluoroquinolones)) (PP (IN in) (NP (NP (JJ several) (JJ pediatric) (NNS infections)) (, ,) (PP (VBG including) (NP (NP (NN conjunctivitis)) (, ,) (NP (JJ respiratory) (NN tract) (NNS infections)) (, ,) (CC and) (NP (JJ gastrointestinal)) (CC and) (NP (JJ urinary) (NN tract)) (NP (NP (NNS infections)) (PRN (-LRB- -LSB-) (NP (CD 150)) (-RRB- -RSB-))))))))))))) (. .)))
(ROOT (S (NP (PRP It)) (VP (VBD was) (VP (VBN concluded) (SBAR (IN that) (S (NP (NP (NN use)) (PP (IN of) (NP (NP (DT a) (JJ fluoroquinolone)) (PP (IN in) (NP (NP (DT a) (NN child)) (CC or) (NP (JJ adolescent))))))) (VP (MD may) (VP (VB be) (VP (VBN justified) (PP (IN in) (NP (NP (NNS situations)) (SBAR (WHADVP (WRB where)) (S (NP (EX there)) (VP (VBZ is) (NP (DT no) (ADJP (ADJP (JJ safe)) (CC and) (ADJP (JJ effective))) (NN alternative)))))))))))))) (. .)))
(ROOT (FRAG (PP (IN In) (NP (NP (NN light)) (PP (IN of) (NP (DT these) (NNS findings))))) (, ,) (NP (DT the) (NN recommendation) (SBAR (WDT that) (S (NP (NN levofloxacin)) (VP (VB be) (VP (VBN used) (SBAR (IN as) (S (NP (NP (DT an) (NN alternative)) (SBAR (S (VP (TO to) (VP (VB amoxicillin-clavulanate) (PP (IN in) (NP (NP (NNS children)) (PP (IN with) (NP (JJ immediate-type) (NN hypersensitivity) (NNS reactions))))) (PP (TO to) (NP (NN penicillin)))))))) (VP (VBZ appears) (VP (VBN warranted)))))))))) (. .)))
(ROOT (S (PP (IN For) (NP (NP (NNS children)) (PP (IN with) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (JJ non))))))) (: --) (S (NP (NP (NP (NP (NP (NN type) (CD I) (NN hypersensitivity) (NN reaction)) (PP (TO to) (NP (NN penicillin)))) (, ,) (NP (NP (DT a) (JJ third-generation) (JJ oral) (NN cephalosporin)) (PRN (-LRB- -LRB-) (NP (FW eg) (, ,) (NN cefixime) (CC or) (NN cefpodoxime)) (-RRB- -RRB-)))) (PP (IN in) (NP (NN combination)))) (PP (IN with) (NP (NN clindamycin)))) (VP (VBZ is) (VP (VBN recommended)))) (. .)))
(ROOT (S (S (NP (DT The) (JJ former)) (VP (VBZ is) (ADJP (JJ active)) (PP (IN against) (NP (NP (JJS most) (NNS strains)) (PP (IN of) (NP (NP (NNP H.) (NNS influenzae)) (CC and) (NP (NN M.) (NN catarrhalis)))))))) (, ,) (IN whereas) (S (NP (NN clindamycin)) (VP (VBZ is) (ADJP (JJ active)) (PP (IN against) (FRAG (NP (JJS most) (NNP S.) (FW pneumoniae)) (VBG including) (NP (DT some) (ADJP (ADJP (JJ penicillin-intermediate)) (CC and) (ADJP (JJ resistant))) (NNS strains)) (-LRB- -LRB-) (NP (NP (NP (QP (CD ∼) (CD 85)) (NN %)) (ADJP (JJ susceptible) (PRN (TO to) (NP (NNP CLSI) (NNS breakpoints)) (-RRB- -RRB-)))) (PRN (-LRB- -LSB-) (NP (CD 94)) (-RRB- -RSB-))))))) (. .)))
(ROOT (S (ADVP (RB However)) (, ,) (NP (NN clindamycin) (NN resistance)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (ADVP (RB frequently)) (PP (IN among) (NP (NP (NNP S.) (FW pneumoniae) (NN serotype) (NN 19A) (NNS isolates)) (PRN (-LRB- -LRB-) (NP (ADJP (CD ∼) (CD 31) (NN %)) (JJ resistant)) (-RRB- -RRB-)))) (PRN (-LRB- -LSB-) (NP (CD 94)) (-RRB- -RSB-))))) (. .)))
(ROOT (S (PP (IN In) (NP (JJ such) (NNS instances))) (, ,) (NP (NN levofloxacin)) (VP (VBZ is) (VP (VBN recommended) (PP (IN as) (NP (DT an) (NN alternative))))) (. .)))
(ROOT (S (NP (EX There)) (VP (VBZ is) (NP (NP (JJ inadequate) (NN experience)) (PP (IN with) (NP (NN cefditoren) (NN monotherapy))) (PP (IN for) (NP (NP (NNS ABRS)) (PP (IN in) (NP (NNS children))) (PP (IN at) (NP (DT this) (NN time))))))) (. .)))
(ROOT (S (NP (NP (DT The) (VBN recommended) (NNS regimens)) (PP (IN for) (NP (NP (JJ empiric) (JJ antimicrobial) (NN therapy)) (PP (IN of) (NP (NP (NN ABRS)) (PP (IN in) (NP (NP (NNS children)) (CC and) (NP (NNS adults)))))) (PP (IN with) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NN penicillin) (NN allergy)))))))) (VP (VBP are) (VP (VBN summarized) (PP (IN in) (NP (NP (NNP Tables) (CD 9)) (CC and) (NP (CD 10)))) (, ,) (ADVP (RB respectively)))) (. .)))
(ROOT (S (NP (NNP Doxycycline)) (VP (VBZ is) (NP (NP (DT a) (JJ cost-effective) (NN alternative)) (PP (TO to) (NP (DT the) (JJ respiratory) (NNS fluoroquinolones)))) (PP (IN in) (NP (NP (NNS adults)) (SBAR (WHNP (WP who)) (S (VP (MD can) (RB not) (VP (VB tolerate) (NP (NN amoxicillin-clavulanate))))))))) (. .)))
(ROOT (S (NP (NP (DT The) (JJ long-term) (NN safety)) (PP (IN of) (NP (NP (JJ respiratory) (NNS fluoroquinolones)) (PP (IN in) (NP (NNS children)))))) (VP (VBZ requires) (NP (ADVP (RB further)) (NN evaluation))) (. .)))
(ROOT (S (NP (NP (JJ True) (NN type) (CD I) (NN hypersensitivity)) (PP (TO to) (NP (NN β-lactam) (NNS antibiotics)))) (VP (VBZ is) (ADJP (RB relatively) (JJ uncommon))) (. .)))
(ROOT (S (NP (DT Every) (NN effort)) (VP (MD should) (VP (VB be) (VP (VBN made) (S (VP (TO to) (VP (VB document) (NP (NP (JJ such) (NNS reactions)) (PP (IN with) (NP (JJ appropriate) (NN skin) (NN testing)))))))))) (. .)))
(ROOT (S (NP (NP (DT The) (VBG increasing) (NN prevalence)) (PP (IN of) (NP (NP (NN PNS)) (CC and) (NP (JJ cross-resistant) (NNP S.) (FW pneumoniae)))) (PP (IN among) (NP (JJ respiratory) (NNS pathogens)))) (VP (VP (VBZ has) (VP (VBN complicated) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (JJ penicillin-allergic) (NNS patients)))))) (CC and) (VP (VBD limited) (NP (NP (DT the) (NN choice)) (PP (IN of) (NP (JJ alternative) (NNS agents)))) (PP (ADVP (RB particularly)) (IN in) (NP (NNS children))))) (. .)))
(ROOT (S (NP (NP (JJ Additional) (NNS studies)) (PP (IN of) (NP (NP (DT the) (NP (NP (NN safety)) (CC and) (NP (NN efficacy)))) (PP (IN of) (NP (NP (JJ respiratory) (NNS fluoroquinolones)) (CC and) (NP (NP (NN monotherapy)) (PP (IN with) (NP (NN cefditoren))) (PP (IN for) (NP (NP (NNS ABRS)) (PP (IN in) (NP (NNS children))))))))))) (VP (VBP are) (VP (VBN warranted))) (. .)))
(ROOT (NP (CD IX) (. .)))
(ROOT (SQ (MD Should) (NP (NP (NNP Coverage)) (PP (IN for) (NP (NNP S.) (NN aureus)))) (VP (PRN (-LRB- -LRB-) (NP (RB Especially) (NN MRSA)) (-RRB- -RRB-)) (VP (VB Be) (S (VP (VBN Provided) (ADVP (RB Routinely)) (PP (IN During) (NP (NP (JJ Initial) (JJ Empiric) (NN Therapy)) (PP (IN of) (NP (NNP ABRS))))))))) (. ?)))
(ROOT (NP (CD 13) (. .)))
(ROOT (S (SBAR (IN Although) (S (NP (NP (NNP S.) (NN aureus)) (-LRB- -LRB-) (PP (VBG including) (NP (NNP MRSA))) (-RRB- -RRB-)) (VP (VBZ is) (NP (NP (DT a) (JJ potential) (NN pathogen)) (PP (IN in) (NP (NNP ABRS))))))) (, ,) (PP (VBN based) (PP (IN on) (NP (NP (NP (JJ current) (NNS data)) (, ,) (NP (NP (JJ routine) (JJ antimicrobial) (NN coverage)) (PP (IN for) (NP (NP (FW S.) (FW aureus)) (CC or) (NP (NNP MRSA)))))) (PP (IN during) (NP (NP (JJ initial) (JJ empiric) (NN therapy)) (PP (IN of) (NP (NN ABRS)))))))) (VP (VBZ is) (RB not) (VP (VBN recommended)) (PRN (-LRB- -LRB-) (ADJP (JJ strong) (, ,) (JJ moderate)) (-RRB- -RRB-))) (. .)))
(ROOT (NP (NN Evidence) (NN Summary)))
(ROOT (S (NP (NP (NNP Payne) (FW et) (FW al)) (PRN (-LRB- -LSB-) (NP (CD 151)) (-RRB- -RSB-))) (VP (VBD performed) (NP (DT a) (NN meta-analysis)) (PP (PP (IN on) (NP (NP (DT the) (NN recovery) (NNS rates)) (PP (IN of) (NP (FW S.) (FW aureus))))) (PP (CC either) (IN by) (NP (NP (NN sinus) (NN puncture)) (CC or) (NP (JJ middle) (NN meatus) (NNS cultures))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN enrolled) (PP (IN in) (NP (NP (JJ prospective) (JJ antimicrobial) (NNS trials)) (PP (IN for) (NP (NNS ABRS))))))))))) (. .)))
(ROOT (NP (NP (NP (DT A) (NN total)) (PP (IN of) (NP (NP (CD 16) (NNS trials)) (VP (VBG involving) (NP (NP (CD 4099) (NN study) (NNS patients)) (VP (VBD reported) (PP (IN in) (NP (DT the) (JJ English) (NN literature))) (PP (IN during) (NP (CD 1990))) (PRN (: --) (S (NP (CD 2006)) (VP (VBD were) (VP (VBN included) (PP (IN for) (NP (NN analysis))))))))))))) (. .)))
(ROOT (S (NP (DT The) (NN recovery) (NN rate)) (VP (VBD was) (ADJP (RB highly) (JJ variable)) (, ,) (S (VP (VBG ranging) (PP (PP (IN from) (NP (CD 0) (NN %))) (PP (TO to) (NP (NP (CD 31) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (NN mean)) (, ,) (NP (NP (CD 8.8) (NN %)) (PRN (-LRB- -LSB-) (NP (NP (ADJP (CD 95) (NN %)) (NN CI)) (, ,) (NP (CD 5.1)) (: --) (NP (CD 12.5))) (-RRB- -RSB-))) (: ;) (NP (NP (NN median)) (, ,) (NP (CD 8.0) (NN %))) (-RRB- -RRB-))))))))) (. .)))
(ROOT (S (ADVP (RB Furthermore)) (, ,) (NP (DT these) (NNS rates)) (VP (VBD were) (ADJP (RB somewhat) (JJ inflated)) (SBAR (IN because) (S (NP (PRP they)) (VP (VBD were) (VP (VBN based) (PP (IN on) (NP (NP (DT the) (NN percentage)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ positive) (NN sinus) (NNS cultures)))))))))))) (. .)))
(ROOT (S (SBAR (WHADVP (WRB When)) (S (NP (NP (DT the) (JJ total) (NNS numbers)) (PP (IN of) (NP (VBN enrolled) (NNS patients)))) (VP (VBP are) (VP (VBN considered))))) (, ,) (NP (NP (DT the) (NN recovery) (NN rate)) (PP (IN of) (NP (FW S.) (FW aureus)))) (VP (VBZ is) (ADJP (RB much) (JJR lower)) (, ,) (S (VP (VBG ranging) (PP (PP (IN from) (NP (CD 0) (NN %))) (PP (TO to) (NP (NP (CD 21) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (NN mean)) (, ,) (NP (NP (CD 5.6) (NN %)) (PRN (-LRB- -LSB-) (NP (NP (ADJP (CD 95) (NN %)) (NN CI)) (, ,) (NP (CD 3.1)) (: --) (NP (CD 8.1))) (-RRB- -RSB-))) (: ;) (NP (NP (NN median)) (, ,) (NP (CD 4.6) (NN %))) (-RRB- -RRB-))))))))) (. .)))
(ROOT (S (NP (NP (NP (NP (NNP Brook) (FW et) (FW al)) (PRN (-LRB- -LSB-) (NP (CD 152)) (-RRB- -RSB-))) (CC and) (NP (NNP Huang)) (CC and) (NNP Hung)) (PRN (-LRB- -LSB-) (NP (CD 153)) (-RRB- -RSB-))) (ADVP (RB also)) (VP (VBD performed) (NP (JJ prospective) (NNS studies)) (PP (IN by) (NP (NP (NP (NN sinus) (NN puncture)) (CC or) (NP (NP (NN culture)) (PP (IN of) (NP (DT the) (JJ middle) (NN meatus))))) (PP (IN from) (NP (NP (NP (CD 845) (NNS patients)) (PP (IN with) (NP (NN ABRS))) (PP (IN during) (NP (CD 2000)))) (: --) (NP (CD 2006))))))) (. .)))
(ROOT (S (NP (NP (NN Recovery) (NNS rates)) (PP (IN of) (NP (FW S.) (FW aureus)))) (VP (VBD were) (NP (NP (NP (CD 8.5) (NN %)) (: --) (NP (NP (CD 8.8) (NN %)) (PP (IN during) (NP (CD 2000)))) (: --) (NP (NP (NP (CD 2003)) (CC and) (NP (CD 10.3) (NN %))) (PP (IN during) (NP (CD 2004))))) (: --) (NP (CD 2006)))) (. .)))
(ROOT (S (NP (NP (DT The) (JJ corresponding) (NN recovery) (NNS rates)) (PP (IN for) (NP (NNP MRSA)))) (VP (VBD were) (NP (NP (NP (CD 2.5) (NN %)) (: --) (NP (NP (CD 2.7) (NN %)) (PP (IN during) (NP (CD 2000)))) (: --) (NP (NP (CD 2003)) (CC and) (NP (NP (CD 7.1) (NN %)) (PP (IN during) (NP (CD 2004)))))) (: --) (NP (CD 2006)))) (. .)))
(ROOT (S (NP (NP (JJ Previous) (JJ antimicrobial) (NN therapy)) (, ,) (NP (JJ recent) (NN hospitalization)) (CC and) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (JJ nasal) (NN surgery))))) (VP (VBD were) (NP (NP (DT the) (ADJP (RBS most) (JJ important)) (NN risk) (NNS factors)) (PP (IN for) (NP (NP (NP (NN recovery)) (PP (IN of) (NP (NNP MRSA)))) (PP (IN from) (NP (NN sinus) (NNS cultures)))))) (PRN (-LRB- -LSB-) (NP (CD 153)) (-RRB- -RSB-))) (. .)))
(ROOT (S (ADVP (RB However)) (, ,) (SBAR (IN because) (S (NP (DT the) (NN nose)) (VP (VBZ is) (NP (NP (DT a) (JJ well-known) (NN reservoir)) (PP (IN for) (NP (FW S.) (FW aureus))))))) (, ,) (NP (EX there)) (VP (VBZ remains) (NP (NP (DT a) (NN concern)) (SBAR (WHNP (WDT that)) (S (PP (ADVP (IN at) (JJS least)) (IN in) (NP (DT some) (NNS instances))) (NP (NP (DT the) (NN recovery)) (PP (IN of) (NP (FW S.) (FW aureus)))) (VP (MD could) (VP (VB be) (ADJP (JJ due) (PP (TO to) (NP (NP (NN contamination)) (PP (IN by) (NP (DT the) (JJ nasal) (NN flora))) (PP (IN during) (NP (NP (NN sinus) (NN aspiration)) (CC or) (NP (NP (NN acquisition)) (PP (IN of) (NP (NP (NNS cultures)) (PP (IN of) (NP (DT the) (JJ middle) (NN meatus))))))))))))))))) (. .)))
(ROOT (S (S (NP (NP (DT The) (NN concordance)) (PP (IN of) (NP (NP (NNS results)) (PP (IN from) (NP (NP (NN sinus) (NN tap)) (CC and) (NP (JJ middle) (NN meatus) (NNS cultures))))))) (VP (VBZ does) (RB not) (VP (VB eliminate) (NP (DT this) (NN possibility)) (PP (IN as) (NP (JJ inadvertent) (NN contamination))))) (VP (MD may) (VP (VB occur) (PP (IN by) (NP (CC either) (NN specimen) (NN collection) (NN technique)))))) (. .)))
(ROOT (S (PP (IN In) (NP (NP (NN support)) (PP (IN of) (NP (DT this) (NN notion))))) (, ,) (S (NP (CD 7) (PP (IN of) (NP (NP (DT the) (CD 16) (NNS patients)) (PP (IN with) (NP (NP (NNP MRSA)) (VP (VBN reported) (PP (IN by) (NP (NNP Huang) (CC and) (NNP Hung))))))))) (VP (VBD were) (ADVP (RB also)) (ADJP (JJ positive)) (PP (IN for) (NP (JJ other) (JJ well-established) (JJ respiratory) (NNS pathogens))))) (, ,) (CC and) (S (NP (DT all) (NNS patients)) (VP (VBD recovered) (PP (IN despite) (NP (DT the) (NN fact) (SBAR (IN that) (S (NP (NP (CD 6)) (PP (IN of) (NP (PRP them)))) (VP (VBD received) (NP (NP (JJ inadequate) (JJ antimicrobial) (NN therapy)) (PP (IN for) (NP (NNP MRSA))))))))))) (. .)))
(ROOT (S (S (NP (NP (IN Because) (NP (NP (NP (DT both) (FW S.) (FW aureus)) (PRN (-LRB- -LRB-) (NP (CD 13) (NN %)) (: --))) (NP (CD 20) (NN %))) (-RRB- -RRB-) (CC and) (FW Staphylococcus) (FW epidermidis)) (PRN (-LRB- -LRB-) (NP (CD 36) (NN %)) (: --))) (NP (CD 50) (NN %))) (-RRB- -RRB-) (VP (MD may) (VP (VB be) (VP (VBN isolated) (PP (IN from) (NP (ADJP (RB endoscopically) (VBN guided)) (JJ middle) (NN meatus) (NNS cultures))) (PP (IN in) (NP (JJ normal) (NNS subjects))) (VP (-LRB- -LSB-) (SBAR (S (NP (NP (CD 154)) (, ,) (NP (CD 155)) (-RRB- -RSB-) (, ,) (NP (NP (RB only) (JJ heavy) (NN growth)) (PRN (-LRB- -LRB-) (NP (QP (CD 3) (CC +) (CC or) (JJR >) (CD 10)) (NN ^) (CD 4) (JJ colony-forming) (NN units/mL)) (-RRB- -RRB-)))) (VP (MD should) (VP (VB be) (VP (VBN considered) (S (NP (NP (JJ potential) (NNS pathogens)) (PP (RB rather) (IN than) (NP (NP (JJ commensal) (NN flora)) (PRN (-LRB- -LSB-) (NP (CD 156)) (-RRB- -RSB-))))))))))))))) (. .)))
(ROOT (S (PP (IN In) (NP (NP (DT the) (NN meta-analysis)) (VP (VBD cited) (NP (IN above) (PRN (-LRB- -LSB-) (NP (CD 151)) (-RRB- -RSB-)))))) (, ,) (NP (PRP it)) (VP (VBZ is) (ADJP (JJ unclear)) (SBAR (S (SBAR (IN whether) (S (NP (JJ quantitative) (NNS cultures)) (VP (VBD were) (VP (VBN performed) (PP (IN in) (NP (DT the) (JJ various) (NNS studies))))))) (VP (VBD included) (PP (IN for) (NP (NN analysis))))))) (. .)))
(ROOT (S (ADVP (RB Collectively)) (, ,) (S (NP (DT these) (NNS data)) (VP (VBP do) (RB not) (VP (VB refute) (NP (NP (DT the) (NN contention)) (SBAR (WHNP (WDT that)) (S (NP (FW S.) (FW aureus)) (VP (MD may) (VP (VB be) (NP (NP (DT an) (JJ important) (JJ causative) (NN agent)) (PP (IN in) (NP (NNP ABRS)))))))))))) (, ,) (CC but) (S (NP (EX there)) (VP (VBZ is) (NP (JJ insufficient) (NN evidence)) (PP (IN at) (NP (DT the) (JJ present) (NN time))) (S (VP (TO to) (VP (VB support) (NP (NP (NN coverage)) (PP (IN for) (NP (DT this) (NN organism)))) (PP (IN during) (NP (NP (JJ initial) (JJ empiric) (NN therapy)) (PP (IN of) (NP (NN ABRS)))))))))) (. .)))
(ROOT (FRAG (UCP (ADVP (RB However)) (, ,) (PP (IN in) (NP (NP (ADJP (RB severely) (JJ ill)) (NNS patients)) (PP (IN with) (NP (NP (JJ clinical) (NNS manifestations)) (ADJP (JJ suggestive) (PP (IN of) (NP (NP (ADJP (JJ orbital))) (CC or) (NP (ADJP (JJ intracranial))) (NP (NP (NN extension)) (PP (IN of) (NP (NN infection))))))))))) (, ,) (CC and) (VP (VBD hospitalized) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ nosocomial) (NN sinusitis)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ prolonged) (JJ nasal) (NN intubation)) (, ,) (NP (NP (JJ empiric) (NN coverage)) (PP (IN for) (NP (NNP MRSA)))))))))) (SBAR (IN while) (S (S (VP (VBG awaiting) (NP (NP (NN confirmation)) (PP (IN from) (NP (NP (JJ positive) (NNS cultures)) (PP (IN of) (NP (NP (DT the) (NN sinus)) (CC or) (NP (JJ middle) (NN meatus))))))))) (VP (MD would) (VP (VB appear) (ADJP (JJ reasonable)))))))) (. .)))
(ROOT (S (NP (NP (ADJP (RBR More) (JJ stringent)) (NNS criteria)) (PP (IN for) (S (VP (VBG establishing) (NP (NP (DT a) (JJ causative) (NN role)) (PP (IN of) (NP (FW S.) (FW aureus))) (PP (IN in) (NP (NNP ABRS)))))))) (VP (MD will) (VP (VB minimize) (NP (NP (NN overutilization)) (PP (IN of) (NP (JJ antistaphylococcal) (NN therapy)))))) (. .)))
(ROOT (S (NP (NP (VBG Obtaining) (NNS cultures)) (PP (IN of) (NP (DT the) (JJ middle) (NN meatus) (CC or) (NN sinus) (NNS aspirates)))) (VP (MD may) (RB not) (VP (VB be) (VP (ADVP (RB well)) (VBN tolerated) (PP (IN in) (NP (NNS children)))))) (. .)))
(ROOT (FRAG (NP (NNP MRSA)) (VBZ is) (NP (DT an) (JJ important) (NN pathogen)) (CC both) (PP (IN in) (NP (NP (DT the) (NN community)) (CC and) (NP (DT the) (NN healthcare) (NN setting)))) (. .)))
(ROOT (S (NP (NP (JJ Accurate) (NN diagnosis)) (PP (IN of) (NP (NP (NNP MRSA) (NN rhinosinusitis)) (PP (IN with) (NP (JJ microbiological) (NN confirmation)))))) (VP (VBZ is) (ADJP (JJ critical) (PP (IN for) (NP (JJ appropriate) (JJ antimicrobial) (NN therapy))))) (. .)))
(ROOT (S (NP (JJR More) (NNS studies)) (VP (VBP are) (VP (VBN needed) (S (VP (TO to) (VP (VB document) (NP (NP (NP (DT the) (NN utility)) (PP (IN of) (NP (NP (ADJP (RB endoscopically) (VBN guided)) (NNS cultures)) (PP (IN of) (NP (DT the) (JJ middle) (NN meatus)))))) (PP (IN for) (S (VP (VBG distinguishing) (NP (JJ true) (NN infection)) (PP (IN from) (NP (NN contamination))) (PP (IN by) (NP (JJ commensal) (NN flora)))))))))))) (. .)))
(ROOT (SBARQ (NP (NNP X.)) (SINV (MD Should) (NP (NP (NNP Empiric) (NNP Antimicrobial) (NN Therapy)) (PP (IN for) (NP (NNP ABRS)))) (VP (VB Be) (VP (VBN Administered) (PP (IN for) (NP (CD 5) (: --) (CD 7) (NNS Days) (NP (NNP Versus) (CD 10)) (: --) (NP (QP (CD 14) (NNS Days)))))))) (. ?)))
(ROOT (NP (CD 14) (. .)))
(ROOT (S (NP (NP (DT The) (VBN recommended) (NN duration)) (PP (IN of) (NP (NN therapy))) (PP (IN for) (NP (JJ uncomplicated) (NNS ABRS))) (PP (IN in) (NP (NNS adults)))) (VP (VBZ is) (NP (CD 5) (PRN (: --) (NP (NP (CD 7) (NNS days)) (PRN (-LRB- -LRB-) (ADJP (ADJP (JJ weak)) (, ,) (ADJP (JJ low-moderate))) (-RRB- -RRB-)))))) (. .)))
(ROOT (NP (CD 15) (. .)))
(ROOT (UCP (PP (IN In) (NP (NP (NNS children)) (PP (IN with) (NP (NN ABRS))))) (, ,) (NP (NP (NP (DT the) (JJR longer) (NN treatment) (NN duration)) (PP (IN of) (NP (CD 10)))) (: --) (NP (NP (CD 14) (NNS days)) (VP (VBZ is) (ADVP (RB still)) (VP (VBN recommended) (PRN (-LRB- -LRB-) (ADJP (JJ weak) (, ,) (JJ low-moderate)) (-RRB- -RRB-)))))) (. .)))
(ROOT (S (S (VP (VBG Existing) (NP (NP (JJ clinical) (NNS guidelines)) (PP (IN for) (NP (NNS ABRS)))))) (VP (ADVP (RB generally)) (VBP recommend) (NP (NP (DT a) (NN course)) (PP (IN of) (NP (NP (JJ antimicrobial) (NN therapy)) (IN for) (NP (CD 10)) (: --) (NP (NP (CD 14) (NNS days)) (, ,) (PP (ADVP (RB primarily)) (IN on) (NP (NP (DT the) (NN basis)) (PP (IN of) (NP (NP (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NN therapy)))) (PP (IN in) (NP (JJ various) (NNS RCTs)))) (PRN (-LRB- -LSB-) (NP (CD 25)) (-RRB- -RSB-))))))))))) (. .)))
(ROOT (S (NP (DT Some) (NNS investigators)) (VP (VBP have) (VP (VBN recommended) (SBAR (IN that) (S (NP (JJ antimicrobial) (NN therapy)) (VP (VB be) (VP (VBN continued) (PP (IN for) (NP (CD 7) (NNS days))))))) (PP (IN beyond) (NP (NP (DT the) (NN resolution)) (PP (IN of) (NP (NP (NNS symptoms)) (PRN (-LRB- -LSB-) (NP (CD 157)) (-RRB- -RSB-)))))))) (. .)))
(ROOT (S (NP (NP (NNP Kutluhan) (CC and) (NNS colleagues)) (PRN (-LRB- -LSB-) (NP (CD 158)) (-RRB- -RSB-))) (ADVP (RB prospectively)) (VP (VBD evaluated) (NP (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (JJ antimicrobial) (NN therapy)))) (CC and) (NP (NP (PRP$ its) (NN effect)) (PP (IN on) (NP (NP (DT the) (JJ nasal) (NNS smears)) (VP (VBN obtained) (PP (IN from) (NP (NP (NP (CD 4) (NN patient)) (NNS groups)) (PP (IN with) (NP (NP (JJ acute) (JJ maxillary) (NN sinusitis)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NNS antibiotics)) (PP (IN for) (NP (NP (CD 7)) (, ,) (NP (CD 14)) (, ,) (NP (CD 21)) (, ,) (CC or) (NP (CD 28) (NNS days))))))))))))))))) (. .)))
(ROOT (S (PP (IN In) (NP (DT all) (NNS patients))) (, ,) (S (NP (NP (DT the) (NN microbiology)) (PP (IN of) (NP (JJ maxillary) (NN sinusitis)))) (VP (VBD was) (VP (VBN confirmed) (PP (IN by) (NP (NN sinus) (NN puncture)))))) (, ,) (CC and) (S (NP (NNS antibiotics)) (VP (VBD were) (VP (VBN selected) (S (VP (VBN based) (PP (IN on) (NP (ADJP (FW in) (FW vitro)) (NN susceptibility)))))))) (. .)))
(ROOT (S (NP (DT These) (NNS authors)) (VP (VBD concluded) (SBAR (IN that) (S (NP (NP (DT the) (ADJP (RBS most) (JJ appropriate)) (NN duration)) (PP (IN of) (NP (NP (JJ antimicrobial) (NN therapy)) (PP (IN for) (NP (JJ acute) (JJ maxillary) (NN sinusitis)))))) (VP (VBD was) (NP (QP (IN at) (JJS least) (CD 2)) (NNS weeks)) (, ,) (SBAR (IN because) (S (NP (NP (DT a) (JJ significant) (NN difference)) (PP (IN in) (NP (NP (DT the) (NN neutrophil) (NNS counts)) (PP (IN of) (NP (JJ nasal) (NNS smears)))))) (VP (VBD was) (VP (VBN observed) (PP (IN in) (NP (NP (DT the) (NN study) (NNS groups)) (PP (IN between) (NP (NP (QP (CD 7) (CC and) (CD 21)) (NNS days)) (PP (IN of) (NP (JJ antimicrobial) (NN therapy))))))))))))))) (. .)))
(ROOT (S (ADVP (RB However)) (, ,) (NP (NP (NN neutrophil) (NN count)) (PP (IN in) (NP (JJ nasal) (NNS smears)))) (VP (VBZ is) (NP (NP (DT a) (JJ poor) (NN criterion)) (PP (IN of) (NP (NP (NN responsiveness)) (PP (TO to) (NP (JJ antimicrobial) (NN therapy))))))) (. .)))
(ROOT (S (PP (IN In) (NP (JJ other) (JJ clinical) (NNS trials))) (, ,) (NP (NP (DT no) (JJ significant) (NN difference)) (PP (IN in) (NP (JJ clinical) (NN resolution) (NNS rates)))) (VP (VBD was) (VP (VBN observed) (PP (IN among) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (CD 6))))) (: --) (NP (NP (NP (CD 10) (NNS days)) (CC vs) (NP (CD 3))) (: --) (NP (NP (QP (CD 5) (NNS days))) (PP (IN of) (NP (NP (JJ various) (JJ antimicrobial) (NNS regimens)) (PRN (-LRB- -LSB-) (NP (NP (CD 159)) (: --) (NP (CD 163))) (-RRB- -RSB-)))))))) (. .)))
(ROOT (S (NP (NP (NP (DT A) (JJ recent) (NN meta-analysis)) (PP (IN by) (NP (NNP Falagas) (FW et) (FW al)))) (PRN (-LRB- -LSB-) (NP (CD 164)) (-RRB- -RSB-))) (VP (VBD examined) (NP (NP (NP (DT the) (NN efficacy)) (CC and) (NP (NN safety))) (PP (IN of) (NP (JJ short) (PRN (CC vs) (NP (NP (RBR longer) (NNS courses)) (PP (IN of) (NP (NP (JJ antimicrobial) (NN therapy)) (PP (IN for) (NP (NP (NNS adults)) (PP (IN with) (NP (NP (NN ABRS)) (VP (VBN enrolled) (PP (IN in) (NP (CD 12) (NNS RCTs)))))))))))))))) (. .)))
(ROOT (S (NP (NP (DT No) (JJ statistical) (NN difference)) (PP (IN in) (NP (NN efficacy)))) (VP (VBD was) (VP (VBN noted) (PP (IN between) (NP (NP (NP (NN short-course)) (PRN (-LRB- -LRB-) (NP (CD 3) (: --) (NP (CD 7) (NNS days))) (-RRB- -RRB-))) (CC vs) (NP (NN long-course) (-LRB- -LRB-) (NP (NP (CD 6) (PRN (: --) (NP (CD 10) (NNS days)) (-RRB- -RRB-)) (JJ antibiotic) (NN therapy)) (PRN (-LRB- -LRB-) (NP (NP (NP (NN OR)) (, ,) (NP (CD 0.95))) (PRN (-LRB- -LSB-) (NP (NP (ADJP (CD 95) (NN %)) (NN CI)) (, ,) (NP (CD .81)) (: --) (NP (CD 1.12))) (-RRB- -RSB-))) (-RRB- -RRB-)))))))) (. .)))
(ROOT (S (PP (IN In) (NP (NN addition))) (, ,) (NP (DT no) (NNS differences)) (PP (IN in) (NP (NP (JJ microbiological) (NN efficacy)) (PRN (-LRB- -LRB-) (NP (NP (NP (NN OR)) (, ,) (NP (CD 1.30))) (PRN (-LRB- -LSB-) (NP (NP (ADJP (CD 95) (NN %)) (NN CI)) (, ,) (NP (CD .62)) (: --) (NP (CD 2.74))) (-RRB- -RSB-))) (-RRB- -RRB-)))) (, ,) (NP (NP (NP (NN relapse) (NNS rates)) (PRN (-LRB- -LRB-) (NP (NP (NN OR)) (, ,) (NP (NP (CD 0.95)) (PRN (-LRB- -LSB-) (NP (NP (NN CI) (CD .63)) (: --) (NP (CD 1.37))) (-RRB- -RSB-)))) (-RRB- -RRB-))) (CC or) (NP (NP (JJ adverse) (NNS effects)) (PRN (-LRB- -LRB-) (NP (NP (NN OR)) (, ,) (NP (NP (CD 0.88)) (PRN (-LRB- -LSB-) (NP (NP (NN CI)) (, ,) (NP (CD .71)) (: --) (NP (CD 1.09))) (-RRB- -RSB-)))) (-RRB- -RRB-)))) (VP (VBD were) (VP (VBN found))) (. .)))
(ROOT (FRAG (ADVP (RB However)) (, ,) (SBAR (IN if) (S (NP (NP (NP (RB only) (DT the) (NNS studies)) (SBAR (WHNP (IN that)) (S (PP (VBN compared) (NP (NP (NP (CD 5) (NNS days)) (PRN (-LRB- -LRB-) (NP (NN short-course)) (-RRB- -RRB-))) (CC vs) (NP (NP (CD 10) (NNS days)) (PRN (-LRB- -LRB-) (ADJP (JJ long-course)) (-RRB- -RRB-))))) (VP (VBD were) (VP (VBN included) (PRN (-LRB- -LRB-) (NP (CD 5) (NNS RCTs)) (-RRB- -RRB-))))))) (, ,) (NP (JJ adverse) (NNS effects))) (VP (VBD were) (ADJP (RB significantly) (JJR fewer)) (PP (IN in) (NP (NP (DT the) (JJ short-course) (NN treatment) (NNS groups)) (PRN (-LRB- -LRB-) (NP (NP (NP (NN OR)) (, ,) (NP (CD 0.79))) (PRN (-LRB- -LSB-) (NP (NP (ADJP (CD 95) (NN %)) (NN CI)) (, ,) (NP (CD .63)) (: --) (NP (CD .98))) (-RRB- -RSB-))) (-RRB- -RRB-))))))) (. .)))
(ROOT (S (NP (DT This) (NN meta-analysis)) (VP (VBZ has) (NP (NP (DT a) (NN number)) (PP (IN of) (NP (NNS limitations))))) (. .)))
(ROOT (S (NP (DT The) (NN study) (NN population)) (VP (VBD was) (ADJP (JJ heterogeneous)) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NP (DT the) (NN entry) (NN criterion)) (PP (IN of) (NP (NP (NN symptom) (NN duration)) (PRN (-LRB- -LRB-) (NP (NP (DT any) (NN patient)) (PP (IN with) (NP (NP (NNS symptoms)) (NP (NP (QP (JJR <) (CD 30)) (NNS days)) (PP (IN with) (NP (JJ positive) (JJ radiologic) (NNS findings))))))) (-RRB- -RRB-))))))))) (. .)))
(ROOT (S (NP (EX There)) (VP (VBD was) (VP (VB overlap) (PP (IN in) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NP (NP (NN short-course)) (PRN (-LRB- -LRB-) (NP (CD 3) (: --) (NP (CD 7) (NNS days))) (-RRB- -RRB-))) (CC vs) (NP (NN long-course) (-LRB- -LRB-) (CD 6) (PRN (: --) (NP (CD 10) (NNS days)) (-RRB- -RRB-)) (NN treatment) (NNS groups)))))))) (. .)))
(ROOT (S (ADVP (JJ Last)) (, ,) (NP (NP (DT the) (JJ concomitant) (NN administration)) (PP (IN of) (NP (JJ adjunctive) (NNS medications)))) (VP (MD may) (VP (VB have) (VP (VBN minimized) (NP (NP (DT any) (JJ real) (NNS differences)) (PP (IN between) (NP (NP (DT the) (NN treatment) (NNS groups)) (PP (IN in) (NP (DT the) (JJ various) (NNS trials)))))) (PRN (-LRB- -LRB-) (NP (NNP Table) (CD 11)) (-RRB- -RRB-))))) (. .)))
(ROOT (S (NP (NP (DT A) (JJ major) (NN concern)) (VP (VBN raised) (PP (IN from) (NP (JJR earlier) (VBN published) (NNS RCTs))))) (VP (VBZ is) (SBAR (IN that) (S (NP (NP (DT the) (JJ favorable) (NN outcome)) (PP (IN of) (NP (NP (JJR shorter) (NN duration)) (PP (IN of) (NP (NN treatment)))))) (VP (MD might) (VP (VB be) (VP (VBN attributed) (PP (TO to) (NP (NP (NN inclusion)) (PP (IN of) (NP (NNS patients))))) (PP (IN without) (NP (NP (JJ microbiological) (NN confirmation)) (PP (IN of) (NP (NN ABRS))))))))))) (. .)))
(ROOT (S (ADVP (RB However)) (, ,) (NP (DT a) (JJ recent) (NN study)) (VP (VBD suggested) (SBAR (IN that) (S (PP (RB even) (IN among) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NN confirmation)) (PP (IN of) (NP (NN ABRS))))) (PP (IN by) (NP (NN sinus) (NN puncture))))) (, ,) (NP (NP (DT the) (JJ clinical) (NN cure) (NN rate)) (PP (IN of) (NP (NP (NN treatment)) (PP (IN with) (NP (NP (CD 5) (NNS days)) (PP (IN of) (NP (NN moxifloxacin)))))))) (VP (VBD was) (RB not) (ADVP (ADVP (RB significantly) (JJR better)) (PP (IN than) (NP (NN placebo)))) (NP (PRN (-LRB- -LRB-) (NP (NP (NP (CD 78) (NN %)) (CC vs) (NP (CD 67) (NN %))) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-)) (PRN (-LRB- -LSB-) (NP (CD 45)) (-RRB- -RSB-))))))) (. .)))
(ROOT (NP (NP (NP (DT The) (NN duration)) (PP (IN of) (NP (NP (NN treatment)) (PP (IN for) (NP (CD 5)))))) (: --) (NP (NP (CD 7) (NNS days)) (VP (VBZ is) (VP (VBN chosen) (ADVP (RB somewhat) (RB arbitrarily))))) (CC and) (X (VP (VBZ is) (ADJP (JJ intermediate) (PP (IN in) (NP (NP (DT the) (NN range)) (PP (IN of) (NP (NP (NN literature) (NNS recommendations)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ varies) (S (PP (PP (IN from) (NP (NP (CD 3)) (: --) (NP (CD 5) (NNS days)) (, ,))) (PP (TO to) (NP (CD 5)))) (: --) (NP (CD 7) (NNS days)) (, ,) (VP (PP (TO to) (NP (CD 6))) (PRN (: --) (NP (NP (CD 10) (NNS days)) (PRN (-LRB- -LSB-) (NP (CD 164)) (-RRB- -RSB-)))))))))))))))) (. .)))
(ROOT (S (S (NP (DT This) (NN recommendation)) (VP (VBZ is) (VP (VBN considered) (S (ADJP (JJ reasonable))) (SBAR (IN since) (S (PP (IN in) (NP (NP (JJS most) (NNS patients)) (PP (IN with) (NP (NP (NN confirmation)) (PP (IN of) (NP (NN ABRS))))))) (PP (IN by) (NP (NN sinus) (NN puncture))) (, ,) (NP (CC both) (NP (JJ symptomatic) (NN improvement)) (CC and) (NP (NP (JJ bacteriological) (NN eradication)) (PP (IN from) (NP (DT the) (JJ maxillary) (NN sinus))))) (VP (MD can) (VP (VB be) (VP (VBN expected) (PP (IN within) (NP (CD 72) (NNS hours))) (PP (IN after) (NP (NP (NN initiation)) (PP (IN of) (NP (JJ appropriate) (JJ antimicrobial) (NN therapy))))))))))))) (PRN (-LRB- -LRB-) (VP (VB see) (S (NP (NN question) (NNP XIV)) (VP (VBG following)))) (-RRB- -RRB-)) (. .)))
(ROOT (S (PP (IN In) (NP (DT any) (NN event))) (, ,) (NP (NP (NN duration)) (PP (IN of) (NP (JJ antimicrobial) (NN therapy))) (PP (IN beyond) (NP (NP (CD 10) (NNS days)) (PP (IN in) (NP (NP (JJ adult) (NNS patients)) (PP (IN with) (NP (JJ uncomplicated) (NN ABRS)))))))) (VP (VBZ is) (ADJP (JJ likely) (JJ excessive))) (. .)))
(ROOT (S (NP (NP (NNS Data)) (PP (IN in) (NP (JJ pediatric) (NNS patients)))) (, ,) (ADVP (RB however)) (, ,) (VP (VBP are) (ADJP (JJ inconclusive)) (SBAR (IN because) (S (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (NP (JJR shorter) (NNS courses)) (PP (IN of) (NP (NN therapy)))))) (VP (VBZ has) (RB not) (VP (VBN been) (ADVP (RB specifically)) (VP (VBN studied) (PP (IN in) (NP (DT a) (JJ rigorous) (JJ randomized) (NN fashion))) (PRN (-LRB- -LSB-) (NP (CD 165)) (-RRB- -RSB-)))))))) (. .)))
(ROOT (S (NP (NP (JJ Short) (NNS courses)) (PP (IN of) (NP (JJ antimicrobial) (NN therapy)))) (VP (MD may) (VP (VB offer) (NP (JJ several) (NNS advantages)) (PP (IN over) (NP (NP (JJR longer) (NNS courses)) (PP (IN of) (NP (NN therapy))) (PP (VBG including) (NP (VBN improved) (NN patient) (NN compliance))))) (, ,) (NP (NP (JJR fewer) (JJ adverse) (NNS events)) (, ,) (VP (VP (VBD decreased) (NP (JJ bacterial) (JJ antibiotic) (NN resistance))) (, ,) (CC and) (NP (NP (JJR lower) (NN cost)) (PRN (-LRB- -LSB-) (NP (NP (CD 159)) (, ,) (NP (CD 160)) (, ,) (NP (CD 166)) (: --) (NP (CD 168))) (-RRB- -RSB-))))))) (. .)))
(ROOT (S (NP (NP (JJR Shorter) (NNS courses)) (PP (IN of) (NP (JJ antimicrobial) (NN therapy)))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (NN relapse)) (CC or) (NP (JJ recurrent) (NN infection)) (, ,) (PP (ADVP (RB particularly)) (IN among) (NP (NP (DT the) (JJ elderly)) (CC and) (NP (NP (DT those)) (PP (IN with) (NP (VBG underlying) (NN disease)))) (CC or) (SBAR (WHNP (WP who)) (S (VP (VBP are) (VP (VBN immunocompromised))))))))))) (. .)))
(ROOT (NP (NP (JJ Other) (NNS Considerations)) (. .)))
(ROOT (S (NP (NP (JJS Most) (JJ clinical) (NNS trials)) (PP (IN of) (NP (NP (JJ antimicrobial) (NN therapy)) (PP (IN in) (NP (NNS ABRS)))))) (VP (VP (VBP have) (VP (VBN excluded) (NP (ADJP (RB severely) (JJ ill)) (NNS patients)))) (CC and) (VP (VBP have) (VP (VBN focused) (ADVP (RB exclusively)) (PP (IN on) (NP (NP (JJ acute) (JJ maxillary) (NN sinusitis)) (PP (IN with) (NP (NP (JJ little) (NN information)) (PP (IN on) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NN involvement)) (PP (IN of) (NP (JJ other) (NNS sinuses)))))))))))))) (. .)))
(ROOT (S (NP (JJ Further) (NN research)) (VP (VBZ is) (VP (VBN needed) (S (VP (VBG regarding) (NP (NP (NP (DT the) (JJ optimal) (NN duration)) (PP (IN of) (NP (NP (JJ antimicrobial) (NN treatment)) (PP (IN in) (NP (NP (NNS children)) (CC and) (NP (NNS adults))))))) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (NP (DT the) (NN likelihood)) (PP (IN of) (NP (DT a) (JJ viral) (NNP URI)))) (VP (VBZ has) (VP (VBN been) (VP (VBN minimized) (PP (IN by) (ADJP (JJ adhering) (PP (TO to) (NP (JJ stringent) (JJ clinical) (NN inclusion) (NNS criteria))))))))))))))) (. .)))
(ROOT (NP (NN XI) (. .)))
(ROOT (SQ (VBZ Is) (NP (NP (JJ Saline) (NN Irrigation)) (PP (IN of) (NP (NP (DT the) (JJ Nasal) (NNS Sinuses)) (PP (IN of) (NP (NNP Benefit)))))) (PP (IN as) (NP (NP (JJ Adjunctive) (NN Therapy)) (PP (IN in) (NP (NP (NNS Patients)) (PP (IN With) (NP (NN ABRS))))))) (. ?)))
(ROOT (NP (CD 16) (. .)))
(ROOT (NP (NP (NP (JJ Intranasal) (NN saline) (NNS irrigations)) (PP (IN with) (NP (CC either) (SBAR (S (NP (ADJP (ADJP (JJ physiologic)) (CC or) (ADJP (JJ hypertonic))) (NN saline)) (VP (VBP are) (VP (VBN recommended) (PP (IN as) (NP (NP (DT an) (JJ adjunctive) (NN treatment)) (PP (IN in) (NP (NP (NNS adults)) (PP (IN with) (NP (NP (NN ABRS)) (PRN (-LRB- -LRB-) (ADJP (ADJP (JJ weak)) (, ,) (ADJP (JJ low-moderate))) (-RRB- -RRB-))))))))))))))) (. .)))
(ROOT (S (NP (EX There)) (VP (VBZ is) (NP (NP (JJ limited) (NN evidence)) (PP (IN in) (NP (NP (NP (NN support)) (PP (IN of) (NP (ADJP (ADJP (JJ physiologic)) (CC or) (ADJP (JJ hypertonic))) (NN saline) (NNS irrigations)))) (PP (IN as) (NP (NP (JJ adjunctive) (NN therapy)) (PP (IN for) (NP (NP (NNS patients)) (PP (IN with) (NP (NN ABRS))))))))))) (. .)))
(ROOT (S (NP (DT A) (JJ recent) (NNP Cochrane) (NN review)) (VP (VBD evaluated) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (NN saline) (JJ nasal) (NNS irrigations)))) (PP (IN in) (S (VP (VBG treating) (NP (NP (JJ acute) (NNS URIs)) (PP (VBG including) (NP (NP (JJ acute) (NN rhinosinusitis)) (PRN (-LRB- -LSB-) (NP (CD 169)) (-RRB- -RSB-))))))))) (. .)))
(ROOT (S (S (NP (NP (CD Three) (NNS RCTs)) (PRN (-LRB- -LRB-) (NP (NP (NN total)) (PP (IN of) (NP (CD 618) (NNS participants)))) (-RRB- -RRB-))) (VP (VBD were) (VP (VBN included) (PP (IN for) (NP (NP (NN analysis)) (CC and) (NP (JJ various) (JJ nasal) (NN symptom) (NNS scores))))))) (VP (VBD were) (VP (VBN assessed))) (. .)))
(ROOT (S (SBAR (IN Although) (S (NP (JJ significant) (NNS improvements)) (VP (VBD were) (VP (VBN observed) (PP (IN in) (NP (NP (DT some) (NN symptom) (NNS scores)) (PRN (-LRB- -LRB-) (NP (NP (JJ nasal) (NN secretion)) (, ,) (NP (JJ nasal) (NN patency)) (, ,) (CC and) (NP (JJ overall) (NN health) (NN status))) (-RRB- -RRB-)))))))) (, ,) (S (NP (DT these) (NNS changes)) (VP (VBD were) (ADJP (RB relatively) (JJ minor)))) (PRN (-LRB- -LRB-) (NP (NNP Table) (CD 12)) (-RRB- -RRB-)) (. .)))
(ROOT (S (NP (DT The) (NNS authors)) (VP (VP (VBD concluded) (SBAR (IN that) (S (NP (DT the) (NNS trials)) (VP (VBD were) (ADJP (RB too) (JJ small)))))) (CC and) (VP (VBD had) (S (ADJP (RB too) (JJ high)) (NP (NP (DT a) (NN risk)) (PP (IN of) (NP (NN trial) (NN bias))) (S (VP (TO to) (VP (VB be) (ADJP (JJ confident) (SBAR (IN that) (S (NP (DT the) (NNS benefits)) (VP (VBD were) (ADJP (JJ meaningful))))))))))))) (. .)))
(ROOT (S (ADVP (RB Nevertheless)) (, ,) (NP (EX there)) (VP (VBD was) (NP (NP (DT a) (NN trend)) (PP (IN toward) (NP (NP (VBN reduced) (NP (JJ antibiotic) (NN use))) (CONJP (PP (IN in) (NP (CD one) (NN study))) (CONJP (RB as) (RB well) (IN as))) (NP (NP (DT a) (JJ significant) (NN reduction)) (PP (IN in) (NP (NP (NN time)) (VP (VBN lost) (PP (IN from) (NP (NN work))) (PRN (-LRB- -LSB-) (NP (CD 172)) (-RRB- -RSB-)))))))))) (. .)))
(ROOT (S (NP (NP (DT The) (NN value)) (PP (IN of) (NP (JJ intranasal) (NN saline) (NN irrigation))) (PP (IN in) (NP (JJ young) (NNS children)))) (VP (VBZ is) (ADJP (RBR less) (JJ certain))) (. .)))
(ROOT (S (PP (IN In) (NP (DT a) (JJ small) (JJ clinical) (NN trial))) (, ,) (NP (NP (CD 69) (NNS children)) (PP (IN with) (NP (NP (JJ acute) (NN sinusitis)) (PRN (-LRB- -LRB-) (NP (NP (NN mean) (NN age)) (, ,) (NP (NP (CD 6) (NNS years)) (PRN (-LRB- -LSB-) (NP (NP (NN range)) (, ,) (NP (CD 3)) (: --) (NP (CD 12))) (-RRB- -RSB-))) (-RRB- -RRB-)))))) (VP (VBD were) (VP (VBN randomized) (S (VP (TO to) (VP (VB receive) (NP (NP (CC either) (NP (JJ saline) (NN irrigation)) (CC or) (NP (DT no) (NN irrigation))) (PRN (-LRB- -LSB-) (NP (CD 173)) (-RRB- -RSB-)))))))) (. .)))
(ROOT (S (NP (NP (DT The) (JJ Total) (JJ Nasal) (NN Symptom) (NNS Scores)) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT the) (NNP Pediatric) (NNP Rhinoconjunctivitis) (NNP Quality)) (PP (IN of) (NP (NNP Life) (NNP Questionnaire))))) (VP (VBD were) (VP (ADVP (RB significantly)) (VBN improved) (PP (IN in) (NP (DT the) (NN saline) (NN group))))) (. .)))
(ROOT (S (ADJP (RBR More) (JJ important)) (, ,) (NP (DT the) (JJ nasal) (NN peak) (NN expiratory) (NN flow) (NN rate)) (VP (VBD was) (VP (ADVP (RB significantly)) (VBN improved) (PP (IN in) (NP (DT the) (NN saline) (NN irrigation) (NN group))) (PP (VBN compared) (PP (IN with) (NP (DT no) (NN irrigation)))))) (. .)))
(ROOT (S (ADVP (RB However)) (, ,) (NP (PRP it)) (VP (VBZ is) (ADJP (JJ unclear)) (SBAR (WHADVP (WRB how) (RB well)) (S (NP (DT the) (NN saline) (NN irrigation) (NN procedure)) (VP (VBD was) (VP (VBN tolerated) (PP (ADVP (RB particularly)) (IN among) (NP (DT the) (JJR younger) (NNS children)))))))) (. .)))
(ROOT (S (S (NP (JJ Minor) (NN discomfort)) (VP (VBZ is) (ADJP (JJ common) (PP (IN during) (NP (NN saline) (NN irrigation)))))) (, ,) (CC and) (S (NP (NP (NN installation)) (PP (IN of) (NP (JJ nasal) (NNS drops)))) (VP (VBZ is) (VP (ADVP (RBR less) (RB well)) (VBN tolerated) (PP (IN by) (NP (NNS babies)))) (, ,) (S (ADVP (RB often)) (VP (VBG making) (S (NP (PRP them)) (NP (NP (NP (NN cry)) (CC and) (NP (NN undoing))) (NP (NP (DT any) (JJ potential) (NN benefit)) (PP (IN of) (NP (NN symptom) (NN relief)))))))))) (. .)))
(ROOT (S (NP (JJ Several) (JJ other) (NNS studies)) (VP (VBD evaluated) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (ADJP (JJ hypertonic) (CC vs) (JJ physiologic)) (NN saline))) (PP (IN on) (NP (NP (JJ nasal) (NN airway) (NN patency)) (CC and) (NP (JJ mucociliary) (NN clearance))))) (S (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ symptomatic) (NN rhinosinusitis))))) (NP (-LRB- -LSB-) (NP (CD 174)) (, ,) (NP (CD 175)) (-RRB- -RSB-)))) (. .)))
(ROOT (S (S (NP (DT Both) (NN saline) (NNS preparations)) (VP (ADVP (RB significantly)) (VBD improved) (NP (JJ mucociliary) (NN clearance)) (PP (VBN compared) (PP (IN with) (NP (NN pretreatment) (NNS values))))) (: ;)) (S (ADVP (RB however)) (, ,) (NP (RB only) (JJ physiologic) (NN saline)) (ADVP (RB significantly)) (VP (VBD improved) (NP (NP (JJ nasal) (NN airway) (NN patency)) (PRN (-LRB- -LSB-) (NP (CD 174)) (-RRB- -RSB-))))) (. .)))
(ROOT (S (PP (IN In) (NP (JJ other) (NNS studies))) (, ,) (NP (JJ hypertonic) (NN saline)) (VP (VBD was) (VP (VBN found) (S (VP (TO to) (ADVP (RB significantly)) (VP (VB improve) (NP (NP (JJ nasal) (NNS symptoms)) (CONJP (RB as) (RB well) (IN as)) (NP (NP (NP (JJ global) (NN quality)) (PP (IN of) (NP (NN life)))) (PRN (-LRB- -LSB-) (NP (NP (CD 176)) (, ,) (NP (CD 177))) (-RRB- -RSB-))))))))) (. .)))
(ROOT (S (ADVP (RB Finally)) (, ,) (NP (JJ hypertonic) (NN saline)) (VP (VBD caused) (NP (VBN increased) (JJ nasal) (NN burning) (CC or) (NN irritation))) (. .)))
(ROOT (NP (NP (NP (DT The) (NN mechanism)) (SBAR (WHPP (IN by) (WHNP (WDT which))) (S (NP (ADJP (JJ physiologic) (CC or) (JJ hypertonic)) (NN saline) (NN irrigation)) (VP (VBZ improves) (SBAR (S (NP (JJ sinus-specific) (NNS symptoms)) (VP (VBZ is) (ADJP (JJ unclear))))))))) (. .)))
(ROOT (S (NP (PRP It)) (VP (VBZ has) (VP (VBN been) (VP (VBN postulated) (SBAR (IN that) (S (NP (NN saline) (NN irrigation)) (VP (VBZ improves) (NP (JJ nasal) (NNS symptoms)) (PP (IN by) (S (VP (VBG enhancing) (NP (JJ mucociliary) (NN function)) (, ,) (VP (VBG decreasing) (NP (JJ mucosal) (NN edema))) (, ,) (VP (ADVP (RB mechanically)) (VBG clearing) (NP (NP (JJ inspissated) (NN mucus)) (, ,) (CC and) (VP (VBG decreasing) (NP (NP (JJ inflammatory) (NNS mediators)) (PRN (-LRB- -LSB-) (NP (CD 176)) (-RRB- -RSB-))))))))))))))) (. .)))
(ROOT (S (S (NP (JJ Intranasal) (NN saline) (NN irrigation)) (VP (MD may) (VP (VB relieve) (NP (NNS symptoms)) (PP (IN in) (NP (DT both) (NNS children) (CC and) (NNS adults)))))) (, ,) (CC and) (S (VP (VB improve) (NP (NP (JJ disease-specific) (NN quality)) (PP (IN of) (NP (NN life)))))) (. .)))
(ROOT (S (S (NP (NP (DT The) (NN recommendation)) (PP (IN in) (NP (NP (NN favor)) (PP (IN of) (NP (NN saline) (NN irrigation)))))) (VP (VBZ places) (NP (DT a) (ADJP (RB relatively) (JJ high)) (NN value)) (PP (IN on) (NP (NP (JJ potential) (NNS benefits)) (PP (IN of) (NP (NP (NP (VBN increased) (NN comfort)) (CC and) (NP (NN safety))) (PP (IN of) (NP (DT the) (NN saline) (NNS irrigations))))))))) (, ,) (CC and) (NP (NP (ADJP (RB relatively) (JJ low)) (NN value)) (PP (IN on) (NP (NP (JJ local) (JJ adverse) (NNS effects)) (PP (JJ such) (IN as) (NP (NP (NN irritation)) (CC and) (NP (DT a) (NN burning) (NN sensation))))))) (. .)))
(ROOT (S (NP (NP (JJ Nasal) (NN burning)) (, ,) (NP (NN irritation)) (, ,) (CC and) (NP (NN nausea))) (VP (VBD were) (NP (NP (DT the) (ADJP (ADVP (RBS most) (RB frequently)) (VBN reported)) (JJ adverse) (NNS effects)) (PP (IN from) (NP (NP (JJ intranasal) (NN saline) (NN irrigation)) (PRN (-LRB- -LRB-) (NP (CD 7) (NN %)) (: --))))) (NP (NP (CD 32) (NN %)) (PP (IN in) (NP (JJ various) (NNS studies))))) (-RRB- -RRB-) (. .)))
(ROOT (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NN saline) (NNS irrigants)) (VP (MD should) (VP (VB be) (VP (VBN prepared) (PP (IN from) (NP (ADJP (ADJP (JJ sterile)) (CC or) (ADJP (JJ bottled))) (NN water))) (PP (IN in) (NP (NP (NN light)) (PP (IN of) (NP (NP (NP (JJ recent) (NNS reports)) (PP (IN of) (NP (NP (JJ primary) (JJ amebic) (NN encephalitis)) (PP (IN from) (NP (NP (VBN contaminated) (NN tapwater)) (VP (VBN used) (PP (IN for) (NP (NN saline) (JJ nasal) (NN irrigation))))))))) (-LRB- -LSB-) (NP (CD 178)) (, ,) (NP (CD 179)) (-RRB- -RSB-)))))))) (. .)))
(ROOT (S (S (NP (JJ Nasal) (NN saline) (NN irrigation)) (VP (VP (VBZ is) (VP (ADVP (RBR less) (RB well)) (VBN tolerated) (PP (IN in) (NP (NP (NNS babies)) (CC and) (NP (JJ young) (NNS children)))))) (CC and) (VP (MD may) (VP (VB make) (S (NP (PRP them)) (VP (VB cry))))))) (, ,) (S (NP (NN undoing)) (NP (DT any) (JJ potential) (NN benefit))) (. .)))
(ROOT (S (PP (VBN Given) (NP (NP (DT the) (ADJP (JJ small) (CC but) (JJ consistent)) (NN effect)) (PP (IN on) (NP (NP (NP (NNS symptoms)) (CC and) (NP (NN quality))) (PP (IN of) (NP (NN life))))))) (CC and) (NP (ADJP (RB relatively) (JJ mild)) (JJ adverse) (NNS effects)) (, ,) (NP (EX there)) (VP (VBZ is) (NP (NP (DT a) (JJ net) (JJ clinical) (NN benefit)) (PP (IN of) (NP (JJ intranasal) (ADJP (ADJP (JJ physiologic)) (CC or) (ADJP (JJ hypertonic))) (NN saline) (NN irrigation)))) (PP (IN as) (NP (NP (DT an) (NN adjunct)) (PP (TO to) (NP (NP (JJ antimicrobial) (NN therapy)) (PP (IN in) (NP (CC both) (NP (NNS adults)) (CC and) (NP (NP (NNS children)) (PP (IN with) (NP (NN ABRS))))))))))) (. .)))
(ROOT (S (NP (NP (DT The) (JJ optimal) (NN concentration) (, ,) (NN volume) (, ,) (NN frequency) (, ,) (CC and) (JJS most) (JJ appropriate) (NN technique)) (PP (IN for) (NP (JJ nasal) (NN saline) (NN irrigation)))) (VP (VBP remain) (S (VP (TO to) (VP (VB be) (VP (VBN determined)))))) (. .)))
(ROOT (NP (NNP XII) (. .)))
(ROOT (SQ (VBP Are) (NP (JJ Intranasal) (NNS Corticosteroids)) (VP (VBN Recommended) (PP (IN as) (NP (NP (DT an) (NN Adjunct)) (PP (TO to) (NP (JJ Antimicrobial) (NN Therapy))))) (PP (IN in) (NP (NP (NNS Patients)) (PP (IN With) (NP (NN ABRS)))))) (. ?)))
(ROOT (NP (CD 17) (. .)))
(ROOT (S (NP (NNS INCSs)) (VP (VBP are) (VP (VBN recommended) (PP (IN as) (NP (NP (DT an) (NN adjunct)) (PP (TO to) (NP (NP (NNS antibiotics)) (PP (IN in) (NP (NP (DT the) (JJ empiric) (NN treatment)) (PP (IN of) (NP (NP (NNP ABRS)) (, ,) (PP (ADVP (RB primarily)) (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NP (JJ allergic) (NN rhinitis)) (PRN (-LRB- -LRB-) (ADJP (ADJP (JJ weak)) (, ,) (ADJP (JJ moderate))) (-RRB- -RRB-)))))))))))))))))) (. .)))
(ROOT (S (NP (NNS INCSs)) (VP (VBP offer) (NP (NP (JJ modest) (JJ symptomatic) (NN improvement)) (CC and) (NP (NP (JJ minimal) (JJ adverse) (NNS events)) (PP (IN with) (NP (JJ short-term) (NN use)))))) (. .)))
(ROOT (NP (NP (CD Five) (NNS trials)) (S (-LRB- -LSB-) (CD 48) (, ,) (S (NP (NP (CD 180) (PRN (: --) (NP (CD 183)) (-RRB- -RSB-))) (CC and) (NP (NP (DT a) (NNP Cochrane) (NN review)) (PRN (-LRB- -LSB-) (NP (CD 184)) (-RRB- -RSB-)))) (VP (VBP have) (VP (VBN documented) (NP (JJ modest) (JJ symptomatic) (NN improvement)) (PP (IN with) (NP (NP (NNS INCSs)) (PP (VBN compared) (PP (IN with) (NP (DT a) (NN placebo)))))) (, ,) (SBAR (IN although) (S (NP (NP (DT the) (JJ relative) (NN risk)) (PP (IN of) (NP (NN improvement)))) (VP (VBD was) (ADJP (RB only) (JJ marginal) (ADVP (RB statistically))))))))) (PRN (-LRB- -LRB-) (NP (NNP Table) (CD 13)) (-RRB- -RRB-))) (. .)))
(ROOT (S (PP (VBG Combining) (NP (DT all) (NN study) (NNS patients))) (, ,) (NP (NP (CD 73) (NN %)) (PP (IN of) (NP (JJ treated) (NNS patients)))) (VP (VBD improved) (S (ADVP (RB clinically)) (CC vs) (NP (NP (CD 66) (NN %)) (PP (IN in) (NP (NP (DT the) (NN placebo) (NN group)) (PRN (-LRB- -LRB-) (NP (NP (NN RR)) (, ,) (NP (NP (CD 1.11)) (PRN (-LRB- -LSB-) (NP (NP (ADJP (CD 95) (NN %)) (NN CI)) (, ,) (NP (CD 1.04)) (: --) (NP (CD 1.18))) (-RRB- -RSB-)))) (-RRB- -RRB-))))) (, ,) (VP (VBG yielding) (NP (NP (DT an) (NN NNT)) (PP (IN of) (NP (CD 15))))))) (. .)))
(ROOT (S (NP (DT No) (NN difference)) (VP (VBD was) (VP (VBN noted) (PP (IN in) (NP (NP (NNS complications)) (CC or) (NP (NN relapse) (NN rate)))) (PP (IN in) (NP (NP (DT the) (CD 2) (NNS studies)) (SBAR (WHNP (WDT that)) (S (VP (VBD recorded) (NP (DT these) (JJ secondary) (NNS outcomes))))))))) (. .)))
(ROOT (S (NP (DT This)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NP (DT the) (JJ beneficial) (NN effect)) (PP (IN of) (NP (NNS INCSs)))) (, ,) (SBAR (IN although) (S (VP (ADVP (RB consistently)) (VBN demonstrated) (PP (IN in) (NP (JJ several) (NNS studies)))))) (, ,) (VP (VBD was) (ADJP (RB relatively) (JJ small)))))) (. .)))
(ROOT (S (ADVP (RB However)) (, ,) (S (S (NP (NP (DT the) (NN quality)) (PP (IN of) (NP (NP (DT the) (NN evidence)) (PP (IN in) (NP (DT these) (NNS studies)))))) (VP (VBZ is) (ADJP (JJ high)))) (, ,) (CC and) (S (NP (DT a) (JJ dose-response) (NN effect)) (VP (VBD was) (ADVP (RB also)) (VP (VBN demonstrated) (PP (IN between) (NP (NP (NN mometasone) (CD 400) (NN μg) (: /) (NN day)) (PRN (CC vs) (NP (NP (CD 200) (NN μg) (: /) (NN day)) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (NP (NP (NN RR)) (, ,) (NP (CD 1.10))) (PRN (-LRB- -LSB-) (NP (NP (ADJP (CD 95) (NN %)) (NN CI)) (, ,) (NP (CD 1.02)) (: --) (NP (CD 1.18))) (-RRB- -RSB-))) (CC vs) (NP (NN RR)) (, ,) (NP (CD 1.04))) (PRN (-LRB- -LSB-) (NP (NP (ADJP (CD 95) (NN %)) (NN CI)) (, ,) (NP (CD .98)) (: --) (NP (CD 1.11))) (-RRB- -RSB-))) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-)))))))))) (. .)))
(ROOT (S (NP (NP (DT The) (JJ beneficial) (NN effect)) (PP (IN of) (NP (NNS INCSs)))) (VP (MD could) (VP (VB be) (VP (VBN attributed) (PP (TO to) (NP (NP (PRP$ their) (JJ anti-inflammatory) (NNS properties)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VP (VB reduce) (NP (JJ mucosal) (VBG swelling))) (CC and) (VP (VB promote) (NP (NN drainage)))))))))))) (. .)))
(ROOT (S (PP (IN In) (NP (DT another) (NN study))) (, ,) (NP (NP (NNP Williamson) (FW et) (FW al)) (PRN (-LRB- -LSB-) (NP (CD 48)) (-RRB- -RSB-))) (VP (VBN randomized) (NP (CD 207) (JJ adult) (NNS patients)) (SBAR (IN with) (S (NP (NN ABRS)) (VP (TO to) (VP (VB receive) (NP (CC either) (NP (NP (JJ intranasal) (NN budesonide)) (PRN (-LRB- -LRB-) (NP (CD 200) (NN μg) (: /) (NN nostril)) (-RRB- -RRB-))) (CC or) (NP (NN placebo))) (ADVP (RB once) (RB daily)) (PP (IN for) (NP (CD 10) (NNS days)))))))) (. .)))
(ROOT (S (NP (NP (DT No) (JJ significant) (NN difference)) (PP (IN in) (NP (JJ clinical) (NN response) (NNS rates)))) (VP (VBD was) (VP (VBN observed) (PP (IN between) (NP (NP (DT the) (NN treatment) (NNS groups)) (PRN (-LRB- -LRB-) (NP (NP (NP (NN OR)) (, ,) (NP (CD 0.93))) (PRN (-LRB- -LSB-) (NP (NP (ADJP (CD 95) (NN %)) (NN CI)) (, ,) (NP (CD .54)) (: --) (NP (CD 1.62))) (-RRB- -RSB-))) (-RRB- -RRB-)))))) (. .)))
(ROOT (FRAG (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NP (NNS symptoms)) (PP (IN in) (NP (DT these) (NNS patients)))))) (VBD was) (ADJP (RB relatively) (JJ short)) (JJ prior) (TO to) (NP (NN enrollment)) (-LRB- -LRB-) (NP (NP (NP (NN median)) (, ,) (NP (NP (CD 7) (NNS days)) (-LRB- -LSB-) (NP (NN range)) (, ,) (NP (CD 4)) (: --) (PRN (NP (CD 14) (NNS days)) (-RRB- -RSB-) (-RRB- -RRB-) (, ,) (S (VP (VBG raising) (NP (DT the) (NN possibility) (SBAR (IN that) (S (ADVP (IN at) (JJS least)) (NP (NP (DT some)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (VBD did) (RB not) (VP (VB have) (NP (JJ bacterial) (NN infection))))))))))))) (. .)))
(ROOT (S (NP (DT This)) (VP (VBZ is) (VP (VBN supported) (PP (IN by) (NP (DT the) (NN finding) (SBAR (IN that) (NP (NP (CD 69) (NN %)) (PP (IN of) (NP (NP (DT the) (NNS patients)) (VP (VBG receiving) (NP (NN placebo)) (VP (ADVP (RB completely)) (VBN recovered) (PP (IN by) (NP (NP (CD 10) (NNS days)) (PRN (-LRB- -LRB-) (NP (NNP Table) (CD 13)) (-RRB- -RRB-)))))))))))))) (. .)))
(ROOT (S (S (NP (DT The) (NN recommendation)) (VP (VBG supporting) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNS INCSs)))) (SBAR (IN as) (S (NP (JJ adjunctive) (NN therapy)) (VP (VBZ places) (NP (DT a) (ADJP (RB relatively) (JJ high)) (NN value)) (PP (IN on) (NP (NP (DT a) (JJ small) (JJ additional) (NN relief)) (PP (IN of) (NP (NNS symptoms)))))))))) (, ,) (CC and) (NP (NP (DT a) (ADJP (RB relatively) (JJ low)) (NN value)) (PP (IN on) (S (VP (VBG avoiding) (NP (VBN increased) (NN resource) (NN expenditure)))))) (. .)))
(ROOT (S (NP (NNS INCSs)) (VP (VBP provide) (NP (NP (NP (JJ symptomatic) (NN relief)) (CC and) (NP (JJ anti-inflammatory))) (NNS effects)) (PP (IN in) (NP (NP (DT the) (JJ nasal) (NN mucosa)) (, ,) (SBAR (WHNP (WDT which)) (S (ADVP (RB theoretically)) (VP (VP (VBP decrease) (NP (NP (JJ mucosal) (NN inflammation)) (PP (IN of) (NP (DT the) (JJ osteomeatal) (NN complex))))) (CC and) (VP (VB allow) (S (NP (DT the) (NNS sinuses)) (VP (TO to) (VP (VB drain))))))))))) (. .)))
(ROOT (S (NP (NP (JJ Short-term) (NNS risks)) (PP (IN of) (NP (NNS INCSs)))) (VP (VP (VBP are) (ADJP (JJ minimal))) (CC but) (VP (MD may) (VP (VB include) (NP (NP (NN susceptibility)) (PP (TO to) (NP (JJ oral) (NN candidiasis))))))) (. .)))
(ROOT (S (NP (NP (JJ Routine) (NN administration)) (PP (IN of) (NP (NNS INCSs)))) (VP (MD will) (ADVP (RB clearly)) (VP (VB increase) (NP (NP (DT the) (NN cost)) (PP (IN of) (S (VP (VBG treating) (NP (NNP ABRS)))))))) (. .)))
(ROOT (S (NP (NP (NN Use)) (PP (IN of) (NP (NP (DT any) (JJ intranasal) (NNS medications)) (PP (IN in) (NP (NNS children)))))) (VP (MD may) (RB not) (VP (VB be) (ADVP (RB well)) (VP (VBN tolerated)))) (. .)))
(ROOT (S (NP (NP (DT The) (NN recommendation)) (SBAR (S (VP (TO to) (VP (VB prescribe) (NP (NP (NNS INCSs)) (PP (IN for) (NP (NN ABRS))))))))) (VP (VP (VBZ is) (ADJP (RB relatively) (JJ weak))) (CC and) (VP (VBN considered) (S (ADJP (JJ optional))) (SBAR (IN since) (S (NP (DT the) (NNS benefits)) (VP (VBP are) (ADJP (RB only) (JJ marginal) (PP (IN with) (NP (NP (DT an) (NN NNT)) (PP (IN of) (NP (CD 15))))))))))) (. .)))
(ROOT (S (ADVP (RB However)) (, ,) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ concurrent) (JJ allergic) (NN rhinitis))))) (, ,) (NP (NN INCS)) (VP (MD should) (VP (VB be) (ADVP (RB routinely)) (VP (VBN administered)))) (. .)))
(ROOT (S (NP (JJ Clinical) (NNS trials)) (VP (VBP have) (VP (VBN documented) (NP (NP (DT the) (JJ relative) (NN safety)) (CC and) (NP (NP (NN efficacy)) (PP (IN of) (NP (NNS INCSs))))) (PP (IN in) (S (VP (VBG providing) (NP (JJ modest) (NN symptom) (NN relief)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN ABRS)))))))))) (. .)))
(ROOT (S (NP (NP (JJ Further) (NNS studies)) (PP (IN in) (NP (NP (JJR larger) (NNS populations)) (PP (IN with) (NP (DT these) (NNS agents)))))) (VP (VBP are) (ADVP (RB clearly)) (VP (VBN needed))) (. .)))
(ROOT (NP (NN XIII) (. .)))
(ROOT (SQ (MD Should) (NP (NP (NNP Topical) (CC or) (NNP Oral) (NNPS Decongestants)) (CC or) (NP (NNPS Antihistamines))) (VP (VB Be) (VP (VBN Used) (PP (IN as) (NP (JJ Adjunctive) (NN Therapy))) (PP (IN in) (NP (NP (NNS Patients)) (PP (IN With) (NP (NN ABRS))))))) (. ?)))
(ROOT (NP (CD 18) (. .)))
(ROOT (S (NP (NP (DT Neither) (ADJP (ADJP (JJ topical)) (CC nor) (ADJP (JJ oral))) (NNS decongestants)) (CC and/or) (NP (NNS antihistamines))) (VP (VBP are) (VP (VBN recommended) (PP (IN as) (NP (NP (JJ adjunctive) (NN treatment)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NN ABRS)) (PRN (-LRB- -LRB-) (ADJP (ADJP (JJ strong)) (, ,) (ADJP (JJ low-moderate))) (-RRB- -RRB-)))))))))) (. .)))
(ROOT (S (SBAR (IN Although) (S (NP (NNS decongestants) (CC and) (NNS antihistamines)) (VP (VBP are) (ADVP (RB frequently)) (VP (VBN prescribed) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN ABRS))))))))) (, ,) (NP (EX there)) (VP (VBZ is) (NP (NP (JJ scant) (NN evidence)) (SBAR (S (VP (TO to) (VP (VB support) (SBAR (IN that) (S (NP (PRP they)) (VP (VBP hasten) (NP (NN recovery))))))))))) (. .)))
(ROOT (S (SBAR (IN Although) (S (NP (NNS patients)) (VP (MD may) (ADVP (RB subjectively)) (VP (VB feel) (NP (NP (NN improvement)) (PP (IN in) (NP (JJ nasal) (NN airway) (NN patency)))))))) (, ,) (NP (JJ objective) (JJ rhinometric) (NNS findings)) (VP (VBP do) (RB not) (VP (VB support) (NP (DT this) (NN impression) (PRN (-LRB- -LSB-) (NP (CD 185)) (-RRB- -RSB-))))) (. .)))
(ROOT (S (NP (EX There)) (VP (VBP have) (VP (VBN been) (NP (NP (JJ several) (NNS RCTs)) (SBAR (WHNP (WDT that)) (S (VP (VBD assessed) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (NP (DT an) (JJ additive) (NN effect)) (PP (IN of) (NP (NP (ADJP (ADJP (JJ topical)) (CC or) (ADJP (JJ oral))) (NNS decongestants)) (CC or) (NP (NNS antihistamines))))))) (PP (TO to) (NP (NP (JJ antimicrobial) (NN therapy)) (PP (IN in) (NP (NP (NNS adults)) (PP (IN with) (NP (NP (NN ABRS)) (PRN (-LRB- -LSB-) (NP (NP (CD 175)) (, ,) (NP (CD 186)) (, ,) (NP (CD 187))) (-RRB- -RSB-)))))))))))))) (. .)))
(ROOT (S (NP (NP (NNP Inanli) (FW et) (FW al)) (PRN (-LRB- -LSB-) (NP (CD 175)) (-RRB- -RSB-))) (ADVP (RB prospectively)) (VP (VBD evaluated) (NP (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NP (JJ topical) (NNS decongestants)) (PRN (-LRB- -LRB-) (NP (NN oxymetazoline)) (-RRB- -RRB-))) (CC vs) (NP (ADJP (ADJP (ADJP (JJ hypertonic) (PRN (-LRB- -LRB-) (NP (CD 3) (NN %)) (-RRB- -RRB-))) (CC or) (ADJP (JJ isotonic))) (PRN (-LRB- -LRB-) (NP (QP (CD 0.9)) (NN %)) (-RRB- -RRB-)))) (NP (NN saline))))) (CC or) (NP (NP (DT no) (JJ topical) (NN treatment)) (PP (IN on) (NP (NP (JJ mucociliary) (NN clearance)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN ABRS)))))))))) (. .)))
(ROOT (S (NP (DT All) (NNS patients)) (VP (VBD received) (NP (NP (CD 625) (NN mg)) (VP (NN amoxicillin-clavulanate) (ADVP (QP (CD 3) (NNS times)) (RB daily)) (PP (IN for) (NP (CD 3) (NNS weeks)))))) (. .)))
(ROOT (S (PP (IN At) (PP (NP (CD 20) (NNS minutes)) (IN after) (NP (NN application)))) (, ,) (VP (ADVP (RB statistically)) (NP (JJ significant) (NNS improvements)) (PP (IN in) (NP (JJ mucociliary) (NN clearance))) (SBAR (S (PP (VBN compared) (PP (IN with) (NP (JJ basal) (NNS levels)))) (VP (VBD were) (ADVP (RB only)) (VP (VBN observed) (PP (IN in) (NP (DT the) (NP (NP (NN oxymetazoline)) (CC and) (NP (ADJP (CD 3) (NN %)) (NN saline) (NN treatment) (NNS groups)))))))))) (. .)))
(ROOT (UCP (PP (IN At) (NP (CD 3) (NNS weeks))) (, ,) (NP (NP (NP (NP (JJ significant) (NN improvement)) (PP (IN from) (NP (JJ basal) (NNS levels)))) (SBAR (S (VP (VBD was) (NP (VBN observed) (PP (IN in) (NP (DT all) (NN treatment) (NNS groups))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT the) (NN group)) (SBAR (WHNP (WDT that)) (S (VP (VBD received) (NP (DT no) (JJ topical) (NN treatment)))))) (: ;))) (CC and) (S (NP (EX there)) (VP (VBD was) (NP (NP (DT no) (JJ significant) (NN difference)) (PP (IN in) (NP (NP (NN improvement)) (PP (IN among) (NP (DT these) (NNS groups))))))))))) (, ,) (NP (NP (NP (NNP Wiklund) (FW et) (FW al)) (PRN (-LRB- -LSB-) (NP (CD 186)) (-RRB- -RSB-))) (VP (VBN used) (NP (JJ plain) (NN sinus) (NN radiography)) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (JJ topical) (NN oxymetazoline)) (CC vs) (NP (NN placebo)))))))) (, ,) (NP (DT each)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (JJ oral) (NN penicillin)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ acute) (JJ maxillary) (NN sinusitis)))))))))))) (. .)))
(ROOT (S (NP (NP (DT Neither) (JJ subjective) (NN symptom) (NNS scores)) (CC nor) (NP (JJ radiographic) (NNS findings))) (VP (VBD were) (ADJP (RB significantly) (JJ different) (PP (IN in) (NP (DT the) (NN treatment) (NNS groups))))) (. .)))
(ROOT (S (PP (IN On) (NP (DT the) (NN contrary))) (, ,) (NP (NP (JJ topical) (NN treatment)) (PP (IN with) (NP (NNS decongestants)))) (VP (MD may) (NP (PRP itself)) (VP (VB induce) (NP (NN inflammation)) (PP (IN in) (NP (DT the) (JJ nasal) (NN cavity))))) (. .)))
(ROOT (S (NP (NP (NNP Bende) (FW et) (FW al)) (PRN (-LRB- -LSB-) (NP (CD 188)) (-RRB- -RSB-))) (VP (VBD confirmed) (NP (DT this) (RB experimentally)) (PP (IN in) (NP (NP (NNS rabbits)) (PP (IN with) (NP (JJ acute) (JJ bacterial) (NN sinusitis)))))) (. .)))
(ROOT (S (NP (JJ Topical) (NN oxymetazoline)) (VP (VBD was) (VP (VBN instilled) (PP (IN in) (NP (NP (CD one) (JJ nasal) (NN cavity) (CC and) (NN placebo)) (PP (IN in) (NP (DT the) (JJ other))))))) (. .)))
(ROOT (S (PP (IN After) (NP (CD 48) (NNS hours))) (, ,) (NP (NP (JJ histological) (NNS sections)) (PP (IN of) (NP (DT the) (JJ maxillary) (NN sinus) (NN mucosa)))) (VP (VBD revealed) (NP (NP (ADJP (RB significantly) (RBR more) (JJ inflammatory)) (NNS changes)) (PP (IN in) (NP (DT the) (JJ oxymetazoline-treated) (NN side))) (PP (IN than) (PP (IN in) (NP (DT the) (JJ placebo-treated) (NN side)))))) (. .)))
(ROOT (S (NP (NP (NNP McCormick) (FW et) (FW al)) (PRN (-LRB- -LSB-) (NP (CD 187)) (-RRB- -RSB-))) (VP (VBD evaluated) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (NP (JJ oral) (NNS antihistamines)) (PRN (-LRB- -LRB-) (NP (NP (NP (NN brompheniramine)) (CC and) (NP (NN phenylpropanolamine))) (PP (IN in) (NP (NN syrup)))) (-RRB- -RRB-))))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (NP (JJ nasal) (NN oxymetazoline)) (CC vs) (NP (NP (NN placebo)) (PRN (-LRB- -LRB-) (NP (NP (JJ oral) (NN syrup)) (CC and) (NP (JJ nasal) (NN saline))) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NN ABRS)) (PP (IN in) (NP (NNS children)))))))))))) (. .)))
(ROOT (S (NP (DT All) (NNS patients)) (VP (VBD received) (NP (NP (CD 14) (NNS days)) (PP (IN of) (NP (JJ oral) (NNP amoxicillin))))) (. .)))
(ROOT (S (NP (NNS Patients)) (VP (VBD were) (VP (VBN assessed) (PP (IN by) (NP (NP (JJ clinical) (NNS symptoms)) (CC and) (NP (NP (NP (NNP Waters) (POS ')) (NN view) (NN plain) (NNS radiographs)) (PP (IN for) (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NN sinus) (NN involvement)))))))))) (. .)))
(ROOT (S (NP (NP (DT The) (NN addition)) (PP (IN of) (NP (NN decongestant-antihistamine)))) (VP (VBD did) (RB not) (VP (VB provide) (NP (NP (VBN added) (NN benefit)) (PP (VBN compared) (SBAR (IN with) (S (NP (NP (NNP amoxicillin)) (ADVP (RB alone))) (PP (IN in) (NP (DT this) (NN study))))))))) (. .)))
(ROOT (S (NP (DT The) (NN antihistamine) (NN H1) (NN antagonist) (NN loratadine)) (VP (VP (VBZ does) (RB not) (VP (VB possess) (NP (DT any) (JJ anticholinergic) (NNS effects)))) (CC and) (VP (VBZ is) (ADJP (JJ nonsedative)))) (. .)))
(ROOT (S (NP (NP (PRP$ Its) (JJ adjunctive) (NN effect)) (PP (TO to) (NP (NP (JJ standard) (NN treatment)) (PP (IN with) (NP (NP (NNS antibiotics)) (CC and) (NP (JJ oral) (NNS steroids))))))) (VP (VBD was) (VP (VBN examined) (PP (IN in) (NP (DT a) (JJ double-blind) (, ,) (NP (NP (NP (JJ placebo-controlled) (NNP RCT)) (PP (IN in) (NP (NP (CD 139) (NNS adults)) (PP (IN with) (NP (NP (JJ acute) (NN rhinosinusitis)) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (JJ strong) (NN history)) (PP (IN of) (NP (NN allergy))))))))))) (PRN (-LRB- -LSB-) (NP (CD 189)) (-RRB- -RSB-))))))) (. .)))
(ROOT (S (NP (DT All) (NNS patients)) (VP (VBD received) (ADJP (ADJP (JJ amoxicillin-clavulanate)) (PRN (-LRB- -LRB-) (NP (NP (CD 2) (NN g)) (JJ daily)) (-RRB- -RRB-))) (PP (IN for) (NP (CD 14) (NX (NX (NNS days)) (CC and) (NX (JJ oral) (NN prednisone)))))) (. .)))
(ROOT (S (NP (NP (NP (NN Loratadine)) (PRN (-LRB- -LRB-) (NP (NP (CD 10) (NN mg)) (ADJP (JJ daily))) (-RRB- -RRB-))) (CC or) (NP (NN placebo))) (VP (VBD was) (VP (VBN administered) (PP (IN for) (NP (CD 28) (NNS days))))) (. .)))
(ROOT (S (NP (JJ Nasal) (NN symptom) (NNS scores)) (VP (VP (VBN based) (PP (IN on) (NP (NP (NN self-reporting)) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT a) (JJ rhinologic) (NN examination)) (PP (IN at) (NP (NN baseline))))))) (CC and) (SBAR (S (NP (CD 4) (NNS weeks)) (VP (VBD were) (VP (ADVP (RB significantly)) (VBN improved) (PP (IN in) (NP (DT the) (NN loratadine))) (PP (VBN compared) (PP (IN with) (NP (NP (DT the) (NN placebo) (NN group)) (PP (IN at) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (QP (CD 2) (CC and) (CD 4)) (NNS weeks))))))))))))) (. .)))
(ROOT (S (PP (IN In) (NP (JJ particular))) (, ,) (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NN improvement)))) (VP (VBD was) (ADJP (RB significantly) (JJR greater)) (PP (IN for) (NP (NP (JJ certain) (NNS symptoms)) (PP (VBG including) (NP (ADJP (VBG sneezing) (CC and) (JJ nasal)) (NN obstruction)))))) (. .)))
(ROOT (S (ADVP (RB However)) (, ,) (NP (DT this) (NN patient) (NN population)) (VP (VBZ is) (NP (JJ unique) (SBAR (IN in) (IN that) (DT all) (S (VP (VP (VBD had) (NP (NP (JJ acute) (NN exacerbation)) (PP (IN of) (NP (JJ allergic) (NN rhinosinusitis))))) (, ,) (CC and) (S (NP (DT these) (NNS findings)) (VP (VBP do) (RB not) (VP (VB apply) (PP (TO to) (NP (NP (DT the) (JJ typical) (NN patient)) (PP (IN with) (NP (NN ABRS))))))))))))) (. .)))
(ROOT (S (ADVP (RB Furthermore)) (, ,) (NP (PRP it)) (VP (VBZ is) (ADJP (JJ unclear)) (SBAR (IN whether) (S (NP (NNS INCSs)) (ADVP (ADVP (RB rather) (SBAR (IN than) (S (NP (JJ oral) (NNS steroids)) (VP (MD would) (VP (VB have) (VP (VBN been) (ADJP (RBR more) (JJ efficacious)))))))) (CC and) (ADVP (RB thus))) (VP (VBZ minimizes) (NP (NP (DT the) (JJ adjunctive) (NN effect)) (PP (IN of) (NP (NN loratadine)))))))) (. .)))
(ROOT (S (NP (NP (DT The) (NN recommendation)) (PP (IN against) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (NNS decongestants)) (CC or) (NP (NNS antihistamines)))))) (PP (IN as) (NP (NP (JJ adjunctive) (NN therapy)) (PP (IN in) (NP (NN ABRS)))))) (VP (VBZ places) (NP (DT a) (ADJP (RB relatively) (JJ high)) (NN value)) (PP (PP (IN on) (S (VP (VBG avoiding) (NP (JJ adverse) (NNS effects)) (PP (IN from) (NP (DT these) (NNS agents)))))) (CC and) (NP (NP (DT a) (ADJP (RB relatively) (JJ low)) (NN value)) (PP (IN on) (NP (NP (DT the) (JJ incremental) (NN improvement)) (PP (IN of) (NP (NNS symptoms)))))))) (. .)))
(ROOT (S (NP (DT These) (NNS agents)) (VP (MD may) (ADVP (RB still)) (VP (VB provide) (NP (NP (NN symptom) (NN relief)) (PP (IN in) (NP (NP (DT some) (NNS patients)) (PP (IN with) (NP (JJ acute) (JJ viral) (NN rhinosinusitis)))))) (SBAR (WHADVP (WRB when)) (S (NP (JJ antimicrobial) (NN therapy)) (VP (VBZ is) (RB not) (VP (VBN indicated))))))) (. .)))
(ROOT (S (NP (ADJP (ADJP (JJ Topical)) (CC and) (ADJP (JJ oral))) (NNS decongestants)) (VP (MD may) (VP (VB provide) (NP (NP (DT a) (JJ subjective) (NN impression)) (PP (IN of) (S (VP (VBG improving) (NP (JJ nasal) (NN airway) (NN patency)))))))) (. .)))
(ROOT (S (S (NP (JJ Topical) (NNS decongestants)) (VP (MD may) (VP (VB induce) (NP (NP (NN rebound) (NN congestion)) (CC and) (NP (NN inflammation)))))) (, ,) (CC and) (S (NP (JJ oral) (NNS antihistamines)) (VP (MD may) (VP (VB induce) (NP (NP (NN drowsiness)) (, ,) (NP (NN xerostomia)) (, ,) (CC and) (NP (JJ other) (JJ adverse) (NNS effects)))))) (. .)))
(ROOT (S (NP (DT The) (NNP FDA)) (VP (VBZ has) (VP (VBN recommended) (SBAR (IN that) (S (NP (NP (DT these) (NNS drugs)) (PP (IN in) (NP (NP (JJ over-the-counter) (NNS products)) (SBAR (S (RB not) (VP (VB be) (VP (VBN used) (VP (PP (IN for) (NP (NNS infants) (CC and) (NNS children))) (NP (NP (NP (JJR <) (CD 2) (NNS years)) (PP (IN of) (NP (NN age)))) (SBAR (IN because) (S (NP (ADJP (ADJP (JJ serious)) (CC and) (ADJP (RB potentially) (JJ life-threatening))) (JJ side) (NNS effects)) (VP (MD can) (VP (VB occur) (PRN (-LRB- -LSB-) (NP (CD 190)) (-RRB- -RSB-))))))))))))))))))) (. .)))
(ROOT (S (NP (NN Caution)) (VP (VBZ is) (VP (VBN advised) (PP (IN in) (NP (NP (NNS children)) (VP (JJ aged) (NP (NP (NN ≥) (CD 2) (NNS years)) (SBAR (RB particularly) (IN if) (S (NP (JJ such) (JJ over-the-counter) (NNS medications)) (VP (VBP have) (NP (JJ multiple) (JJ active) (NNS ingredients))))))))))) (. .)))
(ROOT (S (NP (NP (ADJP (ADJP (JJ Topical)) (CC and) (ADJP (JJ oral))) (NNS decongestants)) (CC and) (NP (NNS antihistamines))) (VP (MD should) (VP (VB be) (VP (VBN avoided) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN ABRS)))))))) (. .)))
(ROOT (S (ADVP (RB Instead)) (, ,) (NP (JJ symptomatic) (NN management)) (VP (MD should) (VP (VB focus) (PP (IN on) (NP (NP (NN hydration)) (, ,) (NP (NNS analgesics)) (, ,) (NP (NNS antipyretics)) (, ,) (NP (NN saline) (NN irrigation)) (, ,) (CC and) (NP (NNS INCSs)))))) (. .)))
(ROOT (NP (JJ Previous) (NNP SectionNext) (NNP Section)))
(ROOT (NP (NP (NNS RECOMMENDATIONS)) (PP (IN FOR) (NP (DT THE) (JJ NONRESPONSIVE) (NN PATIENT)))))
(ROOT (NP (NNP XIV) (. .)))
(ROOT (SBARQ (WHADJP (WRB How) (JJ Long)) (SQ (MD Should) (NP (NP (JJ Initial) (NNP Empiric) (NNP Antimicrobial) (NN Therapy)) (PP (IN in) (NP (NP (DT the) (NN Absence)) (PP (IN of) (NP (JJ Clinical) (NN Improvement)))))) (VP (VB Be) (VP (VBD Continued) (PP (IN Before) (S (VP (VBG Considering) (NP (NNP Alternative) (NNP Management) (NNS Strategies)))))))) (. ?)))
(ROOT (NP (CD 19) (. .)))
(ROOT (S (NP (DT An) (JJ alternative) (NN management) (NN strategy)) (VP (VBZ is) (NP (VBN recommended) (SBAR (IN if) (S (NP (NNS symptoms)) (VP (VBP worsen) (PP (IN after) (NP (CD 48)))))) (PRN (: --) (NP (NP (NP (CD 72) (NNS hours)) (PP (IN of) (NP (JJ initial) (JJ empiric) (JJ antimicrobial) (NN therapy)))) (, ,) (CC or) (VP (VBP fail) (S (VP (TO to) (VP (VB improve) (PP (IN despite) (NP (NP (CD 3)) (: --) (NP (NP (QP (CD 5) (NNS days))) (PP (IN of) (NP (NP (JJ initial) (JJ empiric) (JJ antimicrobial) (NN therapy)) (PRN (-LRB- -LRB-) (ADJP (ADJP (JJ strong)) (, ,) (ADJP (JJ moderate))) (-RRB- -RRB-))))))))))))))) (. .)))
(ROOT (S (PP (IN In) (ADJP (JJ general))) (, ,) (NP (NP (NNS patients)) (PP (IN with) (NP (NN ABRS)))) (VP (MD should) (VP (VB begin) (S (VP (TO to) (VP (VB respond) (ADVP (RB clinically)) (PP (IN by) (NP (NP (CD 3)) (: --) (NP (NP (NP (CD 5) (NNS days)) (PP (VBG following) (NP (NP (NN initiation)) (PP (IN of) (NP (JJ effective) (JJ antimicrobial) (NN therapy)))))) (PRN (-LRB- -LSB-) (NP (CD 61)) (-RRB- -RSB-)))))))))) (. .)))
(ROOT (S (S (PP (IN For) (NP (NN example))) (, ,) (PP (IN in) (NP (NP (DT the) (JJ placebo-controlled) (JJ prospective) (NN study)) (PP (IN of) (NP (NP (JJ empiric) (JJ antimicrobial) (NN therapy)) (PP (IN for) (NP (NN ABRS))))))) (PP (IN by) (NP (NP (NNP Wald) (FW et) (FW al)) (PRN (-LRB- -LSB-) (NP (CD 64)) (-RRB- -RSB-)))) (, ,) (NP (NP (NP (CD 45) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN on) (NP (NNS antibiotics)))))) (CC vs) (NP (NP (CD 11) (NN %)) (PP (IN of) (NP (NP (NNS children)) (PP (IN on) (NP (NN placebo))))))) (VP (VBD were) (VP (VBN cured) (PP (IN on) (NP (NP (DT the) (JJ third) (NN day)) (PP (IN of) (NP (NN treatment)))))))) (PRN (-LRB- -LRB-) (NP (NP (JJ complete) (NN resolution)) (PP (IN of) (NP (JJ respiratory) (NNS symptoms)))) (-RRB- -RRB-)) (CC and) (S (NP (JJ many) (NNS others)) (VP (VBD were) (VP (VBN improved) (PP (IN by) (NP (CD 3) (NNS days)))))) (. .)))
(ROOT (S (ADVP (RB Conversely)) (, ,) (PP (IN in) (NP (NP (NNP Wald) (NNP et) (NNP al) (POS 's)) (JJ recent) (JJ prospective) (NN study))) (SBAR (IN that) (S (NP (NP (VBN compared) (JJ high-dose) (NN amoxicillin-clavulanate)) (PP (TO to) (NP (NP (NN placebo)) (, ,) (NP (NP (CD 19)) (PP (IN of) (NP (CD 23) (NNS children))) (SBAR (WHNP (WP who)) (S (VP (VBD failed) (NP (NN therapy)))))) (PRN (-LRB- -LRB-) (PP (PP (VBG including) (NP (NP (NP (CD 19)) (PP (IN in) (NP (DT the) (NN placebo) (NN group)))) (CC and) (NP (CD 4)))) (PP (IN in) (NP (DT the) (JJ antibiotic) (NN group)))) (-RRB- -RRB-))))) (CC either) (VP (VP (VBD worsened)) (CC or) (VP (VBD failed) (S (VP (TO to) (VP (VB improve) (ADVP (RB clinically)) (PP (IN within) (NP (CD 72) (NNS hours)))))) (PRN (-LRB- -LSB-) (NP (CD 61)) (-RRB- -RSB-)))))) (. .)))
(ROOT (S (NP (JJ Bacteriological) (NN eradication) (NNS studies)) (ADVP (RB also)) (VP (VBP indicate) (SBAR (IN that) (S (NP (JJS most) (JJ causative) (NNS organisms)) (VP (VBP are) (VP (VBN eliminated) (PP (IN from) (NP (DT the) (JJ maxillary) (NNS sinuses))) (PP (IN by) (NP (CD 3) (NNS days))) (PP (VBG following) (NP (JJ appropriate) (JJ antimicrobial) (NN therapy)))))))) (. .)))
(ROOT (S (NP (NP (NNP Ambrose)) (CC and) (NP (NP (PRP$ his) (NNS colleagues)) (PRN (-LRB- -LSB-) (NP (NP (CD 144)) (, ,) (NP (CD 191)) (, ,) (NP (CD 192))) (-RRB- -RSB-)))) (VP (VBD devised) (NP (NP (DT an) (JJ innovative) (NN technique)) (SBAR (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NN time) (NN course)) (PP (IN for) (NP (NP (JJ bacteriological) (NN eradication)) (CC and) (NP (JJ pharmacodynamic) (NNS endpoints))))))))) (PP (IN in) (NP (NP (DT the) (JJ antimicrobial) (NN treatment)) (PP (IN of) (NP (NNP ABRS)))))) (, ,) (PP (IN by) (S (VP (VBG inserting) (NP (DT an) (NN indwelling) (NN catheter)) (PP (IN into) (NP (DT the) (JJ maxillary) (NN sinus))))))) (. .)))
(ROOT (S (NP (DT This) (VBN allowed) (NN serial) (NN sinus)) (VP (VB aspirate) (S (S (NP (NP (NN sampling)) (PP (IN for) (NP (NN Gram)))) (VP (VBP stain))) (, ,) (NP (NP (NN culture)) (, ,) (CC and) (NP (NN drug) (NN level) (NNS measurements))))) (. .)))
(ROOT (S (NP (NNS Patients)) (VP (VBD were) (VP (VBN treated) (PP (IN with) (NP (CC either) (NP (NN gatifloxacin)) (CC or) (NP (NN levofloxacin)))))) (. .)))
(ROOT (SINV (PP (IN Among) (NP (NP (NP (CD 8) (NNS patients)) (PP (IN with) (NP (JJ positive) (NNS cultures)))) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (CD 5)) (PP (IN with) (NP (NNP S.) (FW pneumoniae)))) (, ,) (NP (NP (CD 2)) (PP (IN with) (NP (NNP H.) (NNS influenzae)))) (, ,) (CC and) (NP (CD 1))) (PP (IN with) (NP (CC both) (NP (NNP H.) (NNS influenzae)) (CC and) (NP (NN M.) (NN catarrhalis))))) (-RRB- -RRB-)) (, ,) (NP (NP (CD 7)) (PRN (-LRB- -LRB-) (NP (CD 87.5) (NN %)) (-RRB- -RRB-))))) (VP (VBD were)) (NP (NP (ADJP (JJ sterile) (PP (IN by) (NP (CD 3) (NNS days)))) (VBG following) (NN initiation)) (PP (IN of) (NP (NN therapy)))) (. .)))
(ROOT (S (ADVP (RB Similarly)) (, ,) (NP (NP (NNP Ariza) (FW et) (FW al)) (PRN (-LRB- -LSB-) (NP (CD 143)) (-RRB- -RSB-))) (VP (VBN obtained) (NP (NP (NNS cultures)) (PP (IN of) (NP (DT the) (JJ middle) (NN meatus)))) (PP (IN by) (NP (NP (NN endoscopy)) (PP (IN from) (NP (NP (CD 42) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (VP (VBG receiving) (NP (NN treatment)) (PP (IN with) (NP (NN moxifloxacin))) (PP (IN for) (NP (ADJP (RB microbiologically) (VBN documented)) (NN ABRS)))))))))))) (. .)))
(ROOT (S (PP (IN After) (NP (CD 3) (NNS days))) (, ,) (NP (NP (CD 97) (NN %)) (PP (IN of) (NP (NNS patients)))) (VP (VBD had) (NP (NP (NN eradication)) (PP (IN of) (NP (DT all) (NN baseline) (NNS bacteria))))) (. .)))
(ROOT (S (NP (NNP Figure) (CD 4)) (VP (VBZ shows) (NP (NP (DT a) (NNP Kaplan-Meier) (NN plot)) (PP (IN of) (NP (NP (DT the) (NN proportion)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ positive) (NNS cultures))) (PP (IN for) (NP (NP (NNP S.) (FW pneumoniae)) (, ,) (NP (NNP H.) (NNS influenzae)) (, ,) (CC or) (NP (NP (NNP M.) (NN catarrhalis)) (PP (IN at) (NP (DT each) (NN day))))))))))) (PP (VBG following) (NP (NP (NN initiation)) (PP (IN of) (NP (NP (JJ antimicrobial) (NN therapy)) (PP (IN with) (NP (NP (DT a) (JJ respiratory) (JJ fluoroquinolone)) (PRN (-LRB- -LRB-) (NP (CC either) (NP (NN moxifloxacin)) (, ,) (NP (NN levofloxacin)) (, ,) (CC or) (NP (NN gatifloxacin))) (-RRB- -RRB-))))))))) (. .)))
(ROOT (S (SBAR (IN As) (S (VP (MD can) (VP (VB be) (VP (VBN seen)))))) (, ,) (NP (NP (CD 96) (NN %)) (PP (IN of) (NP (NNS patients)))) (VP (VBD had) (NP (JJ negative) (NNS cultures)) (PP (IN by) (NP (NN day) (CD 3)))) (. .)))
(ROOT (S (ADVP (RB Interestingly)) (, ,) (NP (NP (DT the) (NN time)) (PP (TO to) (NP (JJ bacterial) (NN eradication)))) (VP (VBD was) (ADJP (JJS longest) (PP (IN for) (NP (NNP S.) (FW pneumoniae)))) (, ,) (S (VP (VBN followed) (PP (IN by) (NP (NP (NNP H.) (NNS influenzae)) (CC and) (NP (NN M.) (NN catarrhalis))))))) (. .)))
(ROOT (S (PP (IN In) (NP (NP (DT the) (NNS studies)) (PP (IN by) (NP (NNP Ambrose) (FW et) (FW al))))) (NP (PRN (-LRB- -LSB-) (NP (CD 192)) (-RRB- -RSB-)) (, ,) (JJ excellent) (NN correlation)) (PP (IN between) (NP (NP (NN time)) (PP (TO to) (NP (NP (JJ bacterial) (NN eradication)) (CC and) (NP (NN time)))))) (PP (TO to) (NP (JJ clinical) (NN resolution))) (VP (VBD was) (VP (VBN observed))) (. .)))
(ROOT (S (PP (IN At) (NP (CD 3) (NNS days))) (PP (VBG following) (NP (NP (DT the) (NN initiation)) (PP (IN of) (NP (NN therapy))))) (, ,) (NP (NP (CD 81) (NN %)) (PP (IN of) (NP (DT all) (NNS signs) (CC and) (NNS symptoms)))) (VP (VBD had) (VP (VBN improved) (PP (IN by) (NP (QP (IN at) (JJS least) (CD 50)) (NN %))))) (. .)))
(ROOT (S (NP (NP (DT The) (JJ median) (NN time)) (PP (TO to) (NP (NP (JJ clinical) (NN resolution)) (PP (IN of) (NP (JJ individual) (NNS signs) (CC and) (NNS symptoms)))))) (VP (VBD was) (SBAR (S (NP (NP (CD 1)) (: --) (NP (NP (CD 3) (NNS days)) (, ,) (CC and) (NP (NP (CD 88) (NN %)) (PP (IN of) (NP (DT all) (NNS signs) (CC and) (NNS symptoms)))))) (VP (VBD were) (VP (ADVP (RB completely)) (VBN resolved) (PP (IN by) (NP (CD 5) (NNS days)))))))) (. .)))
(ROOT (S (ADVP (RB Thus)) (, ,) (NP (DT a) (ADJP (JJ bacteriologic) (CONJP (RB as) (RB well) (IN as)) (JJ clinical)) (NN response)) (VP (MD may) (VP (VB be) (VP (VBN expected) (PP (IN within) (NP (NP (CD 3)) (: --) (S (NP (NP (CD 5) (NNS days)) (PP (IN in) (NP (JJS most) (NNS patients)))) (VP (VBG receiving) (NP (JJ appropriate) (JJ antimicrobial) (NN therapy))))))))) (. .)))
(ROOT (S (SBAR (IN If) (S (NP (NNS symptoms) (CC and) (NNS signs)) (VP (VBP worsen) (PP (IN despite) (NP (NP (CD 72) (NNS hours)) (PP (IN of) (NP (JJ initial) (JJ empiric) (JJ antimicrobial) (NN therapy)))))))) (, ,) (NP (NP (DT the) (JJ possible) (NNS reasons)) (PP (IN for) (NP (NN treatment) (NN failure)))) (VP (MD must) (VP (VB be) (VP (VBN considered) (, ,) (PP (VBG including) (NP (NP (JJ resistant) (NNS pathogens)) (, ,) (NP (JJ structural) (NNS abnormalities)) (, ,) (CC or) (NP (DT a) (JJ nonbacterial) (NN cause))))))) (. .)))
(ROOT (S (ADVP (RB Similarly)) (, ,) (SBAR (IN if) (S (NP (EX there)) (VP (VBZ is) (NP (DT no) (JJ clinical) (NN improvement)) (PP (IN within) (NP (CD 3)))))) (: --) (NP (NP (NP (CD 5) (NNS days)) (PP (IN despite) (NP (JJ empiric) (JJ antimicrobial) (NN therapy)))) (, ,) (NP (DT an) (JJ alternate) (NN management) (NN strategy))) (VP (MD should) (VP (VB be) (VP (VBN considered) (SBAR (RB even) (IN though) (S (NP (EX there)) (VP (VBZ is) (NP (DT no) (JJ clinical) (NN worsening)))))))) (. .)))
(ROOT (S (NP (PRP It)) (VP (MD should) (VP (VB be) (VP (VBN noted) (SBAR (IN that) (S (NP (NP (JJ elderly) (NNS patients)) (CC and) (NP (NP (DT those)) (PP (IN with) (NP (JJ comorbid) (NNS diseases))))) (VP (MD may) (VP (VB require) (NP (NP (JJR longer) (NN time)) (PP (IN for) (NP (JJ clinical) (NN improvement))))))))))) (. .)))
(ROOT (S (NP (NP (NNP Lindbaek)) (PRN (-LRB- -LSB-) (NP (CD 193)) (-RRB- -RSB-))) (VP (VBD conducted) (NP (NP (DT a) (JJ prospective) (NN evaluation)) (PP (IN of) (NP (NP (NNS factors)) (ADJP (JJ present) (PP (IN at) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NP (JJ acute) (NN sinusitis)) (SBAR (WHNP (WDT that)) (S (VP (MD might) (VP (VB predict) (NP (NP (DT the) (JJ total) (NN duration)) (PP (IN of) (NP (NP (NN illness)) (PP (IN among) (NP (NP (NNS adults)) (VP (VBG receiving) (NP (JJ antimicrobial) (NN therapy))))))))))))))))))))) (. .)))
(ROOT (S (SBAR (IN As) (S (VP (MD might) (VP (VB be) (VP (VBN expected)))))) (, ,) (NP (NP (NP (NN age)) (PP (IN of) (NP (DT the) (NN patient)))) (CC and) (NP (NP (NP (DT the) (JJ clinical) (NN severity)) (PP (IN of) (NP (NN sinusitis)))) (PP (IN at) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NN treatment))))))) (VP (VBD were) (NP (NP (JJ independent) (NNS predictors)) (PP (IN of) (NP (NN illness) (NN duration))))) (. .)))
(ROOT (S (ADVP (RB However)) (PRN (, ,) (ADVP (RB even)) (PP (IN among) (NP (ADJP (ADJP (JJ elderly)) (CC and) (ADJP (RB severely) (JJ ill))) (NNS patients))) (, ,)) (NP (DT some) (NN improvement)) (VP (MD should) (VP (VB be) (ADJP (RB clinically) (JJ evident)) (PP (IN after) (NP (NP (CD 3)) (: --) (NP (NP (QP (CD 5) (NNS days))) (PP (IN of) (NP (JJ appropriate) (JJ antimicrobial) (NN therapy)))))))) (. .)))
(ROOT (NP (NP (JJ Careful) (JJ clinical) (NN evaluation)) (PP (IN of) (NP (DT the) (NN patient))) (PP (IN at) (NP (NP (CD 3)) (: --) (S (NP (CD 5) (NNS days)) (VP (VBZ is) (ADJP (JJ critical)) (S (VP (TO to) (VP (VP (VB assess) (NP (NP (DT the) (NN response)) (PP (TO to) (NP (JJ empiric) (JJ antimicrobial) (NN therapy))))) (CC and) (S (VP (TO to) (VP (VB consider) (NP (JJ alternative) (NN management) (NNS options)) (SBAR (IN if) (S (NP (NN treatment) (NN failure)) (VP (VBZ is) (VP (VBN suspected))))))))))))))) (. .)))
(ROOT (S (NP (NP (JJ Premature) (NN discontinuation)) (PP (IN of) (NP (JJ first-line) (JJ antimicrobial) (NN therapy))) (PP (IN in) (NP (NP (NN favor)) (PP (IN of) (NP (JJ second-line) (NNS agents))))) (PP (IN with) (NP (JJR broader) (JJ antimicrobial) (NN coverage)))) (VP (MD may) (VP (VP (VB promote) (NP (NP (NN overuse)) (PP (IN of) (NP (NNS antibiotics))))) (CC and) (VP (VP (VB increase) (NP (NNS costs))) (PP (ADVP (RB as) (RB well)) (IN as) (NP (JJ adverse) (NNS effects)))))) (. .)))
(ROOT (S (NP (JJ Little) (NN information)) (VP (VBZ is) (ADJP (ADJP (RB currently) (JJ available) (PP (IN on) (NP (NP (JJ bacterial) (NN eradication) (NNS rates)) (PP (IN in) (NP (NN ABRS))))) (PP (IN by) (NP (JJ antimicrobial) (NNS classes)))) (ADVP (JJ other) (PP (IN than) (NP (DT the) (JJ respiratory) (NNS fluoroquinolones)))))) (. .)))
(ROOT (S (S (NP (NN Treatment) (NN failure)) (VP (MD should) (VP (VB be) (VP (VBN considered) (PP (IN in) (NP (NP (DT all) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP fail) (S (VP (TO to) (VP (VB improve) (PP (IN at) (NP (CD 3))))))))))))))) (: --) (PP (NP (CD 5) (NNS days)) (IN after) (NP (NP (NN initiation)) (PP (IN of) (NP (JJ antimicrobial) (NN therapy))))) (. .)))
(ROOT (S (PP (IN In) (NP (DT the) (JJ final) (NN analysis))) (, ,) (NP (NP (JJ clinical) (NN judgment)) (CC and) (NP (NP (JJ close) (NN monitoring)) (PP (IN of) (NP (DT the) (NN patient))))) (VP (VBP are) (ADJP (JJ critical) (PP (IN in) (S (VP (VBG determining) (SBAR (IN whether) (S (NP (EX there)) (VP (VBZ is) (NP (NP (NN treatment) (NN failure)) (CC or) (NP (ADVP (RB simply)) (NP (DT a) (JJ slow) (JJ clinical) (NN response)))))))))))) (. .)))
(ROOT (S (NP (JJR More) (NNS studies)) (VP (VP (VBP are) (VP (VBN needed) (S (VP (TO to) (VP (VB examine) (NP (NP (DT the) (JJ bacterial) (NN eradication) (NNS rates)) (VP (VBN associated) (PP (IN with) (NP (JJ different) (JJ antimicrobial) (NNS classes))))) (PP (IN by) (NP (NP (JJ sequential) (NNS cultures)) (PP (IN of) (NP (DT the) (JJ middle) (NN meatus)))))))))) (CC and) (VP (VBP correlate) (NP (PRP them)) (PP (IN with) (NP (DT the) (JJ clinical) (NN response))))) (. .)))
(ROOT (NP (NN XV) (. .)))
(ROOT (SBARQ (WHNP (WDT What)) (SQ (VBZ Is) (NP (DT the) (NNP Recommended) (NNP Management) (NNP Strategy)) (PP (IN in) (NP (NNPS Patients))) (SBAR (WHNP (WP Who)) (S (ADVP (RB Clinically)) (VP (VBP Worsen) (SBAR (IN Despite) (S (NP (NP (CD 72) (NNS Hours)) (CC or) (NP (NN Fail))) (VP (TO to) (VP (VB Improve) (PP (IN After) (NP (NP (CD 3)) (: --) (NP (NP (NP (QP (CD 5) (NNS Days))) (PP (IN of) (NP (JJ Initial) (NNP Empiric) (NNP Antimicrobial) (NN Therapy)))) (PP (IN With) (NP (DT a) (NN First-line) (NN Regimen)))))))))))))) (. ?)))
(ROOT (NP (CD 20) (. .)))
(ROOT (S (NP (NP (DT An) (NN algorithm)) (PP (IN for) (NP (NP (NN managing) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP fail) (S (VP (TO to) (VP (VB respond) (PP (TO to) (NP (JJ initial) (JJ empiric) (JJ antimicrobial) (NN therapy)))))))))))) (VP (VBZ is) (VP (VBN shown) (PP (IN in) (NP (NNP Figure) (CD 1))))) (. .)))
(ROOT (NP (NP (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (ADVP (RB clinically)) (VP (VBP worsen) (PP (IN despite) (NP (NP (CD 72) (NNS hours)) (CC or) (VP (VBP fail) (S (VP (TO to) (VP (VB improve) (PP (IN after) (NP (NP (CD 3)) (: --) (SBAR (S (NP (NP (QP (CD 5) (NNS days))) (PP (IN of) (NP (NP (JJ empiric) (JJ antimicrobial) (NN therapy)) (PP (IN with) (NP (DT a) (JJ first-line) (NN agent)))))) (VP (MD should) (VP (VB be) (VP (VBN evaluated) (PP (IN for) (NP (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (JJ resistant) (NNS pathogens)))) (, ,) (NP (DT a) (JJ noninfectious) (NN etiology)) (, ,) (NP (NP (NP (NP (JJ structural) (NN abnormality)) (, ,) (CC or) (NP (JJ other) (NNS causes))) (PP (IN for) (NP (NN treatment) (NN failure)))) (PRN (-LRB- -LRB-) (ADJP (ADJP (JJ strong)) (, ,) (ADJP (JJ low))) (-RRB- -RRB-)))))))))))))))))))))) (. .)))
(ROOT (S (NP (NP (NNS Patients)) (PP (IN with) (NP (NP (JJ presumed) (NNS ABRS)) (SBAR (WHNP (WP who)) (S (VP (VBP fail) (S (VP (TO to) (VP (VB respond) (PP (TO to) (NP (JJ initial) (JJ empiric) (JJ antimicrobial) (NN treatment)))))))))))) (VP (MD should) (VP (VB be) (FRAG (VBN investigated) (PP (IN for) (NP (NP (JJ possible) (NNS causes)) (PP (IN of) (NP (NN failure))))) (, ,) (PP (VBG including) (NP (NP (NP (NN infection)) (PP (IN with) (NP (JJ resistant) (NNS pathogens)))) (, ,) (NP (JJ inadequate) (NN dosing)) (, ,) (CC and) (NP (NP (JJ noninfectious) (NNS causes)) (PP (VBG including) (NP (NP (NN allergy)) (CC and) (NP (JJ structural) (NNS abnormalities)))))))))) (. .)))
(ROOT (S (NP (EX There)) (VP (VBP are) (NP (NP (JJ few) (NNS RCTs)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NP (DT the) (JJ microbiological) (NN diagnosis)) (PP (IN of) (NP (NN ABRS)))) (VP (VBZ is) (VP (VBN confirmed) (PP (IN by) (NP (NP (NN sinus) (NN puncture)) (PP (IN at) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (NP (JJ clinical) (NN failure)) (CC or) (NP (NN follow-up)))))))))))))) (. .)))
(ROOT (S (NP (NP (DT A) (NN review)) (PP (IN of) (NP (NP (JJ available) (JJ placebo-controlled) (NNS trials)) (PRN (-LRB- -LRB-) (NP (ADJP (RB almost) (DT all)) (PP (VBG involving) (NP (NP (NNS patients)) (PP (IN with) (NP (DT a) (JJ clinical) (NN diagnosis)))))) (-RRB- -RRB-))))) (VP (VBD found) (NP (NP (QP (RB only) (CD 1)) (NN study)) (SBAR (WHNP (WDT that)) (S (VP (VBD provided) (NP (NP (NNS data)) (PP (IN on) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (DT a) (JJ specific) (JJ antimicrobial) (NN agent)))))) (S (VP (TO to) (VP (VB treat) (NP (NP (JJ clinical) (NNS failures)) (PRN (-LRB- -LSB-) (NP (CD 61)) (-RRB- -RSB-))))))))))) (. .)))
(ROOT (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (CD 4) (NNS children)) (VP (VBN randomized) (PP (TO to) (NP (NP (JJ high-dose) (NN amoxicillin-clavulanate)) (CC and) (NP (CD 19) (VP (VBN randomized) (PP (TO to) (NP (NP (NN placebo)) (SBAR (WHNP (WP who)) (S (VP (VBD experienced) (SBAR (S (NP (NN treatment) (NN failure)) (VP (VBD were) (VP (VBN provided) (NP (NN cefpodoxime)))))))))))))))) (. .)))
(ROOT (FRAG (NP (NP (DT All) (JJ experienced) (JJ successful) (NNS outcomes)) (PP (VBG following) (NP (NP (NN treatment)) (PP (IN with) (NP (NN cefpodoxime))) (PP (IN for) (NP (CD 10) (NNS days)))))) (, ,) (SBAR (IN although) (S (NP (NP (NP (DT the) (NN reason)) (PP (IN for) (NP (NN treatment) (NN failure)))) (PP (IN with) (NP (DT the) (NN study) (NNS antibiotics)))) (VP (VBD was) (ADJP (JJ unclear)) (, ,) (SBAR (IN as) (S (NP (NN sinus) (NN puncture)) (VP (VBD was) (RB not) (VP (VBN performed) (PP (IN in) (NP (DT these) (NNS patients)))))))))) (. .)))
(ROOT (S (NP (NP (NNP Brook) (FW et) (FW al)) (PRN (-LRB- -LSB-) (NP (CD 96)) (-RRB- -RSB-))) (VP (VBN performed) (NP (JJ consecutive) (NNS cultures)) (PP (IN from) (NP (NP (JJ maxillary) (NN sinus) (NNS aspirates)) (PP (IN of) (NP (CD 20) (NNS children))) (PP (IN with) (NP (NP (NNS ABRS)) (SBAR (WHNP (WP who)) (S (VP (VBD failed) (NP (JJ initial) (JJ empiric) (JJ antimicrobial) (NN therapy)))))))))) (. .)))
(ROOT (S (NP (NP (VBN Enhanced) (NNS levels)) (PP (IN of) (NP (NN resistance)))) (SBAR (IN as) (S (VP (VBN demonstrated) (PP (IN by) (NP (NP (DT an) (NN MIC)) (ADJP (ADJP (ADVP (ADVP (IN at) (JJS least)) (RB 2-fold)) (JJR higher)) (PP (IN than) (PP (IN for) (NP (DT the) (NN pretreatment) (NN isolate)))))))))) (VP (VBD was) (VP (VBN observed) (PP (IN in) (NP (NP (CD 49) (NN %)) (PP (IN of) (NP (NNS patients))))))) (. .)))
(ROOT (S (ADVP (RB Thus)) (, ,) (NP (DT both) (NP (JJ inadequate) (NN dosing)) (CC and) (NP (JJ bacterial) (NN resistance))) (VP (MD should) (VP (VB be) (VP (VBN considered) (PP (IN in) (NP (NP (DT all) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP fail) (S (VP (TO to) (VP (VB respond) (PP (TO to) (NP (JJ initial) (JJ empiric) (JJ antimicrobial) (NN therapy)))))))))))))) (. .)))
(ROOT (S (NP (NN PK/PD) (NNS principles)) (VP (MD should) (VP (VB be) (VP (VBN followed) (S (VP (TO to) (VP (VB ensure) (NP (NP (JJ adequate) (NN dosing)) (PP (IN for) (NP (JJ respiratory) (NN tract) (NNS infections)))) (PRN (-LRB- -LSB-) (NP (CD 194)) (-RRB- -RSB-)))))))) (. .)))
(ROOT (S (PP (IN In) (S (VP (VBG choosing) (NP (NP (DT a) (JJ second-line) (NN regimen)) (PP (IN in) (NP (DT a) (NN patient))))))) (SBAR (WHNP (WP who)) (S (VP (VBZ has) (VP (VBN failed) (NP (JJ initial) (JJ antimicrobial) (NN therapy)))))) (, ,) (NP (NP (DT an) (NN agent)) (PP (PP (IN with) (NP (NP (JJR broader) (NN spectrum)) (PP (IN of) (NP (NN activity))))) (CC and) (PP (IN in) (NP (DT a) (ADJP (ADJP (JJ different)) (ADJP (JJ antimicrobial))) (NN class))))) (VP (MD should) (VP (VB be) (VP (VBN considered) (S (-LRB- -LSB-) (NP (CD 82) (PRN (, ,) (NP (CD 195)) (-RRB- -RSB-))))))) (. .)))
(ROOT (S (NP (NNS Antimicrobials)) (VP (VBN selected) (VP (MD should) (VP (VB be) (NP (NP (ADJP (ADJP (JJ active) (PP (IN against) (NP (NNP PNS) (NNP S.) (FW pneumoniae) (CC and) (NP (JJ ampicillin-resistant) (NN H.) (NNS influenzae))))) (CONJP (RB as) (RB well) (IN as)) (ADJP (JJ other))) (NN β-lactamase)) (: --) (S (VP (VBG producing) (NP (JJ respiratory) (NNS pathogens)))))))) (. .)))
(ROOT (S (NP (NP (NP (DT The) (VBN recommended) (NN list)) (PP (IN of) (NP (NP (JJ second-line) (JJ antimicrobial) (NNS agents)) (ADJP (JJ suitable) (PP (IN for) (NP (NNS children))))))) (CC and) (PP (IN for) (NP (NP (NNS adults)) (SBAR (WHNP (WP who)) (S (VP (VBP experience) (NP (NN treatment) (ADJP (NN failure) (PP (TO to) (NP (JJ first-line) (NNS agents))))))))))) (VP (VBZ is) (VP (VBN shown) (PP (IN in) (NP (NNP Tables) (CD 9) (CC and) (CD 10))) (, ,) (ADVP (RB respectively)))) (. .)))
(ROOT (S (NP (NP (DT An) (NN algorithm)) (PP (IN for) (NP (NP (NN managing) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP fail) (S (VP (TO to) (VP (VB respond) (PP (TO to) (NP (JJ initial) (JJ empiric) (JJ antimicrobial) (NN therapy)))))))))))) (VP (VBZ is) (VP (VBN shown) (PP (IN in) (NP (NNP Figure) (CD 1))))) (. .)))
(ROOT (S (SBAR (IN If) (S (NP (NNS symptoms)) (VP (VP (VBP persist)) (CC or) (VP (VBP worsen))))) (PP (IN despite) (NP (NP (CD 72) (NNS hours)) (PP (IN of) (NP (NP (NN treatment)) (PP (IN with) (NP (NP (DT a) (JJ second-line) (NN regimen)) (, ,) (NP (NP (NN referral)) (PP (TO to) (NP (NP (DT an) (NN otolaryngologist)) (, ,) (NP (NP (NN allergist)) (, ,) (CC or) (NP (JJ infectious) (NN disease) (NN specialist)))))))))))) (VP (MD should) (VP (VB be) (VP (VBN considered)))) (. .)))
(ROOT (S (NP (NP (JJ Additional) (NNS investigations)) (PRN (-LRB- -LRB-) (NP (PP (JJ such) (IN as) (NP (NP (NN sinus) (NN puncture)) (CC or) (NP (NP (NN acquisition)) (PP (IN of) (NP (NP (NNS cultures)) (PP (IN of) (NP (DT the) (JJ middle) (NN meatus)))))))) (, ,) (CC and) (NN CT) (CC or) (NNP MRI) (NNS studies)) (-RRB- -RRB-))) (VP (MD should) (VP (VB be) (VP (VBN initiated)))) (. .)))
(ROOT (S (VP (VB Provide) (NP (NP (DT a) (ADJP (JJ systematic) (CC and) (JJ algorithm-based)) (NN approach)) (PP (TO to) (NP (NP (JJ antimicrobial) (NN therapy)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBG failing) (NP (JJ initial) (NN therapy))))))))) (. .)))
(ROOT (NP (NP (NP (DT The) (NN potential)) (PP (IN for) (S (VP (VP (VBG adding) (NP (NP (NP (JJR more) (NN selection) (NN pressure)) (PP (IN for) (NP (NN resistance)))) (ADJP (JJ due) (PP (TO to) (`` ``) (NP (JJ antimicrobial) (NN surfing)) ('' ''))))) (CC and) (VP (VBG adding) (NP (NP (JJ adverse) (NNS effects)) (PP (IN without) (NP (JJ antimicrobial) (NN benefit))))))))) (. .)))
(ROOT (S (S (NP (NNS RCTs)) (VP (VBP are) (VP (VP (VBN needed) (S (VP (TO to) (VP (VB evaluate))))) (CC and) (VP (VB optimize) (NP (NP (JJ clinical) (NNS approaches)) (PP (TO to) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP fail) (S (VP (TO to) (VP (VB respond) (PP (TO to) (NP (JJ initial) (JJ empiric) (JJ antimicrobial) (NN therapy)))))))))))))))))) (, ,) (CC and) (S (VP (TO to) (ADVP (RB systematically)) (VP (VB assess) (NP (NP (DT all) (NNS causes)) (PP (IN of) (NP (JJ clinical) (NN treatment) (NN failure))))))) (. .)))
(ROOT (NP (NNP XVI) (. .)))
(ROOT (S (PP (IN In) (S (VP (VBG Managing) (NP (DT the) (NN Patient)) (PP (IN With) (NP (NP (NNP ABRS)) (SBAR (WHNP (WP Who)) (S (VP (VBZ Has) (S (NP (NNP Failed)) (VP (TO to) (VP (VB Respond) (PP (TO to) (NP (NP (NNP Empiric) (NNP Treatment)) (PP (IN With) (NP (DT Both) (NP (NN First-line)) (CC and) (NP (JJ Second-line) (NNS Agents))))))))))))))))) (, ,) (NP (PRP It)) (VP (VBZ Is) (ADJP (JJ Important)) (S (VP (TO to) (VP (VB Obtain) (NP (NNS Cultures)) (PP (TO to) (NP (NNP Document) (NNP Whether)))))) (SBAR (S (NP (EX There)) (VP (VBZ Is) (NP (NP (JJ Persistent) (JJ Bacterial) (NN Infection)) (CC and) (SBAR (IN Whether) (S (NP (JJ Resistant) (NNS Pathogens)) (VP (VBP Are) (ADJP (JJ Present)))))))))) (. .)))
(ROOT (SQ (PP (IN In) (NP (JJ Such) (NNS Patients))) (, ,) (MD Should) (NP (NNS Cultures)) (VP (VB Be) (VP (VBN Obtained) (PP (IN by) (NP (NP (NP (NN Sinus) (NN Puncture)) (CC or) (NP (NNP Endoscopy))) (, ,) (CC or) (VP (VBP Are) (NP (NP (NNS Cultures)) (PP (IN of) (NP (NNP Nasopharyngeal) (NNP Swabs) (NNP Sufficient))))))))) (. ?)))
(ROOT (NP (CD 21) (. .)))
(ROOT (S (NP (PRP It)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (NP (NNS cultures)) (VP (VB be) (VP (VBN obtained) (PP (IN by) (NP (NP (JJ direct) (NN sinus) (NN aspiration)) (CONJP (RB rather) (IN than)) (PP (IN by) (NP (NP (JJ nasopharyngeal) (NNS swabs)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (VBN suspected) (NN sinus) (NN infection))) (SBAR (WHNP (WP who)) (S (VP (VBP have) (VP (VBN failed) (S (VP (TO to) (VP (VB respond) (PP (TO to) (NP (NP (JJ empiric) (JJ antimicrobial) (NN therapy)) (PRN (-LRB- -LRB-) (ADJP (JJ strong) (, ,) (JJ moderate)) (-RRB- -RRB-))))))))))))))))))))))) (. .)))
(ROOT (NP (CD 22) (. .)))
(ROOT (S (NP (NP (ADJP (RB Endoscopically) (VBN guided)) (NNS cultures)) (PP (IN of) (NP (DT the) (JJ middle) (NN meatus)))) (VP (VP (MD may) (VP (VB be) (VP (VBN considered) (PP (IN as) (NP (NP (DT an) (NN alternative)) (PP (IN in) (NP (NNS adults)))))))) (CC but) (SBAR (S (NP (NP (PRP$ their) (NN reliability)) (PP (IN in) (NP (NNS children)))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN established) (PRN (-LRB- -LRB-) (ADJP (JJ weak) (, ,) (JJ moderate)) (-RRB- -RRB-)))))))) (. .)))
(ROOT (NP (CD 23) (. .)))
(ROOT (S (NP (JJ Nasopharyngeal) (NNS cultures)) (VP (VP (VBP are) (ADJP (JJ unreliable))) (CC and) (VP (VBP are) (RB not) (VP (VBN recommended) (PP (IN for) (NP (NP (DT the) (JJ microbiologic) (NN diagnosis)) (PP (IN of) (NP (NP (NN ABRS)) (PRN (-LRB- -LRB-) (ADJP (ADJP (JJ strong)) (, ,) (ADJP (JJ high))) (-RRB- -RRB-))))))))) (. .)))
(ROOT (S (NP (NP (NNP Benninger) (FW et) (FW al)) (PRN (-LRB- -LSB-) (NP (CD 31)) (-RRB- -RSB-))) (VP (VBN reviewed) (NP (DT the) (NNS data)) (PP (IN from) (NP (NP (CD 5) (NNS studies)) (VP (VBG correlating) (NP (NP (DT the) (NN microbiology)) (VP (VBN obtained) (PP (IN from) (NP (NP (JJ nasopharyngeal) (NNS swabs)) (PP (IN with) (NP (NP (NNS cultures)) (PP (IN of) (NP (NN sinus) (NNS aspirates))))))))) (PP (CC both) (IN in) (NP (NP (JJ healthy) (NNS adults)) (CC and) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ acute) (JJ maxillary) (NN sinusitis)))))))))) (. .)))
(ROOT (S (PP (IN In) (NP (NP (CD 4)) (PP (IN of) (NP (CD 5) (NNS studies))))) (, ,) (NP (NN correlation)) (VP (VBD was) (ADJP (ADJP (JJ poor)) (PRN (-LRB- -LRB-) (NP (CD 42) (NN %)) (: --))) (PRN (NP (CD 65) (NN %)) (-RRB- -RRB-) (NP (PRN (-LRB- -LSB-) (NP (NP (CD 28)) (, ,) (NP (CD 39)) (, ,) (NP (CD 196)) (, ,) (NP (CD 197))) (-RRB- -RSB-))))) (. .)))
(ROOT (S (S (ADVP (RB However)) (, ,) (PP (IN in) (NP (CD one) (NN study))) (PP (IN by) (NP (NNP Jousimies-Somer) (FW et) (FW al))) (PRN (-LRB- -LSB-) (NP (CD 198)) (-RRB- -RSB-)) (, ,) (S (NP (VBN presumed) (NP (JJ respiratory) (NNS pathogens))) (VP (VBD were) (VP (ADVP (RB rarely)) (VBN isolated) (PP (IN from) (NP (NP (JJ nasopharyngeal) (NNS swabs)) (VP (VBN obtained) (PP (IN from) (NP (JJ healthy) (NNS adults)))))) (PP (VBN compared) (PP (IN with) (NP (NP (NP (NP (NNS patients)) (PP (IN with) (NP (JJ acute) (JJ maxillary) (NN sinusitis)))) (PRN (-LRB- -LRB-) (NP (CD 0) (NN %)) (: --))) (NP (NP (CD 4) (NN %)) (CC vs) (NP (CD 6) (NN %)) (PRN (: --) (NP (CD 61) (NN %))))))))))) (-RRB- -RRB-) (. .)))
(ROOT (S (SBAR (WHADVP (WRB When)) (S (NP (DT the) (JJ maxillary) (NN sinus)) (VP (VB aspirate) (NP (NN culture))))) (VP (VBD yielded) (NP (NP (NP (DT a) (JJ presumed) (NN sinus) (NN pathogen)) (PRN (-LRB- -LRB-) (NP (ADVP (FW ie)) (, ,) (NP (NP (NNP S.) (FW pneumoniae)) (, ,) (NP (NNP H.) (NNS influenzae)) (, ,) (CC or) (NP (NNP M.) (NN catarrhalis)))) (-RRB- -RRB-))) (, ,) (SBAR (S (NP (DT the) (JJ same) (NNS bacteria)) (VP (VBD was) (VP (VBN found) (PP (IN in) (NP (NP (CD 91) (NN %)) (PP (IN of) (NP (NP (JJ nasopharyngeal) (NNS swabs)) (PRN (-LRB- -LRB-) (NP (NP (JJ positive) (JJ predictive) (NNS values)) (, ,) (NP (CD 20) (NN %)) (: --) (NP (CD 93) (NN %)) (: ;) (NP (JJ negative) (JJ predictive) (NNS values)) (, ,) (NP (CD 84) (NN %)) (: --) (NP (CD 100) (NN %)) (, ,) (PP (VBG depending) (PP (IN on) (NP (DT the) (JJ bacterial) (NNS species))))) (-RRB- -RRB-)))))))))))) (. .)))
(ROOT (S (ADVP (RB Overall)) (, ,) (NP (JJ nasopharyngeal) (NNS cultures)) (VP (VBD were) (VP (VBN considered) (S (ADJP (JJ unreliable) (PP (IN for) (S (VP (VBG establishing) (NP (NP (DT the) (JJ microbiologic) (NN diagnosis)) (PP (IN of) (NP (NN ABRS))))))))))) (. .)))
(ROOT (S (PP (IN In) (NP (NP (NN contrast)) (PP (TO to) (NP (JJ nasopharyngeal) (NNS swabs))))) (, ,) (NP (NP (ADJP (RB endoscopically) (VBN directed)) (NNS cultures)) (PP (IN of) (NP (DT the) (JJ middle) (NN meatus)))) (VP (VBD correlated) (ADVP (RBR better)) (PP (IN with) (NP (NP (NNS cultures)) (PP (IN from) (NP (JJ direct) (NN sinus) (NN puncture)))))) (. .)))
(ROOT (S (NP (NP (NNP Benninger) (FW et) (FW al)) (PRN (-LRB- -LSB-) (NP (CD 199)) (-RRB- -RSB-))) (VP (VBD performed) (NP (NP (DT a) (NN meta-analysis)) (VP (VBG involving) (NP (NP (NP (CD 126) (JJ adult) (NNS patients)) (PP (IN from) (NP (CD 3) (VBN published) (NNS studies)))) (CC and) (NP (JJ additional) (JJ unpublished) (NNS data)))))) (. .)))
(ROOT (S (NP (NP (ADJP (RB Endoscopically) (VBN directed)) (NNS cultures)) (PP (IN of) (NP (DT the) (JJ middle) (NN meatus)))) (VP (VBD had) (NP (NP (DT a) (NN sensitivity)) (PP (IN of) (NP (CD 81) (NN %)))) (, ,) (NP (NP (NP (NN specificity)) (PP (IN of) (NP (CD 91) (NN %)))) (, ,) (NP (NP (JJ positive) (JJ predictive) (NN value)) (PP (IN of) (NP (CD 83) (NN %)))) (, ,) (NP (NP (JJ negative) (JJ predictive) (NN value)) (PP (IN of) (NP (CD 89) (NN %)))) (, ,) (CC and) (NP (NP (JJ overall) (NN accuracy)) (PP (IN of) (NP (ADJP (CD 87) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (CD 95) (NN %)) (NN CI)) (, ,) (NP (CD 81.3) (NN %)) (: --) (NP (CD 92.8) (NN %))) (-RRB- -RRB-))))))) (. .)))
(ROOT (S (NP (NP (DT The) (NN correlation)) (PP (IN between) (NP (NP (ADJP (RB endoscopically) (VBN directed)) (NNS cultures)) (PP (IN of) (NP (DT the) (JJ middle) (NN meatus) (CC and) (NN sinus) (NN puncture))) (PP (IN in) (NP (NP (JJ pediatric) (NNS patients)) (PP (IN with) (NP (NN ABRS)))))))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN established)))) (. .)))
(ROOT (S (ADVP (RB However)) (, ,) (PP (ADVP (RB even)) (IN in) (NP (NP (NNS children)) (PP (IN without) (NP (JJ respiratory) (NNS symptoms))))) (, ,) (NP (NP (NNS cultures)) (PP (IN of) (NP (DT the) (JJ middle) (NN meatus)))) (ADVP (RB often)) (VP (VBP show) (NP (NP (NP (NNP S.) (FW pneumoniae)) (CC and) (NP (NNP H.) (NN influenzae))) (PRN (-LRB- -LSB-) (NP (CD 200)) (-RRB- -RSB-)))) (. .)))
(ROOT (S (S (NP (NN Sinus) (NN culture)) (VP (VBZ provides) (NP (DT the) (ADJP (RBS most) (JJ accurate)) (NN information)) (PP (VBN compared) (PP (IN with) (NP (NP (JJ nasopharyngeal) (NNS swabs)) (CC or) (NP (NP (NNS cultures)) (PP (IN of) (NP (NP (DT the) (JJ middle) (NN meatus)) (VP (VBN obtained) (ADVP (RB endoscopically))))))))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (NP (NNS cultures)) (PP (IN of) (NP (DT the) (JJ middle) (NN meatus)))) (VP (VBP are) (ADJP (JJR easier)) (S (S (VP (TO to) (VP (VB obtain) (CC and) (ADJP (JJR less) (JJ invasive))))) (CC and) (ADVP (RB hence)) (ADJP (JJR better) (S (VP (VBN tolerated) (PP (IN by) (NP (NNS patients))))))))) (. .)))
(ROOT (S (NP (NN Sinus) (NN culture)) (VP (VBZ is) (NP (ADJP (JJ invasive)) (, ,) (NP (NP (NN time) (NN consuming)) (, ,) (CC and) (VP (ADVP (RB not) (RB well)) (VBN tolerated) (PP (IN by) (NP (NNS patients))))))) (. .)))
(ROOT (S (NP (NNP Middle) (NN meatus) (NNS cultures)) (VP (VP (MD may) (RB not) (VP (VB correlate) (PP (IN with) (NP (NP (DT an) (NN infection)) (PP (IN of) (NP (DT the) (JJ sphenoidal) (NNS sinuses))))))) (CC but) (SBAR (S (ADVP (RB still)) (VP (MD would) (VP (VB be) (VP (VBN expected) (S (VP (TO to) (VP (VB correlate) (PP (IN with) (NP (NP (NN infection)) (PP (IN of) (NP (DT the) (NP (NP (NN ethmoid)) (CC or) (NP (JJ frontal) (NNS sinuses))))))) (SBAR (IN because) (S (NP (DT the) (JJ latter)) (ADVP (RB primarily)) (NP (NP (NN drain)) (PP (IN through) (NP (DT the) (JJ middle) (NN meatus))))))))))))))) (. .)))
(ROOT (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (DT a) (JJ maxillary) (NN sinus) (NN tap)) (VP (MD would) (RB not) (VP (VB be) (VP (VBN expected) (S (VP (TO to) (VP (VB identify) (NP (NNS pathogens)) (PP (IN from) (NP (NP (DT the) (NN ethmoid)) (, ,) (NP (JJ frontal)) (, ,) (CC or) (NP (JJ sphenoidal) (NNS sinuses)))))))))) (. .)))
(ROOT (S (NP (RBR More) (NNS data)) (VP (VBP are) (VP (VBN needed) (S (VP (TO to) (VP (VB validate) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (NNS cultures)) (PP (IN of) (NP (DT the) (JJ middle) (NN meatus))))) (PP (IN for) (S (VP (VBG assessing) (NP (NP (JJ microbiological) (NN eradication) (NNS rates)) (CC and) (NP (NP (NN efficacy)) (PP (IN of) (NP (JJ antimicrobial) (NN therapy)))))))))))))) (. .)))
(ROOT (NP (NN XVII) (. .)))
(ROOT (WHNP (WDT Which) (NNP Imaging) (NNP Technique) (SQ (VBZ Is) (NP (JJS Most)) (ADJP (JJ Useful) (PP (IN for) (NP (NP (NNS Patients)) (PP (IN With) (NP (NP (JJ Severe) (NNS ABRS)) (SBARQ (WHNP (WP Who)) (SQ (VP (VBP Are) (VP (VBN Suspected) (S (VP (TO to) (VP (VB Have) (NP (NP (JJ Suppurative) (NNS Complications)) (ADJP (JJ Such) (PP (IN as) (NP (NP (NP (NNP Orbital)) (CC or) (NP (JJ Intracranial) (NNP Extension))) (PP (IN of) (NP (NN Infection)))))))))))))))))))) (. ?)))
(ROOT (NP (CD 24) (. .)))
(ROOT (FRAG (PP (PP (IN In) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NN ABRS)) (VP (VBN suspected) (S (VP (TO to) (VP (VB have) (NP (JJ suppurative) (NNS complications)) (, ,) (S (VP (VBG obtaining) (NP (NP (ADJP (ADJP (JJ axial)) (CC and) (ADJP (JJ coronal))) (NNS views)) (PP (IN of) (NP (JJ contrast-enhanced) (NN CT)))))))))))))) (CONJP (RB rather) (SBAR (IN than) (S (NP (NNP MRI)) (VP (VBZ is) (VP (VBN recommended) (PP (IN for) (NP (NP (NN localization)) (PP (IN of) (NP (NN infection)))))))))) (CC and) (S (S (VP (TO to) (VP (VB guide) (NP (JJ further) (NN treatment))))) (PRN (-LRB- -LRB-) (ADJP (ADJP (JJ weak)) (, ,) (ADJP (JJ low))) (-RRB- -RRB-)))) (. .)))
(ROOT (S (NP (NP (JJS Most) (NNS cases)) (PP (IN of) (NP (NNS ABRS)))) (VP (VBP do) (RB not) (VP (VB require) (NP (JJ radiographic) (NN evaluation)))) (SBAR (IN because) (S (NP (NP (NNS findings)) (PP (IN on) (NP (NP (JJ plain) (NNS radiographs)) (CC or) (NP (NN CT))))) (VP (VP (VBP are) (ADJP (JJ nonspecific))) (CC and) (VP (VBP do) (RB not) (VP (VB distinguish) (NP (JJ bacterial)) (PP (IN from) (NP (JJ viral) (NN infection)))))))) (. .)))
(ROOT (S (S (NP (NP (DT The) (NN usefulness)) (PP (IN of) (NP (NN imaging)))) (VP (VBZ is) (PP (IN in) (S (VP (VBG determining) (NP (NN disease) (NN location))))))) (CC and) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (NN involvement))) (PP (IN beyond) (NP (DT the) (JJ original) (NN source)))) (. .)))
(ROOT (S (ADVP (RB Occasionally)) (, ,) (NP (NN imaging) (NNS studies)) (VP (VP (MD may) (VP (VB be) (ADJP (JJ useful)) (S (VP (TO to) (VP (VB support) (NP (DT the) (NN diagnosis))))))) (CC or) (VP (VBP provide) (NP (NP (NN evidence)) (PP (IN of) (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (JJ mucosal) (NN involvement))))))) (, ,) (VP (ADVP (RB potentially)) (VBG guiding) (NP (DT a) (ADJP (RBR more) (JJ aggressive)) (NN approach)) (PP (TO to) (NP (NN therapy)))) (PRN (-LRB- -LSB-) (NP (CD 23)) (-RRB- -RSB-))) (. .)))
(ROOT (S (PP (IN In) (ADJP (JJ general))) (, ,) (NP (NP (ADJP (RBR more) (JJ advanced)) (NN imaging) (NNS modalities)) (PP (JJ such) (IN as) (NP (NP (NN CT)) (CC or) (NP (NNP MRI))))) (VP (MD should) (VP (VB be) (VP (UCP (VBN reserved) (PP (IN for) (NP (ADJP (ADJP (JJ recurrent)) (CC or) (ADJP (JJ complicated))) (NNS cases))) (CC or)) (SBAR (WHADVP (WRB when)) (S (NP (JJ suppurative) (NNS complications)) (VP (VBP are) (VP (VBN suspected)))))))) (. .)))
(ROOT (S (NP (NP (JJ Suppurative) (NNS complications)) (PP (IN of) (NP (NNS ABRS)))) (VP (VBP are) (ADJP (JJ rare)) (, ,) (VP (VBN estimated) (S (VP (TO to) (VP (VB be) (NP (NP (CD 3.7) (NN %)) (PRN (: --) (NP (NP (CD 11) (NN %)) (PP (IN among) (S (VP (VBN hospitalized) (NP (NP (JJ pediatric) (NNS patients)) (PP (IN with) (NP (NN sinusitis)))))))) (, ,))))))) (CC and) (VP (VBP are) (S (ADVP (RB primarily)) (VP (VBN related) (PP (TO to) (NP (NP (JJ orbital) (NNS cellulitis)) (CC and) (NP (NP (JJ intracranial) (NN extension)) (PP (IN of) (NP (NN infection)))))) (PRN (-LRB- -LSB-) (NP (CD 201)) (-RRB- -RSB-)))))) (. .)))
(ROOT (S (NP (NP (QP (RB Only) (RB approximately) (CD 1))) (PP (IN of) (NP (NP (CD 95) (CD 000) (NN hospital) (NNS admissions)) (PP (IN in) (NP (DT the) (NNP United) (NNPS States)))))) (VP (VBZ is) (ADJP (JJ due) (PP (TO to) (NP (NP (JJ sinusitis-associated) (NN brain) (NN abscess)) (PRN (-LRB- -LSB-) (NP (CD 202)) (-RRB- -RSB-)))))) (. .)))
(ROOT (S (ADVP (RB Overall)) (, ,) (NP (DT the) (NN evidence)) (VP (VBG supporting) (NP (NP (DT a) (NN superiority)) (PP (IN of) (NP (NN CT)))) (SBAR (S (CC vs) (NP (NP (NNP MRI)) (PP (IN for) (NP (NP (DT the) (NN diagnosis)) (PP (IN of) (NP (NP (JJ suppurative) (NNS complications)) (PP (IN of) (NP (NN ABRS)))))))) (VP (VBZ is) (ADJP (RB very) (JJ poor)) (, ,) (S (VP (VBG consisting) (ADVP (RB primarily)) (PP (IN of) (NP (NP (NN case) (NNS reports)) (CC and) (NP (JJ small) (JJ retrospective) (JJ observational) (NNS studies)))))))))) (. .)))
(ROOT (S (PP (IN In) (ADJP (JJ general))) (, ,) (S (S (NP (NN CT)) (VP (VBZ is) (VP (VBN considered) (S (NP (NP (DT the) (JJ gold) (NN standard)) (SBAR (S (NP (UCP (IN for) (S (VP (VBG assessing) (NP (NN bony)))) (CC and)) (JJ anatomical) (NNS changes)) (VP (VBN associated) (PP (IN with) (NP (ADJP (JJ acute) (CC or) (JJ chronic)) (NN sinusitis))))))))))) (, ,) (IN whereas) (S (NP (NNP MRI)) (VP (VBZ is) (ADJP (JJ useful) (S (VP (TO to) (ADVP (RB further)) (VP (VB delineate) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (NP (JJ soft) (NN tissue) (NNS abnormalities) (CC and) (NN inflammation)) (PRN (-LRB- -LSB-) (NP (NP (CD 203)) (: --) (NP (CD 205))) (-RRB- -RSB-)))))))))))) (. .)))
(ROOT (S (NP (NN CT)) (VP (VBZ is) (ADVP (RB also)) (ADJP (JJ necessary)) (PP (PP (IN for) (NP (JJ surgical) (NN planning))) (CC and) (PP (IN for) (NP (JJ intraoperative) (JJ image-guided) (JJ surgical) (NN navigation))))) (. .)))
(ROOT (S (NP (NP (NNP Younis) (FW et) (FW al)) (PRN (-LRB- -LSB-) (NP (CD 206)) (-RRB- -RSB-))) (VP (VBD evaluated) (NP (NP (NP (DT the) (JJ diagnostic) (NN accuracy)) (PP (IN of) (NP (NP (JJ clinical) (NN assessment)) (CC vs) (NP (NN CT))))) (CC or) (NP (NNP MRI))) (S (PP (IN in) (NP (NP (DT the) (NN diagnosis)) (PP (IN of) (NP (NP (ADJP (JJ orbital) (CC and) (JJ intracranial)) (NNS complications)) (VP (VBG arising) (PP (IN from) (NP (NN sinusitis)))))))) (CC and) (VP (VBN confirmed) (PP (IN by) (NP (JJ intraoperative) (NNS findings)))))) (. .)))
(ROOT (S (NP (NP (DT A) (NN total)) (PP (IN of) (NP (NP (CD 82) (NNS adults)) (CC and) (NP (NNS children))))) (VP (VBD were) (VP (VBN studied) (PP (ADVP (RB retrospectively)) (IN from) (NP (DT a) (JJ single) (JJ medical) (NN center))) (PP (IN during) (NP (NP (CD 1985)) (: --) (NP (CD 1999)))))) (. .)))
(ROOT (PP (IN Among) (NP (NP (CD 43) (NNS patients)) (PP (IN with) (NP (JJ orbital) (NNS infections))) (S (-LRB- -LRB-) (ADVP (RBS most)) (VP (VBD had) (NP (NP (JJ unilateral) (NN ethmoid) (NN sinusitis)) (VP (VBN complicated) (PP (IN by) (NP (JJ periorbital) (NNS cellulitis))))) (S (VP (-RRB- -RRB-))) (, ,) (SBAR (S (NP (DT the) (JJ diagnostic) (NN accuracy)) (VP (VBD was) (NP (CD 82) (NN %)) (PP (IN by) (NP (NP (JJ clinical) (NN assessment)) (CC and) (NP (NP (CD 91) (NN %)) (PP (IN by) (NP (NN CT) (NN imaging)))))))))))) (. .)))
(ROOT (PP (IN Among) (NP (NP (CD 39) (NNS patients)) (PP (IN with) (NP (JJ intracranial) (NNS infections))) (S (-LRB- -LRB-) (VP (ADVP (RBS most)) (VBD had) (NP (NP (JJ sphenoidal) (NN sinusitis)) (VP (VBN complicated) (PP (IN by) (NP (NN meningitis))))) (S (VP (-RRB- -RRB-))) (, ,) (S (S (NP (DT the) (JJ diagnostic) (NN accuracy)) (VP (VBD was) (NP (CD 82) (NN %)) (PP (IN by) (NP (JJ clinical) (NN assessment))))) (, ,) (NP (NP (NP (CD 87) (NN %)) (PP (IN by) (NP (NNP CT)))) (, ,) (CC and) (NP (NP (CD 97) (NN %)) (PP (IN by) (NP (NNP MRI))))))))) (. .)))
(ROOT (S (ADVP (RB Thus)) (, ,) (NP (NNP MRI)) (VP (VBZ appears) (ADJP (ADJP (RBR more) (JJ sensitive)) (PP (IN than) (NP (NP (NN CT)) (PP (IN for) (S (VP (VBG detecting) (NP (NP (JJ soft) (NN tissue) (NN involvement)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (IN with) (S (VP (VP (VBN suspected) (NP (JJ intracranial) (NNS complications))) (CC and) (VP (VBZ is) (RB not) (VP (VBN associated) (PP (IN with) (NP (VBG ionizing) (NN radiation))) (NP (-LRB- -LSB-) (NP (CD 207)) (, ,) (NP (CD 208)) (-RRB- -RSB-))))))))))))))))) (. .)))
(ROOT (S (PP (IN In) (NP (NP (DT a) (JJ retrospective) (JJ descriptive) (NN study)) (PP (IN of) (NP (NP (CD 12) (NNS children)) (PP (IN with) (NP (NP (JJ sinogenic) (JJ intracranial) (NN empyema)) (PRN (-LRB- -LRB-) (NP (NN SIE)) (-RRB- -RRB-)))))))) (, ,) (NP (NP (NNP Adame) (FW et) (FW al)) (PRN (-LRB- -LSB-) (NP (CD 209)) (-RRB- -RSB-))) (VP (VBD reported) (SBAR (IN that) (S (NP (DT the) (NN diagnosis)) (VP (VBD was) (VP (VBN missed) (PP (IN in) (NP (NP (CD 4) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD underwent) (NP (JJ nonenhanced) (NNP CT.)))))))))))) (. .)))
(ROOT (S (S (NP (NP (JJ Axial) (NN imaging)) (ADVP (RB alone))) (VP (VBD was) (ADJP (JJ unable) (S (VP (TO to) (VP (VB demonstrate) (NP (NN SIE)) (PP (IN in) (NP (NP (CD 1) (NN child)) (PP (IN with) (NP (NP (NN sphenoidal)) (CC and) (NP (NN ethmoid) (NN sinusitis)))))))))))) (, ,) (CC and) (S (NP (JJ coronal) (NNS images)) (VP (VBD were) (VP (VBN needed) (S (VP (TO to) (VP (VB demonstrate) (NP (PRP$ its) (NN presence) (CC and) (NN extent)))))))) (. .)))
(ROOT (S (S (VP (VBG Using) (NP (NP (JJ contrast-enhanced) (NN CT)) (CC or) (NP (NNP MRI))))) (, ,) (NP (NN SIE)) (VP (VBD was) (VP (VBN diagnosed) (PP (IN in) (NP (DT all) (CD 12) (NNS children))))) (. .)))
(ROOT (S (NP (NP (DT The) (NNP American) (NNP College)) (PP (IN of) (NP (NNP Radiology)))) (VP (VP (VBZ has) (ADVP (RB recently)) (VP (VP (VBN developed) (NP (NP (NN appropriateness) (NNS criteria)) (PP (IN for) (NP (NN imaging) (NNS examinations))) (PP (IN for) (NP (NP (JJ acute) (NN rhinosinusitis)) (PP (IN in) (NP (CC both) (NNS adults)))))) (PRN (-LRB- -LSB-) (NP (CD 210)) (-RRB- -RSB-))) (CC and) (NP (NP (NNS children)) (PRN (-LRB- -LSB-) (NP (CD 211)) (-RRB- -RSB-))))) (, ,) (CC and) (VP (VBD stated) (SBAR (IN that) (S (NP (NNP MRI) (CC and) (NNP CT)) (VP (VBP are) (NP (NP (JJ complementary) (NNS studies)) (PP (IN for) (NP (NP (DT the) (NN investigation)) (PP (IN of) (S (VP (VBN suspected) (NP (NP (ADJP (ADJP (JJ orbital)) (CC and/or) (ADJP (JJ intracranial))) (NNS complications)) (PP (IN of) (NP (NN sinusitis))))))))))))))) (. .)))
(ROOT (FRAG (ADVP (RB Thus)) (, ,) (NP (NP (DT the) (NN recommendation)) (PP (IN of) (NP (DT the) (NNP IDSA) (NN panel))) (PP (IN in) (NP (NP (NN favor)) (PP (IN of) (NP (NP (JJ contrast-enhanced) (NN CT)) (PP (IN over) (NP (NP (NNP MRI) (NNS places)) (NP (JJR greater) (NN value)) (PP (IN on) (NP (NP (JJ relative) (NN availability)) (CC and) (NP (NP (NN speed)) (PP (IN of) (NP (NP (NN diagnosis)) (PP (IN by) (NP (NNP CT)))))))))))))) (, ,) (CC and) (NP (NP (DT a) (NN lack)) (PP (IN of) (NP (NP (NN need)) (PP (IN for) (NP (NP (NN sedation)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (ADVP (RB frequently)) (VP (VBN required) (PP (IN for) (NP (NP (NNP MRI) (NNS studies)) (PP (IN in) (NP (NNS infants) (CC and) (NNS children))))))))))))))) (. .)))
(ROOT (S (NP (NP (DT The) (NN availability)) (PP (IN of) (NP (NP (NN CT)) (CC and) (NP (NNP MRI))))) (VP (VBZ has) (VP (ADVP (RB greatly)) (VBN improved) (NP (NP (DT the) (NN management) (CC and) (NN outcome)) (PP (IN of) (NP (NP (NNS patients)) (SBAR (IN with) (S (VP (VBN suspected) (NP (NP (ADJP (JJ orbital))) (CC or) (NP (ADJP (JJ intracranial))) (NP (NP (NN complication)) (PP (IN of) (NP (NN ABRS))))))))))))) (. .)))
(ROOT (S (NP (EX There)) (VP (VBP are) (NP (NP (JJ definite) (NNS risks)) (VP (VBN associated) (PP (IN with) (NP (DT these) (NNS procedures)))))) (. .)))
(ROOT (S (NP (NN CT) (NN scanning)) (VP (VBZ results) (PP (IN in) (NP (NP (NP (JJ low) (NNS levels)) (PP (IN of) (NP (NN radiation) (NN exposure)))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB lead) (PP (TO to) (NP (JJ radiation-induced) (NNS illnesses))) (SBAR (IN if) (S (NP (JJ multiple) (NNS scans)) (VP (VBP are) (VP (VBN obtained) (PRN (-LRB- -LSB-) (NP (CD 212)) (-RRB- -RSB-))))))))))))) (. .)))
(ROOT (S (PP (IN With) (NP (CC either) (NP (NN CT)) (CC or) (NP (NNP MRI)))) (, ,) (NP (EX there)) (VP (VP (VBZ is) (NP (NP (NP (DT a) (JJ potential) (NN risk)) (PP (IN of) (NP (JJ allergic) (NNS reactions)))) (PP (TO to) (NP (DT the) (NN contrast) (NN material))))) (, ,) (CC and) (SBAR (S (NP (JJ appropriate) (NN precaution)) (VP (MD should) (VP (VB be) (VP (VBN undertaken) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ renal) (NN impairment))))))))))) (. .)))
(ROOT (S (SBAR (IN Because) (S (NP (NP (JJS most)) (PP (IN of) (NP (NP (PRP$ our) (NN knowledge)) (PP (IN in) (NP (DT this) (NN area)))))) (VP (VBZ is) (VP (VBN based) (PP (IN on) (NP (NP (JJ retrospective) (NN case) (NN series)) (CC or) (NP (NNS reports)))))))) (, ,) (NP (NP (DT the) (JJ overall) (NN quality)) (PP (IN of) (NP (NN evidence)))) (VP (VBZ is) (ADJP (JJ weak))) (. .)))
(ROOT (S (SBAR (IN As) (S (NP (NN technology)) (VP (VBZ continues) (S (VP (TO to) (VP (VB evolve))))))) (, ,) (NP (JJR more) (NNS studies)) (VP (VBP are) (VP (VBN needed) (S (VP (TO to) (VP (VB clarify) (NP (NP (NP (DT the) (NNS indications)) (PP (IN of) (NP (DT these) (NN imaging) (NNS techniques)))) (PP (IN in) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (NN ABRS))))))))))) (. .)))
(ROOT (NP (NNP XVIII) (. .)))
(ROOT (SBARQ (WHADVP (WRB When)) (SQ (SQ (VBZ Is) (NP (NN Referral)) (PP (TO to) (NP (DT a) (NNP Specialist) (NNP Indicated)))) (PP (IN in) (NP (DT a) (NN Patient))) (PP (IN With) (NP (VBN Presumed) (NNS ABRS)))) (. ?)))
(ROOT (NP (CD 25) (. .)))
(ROOT (S (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (VP (VBP are) (ADVP (RB seriously)) (ADJP (RB ill))))) (, ,) (JJ immunocompromised) (, ,) (VP (VBP continue) (S (VP (TO to) (VP (VB deteriorate) (ADVP (RB clinically)) (SBAR (IN despite) (S (NP (NP (JJ extended) (NNS courses)) (PP (IN of) (NP (NP (JJ antimicrobial) (NN therapy)) (, ,) (CC or) (VP (VBP have) (NP (NP (JJ recurrent) (NNS bouts)) (PP (IN of) (NP (JJ acute) (NN rhinosinusitis)))) (PP (IN with) (NP (NP (NN clearing)) (PP (IN between) (NP (NNS episodes))))))))) (VP (MD should) (VP (VB be) (VP (VBN referred) (PP (TO to) (NP (NP (DT a) (NN specialist)) (PRN (-LRB- -LRB-) (PP (JJ such) (IN as) (NP (NP (DT an) (NN otolaryngologist)) (, ,) (NP (JJ infectious) (NN disease) (NN specialist)) (, ,) (CC or) (NP (NN allergist)))) (-RRB- -RRB-)))) (PP (IN for) (NP (NN consultation)))))))))))) (. .)))
(ROOT (S (SBAR (IN As) (S (NP (DT this)) (VP (VBZ is) (NP (NP (DT a) (`` ``) (JJ good) (JJ clinical) (NN practice) ('' '') (NN statement)) (CONJP (RB rather) (IN than)) (NP (DT a) (NN recommendation)))))) (, ,) (NP (PRP it)) (VP (VBZ is) (RB not) (ADVP (JJ further)) (VP (VBN graded))) (. .)))
(ROOT (S (NP (NP (JJS Most) (NNS patients)) (PP (IN with) (NP (NN ABRS)))) (VP (MD will) (VP (VB respond) (PP (TO to) (NP (NP (JJ empiric) (JJ antimicrobial) (NN therapy)) (, ,) (PP (ADVP (RB usually)) (IN within) (NP (CD 3))) (: --) (PP (NP (CD 5) (NNS days)) (IN after) (NP (NP (NN initiation)) (PP (IN of) (NP (NN treatment))))))))) (. .)))
(ROOT (FRAG (ADVP (RB However)) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (JJ such) (NNS patients)) (VP (VBP fail) (S (VP (TO to) (VP (VB respond) (SBAR (IN despite) (S (NP (NP (DT a) (NN change)) (PP (IN in) (NP (JJ antimicrobial) (NN therapy))) (SBAR (S (VP (TO to) (VP (VB broaden) (NP (NP (NN coverage)) (PP (IN for) (NP (NP (JJ presumed) (JJ bacterial) (NN resistance)) (, ,) (NP (NP (JJ prompt) (NN referral)) (PP (TO to) (NP (NP (DT a) (NN specialist)) (PP (JJ such) (IN as) (NP (NP (DT an) (NN otolaryngologist)) (, ,) (NP (NN allergist)) (, ,) (CC or) (NP (JJ infectious) (NN disease) (NN specialist))))))))))))))) (VP (MD should) (VP (VB be) (VP (VBN considered)))))))))))) (. .)))
(ROOT (S (S (S (NP (NP (DT The) (NN choice)) (PP (IN of) (NP (DT the) (NN specialist)))) (VP (MD should) (VP (VB be) (VP (VBN based) (PP (IN on) (NP (NP (DT the) (NN indication)) (PP (IN for) (NP (NN referral)))))))) (PRN (-LRB- -LRB-) (VP (VB see) (NP (NNP Table) (CD 14))) (-RRB- -RRB-))) (, ,) (CC and) (UCP (SBAR (IN whether) (S (NP (NP (DT the) (VBN suspected) (NN cause)) (PP (IN of) (NP (NN treatment) (NN failure)))) (VP (VBZ is) (ADVP (RB primarily)) (ADJP (JJ surgical))))) (, ,) (JJ medical) (, ,) (CC or) (PP (IN of) (NP (DT an) (JJ immunologic/allergic) (NN nature))))) (. .)))
(ROOT (S (NP (NP (DT A) (NN confirmation)) (PP (IN of) (NP (NN diagnosis)))) (VP (VBZ is) (ADVP (RB probably)) (ADVP (JJS best)) (VP (VBN determined) (PP (IN by) (NP (NP (DT an) (NN otolaryngologist)) (, ,) (SBAR (WHNP (WP who)) (S (VP (MD may) (VP (VB assist) (PP (IN in) (S (VP (VBG obtaining) (NP (NP (NNS cultures)) (PP (IN by) (NP (NP (NN sinus) (NN puncture)) (CC or) (NP (JJ middle) (NN meatus) (NN endoscopy)))))))))))))))) (. .)))
(ROOT (NP (NP (JJ Severe) (NN infection)) (, ,) (NP (UCP (RB particularly) (PP (IN in) (NP (NP (DT the) (JJ immunocompromised) (NN host)) (, ,) (CC or) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ multiple) (JJ medical) (NNS problems)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB complicate) (NP (JJ appropriate) (NN dosing))))))))))) (CC or)) (S (VP (VB predispose) (PP (TO to) (NP (JJ unusual) (NNS microorganisms))) (, ,) (VP (MD should) (VP (VB be) (VP (VBN referred) (PP (TO to) (NP (DT an) (JJ infectious) (NN disease) (NN specialist))))))))) (. .)))
(ROOT (S (NP (NNS Patients)) (NP (PP (IN with) (NP (JJ recurrent) (NN infection))) (VP (CC or) (VBN suspected) (S (VP (TO to) (VP (VB have) (NP (NP (DT an) (JJ underlying) (NN hypersensitivity)) (CC or) (NP (JJ immunologic) (NN disorder)))))))) (VP (MD should) (VP (VB be) (VP (VBN referred) (PP (TO to) (NP (DT an) (NN allergist)))))) (. .)))
(ROOT (S (NP (NP (NNS Patients)) (PP (IN with) (NP (NP (JJ rapid) (NN deterioration) (CC and) (NNS manifestations)) (ADJP (JJ suggestive) (PP (IN of) (NP (NP (ADJP (JJ orbital))) (CC or) (NP (ADJP (JJ intracranial))) (NP (JJ suppurative) (NNS complications)))))))) (VP (VBP require) (NP (NP (JJ urgent) (NN consultation)) (CC and) (NP (DT a) (JJ multidisciplinary) (NN approach)))) (. .)))
(ROOT (S (S (VP (VB Prompt) (NP (CC and) (JJ appropriate) (NN referral)))) (VP (MD should) (VP (VB hasten) (NP (NP (DT the) (NN recovery)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ complicated) (NNS ABRS)))))))) (. .)))
(ROOT (S (S (VP (VB Delay) (PP (IN in) (NP (JJ appropriate) (NN referral))) (PP (TO to) (NP (NNS specialists))))) (VP (MD may) (VP (VB prolong) (S (NP (NP (NN illness)) (, ,) (VP (VBP result) (PP (IN in) (NP (JJ chronic) (NN disease)))) (, ,) (CC and) (ADVP (RB occasionally))) (VP (VB lead) (PP (TO to) (NP (JJ catastrophic) (NNS consequences))) (SBAR (IN if) (S (NP (JJ life-threatening) (NNS complications)) (VP (VBP are) (RB not) (VP (VBN recognized))))))))) (. .)))
(ROOT (S (NP (JJ Unnecessary) (NN referral)) (VP (VBZ adds) (PP (TO to) (NP (NP (DT the) (NN burden)) (PP (IN of) (NP (NN healthcare) (NNS costs)))))) (. .)))
(ROOT (S (NP (JJ Timely) (NN referral)) (VP (VBZ is) (VP (VBN indicated) (SBAR (IN if) (S (NP (ADJP (ADJP (JJ chronic)) (CC or) (ADJP (JJ recurrent))) (NNS symptoms)) (VP (ADVP (RB severely)) (VBP affect) (NP (NP (DT the) (NN patient) (POS 's) (NN productivity) (CC or) (NN quality)) (PP (IN of) (NP (NN life))))))))) (. .)))
(ROOT (S (NP (NP (RB Early) (NN access)) (PP (TO to) (NP (NP (JJ critical) (JJ diagnostic) (NNS facilities)) (PRN (-LRB- -LRB-) (PP (JJ such) (IN as) (NP (NP (NN imaging) (NNS studies)) (, ,) (NP (NN endoscopy)) (, ,) (NP (JJ surgical) (NNS biopsies)) (, ,) (CC and) (NP (JJ immunologic) (NN testing)))) (-RRB- -RRB-))))) (VP (VBZ is) (VP (VBN needed) (S (VP (TO to) (VP (VP (VB improve) (NP (NN healthcare))) (CC and) (VP (VB prevent) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (JJ chronic) (NN sequelae)))))))))) (. .)))
(ROOT (NP (NP (DT The) (NNP American) (NNP Medical) (NNP Association)) (: --) (S (NP (NP (NP (NN Physician) (NNP Consortium)) (PP (IN for) (NP (NNP Performance) (NNP Improvement)))) (PRN (-LRB- -LRB-) (NP (NNP AMA-PCPI)) (-RRB- -RRB-))) (VP (VBZ has) (VP (VBN developed) (NP (NP (NN performance) (NNS measures)) (PP (IN for) (NP (NN sinusitis))))))) (. .)))
(ROOT (S (NP (NP (DT The) (NN measure) (NN set)) (, ,) (NP (NNS specifications)) (, ,) (NP (NN patient) (NN selection) (NNS criteria)) (, ,) (CC and) (NP (JJ other) (NN information))) (VP (MD can) (VP (VB be) (VP (VBN found) (PP (IN on) (NP (NP (DT the) (NNP AMA-PCPI) (NN website)) (PRN (-LRB- -LRB-) (NP (NN http://www.ama-assn.org/apps/listserv/x-check/qmeasure.cgi?submit=PCPI)) (-RRB- -RRB-))))))) (. .)))
(ROOT (S (VP (NP (NP (NNS Examples)) (PP (IN of) (NP (JJ suitable) (NN performance) (NNS measures)))) (VBP include) (: :))))
(ROOT (NP (NP (NP (NN Percentage)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN for) (NP (NP (NN sinusitis)) (SBAR (WHNP (WP who)) (S (VP (VBD met) (NP (NP (DT the) (NNS criteria)) (PP (IN for) (NP (NN therapy)))))))))))) (PRN (-LRB- -LRB-) (PP (VBN based) (PP (IN on) (NP (NN question) (NN I.)))) (-RRB- -RRB-))) (. .)))
(ROOT (NP (NP (NP (NN Percentage)) (PP (IN of) (NP (NP (NNS patients)) (ADJP (VBN treated) (PP (IN for) (NP (NN sinusitis))) (SBAR (WHPP (IN for) (WHNP (WDT which))) (S (NP (DT the) (JJ appropriate) (JJ antimicrobial)) (VP (VBZ is) (VP (VBN used) (SBAR (IN as) (S (VP (VBN listed) (PP (IN in) (NP (NP (NNP Tables) (CD 9)) (CC and) (NP (CD 10))))))))))))))) (. .)))
(ROOT (NP (NP (NN Percentage)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN for) (NP (NP (VBN recommended) (NN duration)) (PP (IN of) (NP (NN therapy)))))))) (PRN (-LRB- -LRB-) (PP (VBN based) (PP (IN on) (NP (NN question) (NNP X.)))) (-RRB- -RRB-))))
(ROOT (NP (NP (NP (NP (NN Percentage)) (PP (IN of) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP fail) (NP (JJ initial) (NN therapy)))))))) (CC and) (VP (VBP have) (NP (NP (NP (DT an) (JJ appropriate) (NN culture)) (VP (VBN obtained))) (PRN (-LRB- -LRB-) (PP (VBN based) (PP (IN on) (NP (NN question) (NN XVI)))) (-RRB- -RRB-))))) (. .)))